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SUMMARY 
This draft preparatory document contains a review of data on aspartame, undertaken to support the 
EFSA re-evaluation of the safety of this food additive. The material evaluated during this review 
comprised information submitted in response to the EFSA call for data on aspartame and publications 
identified in the course of a comprehensive search of the published literature on aspartame. This 
document  summarises  the  findings  of  the  review,  provides  an  overview  of  current  knowledge 
regarding the metabolism and toxicity of aspartame and presents an in depth quality assessment of 15 
toxicity studies.  
Results of literature search 
A tiered strategy was adopted for the literature search. In the first tier, a wide-ranging, high level 
overview of the literature was undertaken in order to identify all publications in which aspartame 
and/or other intense artificial sweeteners is/are mentioned. This generated a database containing 5023 
references. 
In the second tier the primary database was filtered, focusing on the published literature that could 
contribute directly or indirectly to the safety assessment of aspartame, and unpublished documents 
from the EFSA call for data were added manually. The result of this process was a filtered database 
listing 1326 documents of direct or indirect relevance to the risk assessment of aspartame. Copies of 
references identified during the literature search which are not included in the EFSA database were 
obtained and will be provided to EFSA upon completion of the project. 
The database was subsequently amended twice; 37 references on the epidemiology of bladder cancer 
which also mention artificial sweeteners were reinstated in response to a request from EFSA and three 
references were added to support statements made in reports. The version of the database submitted 
upon completion of the project therefore contains 1366 references. 
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In  order  to  ensure  evaluation  of  all  these  documents  in  a  consistent,  well-structured  and  timely 
manner, a proforma-based approach was adopted in the next stage of the project. The proforma used 
for this review was designed to facilitate the review of each document in the database by: 
capturing the publication details, source, topic, type and quality of each document; 
recording an expert judgment as to which studies meet the reliability, relevance and adequacy criteria 
for further in depth analysis; 
identifying documents which require input from the quality assurance (QA) and/or pathology experts 
on the team.  
The results of the proforma-based review were used to facilitate the selection of documents for further 
evaluation.  The  tiered  selection  strategy  involved  initial  selection  by  document  category,  then 
selection by topic. Following application of these criteria, 358 documents were taken forward for 
further evaluation. Information from these documents was used to create the summary of data which 
will inform the risk assessment of aspartame. 
Summary of the data  
The approved use of aspartame is as a dietary sweetener; as such, the only route by which consumers 
are exposed to this compound is via ingestion (although other routes may become relevant in the 
occupational setting). 
Following  oral  exposure,  aspartame  undergoes  hydrolysis  catalysed  by  esterases  and  dipeptidases 
leading to release of its individual components (aspartate, phenylalanine and methanol). This may 
occur either in the lumen of the gastrointestinal tract or within intestinal mucosal cells; either way, it is 
the individual components which undergo absorption. Intact aspartame is not detected in the systemic 
circulation, and aspartame therefore has an effective oral bioavailability of zero. 
Two of the three components of aspartame (aspartate and methanol) are cleared rapidly from the 
circulation.  Under  some  circumstances  (e.g.  when  aspartame  is  ingested  in  the  absence  of 
carbohydrates) aspartate is briefly measurable in the plasma following ingestion, but under normal 
conditions  of  use  aspartate  is  rapidly  metabolised  and  excreted  predominantly  in  expired  CO2, 
although a small proportion may be incorporated into proteins. Even after ingestion of large doses of 
aspartame, blood methanol levels usually remain below or very close to the limits of detection.  
The  effective  pharmacokinetics  of  aspartame  are  therefore  those  of  its  phenylalanine  component. 
Plasma  phenylalanine  usually  peaks  about  60  min  after  ingestion  and  is  then  cleared  from  the 
circulation over a period of about 2-3 hours depending on the dosing regimen used. If repeated high 
doses are administered (e.g. at 2 hour intervals), phenylalanine may accumulate and reach a plateau 
after about 6 hour; however, levels invariably return to background following overnight abstinence. 
The ultimate fate of the phenylalanine component of aspartame is incorporation into proteins. 
The  potential  physiological  consequences  of  exposure  to  aspartame-derived  phenylalanine  are  a 
function of its effects on the phenylalanine/large neutral amino acid ratio. It has been suggested that 
changes in this ratio could affect the uptake of other large neutral amino acids via the blood-brain 
barrier leading to changes in neurotransmitter levels in key brain regions; however, no consistent 
changes in neurotransmitter levels either in whole brain or specific brain regions have been identified 
following exposure of rodents to aspartame, even at high doses. In this context, a species difference in 
the metabolism of phenylalanine should be noted: rodents have much higher hepatic phenylalanine 
hydroxylase activity than do humans. Rodents therefore metabolise aspartame-derived phenylalanine 
rapidly to form tyrosine, so that dosing with aspartame leads to an increase in plasma tyrosine and the   Review of data on the food additive aspartame 
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tyrosine/large neutral amino acid ratio, whereas in humans the main effect observed is on plasma 
phenylalanine itself and on the phenylalanine/large neutral amino acid ratio. 
No significant acute or subchronic toxicity has been observed in animal models even at the highest 
doses  of  aspartame  which  could  reasonably  be  administered,  and  humans  given  high  doses  over 
periods of up to 27 weeks have reported no significant adverse effects. Early concerns that aspartame 
might cause neurotoxicity in neonates and infants were not substantiated by subsequent experimental 
data. 
There is no evidence to indicate that aspartame is genotoxic, either in vitro (with or without metabolic 
activation) or in vivo. Occasional marginal positive results have been reported, but such results only 
occur sporadically and do not indicate any particular cause for concern. 
The  results  of  chronic  toxicity  studies  carried  out  in  the  1970s  did  not  indicate  any  significant 
neoplastic or non-neoplastic pathological effects in rodents dosed with aspartame via the diet. These 
studies  were  unsatisfactory  in  a  number  of  ways,  including  the  presence  of  infections  requiring 
antibiotic treatment in one study, and they were subjected to detailed investigation by the US Bureau 
of Foods in the 1970s. The outcome of the investigation was that the studies were essentially reliable 
but  that  they  were  limited  by  a  number  of  shortcomings  in  terms  of  diet  preparation,  protocol 
compliance and QA. Furthermore, when the studies were issued, concern was expressed regarding a 
possible excess of brain tumours in rats dosed with aspartame via the diet; however, further detailed 
examination  of  tissue  from  these  studies  did  not  indicate  any  treatment  related  effects  on  brain 
tumours.  
Three additional chronic toxicity studies (two in rats and one in mice) were recently reported by the 
European Ramazzini Foundation of Oncology and Environmental Sciences (ERF). In these studies, 
aspartame was administered from early life (in utero in one study) until the natural death of the 
animals. Increased incidences of a variety of tumour types (including, in particular, lymphomas and 
leukaemias) were reported in these studies, which have been the subject of intense controversy since 
the first one was published in 2005. The studies are difficult to interpret because the increased tumour 
incidences are close to those seen in control animals in other studies and there is evidence that the 
animals may have been infected with the organism Mycoplasma pulmonis. Furthermore, a number of 
methodological  issues call  these studies  into  question.  These  include  allowing  the  animals  to  die 
naturally, storing the carcasses for up to 19 hr before performing necropsies, and fixing the tissues in 
ethanol rather than a conventional fixative such as 10% neutral buffered formalin which would give 
better morphology. 
Overall,  the  available  chronic  toxicity  studies  do  not  indicate  any  overt  carcinogenic  effect  in 
experimental animals due to aspartame, but all the conventional studies are limited in various ways. 
These studies were subjected to more detailed review during the quality assessment of key studies 
received by EFSA. Reassurance has recently been provided by a Good Laboratory Practice (GLP)-
compliant  study  conducted  by  the  National  Toxicology  Program  (NTP)  using  transgenic  mouse 
models. This indicated that aspartame had no carcinogenic effect in Tg.AC, p53
+/- or Cdkn2a
-/- mice 
dosed for 9 months via the diet. 
Concern regarding possible carcinogenic effects of aspartame has mainly focussed upon tumours of 
the bladder and brain. The issue of bladder carcinogenesis arose mainly by analogy with saccharin, 
which  is  known  to  induce  bladder  tumours  via  a  male  rat  specific  mechanism  involving  2-
microglobulin. A number of epidemiological studies were conducted in the between the 1970s and the 
1990s in an attempt to determine the relevance of these findings to humans; their results were variable 
but the majority did not indicate any increase in risk of bladder cancer in humans due to artificial 
sweetener consumption. None of these studies addressed aspartame directly and many of them were 
carried out in populations diagnosed before aspartame entered the market.   Review of data on the food additive aspartame 
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The issue of brain tumour induction by aspartame arose partly because of the suggestion of increased 
brain tumour incidence in chronic rat studies and partly following the publication of a paper stating 
that an increase in brain tumour incidence in the US had coincided with the release of aspartame. 
Subsequent  epidemiological  studies  have  not  identified  any  association  between  brain  tumour 
incidence and use of aspartame; indeed, studies of artificial sweetener use in which risks associated 
with  saccharin  and  other  sweeteners  (presumed  to  represent  mainly  aspartame)  are  considered 
separately provide no evidence for an increased risk of any tumour type in humans. 
The reproductive toxicity studies carried out prior to release did not indicate any adverse effects due to 
aspartame in mice, rats or rabbits. However, these studies were not conducted to modern standards 
(they predate the introduction of GLP regulations) and several of them are compromised by problems 
with  the  use  of  an  inappropriate  control  diet.  Dietary  studies  in  rabbits  also  proved  problematic 
because the rabbits failed to consume diets containing high doses of aspartame, so that the actual doses 
ingested did not correspond to those planned. There are no modern, GLP-compliant studies addressing 
the reproductive toxicity of aspartame. 
Only  one  epidemiological  study  has  addressed  the  possible  reproductive  effects  of  aspartame  in 
humans. This study addressed preterm delivery and examined the effects of soft drink consumption 
thereon.  It  found  an increased  risk  of  preterm  delivery  in  women  who  frequently  ingested  either 
carbonated or (to a lesser extent) non-carbonated diet drinks. This study did not address aspartame 
directly and it was subject to a number of confounding factors, but as a large, well-designed study its 
results merit careful consideration and further investigation. 
Ever  since  its  release,  anecdotal  reports  have  attributed  numerous  adverse  effects  in  humans  to 
consumption of aspartame. The effects most commonly reported include hypersensitivity reactions, 
headaches,  seizure  induction  and  behavioural  changes.  However,  when  these  are  addressed  by 
properly designed clinical trials it usually proves impossible to detect any effect due to aspartame. 
Only sporadic effects in individual subjects are observed, and these occur in response to placebo at 
least as  often  as  in  response to aspartame.  Similarly,  when  effects  such as seizure  induction  and 
behavioural change are addressed in animal models the number of positive findings is well within the 
range expected by chance, although it should be noted that grand mal seizures were observed in 
monkeys treated with high doses of aspartame during the only chronic toxicity in primates. These 
seizures were attributed to high plasma phenylalanine concentrations (similar effects were observed in 
response to equimolar doses of phenylalanine) and to stress caused by handling. 
With regard to potentially vulnerable groups, it is important to note that phenylketonurics (who have a 
genetic deficiency in phenylalanine hydroxylase activity) represent a known and well-characterised 
susceptible  subgroup  within  the  population.  These  individuals  need  to  restrict  their  intake  of 
aspartame,  and  aspartame-containing  products  are  required  to  carry  warning  labels  to  this  effect. 
However, controlled administration of single doses of aspartame to phenylketonurics has provided 
reassurance  that  the  inadvertent  ingestion  of  a  small  dose  by  these  individuals  is  not  hazardous. 
Furthermore, studies on phenylketonuria heterozygotes (“carriers”) have demonstrated that, while they 
exhibit higher plasma phenylalanine peaks and slower clearance than controls following ingestion of 
aspartame, no accumulation or long term effects are observed. 
Other population subgroups whose potential vulnerability to adverse effects following ingestion of 
aspartame  has  been  investigated  include  monosodium  glutamate-sensitive  individuals,  the  obese, 
diabetics, individuals with alcoholic liver disease, Parkinson’s disease sufferers and individuals with 
mood disorders. No untoward effects have been reported in any of these groups.  
There is no consistent evidence that aspartame has adverse effects, either in healthy individuals or in 
potentially susceptible groups, under normal conditions of use although phenylketonurics do need to   Review of data on the food additive aspartame 
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regulate  their  intake  of  aspartame  for  health  reasons.  They  are  supported  in  doing  this  by  clear 
labelling of aspartame-containing products. 
Quality assessment of key studies 
For the detailed review of 15 key studies, a consistent approach was ensured by adopting a proforma-
based methodology. Every study was reviewed by at least two team members; carcinogenicity studies 
were considered by all three reviewers. 
The studies conducted by or on behalf of Searle in the early 1970s were performed according to 
standards which were considered appropriate at the time; indeed, they were probably “state of the art” 
for the period. In order to provide a modern day perspective, the QA assessment conducted in this 
review  evaluated  these  studies  against  current  (i.e.  2012)  GLP  regulations  and  Organisation  for 
Economic Co-operation and Development (OECD) guidelines. 
In general, no major deficiencies were identified but every study was found to lack certain key items 
that would exist in a GLP study and minor inconsistencies in data presentation were identified. It was 
not possible to confirm protocol objectives and any changes, as protocols for these studies were not 
provided. The main criticism made, which applies to all the Searle studies, was that they contain 
insufficient information to support adequate characterisation of the test item(s), including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
Despite these caveats, the view of the review team is that these studies are adequate for use in risk 
assessment as long as their limitations are taken into account. 
The  study  reported  by  Soffriti  (Soffritti  and  Belpoggi,  2005)  has  been  the  subject  of  intense 
controversy. The most important concerns of the review team were that it claims compliance with 
GLP but lacks supporting documentation and that there are significant doubts about the pathology 
findings. The opinion of the review team is that, before the results of this study are used for risk 
assessment, the pathology should be subjected to a comprehensive independent peer review and the 
whole study should be audited. 
The study reported by Ajinomoto in 2006 (Iwata, 2006) was difficult to evaluate because it only 
comprises  histopathological  re-evaluation  of  a  previous  study  which  could  not  be  identified 
unequivocally. The review team had significant concerns regarding this study and took the view that it 
should not be used for risk assessment unless/until these issues are resolved. 
Overall, the opinion of the review team is that the Searle studies can be used in risk assessment if their 
limitations  are  taken  into  account,  but  issues  relating  to  the  Ajinomoto  and  ERF  studies  require 
resolution before these studies can be relied upon. The team notes that the only two generation study, 
while  without  major  quality  issues,  has  serious  limitations.  Reassurance  would  be  provided  by 
conducting another two generation study according to current OECD guidelines. 
A huge amount of evidence already exists regarding the potential adverse effects of aspartame, both in 
animal models and in humans, and most of this is reassuring. Overall, the opinion of the review team 
is that the studies conducted by or on behalf of Searle in the 1970s can be used in risk assessment if 
their limitations are taken into account, but issues relating to the ERF and Ajinomoto studies require 
resolution before they are relied upon. Specifically: 
The ERF study should be subjected to independent audit; its pathology findings should undergo a 
comprehensive independent peer review.   Review of data on the food additive aspartame 
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The Ajinomoto study should be authenticated with respect to the identity of the original study to which 
it relates; in particular, the genetic background of the rats used in this study should be confirmed. 
The team notes that the only two generation reproductive toxicity study, while without major quality 
issues, is limited with respect to procedures carried out, parameters measured and outcomes reported. 
Reassurance would be provided by conducting another two generation study according to current 
OECD guidelines. 
There  are,  therefore,  two  areas  in  which  the  existing  data,  while  still  essentially  reassuring,  are 
compromised by issues of methodology and QA: 
The original chronic toxicity studies conducted by Searle and the more recent studies carried out by 
the European Ramazzini Foundation of Oncology and Environmental Sciences have created vigorous 
debate regarding possible carcinogenic effects due to aspartame. Recent National Toxicology Program 
studies in transgenic mice are reassuring; however, a GLP-compliant 2-year bioassay conducted by an 
organisation  such  as  the  National  Toxicology  Program  would  help  to  resolve  the  issue  of 
carcinogenicity once and for all. 
The reproductive toxicity studies conducted by Searle in the 1970s, while essentially reassuring, were 
conducted to the standards current at the time and beset by technical difficulties. A modern, GLP-
compliant reproductive toxicity study conducted to the appropriate guidelines would, it is to be hoped, 
confirm the lack of any embryotoxic, teratogenic or reproductive effect due to aspartame. Such further 
data would provide further reassurance, especially in the light of recent epidemiological findings. 
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 INTRODUCTION 
The dipeptide aspartame (L-aspartyl-L-phenylalanine methyl ester) is 200 times sweeter than sucrose 
and is sold as an artificial sweetener under trade names such as Equal and NutraSweet. The current EU 
Acceptable Daily Intake (ADI) for aspartame is 40 mg/kg/day, equating to 2.8 g/day for a 70 kg adult. 
This draft preparatory document contains a review of data on aspartame, undertaken to support the 
EFSA re-evaluation of the safety of this food additive. The material evaluated during this review 
comprised information submitted in response to the EFSA call for data on aspartame and publications 
identified in the course of a comprehensive search of the  published literature on aspartame. This 
document  summarises  the  findings  of  the  review,  provides  an  overview  of  current  knowledge 
regarding the metabolism and toxicity of aspartame and presents an in depth quality assessment of 15 
key studies.  
The initial literature search, whose objective was to capture all published material on aspartame, was 
comprehensive in scope. During the selection of documents for further evaluation, however, it was 
agreed that this review would focus on biological and toxicological data on aspartame. 
The potential human toxicity of aspartame is surrounded by controversy. Several issues are the subject 
of intense debate; these include: 
  Carcinogenicity:  The  results  of  carcinogenicity  bioassays  undertaken  by  different 
investigators  have  differed.  The  proposed  review  will  identify  and  critique  the  various 
carcinogenicity bioassays carried out to date. 
  Metabolism: Aspartame undergoes breakdown in the intestine resulting in the generation of 
aspartate, phenylalanine and methanol which are absorbed via the intestinal epithelium. The 
generation  of  methanol  from  Aspartame  has  led  to  the  expression  of  concern  among  lay 
consumers and some members of the scientific community. The proposed review will consider 
data addressing the production and fate of methanol generated during the intestinal breakdown 
of Aspartame. 
  Human effects: Aspartame has been linked anecdotally to a plethora of adverse effects in 
humans  including,  among  others,  headache,  dry  mouth,  dizziness,  mood  change,  nausea, 
vomiting, reduced seizure threshold and thrombocytopenia. The proposed review will evaluate 
these observations and identify those requiring further follow up. 
These issues, while not the exclusive topic of the review, were given careful consideration during the 
review process.   Review of data on the food additive aspartame 
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RESULTS OF LITERATURE SEARCH 
The objectives of the first phase of this project were: 
To perform and document a complete and exhaustive review of the published literature that could 
contribute directly or indirectly to the safety assessment of the food additive aspartame (E951). 
To review all the data received by EFSA or identified by the literature search. 
To select, from both the data by the literature identified search and the data received by EFSA, the 
data relevant to perform a full safety assessment of the food additive aspartame (E951), according to 
criteria defined by the Scientific Panel on Food Additives and Nutrient Sources added to food (ANS 
Panel). 
A tiered strategy was adopted for the literature search. In the first tier, a wide-ranging, high level 
overview of the literature was undertaken in order to identify all publications in which aspartame 
and/or other intense artificial sweeteners is/are mentioned.  
The  primary  literature  database  was  generated  by  a  combination  of  keyword  (Medical  Subject 
Heading (MeSH) terms) and free text searching. The following search terms were used: 




Publications in which aspartame is a major or 
minor topic. 
Free text  Publications in which aspartame is mentioned. 
L-aspartyl-L-phenylalanine 
methyl ester  Free text  Publications in which aspartame is identified as 
L-aspartyl-L-phenylalanine methyl ester. 
E951  Free text  Publications in which aspartame is identified as 
E951. 
Sweetening agents  Major/minor 
MeSH heading 
Publications  in  which  artificial  sweetening 
agents are a major or minor topic 
(Sweeten*) and (artificial* or 
intens*)  Free text 
Publications  mentioning  sweeteners, 
sweetening,  sweetened…..  etc.,  together  with 
artificial,  artificially…..  or  intense,  intensity, 
intensified….. etc. 
The primary source of references was the PubMed (National Library of Medicine) database. The 
search was extended by searching other databases (ToxNet, the National Toxicology Program studies 
database and TOXSEEK). In additional, a search of open toxicology databases and a free text search 
using Google was undertaken. 
The primary search (which was independent of the existing EFSA database) generated a database 
containing 5023 references. This was saved as an EndNote X4 database entitled “Aspartame database 
(unfiltered)”. 
   Review of data on the food additive aspartame 
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Database refinement 
The primary database was filtered, focusing on the published literature that could contribute directly or 
indirectly to the safety assessment of aspartame. This process was based upon a review of titles during 
which: 
Papers published before 1972 (the first year in which aspartame was reported) were excluded. 
Papers considered irrelevant to the risk assessment of aspartame were removed. This included the 
removal of: 
Publications whose titles mention other artificial sweeteners (e.g. saccharin) but not aspartame. Papers 
which discuss artificial sweeteners in general were retained at this stage if they met the other search 
criteria. 
Publications which discuss aspects of aspartame which are uninformative for toxicity assessment (e.g. 
perception of sweetness, prevention of dental caries). 
A supplementary search using the keywords “NutraSweet” and “Canderel” was carried out and the 
results added to the database. 
Unpublished documents from the EFSA database were added to the database manually. The database 
was then cross-referenced to verify that all publications listed in the EFSA database were present in 
the filtered database.  
The result of the above process was a filtered database listing 1326 documents of direct or indirect 
relevance to the risk assessment of aspartame. Copies of references identified during the literature 
search  but  not included  in  the  EFSA  database  were  obtained; in  order  to  comply  with  copyright 
requirements, these will be provided to EFSA upon completion of the project. The filtered database, 
saved as an EndNote X4 database entitled “Aspartame database (filtered)” and in Word/pdf formats, 
comprised: 
941 documents received by EFSA 
263 documents obtained during the project, as pdf or in hard copy 
101 documents which are not available online 
21 documents which were agreed with EFSA as not relevant and were not downloaded 
The database was amended twice after submission of Deliverable 1: 
37 references on the epidemiology of bladder cancer which also mention artificial sweeteners were 
reinstated in response to a request from EFSA. It was agreed that, since none of these papers address 
aspartame directly and many of them are not available online but the topic is still one which causes 
public concern, the findings of these papers would be tabulated based upon the information available 
in online abstracts. 
3 references were added to support statements made in reports.   Review of data on the food additive aspartame 
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The version of the database submitted upon completion of the project (Aspartame database (01-May-
12)) therefore contains 1366 references. 
A final literature search was carried out during preparation of this Final Report, updating the literature 
search to 30
th April 2012. The references identified are listed in Appendix 1.  
Details of the literature search and database refinement process are provided in Appendix 2. 
Proforma-based review 
Deliverable 1 comprised a database detailing 1326 documents. In order to ensure evaluation of all 
these documents in a consistent, well-structured and timely manner, a proforma-based approach was 
adopted in the next stage of the project. Each document was reviewed against the Core Study headings 
defined by the Scientific Committee on Food in 2001 (SCF 2001 Guidance on submissions for food 
additive evaluations by the Scientific Committee on Food: SCF/CS/ADD/GEN/26 Final. 12 July 2001: 
http://ec.europa.eu/food/fs/sc/scf/out98_en.pdf).  In addition, the compliance of each document with 
the reliability, relevance and adequacy criteria defined by Klimisch et al (Klimisch, Andreae et al, 
1997)  and  those  defined  by  EFSA  for  inclusion  of  documents  in  the  review  of  aspartame  was 
evaluated. 
No specific relevance requirement was established in the written advice from EFSA; however, during 
this review, items in the database which met the scientific criteria but were not relevant to the current 
task  (e.g.  experimental  and  human  volunteer  studies  on  taste  perception)  were  classified  as  not 
meeting the EFSA criteria. 
The proforma used for this review (Figure 1) was designed to facilitate the review of each document in 
the database by: 
capturing the publication details, source, topic, type and quality of each document; 
recording an expert judgment as to which studies meet the reliability, relevance and adequacy criteria 
for further in depth analysis; 
identifying documents which require input from the QA and/or pathology experts on the team.    Review of data on the food additive aspartame 
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Figure 1:   Aspartame Document Assessment Proforma 
 
Every  document  identified  in  the  filtered  database  was  reviewed  using  this  proforma  (1326 
documents).  For  documents  which  could  not  be  obtained  online  or  via  local  university  libraries, 
proformas indicating that the papers exist but are not available were created. References added to the   Review of data on the food additive aspartame 
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database subsequently, either in response to a direct request from EFSA (epidemiology of bladder 
cancer) or to support statements made in reports, were not downloaded or subjected to proforma-based 
review. 
Selection of documents for further evaluation 
The results of the proforma-based review were used to facilitate the selection of documents for further 
evaluation, as summarised in Appendix 3. In particular it was agreed that, in order to avoid duplication 
of effect, the current review would focus on material for Section 3 of the Preparatory Document 
Template (biological and toxicological data) while EFSA would deal with Section 2 (technical data). 
Briefly, the tiered selection strategy adopted was as follows: 
Selection by category; document types selected for Tier 2 were: 
Unpublished study reports 
Secondary sources <10 years old 
Documents from national authorities 
Primary research papers 
This process identified 805 documents for consideration in Tier 2. Letters and brief comments were 
not taken on to further review because their contents had already been noted. 
Selection by topic; for details, see Appendix 3. It was agreed with EFSA that the following would be 
excluded from further consideration: 
Topics to be handled by EFSA: 
Previous JECFA and EFSA evaluations 
Dietary intake/exposure assessments 
Analytical and chemical data 
Primary research papers addressing 
Non-adverse biological effects  
Proposed beneficial effects 
Effects on ochratoxin A toxicity 
In vitro effects 
Methanol and formaldehyde toxicity 
Papers considered unreliable according to the Klimisch/EFSA criteria 
The inclusion of secondary sources less than 10 years old and documents from national authorities was 
based upon the extent to which they would assist in the interpretation of the primary sources.   Review of data on the food additive aspartame 
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Following application of these criteria, 358 documents were taken forward for further evaluation. 
Information from these documents was used to create the summary of data which will inform the risk 
assessment of aspartame. 
Information sources 
As indicated above, the main information sources used for this review were: 
Peer-reviewed primary research papers identified during a comprehensive search of the published 
literature. 
Unpublished study reports provided by the manufacturers of aspartame, including the original dossier 
submitted  by  G.D.  Searle  and  Co.  (Searle)  and  follow  up  studies  conducted  by  The  NutraSweet 
Company (NutraSweet) and Ajinomoto Co. Inc. 
Other sources which are cited as appropriate are items of correspondence from the scientific and 
medical literature, recent secondary sources (e.g. reviews less than 10 years old) and information 
provided to EFSA by various national authorities, including the US Food and Drug Administration 
(FDA). This review does not consider information from conference abstracts because these do not 
meet the criterion set by EFSA in terms of details provided on the performance or outcome of the 
studies (EFSA, 2009a). 
This  review  is  independent  of  the  comprehensive  review  published  by  Magnuson  et  al  in  2007 
(Magnuson, Burdock et al, 2007; Magnuson, 2010; Waddell, Doull et al, 2006). It covers the same 
material up to 2007 but also addresses material published up to the end of 2011. 
Status of the Searle dossier 
The dossier submitted by Searle when applying for approval of aspartame as a sweetener quickly 
became the subject of intense controversy. This was addressed internally by Searle and externally in a 
series of reviews commissioned by the US FDA. The issues raised by critics and the outcomes of the 
various reviews are summarised briefly below. 
The  data  reassurance  programme  initiated  by  Searle  to  evaluate  the  aspartame  approval  dossier 
reported in 1976 (Rust, 1976). Two studies discussed later in this review (Rao, McConnell et al, 1972; 
Rao, Mauro et al, 1972d) were rejected as a consequence of this investigation; however, the overall 
conclusion drawn was that the dossier contained no evidence of toxicity due to aspartame. 
An  investigation  by  the  FDA  into  preclinical  animal  studies  conducted  by  Searle  involved  a 
verification of raw data against the Food Additive Petition submitted to the FDA as well as a review of 
other documentation and inspection of facilities (FDA, 1976). Several significant issues, as well as 
numerous minor deficiencies, were identified. These included poor protocol compliance, inappropriate 
handling of intercurrent deaths, failure to undertake planned analyses, lack of homogeneity testing of 
the diets used in several studies and the fact that the protocol for one study was written in retrospect. 
Overall,  the  problems  identified  were  largely  ascribed  to  lack  of  adequate  QA  and  the  Searle 
Investigation Task Force recommended the establishment of Good Laboratory Practice regulations 
modelled upon the Good Manufacturing Practice regulations which were already in existence (Sharp, 
Halperin et al, 1976). 
As a consequence of these issues, the Bureau of Foods commissioned an in depth investigation of 
various Searle studies by Universities Associated for Research and Education in Pathology (UAREP) 
(Taylor, Goldberg et al, 1977; Unattributed, 1978a; 1978b; 1978c). The report of this investigation 
runs to three volumes, but the key observations are as follows:   Review of data on the food additive aspartame 
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There was a good correlation between reviewers’ diagnoses and those in the original reports. Some 
discrepancies were noted, but these did not seem to follow a particular pattern. The extent of autolysis 
was not felt by the reviewers to preclude interpretation in the majority of cases. 
UAREP teratology findings generally agreed with those in the study reports. 
There were some discrepancies in calculated survival data and tumour incidences and vagueness in the 
description of statistical analyses performed. 
There was no evidence of deliberate attempts to produce biased results. The discrepancies observed 
appeared randomly distributed between treated and control groups. 
The panel identified a number of so-called “deviant practices”, and noted that differences did exist 
between the raw data and that submitted for the approval process; however, these were not of such 
magnitude as to alter the overall conclusions from individual studies.  
Following peer review of the UAREP report, the Chief of the Food Additives Evaluation Branch 
paraphrased the conclusions as follows: “Although UAREP noted some discrepancies in the aspartame 
data, the  summation  of  the  team  review  of  the  UAREP  report  may  be  stated  as: There  were  no 
discrepancies  in  any  of  the  reports  that  were  of  sufficient  magnitude  or  of  a  nature  that  would 
compromise the data as originally submitted by the G.D. Searle Co. petitioner of aspartame” (Kokoski, 
1979). 
The only materials available for the current review were the original study reports, as submitted by 
Searle and reviewed in the various investigations mentioned above. Given the final outcome of these 
investigations, this review assumes that the reports are essentially reliable; however, comment is made 
upon  any  limitations,  inconsistencies  and  inaccuracies  which  are  evident  in  the  study  reports 
themselves.   Review of data on the food additive aspartame 
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SUMMARY OF DATA WHICH WILL INFORM THE RISK ASSESSMENT OF ASPARTAME 
1.  Metabolism and Pharmacokinetics 
The approved use of aspartame is as a dietary sweetener; as such, the only route by which consumers 
are exposed to this compound is via ingestion (although other routes may become relevant in the 
occupational setting). 
1.1.  Presystemic metabolism 
1.1.1.  Intestinal hydrolysis 
Aspartame  undergoes  complete  hydrolysis  in  the  gastrointestinal  (GI)  tract.  The  initial  hydrolytic 
reaction is catalysed by esterases such as chymotrypsin: 
Aspartame   methanol + aspartylphenylalanine ( AspPhe) 
Subsequent secondary cleavage is mediated by dipeptide hydrolases: 
AspPhe   aspartic acid (Asp) + phenylalanine (Phe) 
This  reaction  was  initially  assumed  to take  place in  the  brush  border  of intestinal  mucosal  cells; 
subsequent data in support of this hypothesis are summarised below. Absorption of aspartate (Asp) 
from  the  intestinal  lumen  is  thought  to  be  carrier-mediated,  and  Asp  may  share  a  carrier  with 
glutamate (Glu). The dipeptide  AspPhe could theoretically exist in the portal circulation but is not 
observed in the systemic circulation. 
Following  hydrolysis  of  the  methyl  ester  bond  of  aspartame  by  esterases,  the  resulting  dipeptide 
( AspPhe)  undergoes  hydrolysis  catalysed  by  enzymes  of  the  intestinal  mucosa.  The  potential 
involvement  of  brush  border  and  cytosolic  enzymes  has  been  investigated  using  brush  borders 
prepared from normal-appearing portions of human small intestine removed during surgery (Tobey 
and  Heizer,  1986).  Freshly  prepared  cytosol  samples  and  brush  border  proteins  solubilised  using 
papain  were  separated  on  starch  gel  chromatograms  and  by  ion  exchange  chromatography  and 
hydrolytic activity was determined by published colorimetric methods. 
When  AspPhe  hydrolytic  activity  was  determined  in  biopsy  specimens  from  7  individuals, 
approximately 60% of the activity was located in the brush border and about 40% was in the cytosol. 
The contribution of known brush border peptidases was: aminopeptidase A, 44%; membrane glycine-
leucine (Gly-Leu) peptidase, 30%; aminopeptidase N, 5%; and Zn
2+-stable Asp-Lys peptidase, 21%. 
Only one cytosolic enzyme with activity towards  AspPhe was identified, and this did not co-elute 
with any known peptidase. 
It was noted that the hydrolytic activity of 11 abnormal samples was reduced by 44% in the brush 
border and 22% for cytosol. This deficiency was similar to deficiencies in other brush border enzymes 
(47% for maltose, 65% for sucrose, 71% for lactase). 
The authors conclude that the dipeptide  AspPhe is metabolised approximately equally by three brush 
border  enzymes  (aminopeptidase  A,  membrane  Gly-Leu  peptidase  and  Zn2+-stable  Asp-Lys 
peptidase) and one (as yet unidentified) cytosolic enzyme. Hydrolysis by brush border membrane 
peptidases  may  occur  before  or  during  transport,  or  the  dipeptide  may  be  transported  intact  and 
hydrolysed in the cytosol.  
Further studies on the roles of specific peptidases in aspartame metabolism using specific inhibitors 
and purified enzyme preparations indicated that aminopeptidase A was the major activity involved in   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  19 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
the hydrolysis of aspartame,  AspPhe and  AspPheNH2 by human and pig microvillar membranes, 
while aminopeptidase W also made a contribution (Hooper, Hesp et al, 1994). Two other aspartame 
decomposition  products,  N-β-L-aspartyl-L-phenylalanine  methyl  ester  and  5-benzyl-3,6-dioxo-2-
piperazineacetic  acid  (cycloAspPhe)  were  found  to  be  resistant  to  hydrolysis  by  microvillar 
preparations and purified peptidases. 
It would appear that dipeptides containing Asp and Phe are normal constituents of human urine: N-β-
L-aspartyl-L-phenylalanine  (β-AspPhe)  has  been  identified  by  high  performance  liquid 
chromatography (HPLC) and GC-MS in urine and plasma from normal human volunteers (6M and 8F) 
whose food and beverage consumption was monitored to document the absence of aspartame from 
their diet (Burton, Schoenhard et al, 1989). The mean urinary concentration was 0.63 ± 0.14  g/g 
creatinine when averaged across two days of urine collection. Daily excretion was estimated to be 2.7 
mol/day  and  there  was  no  evidence  of  a  diurnal  rhythm.  It  is  possible  that  N-β-L-aspartyl-L-
phenylalanine is generated endogenously: it was found to be formed in vitro when Asn and Phe are 
incubated with an extract of human kidney. 
1.1.2.  Formation and disposition of diketopiperazine (DKP) 
Under certain conditions, a small fraction of aspartame may be demethylated and cyclised generating 
DKP,  which  also  forms  spontaneously  in  certain  foodstuffs  (Ranney,  Kraychy  et  al,  1972a). 
Furthermore,  studies  in  monkeys  indicate  that  DKP  can  undergo  secondary  metabolism  (Ranney, 
Kraychy  et  al,  1974)  to  form  phenylacetic  acid.  This  compound  is  subsequently  absorbed  and 
conjugated  to  Glu,  forming  phenylacetylglutamine,  a  naturally  occurring  compound  which  is 
generated  during  the  metabolism  of  Phe.  It  is  not  observed  following  direct  intravenous  (i.v.) 
administration of DKP in monkeys, suggesting that it is generated by bacterial metabolism in the gut 
rather than by endogenous metabolism following absorption.  
Further  studies  were  carried  out  to  characterise  the  biotransformation  of  DKP  by  intestinal  flora 
(Ranney, Kraychy et al, 1974). The urinary metabolites of DKP were compared in conventional rats 
with normal microflora and in germ-free rats following dosing with 
14C-Phe DKP. In the absence of 
gut flora, 89% of urinary 
14C was present as DKP itself whereas in conventional rats only 24% of the 
urinary label was in this form. When the germ-free rats were populated with microflora, the pattern of 
metabolism was converted to that seen in conventional rats. It appeared, therefore, that the primary 
metabolites of DKP (benzoic acid and hippuric acid) arose as a result of bacterial biotransformation in 
the gut. 
When 
14C-labelled DKP was administered orally to monkeys by Ranney et al. (Ranney, Kraychy et al, 
1974),  the  distribution  curve  was  biphasic,  with  an  early  phase  representing  absorption  and 
distribution among tissues while the second phase represented the appearance in the circulation of 
phenylacetylglutamine. This, the major metabolite of DKP, is the major form excreted via the urine 
following  oral  administration  of  DKP.  It  has  also  been  identified  in  human  urine  following 
administration of 
14C-DKP (Ranney, Kraychy et al, 1974). 
The metabolism of DKP was also studied in the rabbit (Stephen and Ranney, 1972). The level of 
radioactivity in plasma peaked about 2 hr after dosing and was thought to represent DKP itself. The 
recovery of labelled material in the excreta was poor (total recovery only 30%) and represented faecal 
excretion  of  DKP  together  with  an  unidentified  metabolite.  This  indicated  a  difference  in  the 
metabolism of DKP between the monkey and rabbit. 
During the initial assessment of aspartame, the FDA raised a question regarding the effect of acid 
hydrolysis on aspartame and DKP. A small study was therefore undertaken by Searle to address the 
susceptibility of aspartame and DKP to acid hydrolysis (Unattributed, N/K-c). 
14C-labelled aspartame 
n layer   Review of data on the food additive aspartame 
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chromatography. The results confirmed that both aspartame and DKP underwent complete hydrolysis 
under these conditions; however, the conditions used were extremely aggressive so the results may not 
be relevant to in vivo metabolism. 
1.1.3.  Absorption 
The absorption and metabolism of aspartame breakdown products has been studied in rats using an in 
vivo one pass in situ perfusion technique (Lipton, Li et al, 1991). In vitro studies of stability were also 
carried out in rat blood, intestinal mucosal and liver homogenates, caecal contents and cultures of 
Escherichia coli. 
In  the  perfusion  studies,  Phe  and  AspPhe  were  absorbed  more  rapidly  than  βAspPhe  and 
cycloAspPhe.  The  absorption  curves  were  non-linear,  suggesting  carrier-mediated  transport,  and 
absorption was diffusion limited at higher concentrations. In vitro studies indicated that dipeptidase 
activity towards different compounds also differed: rat liver homogenates hydrolysed  AspPhe to Asp 
and Phe but had no activity towards βAspPhe or cycloAspPhe. 
These data suggest that  AspPhe is rapidly absorbed from the gut lumen and hydrolysed within the 
enterocyte forming Asp and Phe. Any  AspPhe which escaped hydrolysis at this stage would be 
transported via the hepatic portal vein to the liver, where it would be hydrolysed. Much less βAspPhe 
and cycloAspPhe is absorbed, but any which is absorbed would be expected to enter the circulation 
intact, while any which remains in the gut would pass to the large intestine. There, a proportion will 
undergo hydrolysis to generate Asp and Phe or further metabolism by microflora while any which 
escapes these processes will be excreted in the faeces. 
An alternative pathway for aspartame hydrolysis in the GI tract involves primary hydrolysis of the 
peptide bond to release L-phenylalanine methyl ester and Asp: 
Aspartame   Asp + L-phenylalanine methyl ester 
The intestinal metabolism of aspartame and L-phenylalanine methyl ester in the gut lumen has been 
studied in a young pig model in vitro and in vivo (Burgert, Andersen et al, 1991). 
In the in vivo studies, 6 young female Chester white pigs (10-15 kg) were catheterised and had a 10-
French double lumen tube with a proximal port opening in the proximal jejunum and the distal port 30 
cm further down the intestine. At least three days were allowed for recovery after surgery. In bolus 
dosing studies, compounds (L-phenylalanine methyl ester, aspartame or L-Phe) were administered at a 
dose of 2.5 mmol/kg in a Latin square design. Portal vein and vena cava blood samples were taken 
over a period of 4 hr following dosing and each animal received all three compounds with three days 
for recovery between doses. In steady state perfusion studies, equimolar doses (25 mmoles) of each 
compound were administered directly into the jejunum and the perfusate was analysed. 
Portal blood [Phe] increased similarly after dosing with L-Phe, aspartame or L-phenylalanine methyl 
ester and no significant differences were observed with regard to AUC (area under the concentration-
time  curve).  A  similar  pattern  was  observed  in  vena  caval  blood  although  the  absolute  Phe 
concentration ([Phe]) detected and corresponding AUCs were lower. Portal blood Tyr concentration 
([Tyr]) was similar after all three compounds but lower than [Phe]. 
Portal blood Asp concentration ([Asp]) was not significantly altered after dosing with Phe but did 
increase significantly after aspartame, with a similar but less marked effect being observed in vena 
caval blood. Similarly, Glu concentration ([Glu]) increased after aspartame dosing, reflecting synthesis 
of Glu from aspartame-derived Asp.   Review of data on the food additive aspartame 
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Neither portal nor vena caval [methanol] changed after bolus administration of Phe, but values in 
portal blood peaked at 3.50 ± 0.75 mM after aspartame and 3.25 ± 0.65 mM after phenylalanine 
methyl ester, while vena caval levels peaked at 3.26 ± 0.65 mM after aspartame and 3.13 ± 0.75 mM 
after phenylalanine methyl ester. Thus the vena caval values were slightly, but not significantly, lower 
than those in the portal circulation. 
No intact aspartame, phenylalanine methyl ester or  AspPhe was detected in the circulation following 
direct bolus administration into the gut. 
In  steady  state  perfusion  studies,  direct  infusion  of  aspartame  into  the  jejunum  resulted  in  the 
appearance of methanol, Asp, Phe and  AspPhe in the perfusate. L-Phenylalanine methyl ester was 
also present at detectable levels. Perfusion with L-phenylalanine methyl ester itself resulted in the 
appearance of Phe and methanol. Perfusion with Phe resulted in rapid disappearance of Phe but not 
any of the other compounds in the perfusate. The steady state perfusion data indicate that aspartame 
was hydrolysed to methanol and  AspPhe in the intestinal lumen. The resulting  AspPhe is believed 
to be either further hydrolysed in the lumen or absorbed via peptide transport sites.  
The extent to which L-phenylalanine methyl ester might be absorbed intact from the GI tract and its 
metabolism by the intestinal mucosa and blood from different species has also been investigated in 
monkeys (Burton, Dal Monte et al, 1984). An in vivo study in two female rhesus monkeys dosed with 
L-phenylalanine methyl ester (20 mg, 1 mCi/mg) either periorally (p.o.) or intraperitoneally (i.p.) (one 
monkey each) with blood sampling over a 5 hr period after dosing revealed that small amounts of the 
parent compound (<0.1  g/ml) were detectable in portal and peripheral blood samples during the first 
1-2 hr after administration but not at later times. Only 0.2% of the administered dose reached the 
portal blood unchanged and <0.1% reached the peripheral circulation. 
If it is assumed that the absorption of intact L-phenylalanine methyl ester in humans is unlikely to be 
greater  than  that  in  monkeys,  the  results  of  this  study  suggest  that  systemic  levels  of  this 
decomposition product in the human systemic circulation is likely to be very low following aspartame 
ingestion. 
1.1.4.  Bioavailability 
It is important to note that no unchanged aspartame was identified in body fluids from any species in 
the preliminary studies undertaken by Searle (Ranney, Kraychy et al, 1972a; 1972b; Ranney, Kraychy 
et  al,  1974;  Ranney,  Oppermann  et  al,  1976;  Stephen  and  Ranney,  1972).  Furthermore,  intact 
aspartame has never subsequently been detected in the systemic circulation or in tissues. The oral 
bioavailability  of  aspartame  itself  is,  therefore,  effectively  zero.  All  the  pharmacokinetic  studies 
discussed below and in the remainder of this report therefore relate to the disposition of the individual 
components of aspartame, i.e. methanol, Asp and Phe. 
1.1.5.  Summary 
Following  oral  exposure,  aspartame  undergoes  hydrolysis  catalysed  by  esterases  and  dipeptidases 
leading to release of its individual components (Asp, Phe and methanol). This may occur either in the 
lumen of the GI tract or within intestinal mucosal cells; either way, it is the individual components 
which undergo absorption. Intact aspartame is not detected in the systemic circulation, and aspartame 
therefore has an effective oral bioavailability of zero. 
   Review of data on the food additive aspartame 
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1.2.  Disposition of the individual components of aspartame 
1.2.1.  Preliminary studies on aspartame metabolism 
A series of studies on the metabolism and pharmacokinetics of aspartame was summarised in a series 
of compendia issued by Searle in the early 1970s (Ranney, Kraychy et al, 1972a; 1972b; Ranney, 
Kraychy et al, 1974; Stephen and Ranney, 1972) and summarised in a compilation paper (Ranney, 
Oppermann et al, 1976). The contents of these compendia are summarised below together with the 
results of subsequent studies on the disposition of aspartame and its components. 
1.2.2.  Fate of the methyl group 
Preliminary studies in the rat indicated no difference in the metabolism of the 
14C-Me  moiety of 
aspartame and 
14C-methanol in the rat. Briefly, aspartame was hydrolysed by esterases in the intestine, 
releasing methanol which was absorbed and entered the one-carbon pool in the body. The major 
fraction of excreted 
14C was in expired air, and the rate of excretion and fraction in expired air at given 
time points reflected each other. In both cases, plasma levels peaked at t = 3h and declined thereafter. 
In a study of the disposition of radiolabelled aspartame and its individual components (Oppermann, 
Muldoon et al, 1973b; Ranney, Kraychy et al, 1972a; 1972b), young female monkeys were dosed with 
14C-labelled compounds (68  moles/kg/10-50  Ci/dose p.o.). On the day of dosing with radiolabelled 
compounds, expired CO2, plasma, urine and faeces were collected. The results obtained indicated that 
14C from 
14C-methanol or 
14C-methyl-aspartame was converted to CO2 to the same extent, but 
14CO2 
appeared in the breath more rapidly (within 1 hr) after the administration of methanol itself than after 
oral dosing with aspartame. Plasma levels of 
14C following administration of 
14C-methanol or 
14C-
methyl-aspartame  remained  low,  but  were  slow  to  disappear.  Following  administration  of 
14C-
methylaspartame, approximately 70% of the label was excreted in expired CO2 while the remainder 
(~30%) was incorporated into the one-carbon metabolic pool. 
Overall, in the monkey, differences were noted at early time points and 
14CO2 appeared more slowly 
following administration of 14C-methyl-aspartame than 
14C-methanol, but the total amount excreted 
after 8 hr was similar. Plasma levels also increased more slowly after 
14C-methyl-aspartame than 
14C-
methanol  but  the  rates  of  elimination  from  plasma  were  similar.  This  pattern  was  attributed  to 
absorption of methanol itself in the stomach, whereas aspartame has to pass to the small intestine and 
be hydrolysed before its methyl component can be absorbed as methanol. 
In combination, these results indicated that rats and monkeys handled the methyl group of aspartame 
in a qualitatively similar way and in the same way as they handled the methyl groups of methylated 
components of the diet. The main species difference observed was that hydrolysis was much slower in 
monkeys than in rats. Urine and faeces were minor routes of excretion in both rats and monkeys. 
In  1976,  Ranney  et  al  (Ranney  and  McKeown,  1976)  summarised  the  evidence  regarding  the 
metabolism of the methyl moiety of aspartame as follows: 
The methyl group of aspartame undergoes stepwise metabolism via methanol to CO2; it may also 
undergo  alternative  pathways  via  the  one  carbon  metabolic  pool.  Methanol  is  also  available  for 
metabolism from endogenous S-adenosylmethionine. 
The main enzyme involved is chymotrypsin, which is both an esterase and a proteolytic enzyme. 
Methanol undergoes species-specific first pass metabolism in the liver. In the rat the main enzyme 
system  involved  is  the  catalase:peroxidase  system  whereas  in  primates  and  humans  alcohol 
dehydrogenase plays a more important role.   Review of data on the food additive aspartame 
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The resulting formaldehyde is further metabolised to formic acid by a glutathione (GSH) and NAD-
dependent dehydrogenase. The activity of this enzyme in human liver is several-fold higher than that 
in rat. Alternative pathways include alcohol dehydrogenase and unclassified pyruvate:formaldehyde 
ligase. 
The major metabolic route for formic acid is oxidation to CO2 catalysed by the catalase:peroxidase 
system; alternatively it can enter the one carbon metabolic pool via formylation of tetrahydrofolate 
(THF).  Formate  can  also  be  incorporated  into  body  constituents  following  activation  by 
formyltetrahydrofolate synthetase or direct reaction of formaldehyde with tetrahydrofolic acid. 
Subsequent  evidence  in  support  of  this  model  was  provided  by  a  study  of  serum  methanol 
concentrations in male Charles River CD-COBS rats given aspartame at 34 mg/kg and in four healthy 
male humans given a fixed dose of 500 mg in tap water (equivalent to 6.0 – 8.7 mg/kg) (Davoli, 
Cappellini et al, 1986). In the human volunteer study, alcohol was avoided for 24 hr and no fruit, 
vegetables or fruit juices were consumed for 18 hr before dosing. Methanol was analysed by GC—MS 
with selected ion monitoring, taking care to avoid contamination and using tetra-
2H-methanol as an 
internal standard. 
In rats, methanol concentrations above control values were observed in aspartame-dosed rats for up to 
3 hr after dosing but methanol returned to background levels by t = 4 hr. Marked intra-individual 
variation was observed in humans; on average, there was a slight increase in methanol concentration 
(<2 fold) 30-60 min after dosing, but one individual had unusually high basal levels which increased 
further (though still less than 2 fold) after dosing. In general, Tmax was ~ 45 min and Cmax was ~ 0.35 
mg/dl in both rats and humans. 
The  conclusion  drawn  was  that  the  increase  in  methanol  concentrations  due  to  consumption  of 
aspartame was within the range of interindividual variation in endogenous methanol levels and that, 
when consumption is spread out over a whole day, such an increase is likely to be undetectable. 
Concern has been expressed regarding the possibility that aspartame-derived formaldehyde could bind 
to tissue components, leading to cytotoxicity or DNA damage. However, the evidence for this is very 
limited. Studies have been undertaken using male Wister rats dosed with 
14C-methyl-aspartame (4.5 
MBq/rat, in a total of 68  mol/kg aspartame) (Trocho, Pardo et al, 1998). The tissues analysed were 
plasma,  liver,  kidneys,  brain,  cornea,  retina,  hind  leg  striated  muscle,  epididymal  fat  pads  and 
interscapular brown adipose tissue. Radioactivity was detected in the plasma, liver and kidney up to 24 
hr after dosing and was mostly protein-bound (98% in plasma; 75% in liver); however, the use of thin 
layer  chromatography  in  an  attempt  to  characterise  the  adducts  formed  generated  chromatograms 
which are very difficult to interpret, so this study does not provide definitive evidence regarding the 
possibility  of  tissue  binding  by  aspartame-derived  formaldehyde.  Furthermore,  the  levels  of 
radioactivity found in tissue macromolecules could have been accounted for in terms of metabolism 
via the one-carbon pool leading to methylation of DNA, RNA and proteins, as pointed out by Tephly 
(Tephly, 1999). 
In humans, measurement of plasma formate levels in 29 samples from healthy subjects did not indicate 
that the levels reached in response to aspartame would be such as to cause any concern regarding 
potential  toxicity  (Shahangian,  Ash  et  al,  1984).  These  data  were  reported  in  a  brief  item  of 
correspondence so cannot be described or evaluated in full. 
A recent study reported formaldehyde–serum albumin adducts detected immunochemically in Italian 
blood  donors  and  related  to  exposures  determined  by  questionnaire  (Gilli,  Schiliro  et  al,  2008). 
Aspartame intake was estimated from recalled intake of diet foods, while formaldehyde from cigarette 
smoke was calculated from the number of cigarettes smoked per day, environmental exposure was 
estimated on basis of urban or rural residence and occupational exposure was categorised on the basis   Review of data on the food additive aspartame 
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of the nature of employment. No significant association was identified between immunochemically-
detected formaldehyde-serum albumin adducts and estimated aspartame intake whereas significant 
associations were found for cigarette smoking and occupational exposure. The authors conclude that 
low (population) dietary intake of aspartame does not influence the formation of formaldehyde-serum 
albumin adducts. 
Commentators  from  scientific,  medical  and  lay  backgrounds  have  raised  concerns  that  aspartame 
could exert severe toxicity mediated by the methanol and formaldehyde which are released during its 
metabolism  (see,  for  example,  (Monte,  2010)).  This  has  always  been  vigorously  refuted  by  the 
industry, whose position is that “there is no responsible scientific evidence that aspartame ingestion 
can result in methanol toxicity” (Sturtevant, 1985). A review of the toxicity of methanol is beyond the 
scope of this review, but the reader is referred to reviews of the subject undertaken by various national 
authorities including the Committee on Toxicity fo Chemicals in Food, Consumer Products and the 
Environment (COT), US Environmental Protection Agency (EPA) and National Toxicology Program 
Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR) (COT, 2010a; 2010b; 
2010c; 2011b; EPA, 2011; NTP-CERHR, 2003). Expert groups have concluded that exposure from 
methanol from currently permitted levels of aspartame would not be expected to result in adverse 
effects (COT, 2011b; 2011a; EPA, 2011; Magnuson, Burdock et al, 2007; NTP-CERHR, 2003) 
1.2.3.  Fate of the aspartate moiety 
In preliminary in vivo studies in male Charles River rats, male HAM/ICR-derived Charles River CD-1 
mice, female New Zealand White rabbits, female beagle dogs, young female rhesus monkeys and 
human volunteers the metabolism of aspartame labelled with 
14C in each of its moiety was compared 
with  that  of  the 
14C-labelled  free  components.  Expired  air  was  collected  using  metabolism  cages 
(mice,  rats  and  rabbits)  or  helmets/masks  (dogs,  monkeys)  and  blood  samples  were  taken  by 
indwelling  catheters  or  venepuncture.  Radioactive 
14C  was  determined  by  liquid  scintillation 
spectrometry. 
When  young  female  monkeys  were  dosed  with 
14C-labelled  compounds  (68  moles/kg/10-50 
Ci/dose p.o.) (Oppermann, Muldoon et al, 1973b; Ranney, Kraychy et al, 1972a; 1972b), the results 
obtained indicated that the total excretion of 
14C after dosing with free  
14C-Asp or 
14C-Asp-aspartame 
was  similar,  although  there  was  a  slight  lag  in  the  expiration  of 




14C peaked after 1 hr, and excretion via the urine was low (4-6%). 
The plasma 
14C elimination curves were biphasic. The major pathway of metabolism seemed to be 
formation of oxalic acid by transamination followed by excretion as CO2. This accounted for about 
75% of the label, while the remainder was cleared much more slowly, consistent with incorporation 
into proteins. 
Thus, when monkeys were dosed orally with aspartame radiolabelled in the Asp moiety, the Asp 
released during hydrolysis was metabolised in the same way as free L-Asp. Aspartame was hydrolysed 
rapidly in the gut and the resulting Asp was metabolised in the same way as the free amino acid, being 
transaminated to form oxaloacetic acid which enters the TCA cycle and is ultimately expired as CO2. 
This pathway accounted for most of the label, while the remainder was incorporated into body protein.  
In  1978,  Ranney  et  al  (Ranney,  McKeown  et  al,  1978)  summarised  the  evidence  regarding  the 
metabolism of Asp derived from aspartame as follows: 
14C from 
14C-Asp-aspartame enters respiratory CO2 to the same extent as from Asp itself, suggesting 
that aspartame is rapidly and completely cleaved forming free Asp which is subsequently metabolised 
in the same way as that from free Asp itself.    Review of data on the food additive aspartame 
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The major products which reach the portal circulation are the result of oxidation and transamination 
reactions  in  mucosal  cells.  These  involve  aspartic  acid-4-decarboxylase  and  alanine:2-oxoacid 
aminotransferase and lead to the release of Ala, at least in vitro. 
The subsequent metabolic reactions of Asp and Ala are: 
Oxidation to CO2 
Incorporation into proteins 
Formation of arginine and asparagine 
Synthesis of uridine monophosphate 
Synthesis of N-acetylaspartate (in the brain) 
The authors conclude that the Asp moiety of aspartame is metabolised in the same way as dietary Asp 
and is mainly used for energy generation through oxidation in the TCA cycle. 
1.2.4.  Fate of the phenylalanine moiety 
In  preliminary  studies,  young  adult  male  HAM/ICR-derived  Charles  River  CD-1  mice  were  pre-
treated for 6 days with aspartame (20 mg/kg/day
2 p.o. in 0.05M phosphate buffer, pH 7.4) then given 
14C-Phe-labelled aspartame on day 7. As in other studies, the results indicated that aspartame was 
hydrolysed in the gut before absorption. No intact aspartame was detected in the plasma over 24 hr 
following dosing; the major labelled fraction observed in plasma represented radiolabelled Phe or Tyr 
incorporated into plasma proteins (Stephen and Ranney, 1972). 
Young  adult  female  New  Zealand  White  rabbits  were  pre-treated  for  5  days  with  aspartame  (20 
mg/kg/day p.o. in 0.05M phosphate buffer, pH 7.4) then given 
14C-Phe-labelled aspartame on day 6 
(Stephen and Ranney, 1972). Again, aspartame was hydrolysed in the gut prior to absorption and 
14C 
was identified as Phe and Tyr incorporated into plasma proteins. The pharmacokinetics observed were 
biphasic:  there  was  rapid  accumulation  of  labelled  peptides  with  a  short  half-life,  followed  by 
incorporation into a fraction with a longer half-life. Conversion of the label to 
14CO2 was slower than 
in other species, peaking at 5-7 h after dosing compared with 1-3 hr in the monkey. These results were 
interpreted as indicating that the qualitative pattern of metabolism was similar to that in other species 
but quantitatively different in terms of rates. 
Similar results were obtained in dogs (Ranney, Kraychy et al, 1972b). When aspartame (68  moles/kg 
labelled with 
14C, 75 Ci) was administered orally to dogs pre-treated with unlabelled aspartame for 5 
days, aspartame was hydrolysed rapidly in the gut and the Phe moiety was handled in the same way as 
the dietary amino acid. The label appeared in the plasma as 
14C-Phe and 
14C-Tyr. The time taken for 
intestinal hydrolysis meant that the release of 
14CO2 from aspartame was slower than from Phe itself. 
Plasma 
14C peaked after 5 hr in both aspartame- and Phe-treated dogs; the half lives of the label in 
plasma were 12.1 days when the label was in the Asp moiety and 10.8 days when it was in the Phe 
moiety. This was consistent with incorporation of the label into plasma proteins, as confirmed by 
electrophoresis, in which all plasma protein fractions from pre-albumin to  -globulin were labelled. 
In the study of the disposition of radiolabelled aspartame and its individual components mentioned 
previously (Oppermann, Muldoon et al, 1973b; Ranney, Kraychy et al, 1972a; 1972b), young female 
                                                 
2 For consistency, all daily doses of aspartame or DKP administered to laboratory animals are expressed in mg/kg/day 
throughout this report.   Review of data on the food additive aspartame 
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monkeys were dosed with 
14C-labelled compounds (68  moles/kg/10-50  Ci/dose p.o.). The results 
obtained indicated that, following administration of free 
14C-Phe or 
14C-Phe-aspartame, the pattern of 
excretion  of 
14C  was  similar.  Plasma  levels  of 
14C  peaked  after  about  5  hr  in  both  cases  then 
disappeared  slowly,  consistent  with  incorporation  into  proteins.  This  suggested  that  Phe  from 
aspartame was metabolised in the same way as the free amino acid. 
In a follow up study designed to pursue the question of how the Phe moiety was handled, the effects of 
repeated  ingestion  of  aspartame  on  Phe  metabolism  was  considered  (Oppermann,  Muldoon et  al, 
1973a). Nine female rhesus monkeys were treated with aspartame (0, 15 or 60 mg/kg/day mixed with 
peanut  butter  on  a  slice  of  bread)  for  10  days.  They  were  then  dosed  with 
14C-Phe-aspartame 
(68 moles/kg, 48.3  Ci i.v.) over 1 minute. Following a 30 minute period of distribution, 
14C levels in 
plasma increased to a plateau at 3-7 hr, presumably due to incorporation into proteins. Incorporation of 
14C into proteins started within 1 hr of dosing, reached a plateau at 3 hr and remained at that level until 
24 hr after dosing (the last time point sampled).  Plasma 
14C-Phe levels declined to 1% of their initial 
values  after  3  hr,  with  corresponding  appearance  and  disappearance  of  tyrosine.  Overall,  Phe 
metabolism was not significantly affected by pre-treatment with aspartame. Furthermore, expiration of 
14CO2,  conversion  of  Phe  to  Tyr  and  incorporation  into  proteins  were  unaffected  following  pre-
treatment with aspartame. Ingestion of aspartame (0, 15 or 60 mg/kg/day mixed into peanut butter and 
offered on a slice of bread) over a 10 day period did not affect the metabolism of Phe (administered as 
14C-L-Phe, 68  moles/kg labelled with 
14C, 48.3  Ci i.v.) (Ranney, Kraychy et al, 1972b). 
When the metabolism of 
14C-Phe labelled aspartame in humans and monkeys was compared (Ranney, 
Kraychy et al, 1972a), the pattern of metabolism observed was very similar. In the human volunteer 
studies, three healthy males were treated orally with 14-C Phe labelled aspartame (500 mg, 18.7  Ci in 
120 ml water) and blood and urine were collected. Maximal absorption of the label occurred 4-8 hr 
after dosing, while the initial rate of disappearance from the circulation was also similar. The pattern 
of labelled metabolites in plasma and urine was also similar, the fraction appearing in the urine being 
very small. The authors concluded that monkeys and humans metabolise aspartame very similarly, the 
various moieties being handled as if they were natural components of the diet. Rapid absorption of 
14C-Phe labelled aspartame occurred in humans, half Cmax being achieved within 15 minutes of dosing, 
indicating rapid intestinal hydrolysis. 
When the disposition of 
14C-Phe labelled aspartame was compared among species (Ranney, Kraychy 
et al, 1972a), the pattern observed was similar. The level of 
14C in plasma peaked after 5-7 hr in 
humans, dogs and monkeys and appearance and disappearance rates were similar in all three species. 
Early after administration of 
14C-Phe-aspartame, the principal plasma constituents found to be labelled 
were Phe and Tyr but after 2-3 hr the vast majority (86-94%) of the label was associated with complex 
Phe-containing substances, while only 2-3% of the label was detectable as free amino acids (with a 
thin layer chromatography profile consistent with Phe and Tyr). Excretion as 
14CO2 was 10-24% and 
excretion via urine and faeces was ≤ 6%. 
Thus, when aspartame labelled in the Phe moiety was studied in the dog, monkey and man, the pattern 
of metabolism followed that of free L-Phe. Following hydrolysis in the intestine, 50% of the label was 
absorbed within 4 hr. The label became localised in the form of proteins, peptides and free amino 
acids in the plasma. It was, however, found that conversion of Phe from aspartame to these entities 
was  slower  than  if  free  L-Phe  was  administered  orally  because  of  the  requirement  for  intestinal 
hydrolysis prior to absorption. Excretion as 
14CO2 was much lower than for the other two moieties. 
1.2.5.  Summary 
Two  of  the  three  components  of  aspartame  (Asp  and  methanol)  are  cleared  rapidly  from  the 
circulation.  Under  some  circumstances  (e.g.  when  aspartame  is  ingested  in  the  absence  of 
carbohydrates)  Asp  is  briefly  measurable  in  the  plasma  following  ingestion,  but  under  normal   Review of data on the food additive aspartame 
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conditions of use Asp is rapidly metabolised and excreted predominantly in expired CO2, although a 
small proportion may be incorporated into proteins. Even after ingestion of large doses of aspartame, 
blood methanol levels usually remain below or very close to the limits of detection.  
The effective pharmacokinetics of aspartame are therefore those of its Phe component. Plasma [Phe] 
usually peaks about 60 min after ingestion and is then cleared from the circulation over a period of 
about 2-3 hr depending on the dosing regiman used. If repeated high doses are administered (e.g. at 2 
hr intervals), Phe may accumulate and reach a plateau after about 6 hr; however, levels invariably 
return  to  background  following  overnight  abstinence.  The  ultimate  fate  of the  Phe  component  of 
aspartame is incorporation into proteins. 
1.3.  Pharmacokinetics and effects on plasma amino acids 
The studies summarised above indicate that the only component of aspartame which persists in the 
circulation following oral administration is the Phe moiety. Changes in plasma [Phe] have knock-on 
effects on other amino acids in the circulation. These changes may be marked, especially in response 
to sudden increases in plasma [Phe] following an oral bolus dose of aspartame. Many studies have 
therefore been conducted to clarify the pharmacokinetics of Phe following oral administration; these 
are summarised below. 
1.3.1.  Pharmacokinetics of Phe and Tyr in experimental animals 
The pharmacokinetics of Phe and Tyr have been studied in male Crl:CD
® (SD)BR rats and Crl:CD-1
® 
(ICR)BR mice fasted overnight prior to oral administration of aspartame (Hjelle, Dudley et al, 1992). 
The doses used were 0, 50, 100, 200, 500 and 1000 mg/kg p.o. (rats, n= 5 per group) and 0, 100, 200, 
500,  1000  and  2000  mg/kg  p.o  (mice,  n=35  per  group)  in  0.5%  aqueous  methylcellulose/0.1% 
polysorbate 80. Terminal blood samples were taken from mice at various time points up to 8hr, while 
rat blood was taken by retro-orbital sampling under examine anaesthesia. 
Maximal plasma [Phe] and [Tyr] were observed within two hours after dosing and returned to baseline 
within 4-8 hr regardless of dose. The mean Cmax values for Phe ranged from 73.8 – 1161  M
3 in rats 
and 78.6 – 1967  M in mice, while those for Tyr ranged from 91.6 - 502  M in rats and 89.2 - 792 
M in mice. AUC and Cmax values were linear with dose in both species. 
Changes in the relative concentrations of large neutral amino acids (LNAAs) are usually reported in 
terms of LNAA ratios. For each amino acid, the denominator of the LNAA ratio is the sum of the 
concentrations of Tyr, Phe, Leu, tryptophan (Trp), isoleucine (Ile), valine (Val), and methionine (Met), 
minus the amino acid in the numerator (Wurtman, Wurtman et al, 2003). Thus, for example, the 
Phe/LNAA ratio is calculated as: 
[Phe] 
_______________________________________________________ 
[Trp] + [Tyr] + [Leu] + [Ile] + [Val] + [Met] 
Rodents require 2 – 6 times higher doses of aspartame than humans to generate the same increases in 
Phe/LNAA ratio: in this study, Phe/LNAA ratios ranged from 0.112 – 1.117 in rats and 0.121 - 1769 
in mice. The maximal plasma [Phe] in rat and mouse at 100 and 200 mg/kg were approximately 50-
80% of those reported in humans at the same doses. 
                                                 
3 For consistency, all plasma amino acid concentrations have been converted to  M throughout this report. Concentrations of 
other analytes have been left in the units reported by the original investigators.   Review of data on the food additive aspartame 
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Role of hepatic phenylalanine hydroxylase 
The difference in hepatic phenylalanine hydroxylase activity between rodents and humans should 
always  be  taken  into  account  when  considering  the  results  of  animal  studies,  especially  those 
involving acute dosing. The much higher activity seen in rodent liver means that plasma Phe, whether 
from aspartame or food or administered directly, is processed to Tyr much more rapidly in rodents 
than humans, thus significantly reducing the relative exposure of rodents to Phe itself. Indeed, it has 
been calculated that rodents need 60 times as much aspartame, on a mg/kg basis, as humans to obtain 
comparable  elevations  in  Phe  with  respect  to  tyrosine  (Wurtman  and  Maher,  1987).  This  should 
always be taken into account when carrying out dose extrapolations for aspartame. 
Preliminary studies conducted by Searle addressed the possible modulatory effects of aspartame on 
hepatic phenylalanine hydroxylase activity. When male Charles River rats were treated with either 
aspartame (0.15% or 1.5%) or 0.85% L-Phe (equimolar with the higher dose) via the diet for 2, 4 or 8 
weeks (Ranney, Kraychy et al, 1972b), the lower dose (0.15%) had no effect on hepatic phenylalanine 
hydroxylase or  plasma [Phe]. However, hepatic activity was suppressed and [Phe] was increased by 
the higher dose of aspartame (1.5%) or an equimolar dose of L-Phe. The effect on hepatic enzyme 
activity was more sensitive to suppression than the elevation of plasma Phe levels, indicating a role for 
additional homeostatic mechanisms controlling plasma Phe levels. 
Potential effects of aspartame on the circadian rhythm of hepatic phenylalanine hydroxylase were also 
studied in the rat. Male Charles River rats were treated with either 1.5% aspartame or 0.85% L-Phe via 
the  diet  for  2  weeks  (Ranney,  Kraychy  et  al,  1974).  This  treatment  did  not  affect  the  circadian 
fluctuation  of  hepatic  phenylalanine  hydroxylase  activity,  although  both  supplements  suppressed 
overall  activity,  as  in  the  study  mentioned  above.  There  were,  however,  no  significant  circadian 
changes in plasma Phe and Tyr concentrations. 
Effects of DKP on the pharmacokinetics of aspartame 
Small quantities (usually <2%) of the aspartame breakdown product DKP are found in most batches of 
aspartame, and DKP may also be generated during metabolism of aspartame by the gut microflora. In 
order  to  verify  that  the  presence  of  DKP  did  not  affect  the  disposition  of  aspartame,  the 
pharmacokinetics of a 3:1 mixture of DKP and aspartame were examined over a 24 hr period in male 
Sprague-Dawley derived Charles River CD rats given 5 daily doses of 27 mg/kg p.o. in 0.05 M 
phosphate buffer pH 7.4, followed by the same mixture labelled with 
14C (5.5  Ci  in the Phe moiety) 
(Stephen and Ranney, 1972). Co-administration of DKP under these conditions had little effect on the 
metabolism of aspartame and the derived pharmacokinetic curves were very similar to those in studies 
using aspartame alone: plasma radioactivity peaked at t = 3 hr and the major fraction of 
14C was found 
in Phe and Tyr which were incorporated into plasma proteins. Excretion via CO2 was also similar to 
that observed after administering aspartame alone. The authors concluded that the presence of DKP 
does not significantly alter the metabolism of aspartame in the rat. 
Pharmacokinetics in pregnant females 
Rabbits were used in preliminary studies of the effects of dietary aspartame on maternal and foetal Phe 
metabolism (Ranney, Kraychy et al, 1974; Ranney, Mares et al, 1975). Aspartame was administered 
to pregnant rabbits (6% in the diet, giving an actual intake of ~1,600 mg/kg/day, on post coital day 
(pcd) 6-16) and sacrifices were carried out on pcds 16 and 20. Analysis was carried out on maternal 
and foetal blood and whole foetal homogenates. Maternal plasma [Phe] and [Tyr] increased on pcd 9, 
but both amino acids returned to normal by pcd 20. There was a greater increase  in plasma Tyr 
compared with Phe at pcd 20, meaning that the plasma Phe/Tyr ratio dropped significantly. This may 
be linked to the fact that the increased plasma [Phe] in this study did not seem to be sufficient to affect 
hepatic  phenylalanine  hydroxylase activity  (see  above).  Amniotic  fluid  amino  acid  concentrations 
were higher in treated than control animals, consistent with an excretory function, but foetal/maternal   Review of data on the food additive aspartame 
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aromatic amino acid ratios on pcd 20did not differ significantly between controls and treated rabbits 
(1.40 in treated animals vs. 1.58 in controls for Phe and 2.06 in treated animals vs. 2.29 in controls for 
Tyr). The results of this study indicated that plasma aromatic amino acid levels in pregnant rabbits 
were directly related to dietary intakes. Furthermore, treatment of pregnant rabbits with a high dose of 
aspartame via the diet did not affect transport across the placental barrier, since foetal/maternal ratios 
amino acid ratios were unaffected.  
1.3.2.  Effects on xenobiotic metabolising enzymes 
Preliminary studies conducted by Searle (Ranney, Kraychy et al, 1972a) indicated that aspartame 
administered to male Charles River rats (2,000 – 4,000 mg/kg p.o. as an aqueous suspension) had no 
acute effect on cytochrome P450 (CYP)-mediated xenobiotic metabolism, as measured in terms of 
aminopyrine  N-demethylation,  p-nitroanisole  N-demethylation,  hexobarbital  sleeping  time  or 
xoxazolamine paralysis time. 
The limited subsequent data available are in agreement with these observations. In  a preliminary 
study, no significant changes were observed in hepatic CYPs, UDP-glucuronyl transferases (UGTs) or 
glutathione S-transferases (GSTs) in male Wistar rats treated with aspartame (40 or 4000 mg/kg/day in 
the diet) for 45 or 90 days (Tutelyan, Gapparov et al, 1989). The only marked change noted was a 
35% increase in UGT activity at 45 days, but activity had reverted to normal by day 90. A follow up 
study (Tutelyan, Kravchenko et al, 1990) had similar results: following the same dosing schedule, 
measurement  of  GST  activity,  CYP  concentration,  7-ethoxycoumarin  O-deethylase,  microsomal 
carboxyl esterase, epoxide hydrolase, p-nitrophenol UGT and 4-hydroxybiphenyl UGT indicated only 
slight increases in epoxide hydrolase, carboxyl esterase and p-nitrophenol UGT activity after 45 days’ 
dosing at 4000 mg/kg (but not at 40 mg/kg); again all activities had returned to normal by day 90. 
A single study addressing changes in brain xenobiotic metabolism in response to aspartame (Vences-
Mejia, Labra-Ruiz et al, 2006) has been published. Male Wistar rats were dosed with aspartame (75 or 
125 mg/kg/day p.o. in distilled water) daily for 30 days. Individual hepatic microsomal samples were 
prepared  together  with  pooled  microsomal  samples from  cerebrum  and  cerebellum.  The activities 
measured were: ethoxyresorufin O-deethylase, methoxyresorufin O-demethylase, pentoxyresorufin O-
depentylase,  benzyloxyresorufin  O-debenzylase,  4-nitrophenol  hydroxylase  and  erythromycin-N-
demethylase. Western immunoblot analysis of CYPs 1A1, 1A2, 2B, 3A2 and 2E1 was also performed. 
No  changes  in  hepatic  activities  or  immunodetectable  proteins  were  identified.  The  only 
immunodetectable CYP in control brain was CYP2E1, and the expression of this isoform was not 
affected by aspartame. Faint immunodetectable bands corresponding to CYP2B1 and CYP3A2 were 
observed in cerebral samples at 125 but not 75 mg/kg, while bands corresponding to CYPs 1A1, 1A2, 
2B, 3A2 were detected in cerebellar microsomes at both doses of aspartame. Increases in all the 
enzyme activities determined were reported at both doses and in both cerebrum and cerebellum. These 
results should, however, be interpreted with caution: the analysis of CYP expression and activity in 
brain  samples  is  notoriously  difficult,  and  the  fact  that  pooled  microsomal  samples  were  used 
(certainly for the Western blots, and probably for the enzyme activity measurements since individual 
rat brain samples would not provide sufficient microsomes for activity measurements on individual 
brain regions) means that these results may not be reliable. 
In conclusion, treatment with aspartame has few or no effects on hepatic xenobiotic metabolism, at 
least in rats, and probably does not affect activities in the brain to any marked extent. 
1.3.3.  Pharmacokinetics of single doses of aspartame in humans 
The use of aspartame as an elective component of the diet in humans made it possible to study the 
pharmacokinetics and disposition of this compound in human volunteers even in the early stages of its   Review of data on the food additive aspartame 
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development.  The  results  of  studies  in  healthy  individuals  are  summarised  here  while  studies  in 
potentially vulnerable groups are discussed later in this review (Section 2.7). 
Effect of aspartame loading on plasma amino acid levels in adults 
The effects on plasma and erythrocyte amino acids of a dose of aspartame set to represent the 99
th 
percentile of predicted U.S. daily intake as a single dose (34 mg/kg), as well as those of an equimolar 
dose of free Asp (13 mg/kg), were studied in normal adult volunteers (Stegink, Filer et al, 1977a; 
Stegink, Filer et al, 1977b). This comparison was carried out because of a lack of data regarding the 
effects of aspartame loading on plasma [Asp]. The subjects involved were healthy volunteers (6M/6F). 
Test materials were administered to overnight fasted subjects in 300 ml orange juice according to a 
randomised cross-over design and blood was sampled frequently for 8 hr with a final sample at t = 24 
hr. The results of this study were as follows: 
Neither treatment affected plasma [Asp], [Asn] or [Gln] at any time point tested, while there was a 
slight increase in plasma [Glu] although the concentrations remained within the normal range. 
Plasma [Phe] decreased slightly after dosing with Asp, whereas it increased from fasting levels (49 ± 
10  M)  to  the  normal  postprandial  range  (107  ±  19  M)  after  the  aspartame  load
4.  This  was 
companied by a smaller increase in plasma [Tyr], although this remained within the fasting range (60 
± 20  M). Plasma [Phe] returned to normal by the 4 hr time point. 
There were increases in plasma alanine (Ala) and proline (Pro) with both aspartame and Asp; however 
this also occurred with orange juice alone or orange juice plus lactose, suggesting that it was either due 
to stress or was triggered by components of the vehicle.
 A subsequent study (Stegink, Brummel et al, 
1990) suggested that the sucrose in orange juice may have caused these effects, as well as changes in 
branched  chain  amino  acids,  independent  of  those  due  to  aspartame.  More  importantly,  co-
administration of sucrose seemed to suppress a peak of Asp which is detectable within about 30 min of 
ingestion when aspartame is administered in the absence of carbohydrate. Most recent studies have 
therefore tended to avoid the use of orange juice, and studies which do use this vehicle should be 
interpreted in the light of possible vehicle effects. 
All other amino acid levels either remained the same or decreased in response to dosing and the 
concentrations of amino acids in erythrocytes reflected those in plasma. 
The observation that plasma [Phe] returned to normal levels within 4 hr of an acute dose is consistent 
with the finding that plasma levels are not elevated in chronic studies in which the intake of aspartame 
is spread out over an entire day.  
The conclusion drawn from this study was that no risk arises from aspartame ingestion at 34 mg/kg 
body  weight.  Since  plasma  [Asp]  was  unchanged,  the  study  was  taken  to  provide  reassurance 
regarding the suggested possibility of Asp-induced neurotoxicity in infants as a result of aspartame 
exposure  (see  Section  2.2.3).  Plasma  [Phe]  remained  within  the  normal  postprandial  range  at  all 
concentrations tested. 
The samples from this study were further analysed in a subsequent study addressing possible effects 
on blood methanol levels (Stegink, Brummel et al, 1981). Blood methanol was below the limit of 
detection  (0.4  mg/dl)  in  all  the  samples,  indicating  that  methanol  does  not  accumulate  following 
ingestion of the 99
th percentile daily dose of aspartame, even when taken as a single bolus dose. 
                                                 
4 N.B. These values differ slightly between the study report and the published version of the study; the values quoted are 
taken from the published version Stegink, L. D., Filer, L. J., Jr. and Baker, G. L. (1977b). "Effect of aspartame and 
aspartate loading upon plasma and erythrocyte free amino acid levels in normal adult volunteers." J Nutr 107(10): 1837-
1845.   Review of data on the food additive aspartame 
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Effects of “abuse doses” of aspartame in humans 
A follow-up study (published as two papers, (Stegink, Brummel et al, 1981; Stegink, Filer et al, 
1981b)) was carried out to investigate the effects of very high doses of aspartame (100, 150 or 200 
mg/kg)  on  plasma  and  erythrocyte  amino  acid  levels  and  methanol  levels  in  healthy  volunteers. 
Aspartame was administered in 500 ml orange juice after an overnight fast. Alcohol was avoided for 
24 hr before and after dosing. Blood was sampled frequently for 8 hr with a final sample at t = 24 hr.  
The results indicated that plasma [Asp] increased slightly, but significantly, after each dose (p < 0.05). 
Plasma [Phe] increased significantly over fasting concentrations from 15 min to 6 hr after each dose ( 
p ≤ 0.01) and the increases observed were proportional to dose. The mean peak Phe levels observed in 
plasma were 203 ± 20.3  M at 100 mg/kg, 351 ± 113  M at 150 mg/kg and 487 ± 155  M at 200 
mg/kg.  These  values  are  above  normal  postprandial  ranges  but  below  the  values  associated  with 
toxicity.  The  highest  plasma  value  of  [Phe]  observed  was  744  M  after  a  dose  of  200  mg/kg 
aspartame.  
At these doses, measurable increases in blood methanol were observed from 15 min to 7 hr after 
dosing.  The  increases  in  blood  [methanol]  were  proportional  to  dose,  as  were  the  AUCs.  Peak 
methanol concentrations observed in plasma were 1.27 ± 0.48 mg/dl at 100 mg/kg, 2.14 ± 0.35 mg/dl 
at 150 mg/kg and 2 58 ± 0.78 mg/dl at 200 mg/kg. At a dose of 100 mg/kg, blood [methanol] returned 
to baseline after 8 hr; methanol was still detectable at this time point at 150 and 200 mg/kg but had 
returned to baseline by t = 24 hr. 
Analysis of blood and urinary formate indicated that, at a dose of 200 mg/kg, urinary (but not blood) 
[formate] was increased significantly 0-4 hr and 4-8 hr after dosing, although urinary formate returned 
to preloading values by t = 24 hr. 
The authors note that blood methanol concentrations considerably higher than those found in this 
study  are  required  to  produce  toxic  concentrations  of  formate  and  that  the  results  obtained  are 
consistent  with  those  of  Frey  (Frey,  1976),  who  found  that  blood  methanol  following  aspartame 
administration was below the limit of detection, which in his study was 3 mg/dl. 
In a further follow up study of the same samples (Cho, Coon et al, 1987), a HPLC-based analytical 
method was used to quantitate DKP and aspartame in plasma and urine. The samples had been taken 
prior to the approval of aspartame for marketing, so there was no other source of aspartame or DKP in 
these samples apart from the dose administered. The dose administered had contained 1.1% DKP, 
giving a dose of 2.2 mg/kg. Analysis of plasma following ingestion of this dose indicated that the 
concentration of DKP was below the limit of detection (1  g), but DKP was detected in urine samples 
from this study: the mean amount ingested was 126.8 ± 26.9 mg and the mean amount excreted via the 
urine  was  6.68  ±  1.3  mg  (4.83  ±  0.23%  of  the  dose  administered).  These  data  suggest  limited 
absorption of ingested DKP, but the authors note that authentic labelled DKP would be needed in 
order to characterise the metabolic pathways followed. 
Potential for interaction with monosodium glutamate (MSG) 
During  the  development  of  aspartame,  concerns  arose  regarding  possible  interactions  with  Glu, 
particularly as ingested in the form of MSG, in two contexts: 
Possible induction of neurotoxicity in the developing foetus, neonate and infant (See section 2.2.3). 
Predicted effects in individuals who experience so-called “Chinese Restaurant Syndrome” in response 
to the ingestion of MSG (See section 2.7.2)   Review of data on the food additive aspartame 
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Studies were, accordingly, performed in order to evaluate the possibility of an interaction between 
aspartame  and  Glu.  The  first  of  these  posed  the  question  “What  changes  occur  in  the  plasma 
aminograms  of  normal  adults  following  ingestion  of  a  test  meal  containing  1  g  protein/kg  body 
weight; the same meal modified to contain MSG (34 mg/kg); and the same meal modified to contain 
both aspartame and  MSG (both 34 mg/kg)?” This study is available as a study report (Stegink, Filer et 
al, 1976) and a published paper (Stegink, Filer et al, 1982). 
Two studies were carried out: in one the effects of a standard protein meal with or without MSG on 
plasma and erythrocyte amino acid levels were compared in 6 males and 6 female volunteers and in 
the second a randomised crossover design was used to compare the effects of the test meal with those 
of a test meal plus both MSG and aspartame in 3 males and 3 females. The test meal used was lean 
ground beef in a bun with 200 ml vanilla flavoured milk shake. Blood was sampled frequently for 8 hr. 
The addition of aspartame plus MSG to the high-protein meal had little effect on either plasma or 
erythrocyte [Glu] or [Asp] beyond those arising from the meal itself. However, plasma [Phe] was 
significantly higher after the meal plus aspartame and MSG compared with the basic meal, reflecting 
the increased load of Phe administered
5. The peak plasma [Phe] values observed were: 
Fasting:         47.2 ± 0.52  M 
Basic meal:         71.4 ± 0.82  M 
Meal plus aspartame plus MSG:   93.4 ± 2.33  M 
All the plasma amino acid levels ([Asp], [Glu], [Phe] and [Tyr]) observed were well within normal 
postprandial  ranges,  despite  the administration  of large  amounts  of MSG  and aspartame,  and the 
pharmacokinetic curves exhibited no spikes of either Phe or Tyr. These results add further support to 
the concept that the Phe moiety of aspartame is metabolised less rapidly than the Asp moiety. 
A similar study was conducted using different doses of MSG and aspartame  (Stegink, Filer et al, 
1979c; Stegink, Filer et al, 1983). Healthy adult subjects (3M/3F) were given a hamburger and milk 
shake meal designed to provide protein at 1 g protein/kg body weight, with or without either MSG 
(150 mg/kg) or MSG (150 mg/kg) plus aspartame (23 mg/kg). A Latin square design was used to 
determine the sequence of administration. Alcohol was avoided for 24 hr before and after dosing and 
blood was sampled frequently for 8 hr. 
The meal alone increased plasma concentrations of most amino acids, with peak concentrations being 
reached 4-6 hr after ingestion. Addition of aspartame to the meal with MSG did not increase plasma 
[Asp] or [Glu] significantly above the level reached in response to the meal supplemented with MSG, 
while [Phe] was similar following either the basic meal or meal plus Asp and Glu. There was no 
apparent interaction between aspartame and MSG when MSG was co-administered at high levels, and 
the authors concluded that the “data do not support the suggestion that aspartame addition to high 
protein meals already containing large amounts of MSG will promote a rapid and dangerous rise in 
plasma glutamate and aspartate levels” (Stegink, Filer et al, 1983). 
                                                 
5 N.B. It should be noted that the original study report  indicates that the results indicated that addition 
of either MSG alone or MSG plus aspartame did not increase plasma amino acid levels above those 
observed  after  ingestion  of  the  high  protein  meal  alone  whereas  the  published  version  reports 
significant increases, as summarised above.   Review of data on the food additive aspartame 
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Concern was also expressed regarding the potential for MSG in a meal to interact with aspartame 
delivered as part of an accompanying beverage. In order to resolve this issue, MSG was administered 
in a soup and aspartame was administered in a soft drink (Stegink, Filer et al, 1979a): 
Soup (no MSG) plus unsweetened beverage (no aspartame) 
Soup (MSG, 50 mg/kg) plus unsweetened beverage (no aspartame) 
Soup (MSG, 50 mg/kg) plus sweetened beverage (aspartame, 34 mg/kg) 
Healthy adults (6M/3F) were treated in a Latin Square design, randomised for each sex so that 2 males 
and 1 female entered each cell. Alcohol was avoided for 24 hr before and after dosing and blood was 
sampled frequently for 4 hr after consumption of the meal and drink. The maximum level of [Glu + 
Asp] observed when the meal with both supplements was consumed was 257 ± 105  M, which was 
not significantly greater than the maximum value after ingestion of the meal with MSG (210 ± 71.4 
M).  
These results were followed up in a further study (Stegink, Filer et al, 1987a) of 12 healthy adult 
volunteers. It is unclear from the published version whether these include the nine subjects from the 
study report. A small experiment in six subjects (3M/3F) also addressed the question of whether the 
rate of soup consumption (over 5 or 15 min) would affect the pharmacokinetics of Asp and Glu. 
Again, additional Asp from aspartame did not affect [Asp + Glu] over and above those due to the 
addition of MSG: the maximum level of [Glu + Asp] observed when the meal with both supplements 
was consumed (273 ± 90.7  M) was not significantly greater than the maximum value after ingestion 
of the meal with MSG (230± 66.1  M). Furthermore, the rate of consumption of the soup had no 
significant effect on mean peak levels of plasma amino acids ([Asp], [Glu] or [Asp + Glu]), although it 
did affect peak values slightly in individual patients, reflecting interindividual differences in the timing 
of Cmax (between 15 and 45 minutes). 
The authors concluded that these results did not support the suggestion that the addition of aspartame 
to the food supply would markedly affect plasma [Glu], [Asp] or [Asp + Glu] beyond the effects noted 
following the ingestion of MSG alone, contradicting the contention of commentators such as Olney, 
who  were  concerned  that the  co-consumption  of MSG  plus  aspartame  would  lead to “spikes”  of 
excitotoxins which could lead to neurotoxic effects. 
It should be noted that these studies did not include a meal with addition of aspartame but not MSG, so 
they do not provide any information regarding the effects of aspartame itself on plasma amino acids. 
Effects of formulation 
The nature of the formulation used can have a marked effect on the pharmacokinetics of amino acids 
in response to aspartame dosing. While this may be of peripheral importance under normal conditions 
of use, it can have significant implications for the interpretation of clinical trials using aspartame. 
The absorption and metabolism of a high dose of aspartame (100 mg/kg) administered either as a 
slurry or in solution were studied in 6 normal healthy adults using a randomised crossover design, the 
two doses being separated by 1-2 weeks (Stegink, Filer et al, 1979e). The solution dose was made up 
in 500 ml cold orange juice while the slurry comprised aspartame suspended in orange juice at 1.2 
ml/kg. Dosing took place after an overnight fast and alcohol was avoided for 24 hr before and after 
dosing. Blood was sampled frequently for 8 hr with a final sample at t = 24 hr. The results indicated 
that administration as a slurry generated results which were more variable in terms of plasma [Asp] 
and [Phe] and blood methanol compared with administration as a solution.    Review of data on the food additive aspartame 
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Peak values of plasma [Asp] increased from 1.6 ± 0.05  M to 4.3 ± 2.3  M after dosing with a 
solution formulation, whereas when a slurry was administered two subjects showed a greater increase 
than with the solution dose and four showed no increase at all. 
Plasma [Phe] increased after dosing with either formulation, a peak value of 203 ± 20.5  M being 
achieved after solution dosing whereas there was wide variation after slurry administration. 
Blood methanol levels reached 1.16 ± 0.47 mg/dl and 1.27 ± 0.48 mg/dl 60 – 90 min after solution and 
slurry dosing, respectively. 
These results confirm the rapid metabolism and clearance of all three moieties of aspartame with no 
evidence of toxic levels being reached, but it also illustrates that formulation can markedly affect the 
interindividual  variability  observed,  possibly  due  to  differences  in  gastric  emptying,  luminal 
hydrolysis and/or absorption. 
 A  further  study  on  the  effects  of  formulation  on  the  pharmacokinetics  of  aspartame  addressed 
differences in its disposition following administration in capsules or as a solution (Stegink, Filer et al, 
1987b).  This  is  important  in  considering  the  results  of  human  volunteer  studies  in  which  the 
toxicological effects of aspartame administered as capsules are considered. This study used capsules 
containing 300 mg aspartame, as used in various clinical studies, in a randomised Latin Square dosing 
schedule. Ten human volunteers (5M/5F) took ten capsules (3000 mg; equivalent to ~47 mg/kg body 
weight) washed down with 300 ml of an unsweetened drink; for comparison, the same dose was 
dissolved in the drink and empty capsules were taken. Samples were taken frequently up to 8 hr after 
dosing. The actual dose ingested ranged from 34.9 – 60.0 mg/kg and no adverse effects were reported. 
The results obtained were as follows: 
Plasma [Phe] rose more quickly and reached a peak earlier after dosing with a solution formulation 
compared with the capsule formulation: Tmax was 32 ± 15 vs. 123 ± 74 min and the corresponding 
AUC0-4hr was larger (15,340 ± 4,820 vs. 8,465 ± 3,356  mol/L x min). Peak [Phe] was also greater 
following solution dosing (191 ± 65.4 vs. 117 ± 39.5  M) and the corresponding Phe/LNAA ratio was 
greater (0.36 ± 0.12 vs. 0.23 ± 0.06). 
Peak  plasma  [Asp]  was  also  greater  and  reached  earlier  following  the  solution  formulation  than 
capsule administration: Tmax was 30.0 ± 14 min vs. 106 ± 61.3 min and mean Cmax was 26.2 ± 0.12 vs. 
10.4 ± 5.0  M. 
These findings, which reflect the time taken for capsules to dissolve and for aspartame to dissolve in 
the stomach contents and may be a particular problem with aspartame because of its poor solubility, 
should be taken into account when interpreting the outcome of clinical studies which use aspartame in 
capsule form. It should also be noted that the interindividual variation in amino acid pharmacokinetics 
was greater following capsule administration, so great care must be taken in determining the most 
appropriate observation times and in characterising the pharmacokinetics of the formulation used. 
Another study which has implications for the formulation of aspartame for human volunteer studies 
was one which set out to address the effect of concomitant sucrose on aspartame disposition (Stegink, 
Brummel et al, 1990). Healthy adults (n = 12) ingested either Kool Aid plus aspartame (40 mg/kg, 
equivalent  to  0.136  mmol/kg)  or  Kool  Aid  plus  aspartame  (40  mg/kg)  and  sucrose  (1.2  g/kg, 
equivalent to 3.51 mmol/kg) over a 15 min period in a balanced crossover design with a one week 
interval between doses. Blood samples were taken over an 8 hr period after dosing.  
The results obtained raised questions regarding the use of orange juice as a vehicle in studies with 
aspartame:   Review of data on the food additive aspartame 
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When aspartame was administered alone, a peak in plasma [Asp] was observed at t = 30 min. This 
peak, which had not been observed in earlier studies, was suppressed by sucrose and it was thought 
that carbohydrate in the orange juice used as a vehicle in previous studies might have had the same 
effect. 
Plasma [Ala] decreased after dosing with aspartame alone but increased when aspartame was co-
administered with sucrose, possibly doe to metabolism of monosaccharides to pyruvate and on to Ala 
via  transamination. The  increased [Ala]  observed  after  aspartame  dosing  in  previous  studies  may 
therefore have arisen from the orange juice vehicle by this mechanism. 
Plasma concentrations of branched chain amino acids were lower after dosing with aspartame plus 
sucrose  than  after  aspartame  alone,  possibly  in  response  to  insulin  released  in  response  to  the 
carbohydrate components of orange juice. 
However, peak values of Phe/LNAA were similar after aspartame alone or aspartame plus sucrose, 
although there was a small increase in AUC0-4 hr in the presence of sucrose (0.495 ± 0.177 vs. 0.386 
± 0.116). 
The authors of this study concluded that simultaneous ingestion of sucrose with aspartame has only 
minor effects on aspartame’s metabolic disposition; however, the study does raise questions regarding 
pharmacokinetic studies in which orange juice is used as a vehicle. 
A similar study compared the plasma profiles of Asp and Phe following ingestion of a single dose of 
20 mg/kg as capsules or in solution (Burns, Stargel et al, 1990). Healthy volunteers (10M/ 10F) were 
randomly assigned by computer to dosing schedules in a two way crossover design, doses being 
separated by at least one week. They fasted for 10 hr before dosing and then took either 300 ml 
unsweetened beverage plus sufficient 300 mg capsules to make an aspartame dose of 20 mg/kg, or 
empty capsules plus a beverage sweetened with aspartame to give a dose of 20 mg/kg. Blood samples 
were taken over an  8 hr period after dosing. There was no increase in plasma [Asp] with either 
formulation, but the shape of the [Phe] peak differed depending on the formulation, being steep with a 
Tmax of 30 min after solution dosing but broad and shallow after capsule dosing. There was, however, 
no marked difference in AUC between the two formulations. The shape of the Phe/LNAA curve was 
similar, but the maximum Phe/LNAA ratio was lower after capsule dosing than solution dosing. The 
pattern of plasma [Tyr] values reflected that of [Phe], while there were no significant differences 
between formulations with regard to other LNAAs. The authors concluded that the fact that these 
differences in pharmacokinetics are small means that capsule dosing is suitable for clinical trials as 
long as the slower rate of absorption from capsules is taken into account. 
Pharmacokinetics of amino acids in infants 
Analysis of changes in the concentrations of free amino acids (particularly Glu, Asp and Phe) over 
time following administrations of a high protein meal (Filer, Baker et al, 1977) was carried out in 
order to discover whether young infants have the same ability to transport and metabolise amino acids 
as adults. The subjects studied were 16 healthy one year olds, eight healthy two year olds and six 
healthy  young  adults.  They  were  given  a  chocolate  flavoured  custard  containing  14%  protein  by 
weight, giving a dose of protein at 1g/kg bodyweight. Samples were taken frequently over 6 hr from 
adult volunteers and two samples were taken from each infant to allow construction of a composite 
pharmacokinetic curve for plasma amino acid concentrations. The resulting plasma aminograms were 
similar in infants and young adults, and did not exceed those seen in normal breastfed infants. It was 
concluded that healthy one year old infants have the capacity to transport and metabolise Asp, Glu, 
Phe and Tyr to the same extent as normal healthy young adults. This provided early reassurance 
regarding the likely safety of aspartame in young children.   Review of data on the food additive aspartame 
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The effects of aspartame consumption on free amino acid levels in infants was subsequently addressed 
following loading with doses which would represent either normal or abuse conditions (Filer, Baker et 
al, 1983; Stegink, Brummel et al, 1983; Stegink, Filer et al, N/K). A dose escalation protocol was 
used, and each stage was completed and analysed before the next stage commenced. 
The  first  phase  of  this  study  was  carried  out  in  infants  aged  3-12  months
6.  Aspartame  was 
administered in cherry flavoured Kool Aid. The doses administered were 35, 50 and 100 mg/kg body 
weight. A total of four blood samples were taken by heel prick from each infant (one fasting and three 
post-dosing samples) to create a composite time course covering time points from 0 – 150 min after 
dosing, and amino acid levels were analysed in both plasma and erythrocyte preparations. The values 
were corrected for skin surface amino acid contamination. 
At 34 mg/kg (n=10), the effects on plasma amino acid levels were similar to those in adults given 
aspartame at the same dose. Basal [Asp] was higher even in fasting infants than in adults, but these 
were unchanged or even decreased following administration of aspartame. This was taken to indicate 
that aspartame is metabolised rapidly in one year old infants and the resulting Asp is cleared very 
quickly. Plasma [Phe] increased slightly following dosing (the peak value reached being 93.7 ± 14.4 
M),  similar  to  the  increases  noted  previously  in  adults,  but  was  again  cleared  rapidly  from  the 
circulation. The changes in erythrocytes generally reflected those in plasma. There were very small 
increases in blood methanol levels after aspartame exposure at this dose but these were at or close to 
the limit of detection (<0.35 mg/dl) and were similar to those reported in adults given aspartame at the 
same dose. 
The results at 50 mg/kg (n=6) were very similar, peak [Phe] being 116.2 ± 44.4  M and peak blood 
methanol being 0.30 ± 0.10 mg/dl (compared with 0.34 ± 0.12 in adults); on the basis of this evidence 
the investigators proceeded to an “abuse” dose (100 mg/kg). 
The  follow  up  investigation  was  carried  out  in  eight  infants  aged  8-12  months,  using  the  same 
procedure as for the low/medium dose study but with a dose of 100 mg/kg. The study report states that 
even at this high dose, plasma [Asp] was essentially unchanged from zero time values (Stegink, Filer 
et al, N/K), as in the low/medium dose study; however, the published version (Filer, Baker et al, 1983) 
indicates that peak [Asp] was significantly increased at the 100 mg/kg dose. Plasma [Phe] increased 
from a fasting value of ~50  M to 223 ± 115  M at time points 0.5 – 1 hr after dosing, the pattern 
observed  being  similar  to  that  in  previous  studies  in  adults.  This  value  is  above  the  normal 
postprandial range for [Phe] (120 ± 30  M), but is well below levels which would be expected to be 
toxic. 
Blood methanol levels following the administration of aspartame at 100 mg/kg increased from 0.11 ± 
0.05 mg/dl to 1.02 ± 0.28 mg/dl at t = 90 min; they then decreased to baseline levels by the final 
sampling point (150 min). In adults, the peak value was similar (1.27 ± 0.20 mg/dl) although the AUC 
for the first 25 hr in adults was significantly higher than that in infants (112 ± 23 vs. 66 ± 12.8 units), 
unlike at 50 mg/kg where the AUC values in adults and infants were similar. 
The authors conclude that the one year old child handles aspartame as well as the normal adult at this 
ingestion level and that there is no suggestion of toxicity at the doses used (Stegink, Filer et al, N/K). 
Pharmacokinetics of aspartame during breast feeding 
The effects of aspartame administration on amino acid concentrations in the blood and breast milk of 
lactating women were evaluated by Stegink et al. (Stegink, Filer et al, 1979d). Six healthy women 
                                                 
6  N.B. The numbers stated and some of the amino acid concentrations reported differ slightly between the study report and 
the published version; the published values are given here.   Review of data on the food additive aspartame 
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(aged 20-29 yr) with well established lactation were recruited. The duration of lactation at the time of 
testing  was  49-159  days  (98  ±  39  days).  Aspartame  was  administered  orally  to  overnight  fasted 
subjects at a dose of 50 mg/kg in 300 ml orange juice. The placebo was lactose and the study followed 
a randomised crossover design with a two-week interval between doses. Blood samples were collected 
over 4 hr after dosing and breast milk was collected at t = 0, 1, 2, 3, 4, 8, 12 and 24 hr. 
There were no significant changes in plasma or erythrocyte [Asp], [Asn], [Glu] or [Gln] following 
either aspartame or lactose. Plasma [Phe] increased approximately four-fold over fasting values 45 
min after aspartame loading (p < 0.001) and returned to baseline by t = 4 hr, with similar changes 
being observed in erythrocytes. 
Concentrations of Asp and Phe in breast milk did not differ following loading with aspartame or 
lactose. The application of curve fitting methods allowed small but statistically significant changes in 
overall milk [Asp] and [Phe] to be identified during the first 4 hr after dosing; however, these were not 
sufficient to meaningfully affect the intake of these amino acids by the breast-feeding infant. 
The authors conclude that, although the peak [Phe] reached in breastfeeding women given aspartame 
at 50 mg/kg was slightly above normal postprandial levels or those observed following administration 
of a normal dose of aspartame (34 mg/kg), it was far below those seen under pathological conditions 
such as in phenylketonuria (PKU) (1200 – 3000  M). 
Effects of aging 
The  pharmacokinetics  of  aspartame  have  been  compared  in  elderly  and  young  volunteers 
(Puthrasingam,  Heybroek  et  al,  1996).  The  “young”  volunteers  were  aged  20-41  years  and  the 
“elderly” volunteers were 65 – 80 years old. They were give aspartame at 40 mg/kg in capsules with a 
glucose drink (Lucozade, 200 ml). Lucozade was given again 2 hr after dosing and a low protein meal 
was taken at t = 4 hr. Blood samples were taken over an 8 hr period following dosing and [Phe] was 
determined using an enzyme diagnostic assay based on the one used to diagnose PKU. The elderly 
group exhibited increases in both AUC and Cmax for Phe (AUC: 518.7 ± 100 vs. 353 ± 94.3  mol/L x 
hr; Cmax: 81.3 vs. 18.9 vs. 63.3 ± 9.6  M). The results in young volunteers were similar to those 
reported  by  other  investigators.  These  results  indicate  that  elderly  people  have  slightly  reduced 
clearance of Phe compared with younger volunteers, but the differences observed were within the 
safety factors used in developing the current ADI.  
1.3.4.  Effects of repeated ingestion of aspartame in humans 
Initial pharmacokinetic studies of aspartame used bolus doses of aspartame, but these do not really 
represent  use  by  consumers.  In  the  mid-1980s,  studies  were  undertaken  to  address  the  effects  of 
successive ingestion of three servings of a beverage containing aspartame at 10 mg/kg (Stegink, Filer 
et al, 1988). Eight healthy adults (4M/4F) were treated in a standard crossover design with 3 x 12 oz 
servings of Kool Aid with or without aspartame, leaving a 2 hr gap between each dose. Blood was 
sampled over the two hour period between each dose. 
Neither beverage had any effect on plasma [Asp]. Plasma [Glu] increased transiently after each dose 
of either drink, but did not exceed that normal postprandial range. Plasma [Phe] did not rise after the 
unsweetened drink but did increase significantly after each dose of the sweetened drink. It declined 
towards the end of each inter-dosing period but did not quite return to baseline in between doses so 
that  there  was  a  slight  (but  non-significant)  accumulation  over  the  six  hours  of  the  study.  The 
concentrations just before each dose were: 
At t = 0hr, 50.9 ± 8.2  M 
At t = 2hr, 56.8 ± 8.3  M   Review of data on the food additive aspartame 
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At t = 4hr, 64.6 ±  12.2  M 
At t = 6hr, 65.0 ± 9.3  M 
The same pattern was seen when Phe/LNAA ratios were calculated. Effects on [Tyr] were similar to 
those on [Phe] but less marked, with no corresponding change in the Tyr/LNAA ratio, and there were 
no marked changes in branched chain amino acids (Val, Ile, Leu) 
The authors conclude that “The ingestion of three successive doses of aspartame at 10 mg/kg body 
weight at 2 hour interval has only a small effect on plasma Phe or Phe/LNAA values”; however, the 
increase  in  trough  [Phe]  values  raises  the  question  of  what  would  happen  to  [Phe]  values  with 
continual “topping up” during the day followed by overnight abstinence.  
A detailed study was undertaken to address such questions (Burns, W.W. et al, 1987a; Stegink, Filer et 
al, 1989b); presumably this was carried out after the study discussed above, although the study report 
precedes the published version of the previous study. Six healthy adult subjects (3M and 3F) were 
dosed according to a balanced crossover protocol with at least 1 wk washout between treatments. The 
dosing schedules were: 
One 8 oz serving of unsweetened beverage per hour for 8 hr. 
One 8 oz serving of sweetened beverage (600 mg aspartame added) per hour for 8 hr. 
One 8 oz serving of unsweetened beverage (150 mg DKP added) per hour for 8 hr. 
Blood samples for amino acid analysis were taken every 30 min for 9 hr then at t=24 hr. additional 
samples were taken at t = 0, 4, 8 and 24 hr for determination of formate and urine was collected over 
the periods -8 to 0, 0 to 4, 4 to 8 and 8 to 24 hr for determination of DKP, formate and creatinine. 
Plasma [Phe] and [Tyr] increased significantly after repeated administration of aspartame, reaching a 
plateau  after  several  doses  (5  for  Phe,  3-6  for  Tyr);  the  plateau  levels  were  within  the  normal 
postprandial range and returned to baseline values by t = 24 hr. Representative [Phe] values were: 
54.5 ± 7.1  M at t = 0 
81.5 ± 15.8 at t = 4 hr 
88.9 ± 15.4 at t = 7 hr 
63.6 ± 6.9  M at t = 24 hr. 
Correspondingly, peak plasma Phe/LNAA and Tyr/LNAA ratios were elevated, but not more than 
expected under normal dietary conditions. No significant changes in [Asp] and [Glu] were observed, 
and other amino acids were also unaffected. Blood methanol levels were below the limit of detection 
at all time points tested; no significant changes in blood methanol or formate levels occurred and all 
the urinary parameters measured were unchanged. 
Most  plasma  levels  of  DKP  were  below  the  limit  of  detection  after  the  administration  of  either 
aspartame or placebo, but there was a small increase in plasma [DKP] following administration of 
DKP itself. This reached a plateau after four doses and persisted for 24 hr. Administration of DKP did 
not affect blood methanol or formate or urinary formate levels and plasma LNAA ratios and individual 
amino acids levels were also unchanged after DKP. There was some evidence that DKP could exist as 
an endogenous compound in humans.   Review of data on the food additive aspartame 
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Overall,  the  changes  in  [Phe]  and  [Tyr]  observed  during  this  study  were  within  the  normal 
postprandial range and there was no effect on other amino acids, methanol or formate. 
1.3.5.  Effects on LNAA ratios and brain amino acids 
Considerable effort has been devoted to trying to characterise possible effects of aspartame-derived 
Phe on the brain because of the possibility that Phe could compete for the transporter which mediates 
the movement of LNAAs across the blood-brain barrier (BBB) and subsequently affect serotonin (5-
HT) and catecholamine synthesis. 
Studies in rodents 
Humans  are  likely  to  consume  aspartame  together  with  other  foodstuffs;  studies  were  therefore 
undertaken to examine the effects of aspartame with or without glucose in fasted rats given food at the 
same  time.  Under  normal  circumstances,  the  release  of  insulin  following  consumption  of  a 
carbohydrate-rich, protein free meal (or direct administration of insulin) causes an increase in 5-HT in 
the brain. This can be prevented by glucose (3000 mg/kg) or aspartame, leading to the suggestion that 
aspartame could potentially exert adverse effects when co ingested with carbohydrate. High doses of 
aspartame also increase plasma and brain [Phe] and [Tyr] in fasted rats, although this effect does not 
seem to be associated with increases in dopamine or norepinephrine.  
Preliminary studies indicated no behavioural effect of aspartame in rats given diets containing 5% 
aspartame. In a study addressing the effects of concomitant food consumption on plasma and brain 
amino acid levels in rats (Torii, Mimura et al, 1986b), a protein-containing meal stabilised plasma 
glucose and LNAA levels and brain LNAA and monoamine levels. Aspartame (up to 250 mg/kg) had 
no effect on brain monoamines when administered following water or free glucose and followed by 
feeding ad lib, leading to the conclusion that normal food consumption should have a stabilising effect 
on physiological responses to treatments which would have a marked effect in fasted animals. 
In a study in which adult male COBS™ Sprague Dawley rats were dosed with aspartame, Phe or Asp 
(p.o. as a slurry in water), [Trp], [Tyr] and [Phe] were determined in halved brains, cerebellum and 
blood (Fernstrom, Fernstrom et al, 1983). Peak effects on amino acid concentrations in plasma and 
brain occurred 30 – 60 min after dosing at 200 mg/kg. Plasma and brain [Tyr] and [Phe] increased by 
similar amounts, while [Trp] was only affected in the brain (reduced), plasma [Trp] being unaffected. 
A dose response was observed, with both plasma and brain levels elevated at 100 and 200 mg/kg 
whereas at 50 mg/kg only blood [Phe] and brain [Tyr] were affected. Only minimal effects were 
observed when the rate of Tyr/Trp hydroxylation was measured in brain samples and no effects were 
observed on brain levels of 5-HT, 5-HT, its breakdown product 5-hydroxyindoleacetic acid (5HIAA), 
norepinephrine,  dopamine  or  dopamine  metabolites.  The  preliminary  conclusion  drawn  from  this 
study was that some changes in blood and brain amino acid ratios did occur in response to aspartame 
but these were “by and large, pharmacologically modest”. 
A further study by the same team addressed the possible consequences of large doses of aspartame in 
terms of suppression of the increase in brain [Trp] and 5-HT synthesis which normally accompanies 
ingestion of a high carbohydrate meal (Fernstrom, Fernstrom et al, 1986). Such an effect is predicted 
from  the  competition  among  LNAAs  for  transport  across  the  BBB.  When  a  rat  consumes  a 
carbohydrate meal, insulin secretion reduces the blood levels of branched chain amino acids, but does 
not decrease (and may increase) blood [Trp], thus increasing the Trp/LNAA ratio. Thus Trp gains a 
competitive advantage over other LNAAs for transport into the brain leading to increased brain [Trp]. 
Since  brain  Trp  hydroxylase  is  not  normally  saturated,  an  increased  [Trp]  in  brain  leads  to  a 
corresponding increase in Trp hydroxylation and hence 5-HT synthesis. Concern therefore arose that 
increased Phe ingested as aspartame could prevent this effect by competing for transport mechanisms 
at the BBB.   Review of data on the food additive aspartame 
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In  a  study  addressing  such  potential  effects  in  response  to  high  doses  of  aspartame  (Fernstrom, 
Fernstrom et al, 1986), male Sprague Dawley rats consumed a high carbohydrate, protein free meal 
containing aspartame (64 g/kg dry weight) and were sacrificed 30, 60, 120 or 240 min later, giving 
effective doses of 650, 800, 1025 or 1215 mg/kg. A second experiment, using doses of 0, 4, 8, 16, 32 
or  64  g/kg  in  the  diet,  was  also  undertaken.  In  this  experiment,  rats  were  also  given  m-
hydroxybenzylhydrazine  (100  mg/kg),  which  inhibits  5-HT  decarboxylation  in  5-HT-synthesising 
neurons. This allowed the in vivo rate of Trp hydroxylation to be estimated. The results of these 
studies  indicated  the  existence  of  a  dose-response  relationship  between  the  amount  of  aspartame 
consumed in a single meal and effects on variables relevant to 5-HT synthesis in the brain. There were 
no marked effects at doses up to 440 mg/kg but at high doses (881 and 1440 mg/kg), suppression of 
the carbohydrate-induced increase in Trp hydroxylation did occur. This effect could have occurred via 
direct inhibition of Trp hydroxylation or, more likely, via competition for transport systems. 
When  adult  male  Sprague  Dawley  rats  were  treated  sequentially  with  glucose  and  aspartame 
(Yokogoshi, Roberts et al, 1984), it was found that simultaneous ingestion of glucose and aspartame 
potentiated aspartame-induced increases in brain [Phe] and [Tyr] and decreases in [Ile], [Leu] and 
[Val].  The  increases  in  brain  5-HT  which  would  normally  occur  after  a  carbohydrate  meal  were 
blocked. These effects would normally be mitigated by protein. The doses used were 200 mg/kg for 
aspartame and 3 g/kg for glucose or both (1 hr apart), administered to overnight fasted rats p.o.as 
slurries in distilled water. Brains and terminal blood samples were taken 1 hr after the second dose. 
Both [Phe] and [Tyr] increased in plasma in response to aspartame (by 62% and 142%, respectively), 
while these amino acids were not affected by glucose alone; however, glucose did alter branched chain 
amino  acids  enough  to  increase  plasma  Phe/LNAA  ratios  and to  potentiate  the  effects  seen  with 
aspartame.  Glucose  consumption  increased  brain  [Trp]  and  hence  levels  of  5-HT  and  5-HIAA. 
Aspartame had no effect on these, but blocked the effects of glucose. The effects of both glucose and 
aspartame on brain constituents were secondary to changes in plasma composition, suggesting that the 
main way in which aspartame affects the brain is via changes in [Phe] and [Tyr] in the systemic 
circulation. 
Studies in  animals  and  human  volunteers  have  further  characterised the  effects  of  aspartame  and 
dietary carbohydrates on plasma amino acid ratios in humans and corresponding brain concentrations 
in rats (Romano, Casacci et al, 1989). The human study involved 30 volunteers (15M/15F) dosed with 
aspartame  (0.83  or  8.3  mg/kg  in  200  ml  water)  after  an  overnight  fast.  The  aspartame  was 
administered  either  alone,  gradually  during  consumption  of  a  basal  meal  (10%  carbohydrate)  or 
gradually throughout a high energy carbohydrate meal (34% carbohydrate). Blood samples were taken 
over 3 hr following dosing. There were no significant changes in [Phe] at either dose of aspartame. 
In the animal studies (Romano, Casacci et al, 1989), male CD-COBS rats were given a control or 
carbohydrate-rich diet containing aspartame to give an average intake of 10 or 250 mg/kg/day for 14 
days. No significant changes in either plasma or brain amino acids were detected following these 
regimans. Acute dosing studies with aspartame (250 mg/kg) and/or glucose (3 g/kg), administered p.o. 
after an overnight fast were also conducted. Glucose was administered 1 hr before aspartame and the 
rats were sacrificed 1 hr after aspartame. Branched chain amino acids were reduced in response to 
glucose but not affected by aspartame while [Phe] and [Tyr] were elevated in rats given aspartame 
only  and  Tyr/LNAA  was  correspondingly  increased  following  aspartame  dosing,  with  or  without 
glucose. Correspondingly, brain [Tyr] and [Phe] were increased following administration of aspartame 
plus glucose; however, no effects on either brain 5-HT or catecholamine neurotransmitters and their 
metabolites were detected in the acute study. Plasma [Trp] was decreased following aspartame plus 
glucose  and,  except  for  Tyr/LNAA,  all  other  LNAA  ratios  were  reduced,  reflecting  the  rapid 
metabolism of Phe to Tyr in rats.    Review of data on the food additive aspartame 
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In an attempt to find out why brain neurotransmitters did not appear to change after an acute dose of 
aspartame (Romano, Diomede et al, 1990), effects on plasma and brain amino acids were further 
studied in male Sprague-Dawley CD-COBS rats. Aspartame was administered p.o. as a slurry in 0.5% 
carboxymethylcellulose  (CMC).  Plasma  [Phe]  and  [Tyr]  peaked  60  min  after  administration  of 
aspartame (either 250 mg/kg or 1000 mg/kg), and brain [Phe] and [Tyr] peaked at the same time, and 
corresponding changes in Phe/LNAA and Tyr/LNAA ratios were observed.  Even at 1000 mg/kg no 
effects on other LNAAs were observed in plasma or brain, and no changes in striatal neurotransmitter 
levels were observed up to 5 hr after dosing. These results were confirmed by the administration of 
Phe itself (500 mg/kg). These data do not support the hypothesis that increased brain [Phe] inhibits 
tyrosine hydroxylase, thereby impairing catecholamine synthesis, since significant increases in brain 
[Phe] and [Tyr] had no effect on catecholamine levels. It was also noted from the results that plasma 
[Phe] is not proportional to dose, suggesting that there is a rate limiting step, possibly at the point of 
absorption in the GI tract. 
Changes  in  monoamine  levels  have  also  been  studied  in  the  brains  of  rats  give  abuse  doses  of 
aspartame with or without protein (Torii, Mimura et al, 1986a). Fasted male Sprague Dawley rats were 
given a protein-free diet containing aspartame (5% w/w) and/or casein (25% or 9.8%; the latter giving 
the same LNAA content as the aspartame diet) for 2 hr and then sacrificed. Brain [Phe] and [Tyr] 
increased significantly in response to feeding a diet supplemented with either aspartame alone or 
aspartame plus 25% protein (p < 0.001) while brain [Trp] did not change regardless of the amount of 
dietary protein. Brain dopamine and norepinephrine levels were not affected by any of the diets. 5-HT 
levels were slightly increased when a protein free diet was consumed, but this was prevented by either 
aspartame or protein in the diet. In a three week follow up study, exposure to aspartame did not affect 
feeding patterns, meal size distributions or patterns of motor activity. The conclusion drawn was that 
brain levels of 5-HT may be slightly altered following acute ingestion of aspartame, but over a three 
week period of administration no changes in behavioural or functional parameters were observed. 
These data indicate that aspartame is unlikely to have a marked effect on neurotransmitter levels in the 
brain; however, debate on this subject remained active for some time (Wurtman and Fernstrom, 1987). 
The above studies used whole brain homogenates and could have missed localised changes in 
neurotransmitter levels. This issue has been addressed in several studies analysing the effects 
of oral aspartame administration on neurotransmitter concentrations in discrete brain regions 
following micro-dissection (Table 1). The results of these studies suggest that any changes in 
neurotransmitter levels in response to aspartame are subtle, even in rodents treated with very 
high acute doses of aspartame. Furthermore, as pointed out by Gaull (Gaull, Coulombe et al, 
1986),    it  should  be  noted  that  the  absolute  concentrations  of  neurotransmitters  or  their 
metabolites, whether in whole brain or segments thereof, do not necessarily correlate with 
neurologic function. 
The question of effects on tyrosine hydroxylase was further examined using the rat retina as a target 
tissue (Fernstrom, Fernstrom et al, 1991). The reason for this is that tyrosine hydroxylase is subject to 
clear cut regulation in the rat retina, being activated rapidly when lights are turned out. When male 
Sprague Dawley rats were dosed with aspartame (up to 1500 mg/kg p.o. in 0.5% methylcellulose + 
0.1% Tween 80), serum [Phe] and [Tyr], and the corresponding LNAA ratios, peaked 40 min after 
dosing and had started to decline by t = 60 min. The increase in [Tyr] was greater than that in [Phe] in 
rats treated with aspartame alone, but when hepatic tyrosine hydroxylase activity was inhibited with p-
chlorophenylalanine  (dosed  as  p-chlorophenylalanine  methyl  ester  hydrochloride,  376  mg/kg, 
equivalent  to  300  mg/kg  of  p-chlorophenylalanine)  this  was  reversed  and  [Phe]  exceeded  [Tyr]. 
However, normal accumulation of L-3,4-dihydroxyphenylalanine (DOPA) in the retina early in the 
daily light period was not prevented by p-chlorophenylalanine and Phe itself did not affect retinal 
tyrosine hydroxylation. This indicated that inhibition of hepatic tyrosine hydroxylase activity did not   Review of data on the food additive aspartame 
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affect  the  retinal  enzyme.  Under  these  conditions,  there  was  no  change  in  retinal  tyrosine 
hydroxylation (measured as DOPA accumulation) at any dose of aspartame tested (0 – 1500 mg/kg). 
These results address effects on the retina rather than in the brain, but their implication is that these 
changes  in  plasma  [Phe]  and  [Tyr]  in  response  to  aspartame  are  unlikely  to  affect  tyrosine 
hydroxylation in the brain, especially given the protection conferred by the BBB. 
A recent study used spatially and temporally resolved techniques to characterise the impact of a single 
high dose of aspartame on dopaminergic signalling in vivo (Bergstrom, Cummings et al, 2007). The 
effects of aspartame were evaluated in intact and partially lesioned animals to investigate the effects of 
depleting dopamine stores. Unilateral lesions were induced by injecting 6-hydroxydopamine into the 
right substantia nigra of adult male Sprague-Dawley rats. Voltammetric and electrochemical methods 
were  then  used  to  quantify  brain  dopamine  levels  brain  directly  before  and  after  treatment  with 
aspartame (500 mg/kg i.p. (vehicle not specified)). The results indicated that evoked dopamine levels 
detected by voltammetry remained steady in controls but declined over 20-160 min following an acute 
dose of aspartame. This effect was frequency dependent and was restricted to frequencies which are 
dominated  by  dopamine  release.  It  prevented  the  maintenance  of  normal  dopamine  levels  during 
extended stimulation in both intact and partially lesioned animals. The effects seemed to be due to a 
decrease in dopamine release rather than any change in dopamine uptake. The authors suggest that the 
effects observed may represent competition between aspartame-derived Phe and Tyr/Trp for uptake 
via the BBB and/or direct inhibition of tyrosine hydroxylase.  
These results are interesting in that they shed additional light on the question of whether and how 
aspartame-derived amino acids might affect neurotransmitter levels in the brain; however, the study is 
compromised by the choice of i.p. injection as the route of administration since the use of this route 
allows  direct  access  of  aspartame  to  the  systemic  circulation,  significantly  altering  the 
pharmacokinetics of aspartame and lacking relevance to the normal conditions of use in humans (i.e. 
low dose oral exposure). 
Studies in humans 
Human liver converts Phe to Tyr less rapidly than rat liver, so the major effect of aspartame in humans 
is to increase plasma Phe/LNAA ratios rather than Tyr/LNAA ratios, as occurs in rodents. 
Changes in plasma Phe/LNAA have been compared following dosing of healthy adult volunteers (4M 
and 4F) with aspartame or a sucrose sweetened beverage of equal sweetness (Burns, Stargel et al, 
1991). Subjects consumed a 300 ml beverage (Kool Aid) which was either unsweetened or sweetened 
with sucrose (100 g), aspartame (500 mg) or sucrose (100 g) plus aspartame (500 mg). A one week 
washout period was allowed between test days. Blood samples were taken over a 6 hr period following 
dosing and analysed for amino acids, glucose, insulin and glucagon. The results obtained were as 
follows: 
Plasma [Phe] increased 15 min after dosing with aspartame but decreased 30 min to 4 hr after dosing 
with sucrose; when both were administered in the same drink, the two effects cancelled each other out 
consistent  with  an  additive  effect.  Phe/LNAA  did  not  change  markedly  after  dosing  with  either 
sucrose or aspartame; an additive effect was observed such that there was a slightly greater increase in 
Phe/LNAA from t = 30 min to 4 hr. 
None of the beverages had any significant effect on Asp levels and there was no evidence for an 
interaction  between  aspartame  and  sucrose;  levels  of  the  other  amino  acids  analysed  decreased 
following ingestion of all the test beverages.   Review of data on the food additive aspartame 
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The  anticipated  changes  in  glucose,  insulin  and  glucagon  occurred  following  administration  of 
sucrose. The unsweetened and aspartame-sweetened drinks had no effect on either glucose or insulin, 
while glucagon declined throughout the study period. 
The authors conclude that changes in Phe/LNAA ratios are similar following consumption of either 
aspartame  or  sucrose-sweetened  beverages,  while  an  additive  effect  is  observed  when  the  two 
sweeteners are administered together. 
The clearance of plasma Phe and availability to the brain of Phe, Tyr and Trp after oral intake of 
aspartame or protein at doses providing equimolar amounts of Phe has been investigated in healthy 
human males (n = 6) (Moller, 1991). The following test items were administered in randomised order 
after an overnight fast: 560 mg Phe (in the form of bovine serum albumin (BSA), 12.2g) or 1000 mg 
aspartame, each in 200 ml tap water.  Blood samples  were taken over 4 hr  following dosing and 
analysed for insulin, glucose and amino acids. 
The increases in plasma [Phe] 15-30 min after dosing were very similar: from 48.8 ± 9.6 to 75.8 ± 27.5 
M after aspartame and from 49.1 ± 6.2 to 80.1 ± 14.6  M after BSA. [Tyr] and [Trp] increased 
following  albumin  but  not  markedly  in  response  to  aspartame  or  vehicle  alone.  Plasma  [Asp], 
however, did increase 15 min after ingesting aspartame. The ratio of Phe/LNAA increased for 2 hr 
following exposure to aspartame but decreased slightly in response to BSA administration; conversely, 
Trp/LNAA  and  Tyr/LNAA  decreased  after  aspartame.  None  of  the  formulations  affected  glucose 
levels, whereas insulin peaked  30 min after consumption of BSA but was unaffected by aspartame. 
The immediate increases in Phe were thus similar following aspartame or albumin; the increased AUC 
for Phe after aspartame compared with albumin may reflect the failure of aspartame to induce insulin 
release. The resulting increased in the Phe/LNAA ratio, which remained above control values for 2 hr 
following dosing, could have increased the availability of Phe to the brain. 
The possible effects of aspartame on brain amino acid levels secondary to increases in plasma [Phe] 
have been addressed in humans by using a positron emission tomography method to examine rates of 
amino acid transport across the BBB and effects on brain distribution volume in 15 normal male 
volunteers  (Koeppe,  Shulkin  et  al,  1991).  The  PET  probe  used  was 
11C-labelled  1-
aminocyclohexanecarboxylate.  Basal  PET  scans  were  taken  before  and  40-45  min  after  a  control 
beverage  or  one  containing  aspartame  (34  mg/kg).  Blood  samples  were  also  taken  for  the 
determination of amino acid levels. Plasma [Phe] and [Tyr], but not other amino acids,  increased from 
a mean baseline value of 50  M to a mean peak of 120  M within 40-45 min of aspartame ingestion. 
The  results  of  PET  scanning  indicated  small  but  measurable  changes  in  brain  LNAA  uptake  in 
response to aspartame: an average of -11% (-22% to +2%) vs. -3% in controls. These results indicate 
that, under normal conditions of use, aspartame is unlikely to cause PET-detectable changes in amino 
acid transport across the BBB. 
1.3.6.  Summary 
The potential physiological consequences of exposure to aspartame-derived Phe are a function of its 
effects on the Phe/LNAA ratio. It has been suggested that changes in this ratio could affect the uptake 
of other LNAAs via the BBB leading to changes in neurotransmitter levels in key brain regions; 
however,  no  consistent  changes  in  neurotransmitter  levels  either  in  whole  brain  or  specific  brain 
regions have been identified following exposure of rodents to aspartame, even at high doses. In this 
context, a species difference in the metabolism of Phe should be noted: rodents have much higher 
hepatic phenylalanine hydroxylase activity than do humans. Rodents therefore metabolise aspartame-
derived Phe rapidly to form Tyr, so that dosing with aspartame leads to an increase in plasma [Tyr] 
and the Tyr/LNAA ratio, whereas in humans the main effect observed is on plasma [Phe] itself and on 
the Phe/LNAA ratio.   Review of data on the food additive aspartame 
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2.  Toxicological data 
2.1.  Acute toxicity 
The results of preliminary acute toxicity testing carried out by Searle (Andress, Martinez et al, 1973a; 
1973b) are summarised in Table 2. No deaths occurred within 7 days of dosing in any of the species 
tested or at any of the doses used, and no abnormalities in behaviour were noted. 
Intravenous tests in rats and dogs also indicated no acute toxic effects. When 10 wk old male Charles 
River rats (n = 6 per group) were dosed with aspartame at 100 mg/kg in sterile saline via an i.v. 
catheter and observed for 72 hr, there were no changes in food consumption, physical appearance, 
behaviour or organ weights. No compound-related pathological effects were reported in a range of 
tissues (Rao, Semler et al, 1974). Similarly, in adult male Beagle dogs dosed with aspartame at 100 
mg/kg in injection quality sodium chloride via the cephalic vein and observed for 72 hr, there were no 
changes  in  food  consumption,  physical  appearance,  behaviour  or  ECG  traces.  No  significant 
compound-related changes in haematology, clinical chemistry and urinalysis parameters were noted, 
and histopathological examination of a range of tissues revealed only sporadic observations, including 
mild to moderate fatty infiltration of the atrium in one test and two control dogs (Rao, Ferguson et al, 
1974). 
Preliminary  investigations  on  a  wide  range  of  potential  pharmacological  and  endocrine  effects, 
summarised in two data compendia (Cook, 1972; Nutting, N/K) also provided no evidence of adverse 
effects; no  significant pharmacological, hormonal or physiological effects were observed in response 
to aspartame administration in a variety of contexts. 
There were no further investigations of acute toxicity due to aspartame for several decades following 
these  studies;  however,  recent  interest  in  the  role  of  oxidative  stress  in  toxicity  has  led  to  the 
publication  of  one  study  addressing  the  acute  effects  of  aspartame  on  oxidative  stress  and  brain 
monoamines in healthy mice and during the acute phase response to lipopolysaccharide (LPS) (Abdel-
Salam, Salem et al, 2011). Male Swiss albino mice were dosed with LPS (100  g/kg i.p. in 0.9% 
NaCl) together with aspartame at doses up to 22.5 mg/kg. Aspartame alone was also administered at 
11.25,  22.5  or  45  mg/kg.  Mice  were  sacrificed  after  4  hr  and  biochemical  analysis  of  lipid 
peroxidation, nitric oxide metabolism, GSH, glucose, tumour necrosis factor  , brain monoamines and 
hepatic  enzymes  (alanine  aminotransferase  (ALT),  aspartate  aminotransferase  (AST)  and  alkaline 
phosphatase (ALP)) was performed. Overall, aspartame had subtle effects on the parameters measured 
and sometimes actually alleviated the adverse effects of LPS (e.g. on brain glucose levels). Aspartame 
did  not  significantly  alter  the  oxidative  status  of  liver  or  alter  hepatic  enzymes  even  after  LPS 
treatment. Its only adverse effect in this study was a possible increase in oxidative stress in the brain 
(manifested as an additive effect of LPS and aspartame on brain nitric oxide) following the induction 
of mild systemic inflammation by LPS. This study does not, therefore, raise significant concerns 
regarding the potential acute toxicity of aspartame.  
A  few  studies  have  reported  the  effects  of  single  doses  of  aspartame  on  various  biochemical 
parameters in humans (Table 3). In some of these, aspartame was used as a control for studies on the 
effects of sugar and they do not generally address, or indicate, overt toxicity. They are, however, 
included here for completeness. Comments relating to individual studies are included in Table 3. 
2.2.  Short-term and subchronic toxicity 
This section addresses studies of lengths up to six months.   Review of data on the food additive aspartame 
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2.2.1.  Studies in experimental animals 
A series of studies conducted by G.D. Searle is summarised in Table 4. These did not indicate any 
significant toxic effects in rats, mice or dogs over dosing periods up to 9 weeks  
There are few published studies on subacute toxicity of aspartame apart from a number which focus on 
potential neurotoxicity (see below). A recent study has, however, studied the effects of 6 months’ 
dosing with aspartame on antioxidant defences in rat liver (Abhilash, Paul et al, 2011).  Male Wistar 
rats (6 per group) were dosed with aspartame (1000 mg/kg or 500 mg/kg p.o. (presumably daily as a 
slurry in water, although this is not made clear)) for 180 days. At the end of this time, terminal blood 
samples were taken and hepatic homogenates (S10 preparations) were made. Formalin fixed liver 
sections  were  also  prepared  and  used  for  the  visual  assessment  of  leukocyte  infiltration.  The 
biochemical parameters measured were plasma ALT, AST, ALP,  -glutamyltranspeptidase ( GT) and 
hepatic  malondialdehyde,  superoxide  dismutase,  catalase,  glutathione  peroxidase  and  glutathione 
reductase. 
Aspartame  induced  significant  increases  in  plasma  ALT,  AST,  ALP  and  GT  at  a  dose  of  1000 
mg/kg/day and in plasma AST and  GT at 500 mg/kg/day, but the increased observed were relatively 
modest (mostly approximately doublings, whereas increases nearer to 10 fold would be expected in 
the case of overt hepatotoxicity). No significant changes were observed in hepatic lipid peroxidation, 
superoxide dismutase and catalase but the activities of glutathione  peroxidase and reductase were 
significantly  suppressed at  1000  mg/kg/day.  This coincided  with leukocyte infiltration  which  was 
evident  at  1000  mg/kg/day  but  not  at  500  mg/kg/day.  These  results  suggest  that  treatment  with 
aspartame at 1000 mg/kg/day for 6 months may have induced mild liver damage associated with an 
inflammatory response and altered hepatic antioxidant status, but no overt toxicity was observed. 
2.2.2.  Repeat dose studies in humans 
Prior to marketing as a sweetener, aspartame was subjected to tolerance testing in healthy human 
subjects. Initial studies  (Langlois, N/K) were carried out in 31 normal men and 38 normal (non-
pregnant)  women  of  normal  body  weight  (not  more  than  20%  above  normal).  Aspartame  was 
administered under double blind conditions in capsules containing placebo, 200 mg aspartame or 300 
mg aspartame. Subjects took an appropriate number of capsules per day to deliver increasing doses of 
aspartame (or placebo) over a six week period (0.6, 1.2, 2.4, 4.5, 6.3 and 8.1 g/day in a weekly dose 
escalation  protocol).  Standard  clinical  chemistry  profiles  were  analysed  together  with  methanol, 
determined by gas chromatography in serum and urine at weeks 4 and 6. All 69 subjects completed the 
study  and  there  were no obvious  physical  or  biochemical  differences between  the  aspartame  and 
placebo group before, during or at the end of the study. No significant differences in glucose and 
insulin homeostasis were identified at weeks 0 or 6, or during follow up (week 7). There was no 
accumulation of Phe or Tyr in subjects taking aspartame and Phe was not detected in urine in weeks 0, 
3,  6  or  7.  The  only  adverse  symptoms  reported  were  very  mild  and  often  contradictory  (loose 
stools/constipation, increased/decreased appetite and headache). 
A follow up study (Frey, N/K-b) was conducted in subjects who agreed to continue from the above 
study together with a number of new recruits. The follow up study ran for 21 weeks, so continuing 
subjects received aspartame for a total of 27 weeks and the new recruits were dosed for 21 weeks. 
Subjects from the previous study stayed on the same regiman (aspartame or placebo) as in the short-
term study, but all subjects were dosed at 1.8 g/day (2 x 300 mg capsules, 3 x daily). Laboratory tests 
conducted  during  weeks  6,  12,  20  and  21  revealed  some  variability  in  results,  but  this  was  not 
associated with consumption of aspartame. There were no consistent differences in glucose and insulin 
homeostasis between aspartame and placebo groups, and, despite fluctuations in plasma [Phe] and 
[Tyr], there was no accumulation of either amino acid in male or female subjects. No phenylpyruvic   Review of data on the food additive aspartame 
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acid was detected in urine. No changes in weight and no product-related side effects were reported; the 
symptoms which were reported were similar to those in the previous study. 
Aspartame tolerance was also evaluated in a 13 wk study in children and adolescents, aged 2-20 yr 
(Frey, 1976; Frey, N/K-a). Five groups of children (ages 2-3, 4-6, 7-9, 10-12 and 13-20) were given 
aspartame at doses of 39.5  – 58.1 mg/kg/day, administered via coded dietary supplements. Older 
subjects (13-20 yr) also took aspartame capsules (200 mg, 3 x daily) and intake was verified using 
Study Menu record sheets completed by the parents. Subjects returned for evaluation at the end of 
weeks 1, 3, 5, 7, 9, 11 and 13. Clinical chemistry profiles indicated some minor differences between 
aspartame  and  placebo  groups,  but  all  were  considered  clinically  trivial  and  none  persisted.  No 
compound-related differences in profiles were detected at the end of the study. Both groups exhibited 
a slight decline in plasma [Phe] during the study but [Tyr] remained unchanged and there were no 
trends in Phe/Tyr ratios. Urinary phenylpyruvic acid measurements were negative and both serum and 
urinary methanol levels (in 33 subjects selected at random) were below the limit of detection at all 
times. There was slight weight gain during the study in all groups, consistent with the age of the 
participants. No severe adverse effects were reported and the minor complaints received were similar 
for aspartame and placebo groups. Four allergic responses (hives, rashes) were observed but these 
were  not  related  to  aspartame  consumption.  No  eye  abnormalities  or  changes  in  acne 
incidence/severity were observed. The authors concluded that “…aspartame appears to be safe for use 
as a sweetening agents by children of all ages”. 
Further studies on long term administration of aspartame in normal subjects were reported in the late 
1980s (Burns, W.W. et al, 1988; Leon, Hunninghake et al, 1989). Aspartame capsules (300 mg) or 
placebo (capsules containing 300 mg microcrystalline cellulose + 0.9 mg SiO2) were used. The study 
adopted  a  randomised,  double  blind,  placebo  controlled  parallel  group  design  in  which  subjects 
received placebo or aspartame (75 mg/kg/day) for 24 weeks. Subjects (51M/57F) were randomised at 
enrolment and subjected to thorough clinical assessment prior to study commencement. This included: 
Medical history, physical examination, vital signs and body weight. 
Clinical chemistry profiles of blood and urine 
repeated for blood in weeks 3, 6, 12, 18 and 24 
repeted for urine in weeks 3. 12 and 24 
Blood formate and methanol levels (repeated in weeks 6, 12, 18 and 24). 
Urinary creatinine and formate (repeated in weeks 3. 12 and 24). 
Serum folate (repeated in week 24) 
Plasma amino acid profiles (repeated in weeks 3, 6, 12, 18 and 24). 
Plasma lipid panels (repeated in weeks 3, 6, 12, 18 and 24). 
During the 24 week dosing period subjects were asked to avoid additional sources of aspartame; dose 
compliance was verified by counting capsules. 
Of 108 subjects recruited, 101 completed the study. No treatment-related haematological changes, 
consistent alterations in clinical chemistry and analyses or urinary abnormalities were observed and no 
significant differences in vital signs or body weight were noted. In addition, no differences were 
observed in relation to: blood formate or methanol; urinary Ca2+ or formate; serum folate; or serum   Review of data on the food additive aspartame 
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lipids. There were no significant changes in amino acid profiles and no evidence of accumulation of 
Phe or Tyr. Various adverse effects were reported by these were all common and mild in nature. The 
authors  conclude  that  aspartame,  consumed  daily  at  doses  equivalent  to  those  contained  in 
approximately  10L  of  an  aspartame-containing  beverage,  is  not  associated  with  any  significant 
changes in clinical measure or adverse experiences in healthy adults. 
Some additional information about the possible effects of aspartame in humans can be gleaned from 
studies  in  which  aspartame  is  used  as  a  control  for  experiments  whose  main  focus  is  on  other 
sweeteners. For example, in a controlled diet study in which 21 men (aged 24-45; 15 obese, 6 non-
obese) were given a baseline diet (25—30% of calories from sucrose) alternating with a calorically 
restricted diet (10 calories from sucrose, sweetness replaced with aspartame) for 12 days at a time, the 
following observations regarding aspartame were reported (Porikos and Van Itallie, 1983): 
Circulating ALT and AST levels were elevated on the baseline diet, fell on the aspartame-containing 
diet then rose again when the baseline diet was reintroduced. 
Small increases in blood urea nitrogen (BUN) were observed on the aspartame-containing diet, but 
renal function remained within normal parameters. 
Serum triglycerides decreased by 33% on the aspartame diet (from 130 mg/dl to 87 mg/dl). 
Too much emphasis should not be placed on these results since the dose of aspartame is not specified 
and there were other changes in the diet, including changes in it caloric content; however, the results 
are consistent with the absence of adverse hepatic or renal effects due to aspartame taken over a period 
of 12 days. 
2.2.3.  Neurotoxicity 
In 1970, concerns were raised by a paper reporting hypothalamic damage in infant mice following oral 
administration  of  MSG  and  various  other  amino  acids  including  Asp  (Olney  and  Ho,  1970); 
apparently, unpublished data indicating a similar effect with aspartame at doses of 2,000  – 2,500 
mg/kg p.o. also exist (Bigwood, 1975). Olney argued, on the basis of his findings, that aspartame itself 
might be neurotoxic and, furthermore, that it might interact with MSG to produce an exacerbated 
neurotoxic effect (Olney, 1975b; 1975a), but Bigwood (Bigwood, 1975) criticised the work on the 
grounds of the very high doses required to produce an effect, the fact that relatively small increases in 
protein should have a similar effect, and the fact than gavage dosing of neonatal mice with large 
volumes of fluid would be expected to cause osmotic disturbances and histological changes even in 
the absence of a compound-related effect. 
The observations of Olney generated concern regarding the possibility that aspartame-derived Asp 
might exert neurotoxic effects in young children and led to an investigation of the acute toxicity of 
aspartame in the neonatal mouse (Lemkey-Johnston, Reynolds et al, N/K). Hybrid A/JAX-ICR mice, 
6-10 days old, were dosed with aspartame at doses of 250, 500, 1000, 1500 or 2000 mg/kg p.o. as a 
10% slurry (N.B. the vehicle and duration of exposure are not stated). Upon sacrifice, brains were 
embedded,  serially  sectioned  in the sagittal  plane  and  stained  with  Cresyl  Echt Violet  stain. The 
following were observed at doses above 1000 mg/kg: 
shrunken neurons with pyknotic nuclei and enlarged dendrites in the arcuate nucleus 
pyknosis and oedema in: 
dorsal dentate gyrus   Review of data on the food additive aspartame 
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dorsal anterior region of the habenula 
vascular changes including: 
enlarged blood vessels in cerebellar folia 
enlarged portal vessels where the arcuate nucleus was damaged 
dilatation of the choroid plexus 
Dilatation of the lateral cerebral and third ventricles was observed at all doses except 250 mg/kg. The 
main areas where damage was observed were in medial locations close to the ventricles, suggesting 
that materials entering the brain from the cerebrospinal fluid or via the BBB were responsible. The 
authors note that the doses of aspartame used in this study were very high, sufficient to affect the 
osmotic load of the blood, and this dehydrating effect may have been responsible for the damage seen. 
Data supporting this contention was obtained in a study in which patterns of water consumption were 
characterised in weanling mice subjected to overnight water restriction and the possible effects of 
aspartame on water-deprived mice were evaluated (Takasaki, Iwata et al, 1981). The results indicated 
that overnight water restriction disturbed the behaviour of newly weaned mice so that they became 
unable to regulate their ingestion of liquids or diets containing aspartame or free Asp (monosodium 
salt). Ingestion of Asp via the drinking water, but not via food, induced hypothalamic lesions but no 
such lesions were observed when aspartame was taken via either drinking water (intake of 730 – 143 
mg/kg) or food (2410 – 7530 mg/kg). These results further suggest a role for dehydration in neuronal 
necrosis in neonatal mice given Asp, and may inform the interpretation of the results of Olney (Olney 
and Ho, 1970). 
Further studies on the disposition of the free amino acid Asp, administered directly to neonatal (15 day 
old) and adult Charles River CD-1 mice (Opperman, Karim et al, 1978), indicated that, in neonates, 
the oral bioavailability of Asp was close to 100% whereas in adults oral bioavailability was poor 
(~15%). This did not seem to be due to first pass metabolism in the liver but was more likely to have 
been due to metabolism in the wall of the GI tract, which did not seem to be fully developed in 
neonates. This was consistent with the greater Cmax value for Asp in neonatal mice than in mature 
animals (554 vs. 141  g/ml). Thus, after equivalent massive oral doses of free Asp, higher plasma 
concentrations were observed in newborn than adult mice. This phenomenon, which had previously 
been observed with Glu, may account for the susceptibility of neonatal mice to neurotoxicity due to 
direct administration of Asp. 
The  need  for  presystemic  metabolism  of  aspartame  before  Asp  is  released  and  absorbed  via  the 
intestinal mucosa suggests that circulating [Asp], even after a high dose of aspartame, is unlikely to 
reach levels sufficient to induce hypothalamic damage even in the baby mouse. Furthermore, the 
combined plasma concentration of Asp + Glu required in order to induce neuronal necrosis in 8 day 
old Swiss Webster mice (1690 ± 230  M), and even the highest no effect level observed (550 ± 190 
M), are much higher than any which are likely to be reached following consumption of aspartame 
(Daabees, Finkelstein et al, 1985). N.B. The effects of Asp alone were not determined in this study. 
The potential neurotoxic effects of high doses of aspartame were also examined in monkeys during the 
premarketing phase of product development (Reynolds, Butler et al, 1976; Reynolds, Stegink et al, 
1980; Reynolds, Stegink et al, N/K). Macaques aged 1-22 days (species Macaca mulatta, Macaca 
fascicularis and Macaca arctoides) were dosed with vehicle (water; n=11), aspartame (2000 mg/kg; 
n=8) or aspartame + MSG (2000 + 1000 mg/kg; n=6) p.o. as a 10% slurry. Blood samples were taken 
up to 4 hours after dosing (this being the maximum period over which an infant monkey can survive   Review of data on the food additive aspartame 
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the stress of the procedures used) and the animals were then sacrificed. Brain sections were prepared 
for light and electron microscopy (1  m and 700 Å sections, respectively). 
Light microscopy revealed no significant changes in response to aspartame or aspartame + MSG, 
although  electron  microscopy  (EM)  did  reveal  a  novel  cell  type  which  had  not  been  observed 
previously. This cell type was observed in all three treatment groups.  No EM abnormalities were 
observed. There was considerable variability in plasma amino acid concentrations, which was ascribed 
to the use of a slurry formulation for dosing but the peak concentrations observed confirmed that 
aspartame-derived amino acids had reached the systemic circulation (Asp: 230 ± 330  M at t = 60 min 
(p<0.0001); Phe: 950 ± 590  M at t = 90 min). This indicated that the lack of morphological effects 
was not due to failure to elevate amino acid levels in plasma, as previously suggested by Olney as an 
explanation for the failure of other investigators to replicate his results. It was noted that the data 
suggested more rapid metabolism of aspartame-derived amino acids in monkeys than in humans. 
When a companion study was carried out in 6-12 day old mice (strain not specified) dosed with 
aspartame  at  500  (n=27), 1000  (n=15),  1500  (n=17)  or  2000 (n=18)  mg/kg  in  a  10% slurry,  the 
majority of mice exhibited no damage in the arcuate area even at 2000 mg/kg (Reynolds, Butler et al, 
1976). However, “modest” damage was observed in ~40% of mice treated with aspartame at 1500 – 
2000 mg/kg, and an oral dose of 1000 mg/kg caused necrosis of a few neurons in the arcuate area with 
an  incidence  of  ~13%.  The  conclusion  drawn  was  that  neonatal  mice  are  more  susceptible  to 
aspartame than are monkeys, possibly due to species differences in its metabolism or in the structure 
and permeability of the BBB. Furthermore, these results were taken to suggest that the results reported 
by Olney (Olney and Ho, 1970) may have been artefactual or part of normal neuronal remodelling in 
the infant mouse brain (Reynolds, Stegink et al, 1980). 
The lack of marked aspartame-induced neurotoxicity in the arcuate nuclei was also observed in a 
French study in the early 2000s (Beck, Burlet et al, 2002). Male weanling Long-Evans rats were dosed 
with  aspartame  (1  g/L  in  drinking  water;  actual  intake  not  specified)  for  14  weeks,  after  which 
terminal blood samples were taken for measurement of plasma glucose, immunoreactive insulin and 
leptin. Epididymal, perirenal and subcutaneous fat pads were dissected and the liver, spleen and heart 
were  also  taken.  Frozen  sections  of  brain  (300  m)  were  cut  and  individual  brain  regions  were 
sampled by micropunching for the analysis of neuropeptide Y. The results were as follows: 
Energy and fluid intakes were similar between treated and control groups, but aspartame treated rats 
gained less body weight than controls. 
All fat pads were heavier in controls than in aspartame treated rats. 
Terminal plasma insulin and glucose did not differ between groups. 
The level of hypothalamic neuropeptide Y in the arcuate nucleus was significantly lower in aspartame-
treated rats than in controls. This correlated with plasma leptin levels. 
There were no significant changes in the paraventricular nucleus, other hypothalamic nuclei involved 
in the regulation of feeding behaviour or in extrahypothalamic areas such as the accumbens nuclei. 
The  authors  note  that  changes  in  neuropeptide  Y  in  response  to  aspartame  were  localised  in  the 
hypothalamus and restricted to the arcuate nucleus. They note that effects observed are not due to 
sweetness since aspartame does not taste sweet to rats; instead they speculate that the effect could be 
due to appetite suppression by Phe, possibly in association with other amino acids. No neurotoxicity 
was observed in the arcuate nucleus in this study, providing further reassurance regarding this issue. 
Indeed, it could be argued that the lower body weight and altered body composition observed in rats 
given aspartame in their drinking water over 14 weeks actually represents a beneficial effect.   Review of data on the food additive aspartame 
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The question of neurotoxicity due to aspartame has recently been revisited in two studies published in 
an in house veterinary medical journal (Puica, Craciun et al, 2008; Puica, Cracuin et al, 2009). The 
titles of the papers indicate that aspartame was administered chronically, but in fact the duration of 
dosing was 30 days so the studies fall under the heading of subchronic toxicity for the purposes of this 
review. Rabbits (juvenile supercuni (Oryctolagus cuniculus L., 3 months old) and rats (Wistar, 30 days 
old) were apparently dosed with aspartame (2000 mg/kg/day in diet slurry). No vehicle or sham-
gavaged control group is mentioned and the frequency of dosing is not stated. At the end of 30 days’ 
dosing,  animals  were  decapitated  and  the  brains  prepared  for  EM  by  published  methods. 
Ultrastructural damage, described as “selective degeneration of all subcellular neurons ultrastructures 
both in CA1 pyramidal neurons of the hippocampus and ventromedial area of the hypothalamus” is 
reported  in  both  species,  and  the  authors  conclude  that  juvenile  rats  and  rabbits  are  particularly 
susceptible  to  neurotoxic effects  induced  by  aspartame.  However,  it  is  difficult  to  interpret  these 
papers because of the lack of experimental detail provided. In particular, it is unclear whether the 
control  animals  were  gavaged,  and  this  raises  the  possibility  that  the  effects  observed  in  treated 
animals were a consequence of the stress of daily handling and gavage dosing. 
2.2.4.  Miscellaneous studies 
A  recent  study  undertook  to  examine  the  physiological  effects  of  aspartame  in  the  presence  of 
hyperlipidaemia using the zebrafish model (Kim, Seo et al, 2011). Aspartame was administered to 
zebrafish at a concentration of 3 mM in the diet and some fish were given a high cholesterol diet. 
Terminal  blood  samples  were  analysed  and  frozen  sections  of  liver  and  brain  were  prepared  for 
histological evaluation and visualisation of reactive oxygen species using dihydroethidium.  When fed 
a high cholesterol diet containing aspartame, zebrafish exhibited acute and severe swimming defects. 
These were associated with increased brain inflammation with infiltration of inflammatory cells and 
increased levels of reactive oxygen species. The effect did not seem to be due to systemic toxicity 
since no increases in liver enzyme release were observed. This study, while interesting, is difficult to 
incorporate into a risk assessment since it is the only reported study using this model. 
2.2.5.  Summary 
No significant acute or subchronic toxicity has been observed in animal models even at the highest 
doses  of  aspartame  which  could  reasonably  be  administered,  and  humans  given  high  doses  over 
periods of up to 27 weeks have reported no significant adverse effects. Early concerns that aspartame 
might cause neurotoxicity in neonates and infants were not substantiated by subsequent experimental 
data. 
2.3.  Genotoxicity 
2.3.1.  Studies conducted by Searle 
The genotoxicity studies submitted as part of the original Searle dossier are summarised in Table 5. 
Many of these studies were carried out prior to the standardisation of methodology for genotoxicity 
testing and development of routine methods such as the Ames test, and now appear very outdated. In 
addition, several of them have minor technical limitation such as the fact that, in some studies (Bost 
and Stolt, 1974; Reno and Bowles, 1972b; 1972a; Reno and Good, 1972b; 1972a), positive control 
animals  maintained  their  weight  while  all  the  other  animals  on  the  study  lost  weight,  an  effect 
attributed to the fact that test and vehicle control animals were dosed daily by gavage whereas positive 
controls were given a i.p. single dose and meaning that the negative control, test and positive control 
groups were not directly comparable. Similarly, in one early study a positive control (cyclohexamine) 
was chosen which had only been shown to be positive in one published study and showed no increase 
in aberration frequency: it is not clear why it was chosen as a positive control for a regulatory study 
(Bowles and Jessup, 1970). However, these issues notwithstanding, none of these studies suggest that 
aspartame had any genotoxic effects in vivo or in vitro under the conditions tested.   Review of data on the food additive aspartame 
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Once the Ames test became available, Searle used it in four studies to investigate the potential in vitro 
genotoxicity of aspartame and KP (Molinary, 1978a; 1978b; Simmon and Kauhanen, 1978; Simmon 
and  Shan, 1978).  Each assay  used  S. typhimurium  strains TA1535, TA1537, TA1538, TA98  and 
TA100. The metabolic activation system used was hepatic S9 from rats treated with Aroclor 1254 (500 
mg/kg i.p.) to induce a range of CYP isoforms and the study reports make reference to in house 
Product  Safety  Assessment  Standard  Procedures.  Aspartame  was tested  at  10-5,000  g/plate  with 
dimethyl sulphoxide as vehicle. No dose-related increase in revertant frequency was observed with or 
without metabolic activation (Molinary, 1978a; Simmon and Shan, 1978). Similarly, when DKP was 
tested at 10-10,000  g/plate, no dose-related increase in revertant frequency was observed with or 
without  metabolic  activation,  despite  using  concentrations  up  to  those  which  caused  precipitation 
(Molinary, 1978b; Simmon and Kauhanen, 1978). 
There has been relatively little activity with regard to the potential genotoxicity of either aspartame 
itself  or  DKP  since  these  studies  were  conducted,  although  sporadic  reports  either  using  other 
techniques,  investigating  potential  chemical  reactions  leading  to  genotoxicity,  or  revisiting  the 
question of genotoxicity by conventional methods have been reported. These are summarised briefly 
below. 
2.3.2.  Other genotoxicity tests 
Direct  binding  of  aspartame  to  calf  thymus  DNA  has  been  reported  in  a  single  study  (Karikas, 
Schulpis et al, 1998). The method used involved exposing test compounds to calf thymus DNA and 
analysing the extent of covalent binding by differential elution on reverse phase HPLC. The results 
state that the binding of aspartame to calf thymus DNA was 11.3% at 0.12 mg/ml, 39.8% at 0.25 
mg/ml and 55.5% at 0.50 mg/ml; they also state that L-Phe gives 31.6% binding and L-Asp gives 
39.3% binding at 0.25 mg/ml. The authors conclude that all three compounds bind to DNA via amino 
groups; however, it is difficult to interpret these results since neither the reaction conditions used nor 
the chromatography method are adequately described. Actual DNA binding is not verified; the results 
depend on a shift in a chromatographic peak to indicate that binding has occurred. In any case, even if 
binding  to  calf  thymus  DNA  is  demonstrated  in  vitro  it  is  not  possible  to  extrapolate  this  to 
conclusions about potential genotoxicity in vivo given that aspartame does not even enter the systemic 
circulation let alone pass through the cell and nuclear membranes to reach the DNA. 
Also in 2000, testing of aspartame in the rat hepatocyte unscheduled DNA synthesis (UDS) assay was 
reported as part of a study addressing five sweetening agents, acesulfame K,  aspartame, cyclamate, 
saccharin and sucralose (Jeffrey and Williams, 2000). The UDS assay was carried out in cultured 
primary rat hepatocytes. All five sweeteners were negative for induction of UDS over the entire dose 
range tested, which for aspartame was 5 x 10
-3 to  x 10
-2 M. 
Aspartame was included among 39 food additives tested in the Comet assay by Sasaki et al. (Sasaki, 
Kawaguchi et al, 2002). Male ddY mice were dosed with aspartame (up to 2,000 mg/kg p.o. in saline) 
and sacrificed after either 4 or 24 hr. Isolated cells were prepared from glandular stomach, colon, liver, 
kidney, urinary bladder, lung, brain and bone marrow, suspended in low melting point agar and used 
for visualisation of comets following electrophoresis. No comet induction was observed in response to 
aspartame in any of the tissues tested. 
In contrast to this result, aspartame has been reported to be positive in the comet assay after a single 
dose as low as 35 mg/kg (Bandyopadhyay, Ghoshal et al, 2008). This study used male Swiss albino 
mice given a single dose of aspartame (7, 14, 28, or 35 mg/kg p.o. in distilled water). The comet assay 
was carried out 18 hours after dosing using bone marrow cells from the femur and scored by image 
analysis using a Kinetic Imaging system with Komet 55 analytical software, which calculates tail 
DNA  percent  and  tail  extent  ( m).  The  induction  of  comets  by  aspartame  was  reported  to  be 
significant at p<0.05% with a two fold increase in tail DNA percent (the corresponding increase with   Review of data on the food additive aspartame 
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EMS was 10 fold). However, aspartame was, as expected, negative in the Ames test the TA97A and 
TA100 and a rat liver S9 metabolic activation system. The authors note that aspartame was the least 
effective of the three sweeteners tested (aspartame, Acesulfame-K, and saccharin). It is difficult to 
evaluate this study: its results do not seem to be consistent with those of other studies but neither is 
there any obvious reason to reject it. 
In  2004,  the  genotoxicity  of  aspartame  was  revisited  using  a  range  of  human  cell-based  tests 
(Rencuzogullari,  Tuylu  et  al,  2004)  including  a  chromosomal  aberration  test,  a  sister  chromatid 
exchange assay and a human lymphocyte micronucleus assay. The Ames test was also used to look for 
frameshifts (TA98) and base pair substitutions (TA100), with hepatic S9 from 3-methylcholanthrene-
treated  rats  (high  activity  of  CYP1A  family  isoforms)  as  a  metabolic  activation  system.  For 
chromosomal aberrations and sister chromatid exchanges, blood from four healthy donors (2M/2F) 
was cultured in the presence of aspartame at 500, 1,000 or 2,000  g/ml. The positive control used was 
mitomycin  C,  0.3  g/ml.  For  the  identification  of  chromosomal  aberrations,  100  well-spread 
metaphases  per  donor  (400  per  concentration  of  aspartame)  were  examined.  For  sister  chromatid 
exchange,  a  total  of  100  second  metaphase  cells/concentration  (25  per  donor)  was  examined. 
Replication  indices  were  also  determined  in  100  cells/donor  and  mitotic  index  in  3,000  cells. 
Micronucleus frequency was determined in 2,000 binucleated cells at the frequency of binucleated to 
mononucleated cells was determined. 
The results of this study were as follows: 
There were increased numbers of chromosomal aberrations at all concentrations and over all treatment 
periods used, but these were not dose dependent and were observed at a much lower frequency than in 
mitomycin C treated cells. 
No induction of sister chromatid exchanges was observed. 
Aspartame had no effect on the replication index (which measures effects in both S and G2 phases) 
but did reduce the mitotic index (specific to G2) at all concentrations and over all treatment periods 
used. 
Induction of micronuclei was observed at the highest concentration tested (2,000 mg/nl) and was dose-
dependent when exposure was for 48 hr. 
No dose-dependent effects were observed in the Ames test. 
These results suggest that aspartame may be able to induce low levels of chromosomal aberrations and 
micronucleus  formation  in  a  purely  in  vitro  system  using  human  lymphocytes.  However,  this  is 
unlikely  to  be  of  significance  following  oral  exposure  because  aspartame  undergoes  complete 
digestion in the GI tract and does not enter the bloodstream. 
Aspartame was also subjected to genetic toxicity testing by the NTP as part of their carcinogenicity 
study in alternative mouse models (NTP, 2005) (for further detail, see section 2.4.5). No mutagenicity 
was  detected  by  Ames  testing  except  for  a  reproducible  small  increase  in  mutant  colonies  in  S 
typhimurium strain TA97 with 30% rat liver S9; this response was judged to be equivocal. In addition, 
an acute bone marrow micronucleus test was conducted with aspartame administered by gavage to 
male F344/N rats. No increase in micronucleated polychromatic erythrocytes was observed at any 
dose level. 
Peripheral blood micronucleus tests were conducted after 9 months exposure of Tg.AC (hemizygous), 
p53
+/- (haploinsufficient), and Cdkn2a
-/- (knockout) mice to aspartame via the diet. Negative results 
were obtained in male and female Tg.AC and Cdkn2a
-/- mice and also in male p53
+/- mice. In female   Review of data on the food additive aspartame 
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p53+/- mice, however, the results of the micronucleus test were judged to be positive, based on a 
significant trend test and a small but statistically significant increased frequency of micronucleated 
erythrocytes in the 50,000 ppm group. It is difficult to assess the importance of this finding: the study 
was conducted to very high standards, but the p53
+/- mouse model is not fully established and there are 
insufficient historical micronucleus test data in this line to allow proper evaluation of this result. 
2.3.3.  Potential chemical reactions leading to genotoxicity: chlorination 
A single study (Tan, Wheeler et al, 1987)has examined the reaction of chlorine dioxide (ClO2) with 
amino  acids  and  peptides,  including  aspartame.  Aspartame  did  not  react  with  ClO2  under  the 
conditions  used  but  for  some  reason  the  aspartame—ClO2  reaction  mix  was  mutagenic  to  S. 
typhimurium TA98 in the absence of metabolic activation and to TA100 in the presence or absence of 
metabolic activation. Neither Asp nor Phe reacted with ClO2 when added to the reaction mix as free 
amino acids. Thus, a mixture of aspartame and chlorine dioxide seemed to be associated with some 
evidence of mutagenic activity. This report is difficult to interpret given that there was no apparent 
reaction with ClO2 and that the authors made no attempt to identify the compounds responsible for the 
mutagenic effect of the reaction mix, so this study does not directly implicate aspartame in the effects 
observed. 
2.3.4.  Potential chemical reactions leading to genotoxicity: Nitrosation 
In preliminary studies using only two Charles River CD rats, dietary nitrite (sodium nitrite, 1 mg/kg 
p.o.) had no effect on the metabolism of DKP (20 mg/kg p.o.) and there was no evidence for any 
reaction between DKP and nitrite when the two compounds were co-administered (Ranney, Kraychy 
et al, 1972a). However, further studies addressing possible reactions between DKP and nitrous acid 
were conducted during initial characterisation of aspartame because DKP, as an amide conversion 
product of aspartame, could react further with nitrous acid under the conditions found in the stomach 
(Unattributed,  N/K-b).  Nitrosamides  have  strong  UV  absorption  meaning  that  it  was  possible  to 
develop an assay which would have been able to detect as little as 0.1% conversion to nitrosated 
derivatives. A nitrosation mixture was prepared by dissolving 0.1% DKP (near saturation) and 0.13% 
sodium nitrite in 0.1 M HCl. The mixture was allowed to stand at room temperature for 1.5 hr. No 
nitrosation  was  detected,  and  the  authors  concluded  that  “the  formation  of  a  nitrosamide,  due  to 
interaction between DKP and nitrites, will not occur under acidity conditions approximating those 
found in the human stomach”. 
Further studies were also carried out in an attempt to determine whether or not aspartame and DKP 
might form nitrosamines under simulated conditions of use (i.e. in the presence of water, HCl and 
(Unattributed, N/K-a).  Under these conditions it was not possible 
to isolate nitrosamides of aspartame or DKP: the yield was <1% using a UV spectroscopic detection 
system  which  could  have  detected  a  1%  yield  from  aspartame  and  a  0.1%  yield  from  DKP. 
Furthermore, studies using analogues indicated that: 
In the case of acetylphenylalanine methyl ester, where the nitrosamide is relatively stable, a yield of a 
few parts per million can be detected. 
Succinylphenylalanine  methyl  ester  (which  is  closely  similar  in  structure  to  aspartame,  with  the 
carboxyl group in the same relative position as in aspartame, yielded a nitrosamide which was very 
unstable in water. 
The apparent nitrosamides of compounds closely related to DKP decompose within a few minutes in 
the presence of water. 
On the basis of this evidence the authors argued that the question of formation and potential toxicity of 
nitrosamides derived from aspartame and DKP could be dismissed (Unattributed, N/K-a).   Review of data on the food additive aspartame 
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Further analysis of potential reactions between DKP and nitrite were carried out as a consequence of 
concern  that  previous  work  had  used  a  suboptimal  system,  since  the  positive  control  compound 
(piperidine) had only generated a nitrosopiperidine yield of 0.5%. In this follow-up study, the reaction 
conditions were modified to give complete nitrosation of piperidine. The same conditions (6.25 mg 
substrate and 0.59 or 0.059 nmoles sodium nitrite made up to 5 ml with 0.25 M phthalate buffer pH4 
answer because of lack of availability of an authentic sample of the hypothetical nitroso derivative of 
DKP, but the results were taken to “strongly suggest” that DKP does not react with nitrite to form a 
nitroso derivative (Unattributed, 1973). 
Little further attention was paid to the issue of nitrosation until 1990, when results from investigations 
into the nitrosation of amino acids and their derivatives, including aspartame, were reported (Meier, 
Shephard et al, 1990). The procedure used in this study was to incubate test compounds (40 mM) with 
40 mM sodium nitrite in 250 mM sodium phosphate buffer pH2.5 for various times. Aliquots of the 
reaction mixture were added to a solution of 4-(p-nitrobenzyl)pyridine, which acted as a nucleophilic 
scavenger. The results state that under these conditions aspartame generated nitrosated products which 
could go on to alkylate 4-(p-nitrobenzyl)pyridine with nitrosation peaking at t=10 min and alkylation 
at t=25 min. The half life of the alkylating product is stated to be 200 min under acidic conditions and 
15 min under neutral conditions. Aspartic acid was also reported to form alkylating species under 
these conditions, and these had a longer half life (500 min and 60  min under acidic and neutral 
conditions,  respectively).    The  reaction  products  are  not  characterised  structurally  in  the  report, 
although it is assumed that they are nitroso compounds.  
This evidence indicating  that the apparent nitrosation products of aspartame have relatively long half 
lives  was  pursued  further  in  1993  by  the  one  of  the  authors  of  the  original  study  (Shephard, 
Wakabayashi et al, 1993). Aspartame was treated with nitrite (40 mM) for 10-30 min at 37 C and 
pH3.5 and the products were subjected to Ames testing in  S. Typhimurium stains TA98, TA100, 
TA102 and TA104 in the presence of hepatic S9 from polychlorinated biphenyl-treated rats. The 
results  suggested  that  “nitrosated  aspartame”  had  a  specific  mutagenicity  of  300  revertants/ mol; 
however,  this  level  of  mutagenicity  was  much  lower  than  that  of  cholecystokinin,  which  yielded 
revertants at  frequency of 4,700/ mol 
It is difficult to interpret these studies given the difficulty experienced by Searle in trying to induce 
aspartame to undergo nitrosation even under aggressive conditions, and the authors of the first study 
(Meier, Shephard et al, 1990) do note that exposure to “nitrosoaspartame” under normal conditions of 
use is likely to be negligible in comparison with the intake of preformed nitroso compounds. These 
studies  should  not  be  ignored,  but  are  unlikely  to be  of  relevance  in the  establishment  of  a risk 
assessment; they are included here for completeness. 
2.3.5.  Revisiting conventional genotoxicity tests 
In a study aimed at clarifying the safety of low calorie foods, DKP was again subjected to Ames 
testing in 1989, this time by an Italian group (Tateo, Berte et al, 1989). The Ames test was conducted 
using S. Typhimurium strains TA97, TA98, TA100, TA535, TA1537 and TA1538. The metabolic 
activation system used on this occasion was hepatic microsomes from rats treated with a mixture of  -
naphthoflavone and phenobarbital (to induce both the CYP1A and CYP2B families of CYP isoforms). 
The Zimmerman test in Saccharomyces cerevesiae was also performed. As in the Searle studies, DKP 
was not mutagenic in the Ames test, with or without metabolic activation; it was also negative in the 
yeast assay. 
A 1995 Russian clastogenicity study reported that aspartame lacks clastogenic activity in C57BL/g 
mice following dosing at 40 or 400 mg/kg over 5 days (Durnev, Oreshchenko et al, 1995). Only the 
abstract of this paper is available in English.   Review of data on the food additive aspartame 
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In 2000, a study using the mouse chromosome aberration test to examine the potential genotoxicity of 
mixtures of aspartame and acesulfame K was reported (Mukhopadhyay, Mukherjee et al, 2000). The 
range  of  doses  used  was  from  3.5  –  350  mg/kg  for  aspartame  and  from  1.5  –  150  mg/kg  for 
acesulfame K. These were intended to represent the proportions of the two sweeteners proposed to be 
permitted to be used together in India. None of the combinations tested induced significant numbers of 
chromosomal aberrations; there was a slight increase in the numbers of aberrations observed but this 
was below statistical significance at all concentrations, and no cytotoxicity was observed. The positive 
control compound, cyclophosphamide, induced both chromosomal aberrations and cellular damage. 
The authors conclude than aspartame in combination with acesulfame K is non-clastogenic within the 
restrictions of the protocol: that is, route of exposure, dose levels used and species tested. 
It has been suggested that, in addition to being non-clastogenic on its own and when dosed as a 
mixture  with  acesulfame  K,  aspartame  may  actually  suppress  the  clastogenic  activity  of  other 
compounds. In one study, combined “therapy” with aspartame (0.4 or 40 mg/kg) and  -carotene (0.5 
or 50 mg/kg) was claimed to alleviate the clastogenic effects of both dioxidine and cyclophosphamide 
in male C57BL/6 mice (Belogolovskaya, Oreshchenko et al, 2000) However, this effect, even if real, 
cannot  be  attributed  to  either  of  aspartame  or  -carotenes  since  the  two  compounds  were  not 
administered separately. 
Not all clastogenicity tests with aspartame have yielded entirely negative results; indeed, the most 
recent study has reported positive results (Al Suhaibani, 2010). In this study, 8-10 week old male 
Swiss albino mice (n=5 per group) were treated with aspartame (3.5, 35 or 350 mg/kg p.o. (vehicle not 
specified)) and sacrificed after 24 h. Femoral bone marrow cells were processed according to standard 
procedures and 50 metaphases per animal were evaluated for chromosomal aberrations (N.B. The 
recommended number of metaphases to count per animal for chromosome aberration studies is 100). 
Sister chromatid exchanges were scored in 30 metaphases per mouse and mitotic index (G2 effects) 
was determined as number of metaphases per 1,000 cells. The results presented indicate that aspartame 
induced an increase in chromosomal aberrations at 35 and 350 mg/kg but not at 3.5 mg/kg; however, 
all the values reported are very low and when combined with the fact that the number of spread 
evaluated does not meet current standards this makes the results difficult to interpret. No increases in 
sister  chromatid  exchanges  or  mitotic  indices  were observed.  The  low  incidence  of chromosomal 
aberrations seen in this study does not give cause for concern given the large amount of data indicating 
that aspartame is non genotoxic in a range of assays. 
Overall, the vast bulk of genotoxicity assay data indicates that aspartame is non-genotoxic and the 
sporadic positive results reported tend to arise in studies which are methodologically compromised. 
2.3.6.  Summary 
There is no evidence to indicate that aspartame is genotoxic, either in vitro (with or without metabolic 
activation) or in vivo. Occasional marginal positive results have been reported, but such results only 
occur sporadically and do not indicate any particular cause for concern. 
2.4.  Chronic toxicity and carcinogenicity 
2.4.1.  Conventional two-year bioassays 
During the early 1970s Searle conducted chronic toxicity studies on aspartame in rats, mice, hamsters, 
dogs and monkeys (McConnell, 1973; Rao, Mauro et al, 1972d; 1972a; Rao, Mauro et al, 1972c; Rao, 
Mauro et al, 1972b; Rao, McConnell et al, 1972; Reno, Ferrell et al, 1973b; Reno, Ferrell et al, 1973a; 
Reno and Ferrell, 1974a; Trutter, Reno et al, 1974). The chronic toxicity of DKP was also investigated 
in the rat and mouse (Rao, Stejskal et al, 1974; Reno and Ferrell, 1974b). The experimental details of 
these  studies  are  summarised  in  Table  6.  Non-neoplastic  lesions  which  could  have  affected  the 
outcome  of  a study  are  included  in Table  6.  A  wide  variety  of  other non-neoplastic lesions  was   Review of data on the food additive aspartame 
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observed  in  these  studies;  those  which  were  present  in  all  treatment  groups  or  showed  no  dose-
dependency are not itemised here but are included in the detailed evaluation of key studies, below  
(Rao, Mauro et al, 1972b; Rao, Stejskal et al, 1974; Reno, Ferrell et al, 1973b; Reno, Ferrell et al, 
1973a; Reno and Ferrell, 1974a; 1974b; Trutter, Reno et al, 1974).  
The initial conclusion drawn from these studies was that aspartame has no marked chronic toxicity 
and,  in  particular,  is  not  carcinogenic  in  animal  models.  However,  some  of  these  studies  were 
compromised by issues such as infections; they were also questioned by some commentators because 
of possible induction of brain tumours in rats and dogs. These issues are discussed in more detail 
below. 
The chronic toxicity study conducted in hamsters (Rao, Mauro et al, 1972d; 1972a; Rao, Mauro et al, 
1972c)  was  severely  compromised  by  an  infection  which  spread  through  the  colony  during  the 
experiment and led to a syndrome resembling “Wet tail”. This caused severe diarrhoea, dehydration, 
GI  tract  distension,  lethargy,  irritability,  anorexia,  emaciation  and  excoriation  of  the  tail  area  in 
affected animals. This led to early termination of the study (at week 46) and means that the study is 
uninterpretable  as  a  lifetime  toxicity  study.  This  study  was  rejected  during  the  in  house  data 
reassurance programme conducted by Searle (Rust, 1976). 
The study conducted by Searle in an attempt to evaluate the safety and tumorigenic potential of DKP 
(Rao, Stejskal et al, 1974) was affected by two intercurrent infections which affected both control and 
DKP-treated  rats.  One  arose  in  weeks  12-14  of  the  study  and  was  diagnosed  as  a  putative  viral 
infection of the salivary and Harderian glands. The other arose during weeks 48-52 and was assumed 
to be bacterial; rats were treated with penicillin G (20,000 u) in an attempt to control this infection. 
This issue, which should be taken into account when interpreting this study, was addressed during 
detailed evaluation of this study; see “Quality assessment of key studies identified by EFSA”, below. 
It should also be noted that this study was severely criticised in an investigation conducted on behalf 
of the Bureau of Foods (Bressler, 1977), which noted (among other deficiencies) that a third outbreak 
of infection resulting in the administration of penicillin had occurred during the course of the study.  
Neither of the chronic studies conducted in rats by Searle indicated any significant increase in tumour 
incidence; however, five brain tumours were identified in one study (Reno, Ferrell et al, 1973a) and 
nine in the other (Trutter, Reno et al, 1974). This led to the expression of concern that aspartame could 
be inducing brain tumours in rats and a request for more detailed evaluation of the brains from these 
studies. In the follow up study conducted in response to this request (Reno, Ferrell et al, 1973b), eight 
coronal sections representing all the major neuroanatomical regions for the brain were evaluated. The 
brains of all rats from both studies were subjected to this level of investigation. 
The outcome of this investigation was as follows: 
In the first study (Reno, Ferrell et al, 1973b), 12 neoplasms affecting the brain were identified. All 
were in aspartame-treated rats; incidence seemed to be treatment-related but not dose- or sex-related. 
The overall incidence of brain tumours in this study (across all groups) was 2.7%. 
No additional brain tumours were identified in brains from the second study (Trutter, Reno et al, 1974) 
but the nine tumours identified in the original study report were confirmed. The incidence of tumours 
in this study appeared to be random. The overall incidence of brain tumours in this study (across all 
groups) was 3.2%. 
The conclusion from this follow-up investigation was that there was no evidence of an intracranial 
tumorigenic effect due to aspartame although brain tumour development did seem to be related to 
treatment in one of the two studies. Further evaluation of this investigation and its conclusions was 
undertaken as part of the quality assessment of key studies identified by EFSA; see below.   Review of data on the food additive aspartame 
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Overall, following internal and external investigation, it was concluded that the rat carcinogenicity 
studies conducted by Searle in the 1970s did not indicate any excess of brain tumours, and their 
findings have been defended vigorously by individuals who were involved in the investigation of these 
studies at the time (Flamm, 1997; Koestner, 1997). 
When a chronic toxicity study was conducted in mice (Reno and Ferrell, 1974a), detailed evaluation of 
brain tissue was built in to the study protocol. Histopathological evaluation of the brain was conducted 
in all mice from which suitable tissue was available. Five coronal sections representing the major 
neuroanatomical areas of the brain were evaluated; ten sections per mouse (2/block) were examined. 
No primary intracranial tumours were observed although four brain metastases from primaries at other 
sites were observed. No other treatment-related neoplastic or non-neoplastic findings were reported in 
this study. 
No brain tumours were reported in the 106 week study conducted in dogs (Rao, Mauro et al, 1972b), 
but focal ependymal proliferation was observed in 2/9 high dose dogs. Histopathological evaluation of 
the original study only included controls and nine high dose dogs, so a follow up study examining all 
brains from this study was requested (McConnell, 1973). Brain sections were evaluated independently 
by two general pathologists and a comparative neuropathologist. The wording of the reports from 
these experts differs slightly, but they agree that in this study “ependymal neoplasms were not present, 
nor was focal ependymal proliferation a notable concern in treated animals” (McConnell, 1973). The 
pathologists did, however, raise issues regarding sample quality and labelling; these are discussed in 
the “Quality assessment of key studies identified by EFSA” section, below. 
When Searle conducted chronic toxicity studies on DKP, detailed histopathological examination of the 
brain was included in the study protocol. In rats (Rao, Stejskal et al, 1974), seven coronal sections 
from each brain, representing all major neuroanatomical areas, were examined. In mice (Reno and 
Ferrell, 1974b) five coronal sections (ten sections per mouse) representing the major neuroanatomical 
areas of the brain were evaluated. One primary brain neoplasm (meningioma) was identified in a 
female control in the mouse study, but no other primary intracranial neoplasms were observed in either 
species in these studies. Metastatic tumours derived from lymphoreticular sarcomas were detected in 
four control and two low dose males and in one female at each dose level. 
One  non-neoplastic  lesion  which  may  merit  further  consideration  is  the  renal  pigment  deposit 
identified in male rats treated with high doses of aspartame (Reno, Ferrell et al, 1973a). This was 
identified as iron-containing haemosiderin and exhibited dose-dependency. Its incidence was: 
7/59 in controls 
1/28 at 1,000 mg/kg/day 
10/30 at 2,000 mg/kg/day 
19/40 at 4,000 mg/kg/day 
29/40 at 8,000 mg/kg/day 
This  was  often  associated  with  focal  hyperplasia  of  the  renal  pelvic  epithelium  and  tubular 
degeneration at 8,000 mg/kg/day. The authors note that “neither renal function nor longevity were 
effected [sic], suggesting that the above effects were of limited biological impact”. It should be noted 
that chronic interstitial nephritis was observed in both treated and control groups, and it is possible that 
the  effects  seen  in  high  dose  animals  are  a  consequence  exacerbation  of  ongoing  inflammatory 
processes  by  the  elevated  concentrations  of  amino  acids  derived  from  high  dose  aspartame.  It  is 
perhaps interesting in this context that a high frequency of chronic progressive nephropathy leading to   Review of data on the food additive aspartame 
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early death has been observed in a study of Sprague-Dawley rats (240M/240F) kept on two different 
basal diets from the age of 5 weeks to the end of the natural lifespan (Nakazawa, Tawaratani et al, 
2001). 
Renal cortical pigmentation has also been observed in other Searle studies (Trutter, Reno et al, 1974), 
although its incidence was only slightly increased in treated animals compared with controls and 
deposits were observed in both sexes. 
A further chronic rat toxicity study was reported in a study report and two published papers in 1981 
(Ishii, 1981; Ishii, Koshimizu et al, 1981a; Ishii, Koshimizu et al, 1981b). An additional document 
reporting follow up histopathological evaluation (Iwata, 2006) also appears to relate to tissues from 
this study. The aim of this 104 week study was to evaluate and characterise the effects of long term 
administration of aspartame of aspartame plus DKP to rats. 
Specific pathogen free SLC Wistar rats aged 4 weeks at the start of the study were treated with 
aspartame (planned to be 1,000, 2,000 or 4,000 mg/kg/day) or aspartame plus DKP (3:1; planned to be 
4,000 mg/kg/day) via the diet. Group sizes were as follows: 
Satellite group 1: 10M/10F per group; sacrificed after 26 weeks 
Satellite group 2: 16M/16F per group; sacrificed after 52 weeks 
Main study: 60M/60F; sacrificed after 104 weeks 
The dietary concentration of aspartame (or aspartame plus DKP) had to be capped at 10% because of 
reduced consumption above this concentration; however, overall actual consumption was within 5% of 
that planned. There were slight variations in mortality between groups, but these were not considered 
to be dose related. Body weight gain was depressed in higher dose (2,000/4,000 mg/k/day)  male 
groups  and  in  all  female  treatment  groups  from  week  20,  in  association  with  reduced  food 
consumption. Increases in urinary specific gravity and reductions in urinary pH were observed at high 
dose levels, as was previously seen in DKP-treated rats; these effects were thought to be due to 
excretion of acidic metabolites of aspartame and/or DKP. In particular, urinary pH may have been 
decreased in response to DKP because it is rapidly excreted almost unchanged in the urine and is 
acidic in aqueous solution (Ishii, Koshimizu et al, 1981b). No adverse biological effects are noted in 
the study report (Ishii, Koshimizu et al, 1981a) although dose-related increases in urinary calcium 
excretion did occur in aspartame-treated animals  (Ishii, Koshimizu et al, 1981b). This effect was 
thought to be due to increased absorption since serum calcium concentrations remained stable and 
there was no evidence of skeletal changes in the study. The increased urinary calcium was associated 
with increased mineralisation in the renal pelvis, but this effect was very slight and was not considered 
to be of biological significance (Ishii, Koshimizu et al, 1981b). 
Histopathological analysis of samples from rats treated with aspartame for 104 weeks is described in 
the original report from this study. The only treatment-related change noted is a dose-related increase 
in mineralisation of the renal pelvis comprising minute deposits in a few epithelial cells. The original 
study  report  states  that  this  was  not  related  to  epithelial  hyperplasia  or  inflammatory  reactions, 
although the follow up study (if this is what it is) reports an increase in transitional cell hyperplasia at 
4,000 mg/kg/day (Ishii, Koshimizu et al, 1981a; Iwata, 2006). An additional search for brain tumours 
is described in one of the accompanying publications (Ishii, 1981). Brains were cut transversely into 
six slices and examined under illumination using a dissecting microscope. Two of the slices were 
further sectioned and prepared for histological analysis, as were any gross abnormalities. No brain 
tumours were observed in the satellite groups dosed for up to 52 weeks; however, six brain tumours 
were  identified  in  rats  treated  with  aspartame  for  104  weeks.  These  comprised  one  atypical 
astrocytoma in a control female and two astrocytomas, 2 oligodendrogliomas and 1 ependymoma   Review of data on the food additive aspartame 
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among the treated groups. These bore no apparent relationship to dose and the only group with more 
than one tumour in the whole group was the 2,000 mg/kg/day (F) group. This finding did not reach 
20%  significance  by  Fischer’s  exact  test.  Overall,  these  findings  were  within  the  range  reported 
previously for brain tumour incidence in Wistar rats (0.09-5.8%; (Ishii, 1981)) and the tumour types 
observed were of the types normally seen in rats of this strain after 1 year of age. 
Further histopathological analysis  (presumably  of  the  same  study),  in  which  a  peer review  of  all 
neoplastic  and  non-neoplastic  lesions  was  undertaken,  was  reported  in  2006  (Iwata,  2006).  No 
significant differences between controls and any treatment group were identified and it was concluded 
that all the tumours observed could have occurred spontaneously. Increased mineralisation of the renal 
pelvis (as reported in the original study) was observed in males at 2,000 and 4,000 mg/kg/day and in 
females at 4,000 mg/kg/day. The mineral deposits were located within or immediately below the 
transitional  epithelium,  especially  at  the  junction  between  the  papilla  and  the  pelvis  and  were 
associated  with  transitional  cell  hyperplasia  in  the  male  high  dose  group.  This  was  attributed  to 
irritation  caused  by  the  mineral  deposition  and  was  considered  by  the  authors  to  be  of  minimal 
toxicological significance. 
2.4.2.  Dietary administration of aspartame until natural death 
Two large chronic dosing studies were recently conducted by the ERF. These studies, the details of 
which have been provided for review in a variety of formats (Belpoggi, Soffritti et al, 2006; Soffritti 
and Belpoggi, 2005; Soffritti, Belpoggi et al, 2005; Soffritti, Belpoggi et al, 2006), differed from 
conventional two year bioassays in a number of ways: 
The rat strain used was Sprague-Dawley, but these were bred in an in house colony at the Cesare 
Maltoni Cancer Research Center (CMCRC) rather than being obtained from commercial suppliers. 
The diet used (“Corticella-type” pelleted diet from Laboratori Dottori Piccioni) is not commercially 
available and its composition is unknown. 
Dosing was continued from 8 weeks of age until the natural death of each animal. 
These  studies  are  summarised  briefly  here;  a  detailed  review  of  their  design  and  findings  was 
conducted as part of the quality assessment of key studies identified by EFSA; see below. 
In the first study, Sprague-Dawley rats (4-5 weeks old) were randomised so as to have no more than 
1M  and  1F  from  each  litter  in  any  given  group.  Aspartame  (purity  >98%;  <1.5%  DKP)  was 
administered  via  the  diet  from  the  age  of  8  weeks  to  natural  death  at  the  following  dietary 
concentrations: 
80 ppm (150M, 150F) 
400 ppm (150M, 150F) 
2,000 ppm (150M, 150F) 
10,000 ppm (100M, 100F) 
50,000 ppm (100M, 100F) 
100,000 ppm (100M, 100F) 
Controls (150M/150F) received the same diet as the test animals. The total duration of the study was 
151 weeks; that is, the last animal died at 159 weeks of age.   Review of data on the food additive aspartame 
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Rat health was monitored frequently (the stated frequency of checks differs in different versions of the 
report, but seems to have been at least twice daily) and necropsies were performed upon natural death. 
Organs and tissues removed at necropsy were preserved in 70% ethanol, except for bones which were 
fixed in 10% formalin and decalcified in 10% formalin/20% acetic acid. All tissues were embedded in 
paraffin, sectioned at 3-5  M and stained with haematoxylin and eosin. Some samples were subjected 
to  immunohistochemical  staining  to  visualise  S100  (a  malignant  Schwannoma  marker)  or 
Chromogranin A (olfactory neuroblastoma). 
Statistical evaluation was carried out using the Cochran-Armitage trend test for linear treads in tumour 
incidence and the poly K-test, a modification of the Cochran-Armitage trend test which takes survival 
into account. 
A complete critique of this study is provided in the quality assessment of key studies identified by 
EFSA, but the following points should be noted when considering its outcomes: 
to take place, thus compromising subsequent histopathological analysis. 
Organs and tissues removed at necropsy were fixed in 70% ethanol. Ethanol is commonly used as a 
fixative  for  cytopathology,  and  sometimes  for  immunohistochemistry  of  antigens  which  could  be 
damaged  by  formalin,  but  it  does  not  provide  adequate  fixation  for  solid  tissues,  especially  for 
purposes of diagnostic histopathology. 
The  study  report  states that  histopathological  evaluation  was conducted  by junior/senior in  house 
pathologists and by a National Institute for Environmental Health Sciences Pathology Working Group; 
it  is  not,  however,  clear  whether  any  diagnoses  were  changed  in  response  to  the  working  group 
findings (Hailey, 2004). 
The study report states that the study was conducted according to GLP; however, the regulations 
followed are not cited although published versions of the study cite Italian animal welfare legislation 
(Decreto Legislativo 116 1992). 
The statistical approach used is unfamiliar to this author; however, a critique of the methods used is 
beyond her expertise. 
The  reported  results  of  this  study  are  summarised  briefly  below;  a  complete  evaluation  of  these 
findings is provided in the quality assessment of key studies identified by EFSA, below. 
There were no evident behavioural changes or differences in water consumption in this study except 
for a slight decrease in intake at the highest dose after week 72. Reductions in food consumption 
occurred in both sexes, but these were not dose-related in males because of a reduction in consumption 
in controls towards the end of the study. No substantial difference in survival was observed among the 
groups. The main non-oncological changes observed were acute and chronic inflammation in the lungs 
and kidneys, including a high incidence of bronchopneumonia in all groups (treated and control). The 
oncological findings which were considered by the study investigators to be aspartame-related were 
total  benign  tumours,  total  malignant  tumours,  malignant  tumours  of  the  brain,  Malignant 
Schwannomas  of  the  peripheral  nerves,  lymphomas  and  leukaemias.  Preneoplastic  and  neoplastic 
lesions of the olfactory epithelium, renal pelvis, ureter and bladder were also reported. 
In the various published versions of the study, the authors highlight the following findings:   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  61 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
A  statistically  significant,  dose-related  increase  in  the  incidence  of  lymphomas  and  leukaemias 
(considered as a single entity) in females at dietary concentrations of 400 – 100,000 ppm (Soffritti, 
Belpoggi et al, 2005). 
“Sparse” malignant brain tumours among treated groups of both sexes, but not in controls (Soffritti, 
Belpoggi et al, 2005; Soffritti, Belpoggi et al, 2006). The brain tumours identified were ten gliomas, 
one medulloblastoma and one meningioma. In considering this finding it should be noted that the 
historical incidence of brain tumours in the rat colony used is 1.7% in males/0.7% in females and that 
this study included 1500 treated animals and only 300 controls. 
Preneoplastic and neoplastic lesions of the renal pelvis and ureter (Soffritti, Belpoggi et al, 2006). 
There was a dose related increases in the incidence of dysplastic hyperplasias and papillomas of the 
renal  pelvis  and  ureter  in  females,  and  21  transitional  cell  carcinomas  of  the  renal  pelvis  were 
diagnosed among the 1500 aspartame-treated animals in this study. No examples of this tumour type, 
which  is  rare  in  untreated  rats,  were  identified  in  the  300  controls  used.  Two  transitional  cell 
carcinomas of the bladder in males (10,000 ppm) and one in a female (2,000 ppm) are also mentioned. 
The relative  numbers  of  treated  and  control  rats  should  be  kept in  mind  when  considering  these 
findings, but it is worth noting that preneoplastic lesions of the renal pelvis were also identified in 
conventional  chronic rat  bioassays  conducted  by  Searle in the  1970s  (Reno, Ferrell  et al,  1973a; 
Trutter, Reno et al, 1974).  
The ERF conducted a further study on lifetime exposure to aspartame. In this study, Sprague-Dawley 
rats (from the same colony as above) were exposed aspartame (>98.7% pure; <0.3% DKP; 400 or 
2,000 ppm in the diet) from prenatal development to natural death (Chiozzotto, Soffritti et al, 2011; 
Soffritti, Belpoggi et al, 2007; Soffritti, Belpoggi et al, 2008). These doses provided daily intakes of 
~20 and ~100 mg/kg/day, respectively (based on assumptions of constant body weight (400 g) and 
food consumption (20 g/day)). Treatment of pregnant females started on pcd 12 and continued in the 
offspring until natural death. The study was carried out according to a similar protocol to the previous 
one and lasted for 147 weeks; the last rat died at 144 weeks of age. Slides were examined by a group 
of pathologists and a senior pathologist reviewed all tumours and other lesions of oncological interest. 
Relationships between tumour incidence and dose were evaluated using the Cox regression model. 
This study is subject to the same comments as the previous one; in particular, dead rats were, in some 
cases, refrigerated for up to 19 hr before necropsy. 
No differences in food and water consumption or mean body weight were observed in this study, 
although there was a slight decrease in survival during the second year of the study in treated groups 
of both sexes. The main findings reported are dose-related increases in benign tumours in females 
(p<0.05), total malignant tumours (significant in males only; p<0.01), mammary adenocarcinomas 
(significant in females, p<0.05) and lymphomas/leukaemias (significant in both sexes; p<0.01 in males 
and p<0.05 in females). The pathologies included under this heading include lymphocytic lymphomas, 
lympho-immunoblastic  lymphomas/leukaemias,  histiocytic  sarcomas  and  myelomonocytic 
leukaemias.  
This study was reviewed by EFSA in a statement issued in 2009 (EFSA, 2009b). This review notes the 
probable association of the lymphomas/leukaemias observed with chronic respiratory disease, as in the 
previous study. The incidence of mammary tumours in the study was not considered to represent a 
carcinogenic  effect  since  mammary  tumour  development  is  a  common  but  variable  pathological 
process in rats. The review also notes that no increases in mammary tumour incidence was observed in 
the previous study, which used a range of doses which overlapped with those used in this study but 
included much higher doses. A further statement, issued by EFSA following submission of additional 
data by the ERF (Soffritti, 2009), reiterates these comments and notes the high and variable incidence 
of mammary tumours in female rats as they age (EFSA, 2009c).   Review of data on the food additive aspartame 
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The ERF has also reported a lifetime study in which aspartame was administered to mice in feed 
beginning prenatally and continuing throughout the life span. The general approach used, including 
the diet used, monitoring  carried out and exposure until natural death, was similar to that in the 
previous rat studies. The mice used were SPF Swiss mice obtained from Charles River. Mating took 
place at 13 weeks of age and was assumed to represent out breeding because of the external origin of 
the mice. All offspring were included in the study; group sizes were 62-122. Aspartame (98.7% pure; 
0.2% DKP) was administered to dams and then offspring via the diet from pcd 12 to natural death of 
the offspring at planned doses of 250, 1,000, 2,000 or 4,000 mg/kg/day. Actual intakes were 247, 987, 
1,919 and 3,909 mg/kg/day.  A final sacrifice was carried out after 130 weeks, at which point survival 
was <10%. There was no apparent difference in survival between groups at this time. All slides were 
evaluated by a junior pathologist and all tumours and lesions of oncologic interest were reviewed by 
two senior pathologists. The results were analysed by the Cox proportional hazard method. 
Aspartame had no effect on the outcome of breeding and food consumption, body weight and survival 
were not substantially different between treated and control groups. There were no clinical findings 
related to aspartame exposure. 
There was no change in the incidence of benign of malignant tumours in male or female mice in 
response  to  aspartame  (the  paper  states  that  there  was  a  “marginal  increasing”  in  the  number  of 
malignant  tumours  in  males,  but  this  was  not  dose-related).  An  increased  incidence  of  hepatic 
neoplasia (hepatocellular adenomas and carcinomas) is reported in males at the two highest doses 
(18.1% at the highest dose vs. 5.1% in controls), but the incidence observed is within the range of in 
house historical controls (3.2%; 0-26.3%). The tumours observed appear, from the photomicrographs 
in  the  paper,  to  be  quite  well  differentiated  with  a  clear  trabecular  structure.  An  increase  in 
alveolar/bronchiolar carcinomas of the lung is also reported in males at the highest dose administered, 
although the increase observed is relatively small (13.3% in the high dose group vs. 6.0% in controls) 
and the incidence in both control and treated groups is within the range of in house historical controls 
(1.45% (0.0-14.3%)), and pulmonary neoplasia has previously been reported as a common finding in 
untreated Swiss mice during long term (≥18 month) studies (Prejean, Peckham et al, 1973). 
The investigators’ conclusion from this study is that “The present study….further confirms that APM 
induces carcinogenic effects in rodents” (Soffritti, Belpoggi et al, 2010). However, this represents over 
interpretation, given that: the total benign tumour rates were not dose-related; the difference between 
controls and the highest dose group was apparently non-significant; and the lung and liver tumour 
incidences observed in controls were relatively low while even at the highest doses used incidences 
were within the range of historical controls. 
A statement by EFSA addressing this study (EFSA, 2011b; 2011a) notes that this study cannot be 
interpreted on the basis of the published report. It also notes that Swiss mice have a high spontaneous 
incidence  of  lung  and  liver  tumours.  The  relevance  of  these  findings  to  humans  is  therefore 
questionable, especially given that mouse liver tumours, particularly those of non-genotoxic origin, are 
not generally considered relevant to human risk assessment. The statement also notes the suggestion 
by Soffriti et al. (Soffritti, Belpoggi et al, 2010) that aspartame-derived methanol could play a role in 
hepatocarcinogenesis, together with the fact that no evidence is provided in support of this suggestion. 
2.4.3.   Commentary on ERF studies 
The  potential  implications  of  the  ERF  studies  on  aspartame  (and  other  compounds,  including 
methanol) have led to intense stakeholder debate (Abdo, Camargo et al, 2007; Abegaz and Soffritti, 
2007; Magnuson, Williams et al, 2008; Manuppello, Willett et al, 2008; Mead, 2006) as well as calls 
for the NTP to conduct its own bioassay on aspartame (Huff and LaDou, 2007). Very soon after the 
publication  of  the  first  study,  an  expert  reviewer  called  for  a    fully  blinded  peer  review  of  the   Review of data on the food additive aspartame 
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aspartame  study  by  board-certified  pathologists,  with  particular  emphasis  on  the  need  for  expect 
consideration of the lymphomas and leukaemias observed (Swenberg, 2005). 
The first study (Soffritti, Belpoggi et al, 2006) was reviewed by EFSA in a statement issued in 2006 
(EFSA, 2006). The statement noted that the lifetime exposure and large number of animals per group 
conferred  on  this  study  the  potential  to  be  sensitive  to  low  incidence  effects;  however,  its  flaws 
(including high background incidence of chronic inflammation of the lungs and other vital organs and 
tissues together with uncertainty regarding the diagnosis of some tumour types) called its findings into 
question. Further consideration of this EFSA opinion is included in the quality assessment of key 
studies identified by EFSA, below. 
The FDA also conducted an evaluation of the ERF study, reaching the conclusion that “...FDA finds 
no reason to alter its previous conclusion that aspartame is safe as a general purpose sweetener in 
food” (FDA, 2007). 
Soffriti  et  al.  (Soffritti,  Belpoggi  et  al,  2007)  note  that  not  all  CMCRC/ERF  studies  show  high 
incidences  of  lymphoma/leukaemia:  the  background  incidence  in  previous  studies  is  20.6%  (8.0-
30.9%) in 2,265 males and 13.3% (4.0-25.0%) in 2,274 females. This represents data from studies  
conducted over a 20 year period, and the comment has been made that a comparison with studies 
conducted over the preceding 5 years would have been more relevant because of possible genetic drift 
within rat colonies (COC, 2006). Other investigators have reported lymphomas and leukaemias to be a 
common neoplastic lesion in aging untreated Sprague-Dawley rats following exposure to two different 
basal diets (Nakazawa, Tawaratani et al, 2001). 
There has been intense debate over the last 3-4 years regarding the possibility that the apparent high 
incidence of lymphomas/leukaemias in ERF rat carcinogenicity studies was a consequence of infection 
by  the  organism  M.  pulmonis.  For  further  information  on  infection  by  this  organism  and  its 
implications  in  animal  studies,  see 
http://www.criver.com/SiteCollectionDocuments/rm_ld_r_Mycoplasma_pulmonis.pdf. 
A detailed evaluation of ERF studies carried out by the National Center for Environmental Assessment 
(EPA) concluded that: “An examination of the bioassays used by the ERF and NTP shows that the 
ERF bioassay program produces credible results, consistent with those of NTP” and that “The study 
length and rat strain used by the ERF may explain why lymphomas/leukaemias in ERF bioassays have 
not  always  been  reproduced  in  NTP  or  similar  bioassays”  (Caldwell,  Jinot  et  al,  2008).  These 
commentators did not consider that M. pulmonis infection was a likely explanation of the results 
obtained. 
Other commentators do not accept this evaluation, noting the lack of testing for mycoplasma infection 
at the ERF, the high background rate of lymphoma and leukaemia in the colony used and the fact that 
the incidence of these tumour types in the aspartame and  methyl tert-butyl ether (MTBE) studies 
conducted at the ERF was within the range of previous control values (Goodman, Beyer et al, 2009). 
Schoeb et al, for example, consider it highly likely that the rats in the ERF bioassays were infected 
with M. pulmonis characterised by accumulation of lymphocytes and plasma cells in the lung (Schoeb, 
McConnell et al, 2009a; Schoeb, McConnell et al, 2009b; Schoeb and McConnell, 2011a; 2011b) and 
that  this  was  the  likely  cause  of  the  bronchopneumonia  observed  in  rat  ERF  studies.  They  also 
consider  that the  olfactory  epithelial  lesions  observed  in  ERF  studies  are  typical  of  M.  pulmonis 
disease. Caldwell et al, however, maintain their position (Caldwell, Jinot et al, 2009). It is interesting, 
in the light of this discussion, to note that the ERF rat colony is conventionally maintained and that the 
mouse study, which used SPF animals, did not indicate a carcinogenic effect due to aspartame. 
The conclusion of Schoeb et al (Schoeb, McConnell et al, 2009a), based upon tabulation of the results 
from  the  aspartame,  MBTE  and  methanol  bioassays  conducted  by  ERF,  is  that  the  pulmonary   Review of data on the food additive aspartame 
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localisation  of  the  tumours  observed,  as  well  as their  mixed cellular  pattern which is atypical  of 
lymphomas, make it likely that these assays were compromised by M. pulmonis disease and that the 
disease lesions were misdiagnosed as lymphomas. They do not, however, consider that pulmonary 
lymphoma induction is a likely consequence of infection with M. pulmonis. They recommend further 
evaluation of slides, including respiratory tract sections, from ERF studies and testing of samples for 
M. pulmonis. 
Such an evaluation has been conducted for the ERF bioassay on methanol (Schoeb and McConnell, 
2011b). The review was conducted by an NTP Pathology Working Group. The group diagnosed fewer 
lymphomas and leukaemias in lung and lymph nodes compared with the ERF pathologists. The NTP 
pathologists diagnosed about twice as many inflammatory lesions as the ERF study pathologist and 
found that 100% of the rats in both dose groups had inflammatory lesions in at least one of the nose, 
ear, and lung. They also noted that ‘‘leukemia or lymphoma was sometimes difficult to distinguish 
from the intense, marked lymphocytic infiltrates related to the chronic inflammation of the lung.” The 
commentators consider these results to be consistent with the view that lesions of M. pulmonis disease 
were interpreted as lymphoma in this bioassay. 
Another commentary by the same authors (Schoeb and McConnell, 2011a) notes the content of a court 
deposition indicating the presence of antibodies to “mycoplasma” in ERF rats. It also notes that the 
distribution of lesions in the lymph nodes and spleen is no more consistent with lymphoma than M. 
pulmonis  disease.  It  concludes  that  “…it  cannot  be  ascertained  whether  lesions  diagnosed  as 
pulmonary lymphoma were caused by chemical exposure, by M pulmonis, or by an interaction of the 
two” and recommends that “For these reasons, we strongly believe that no regulatory agency should 
include the reported induction of lymphoma in these bioassays in cancer risk assessments unless such 
effects can be verified”. 
These evaluations of the ERF studies and observations thereon is considered in more detail as part of 
the quality assessment of key studies identified by EFSA, below. 
2.4.4.  Studies using the intravesical pellet implant technique 
None of the above chronic toxicity studies indicated any increase in tumour incidence in the urinary 
bladder, despite the fact the careful histological evaluation of the bladder was undertaken in most of 
the studies. However, concern regarding the possibility that artificial sweeteners may cause bladder 
cancer led Searle to sponsor several investigations using the intravesical pellet implant technique to 
investigate the possibility that aspartame and/or DKP could induce urothelial tumours following direct 
exposure (Bryan, 1973a; 1973b; 1974b; 1974a). In these experiments, pellets of purified cholesterol 
(20-22 mg) containing 20% (4.4-4.4 mg) aspartame or DKP were surgically implanted into the lumen 
of the albino female mouse bladder. Mice were maintained for either 26 or 56 weeks; the incidence of 
urothelial and other tumour types was then evaluated.  
No bladder tumours were observed in animals killed prior to 175 days’ exposure in any of these 
studies. Control and aspartame-treated mice surviving for longer than 175 days had similar incidences 
of urinary bladder tumours whether determined after 26 or 56 weeks (Bryan, 1973a; 1974b). There 
was a small increase in bladder tumour incidence following implantation of pellets containing DKP 
(17.2 % vs. 7.2%) after 26 weeks (Bryan, 1973b) but this was not statistically significant; nor was it 
observed in the 56 week study (Bryan, 1974a). 
The  incidence  of  other  tumours  in  mice  from  the  56  week  studies  were  comparable  to  reported 
incidences in untreated Swiss mice; there were no differences in overall tumour incidence between 
control aspartame- and DKP-treated mice.   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  65 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
These studies, while interesting, are somewhat esoteric. They were carried out to a good academic 
standard, but they do not suggest any effect of aspartame or DKP on bladder tumour incidence even 
following direct exposure of the urinary epithelium. It should also be noted that they have limited 
relevance in the context if risk assessment since the lack of oral bioavailability of aspartame means 
that the bladder would not normally be exposed to intact aspartame after dietary exposure, even at 
high doses. 
The only additional study addressing bladder carcinogenesis directly is one in addressing the potential 
tumour promoting effects of artificial sweeteners dosed at 5% in the diet (Hagiwara, Fukushima et al, 
1984). In this study, aspartame had no effect on transitional cell hyperplasia induced by N-butyl-N-(4-
hydroxybutyl)nitrosamine dosed at 0.1% in the drinking water for 4 weeks. No clinical abnormality or 
mortality was observed in response to aspartame. Of the other sweeteners evaluated in this study, 
stevioside  had  no  effect  but  saccharin  increased  the  incidence  of  preneoplastic  lesions  and 
nodular/papillary hyperplasia. 
2.4.5.  Studies using transgenic mouse models 
As part of the evaluation of transgenic mouse lines as alternative models for cancer screening, the 
NTP recently undertook to test aspartame in three novel models, the Tg.Ac model, the p53
+/- model 
and the Cdkn2a
-/- strain (NTP, 2005). It is interesting to note that aspartame was chosen for the NTP 
programme of development of alternative carcinogenicity bioassays as an example of a presumed non-
carcinogen. 
In this study, male and female Tg.Ac, p53
+/- and Cdkn2a
-/- mice were given feed containing aspartame 
(>98% pure) for 9 months. The 9 month exposure period was chosen in preference to a 6 month 
regiman (which is more common for studies in these transgenic models) in the hope of enhancing 
sensitivity. 
Briefly, the study design was as follows: 
  Tg.AC mice (FVB/N-TgN(v-Ha-ras)Led (Tg.AC) hemizygous; 15M/15F per group) were fed 
diets containing 0, 3,125, 6,250, 12,500, 25,000, or 50,000 ppm aspartame (equivalent to 
average daily doses of approximately 490, 980, 1,960, 3,960, or 7,660 mg aspartame/kg body 
weight to males and 550, 1,100, 2,260, 4,420, or 8,180 mg/kg to females) for 40 weeks. 
  p53
+/- mice (B6.129-Trp53
tm1Brd (N5) haploinsufficient; 15M/15F per group) were fed diets 
containing 0, 3,125, 6,250, 12,500, 25,000, or 50,000 ppm aspartame (equivalent to average 
daily doses of approximately 490, 970, 1,860, 3,800, or 7,280 mg/kg to males and 630, 1,210, 
2,490, 5,020, or 9,620 mg/kg to females) for 40 weeks. 
  Cdkn2a
-/-  mice  (B6.129-Cdkn2a
tm1Rdp  (N2)  deficient;  15M/15F  per  group)  were  fed  diets 
containing 0, 3,125, 6,250, 12,500, 25,000, or 50,000 ppm aspartame (equivalent to average 
daily doses of approximately of approximately 490, 960, 1,900, 3,700, and 7,400 mg/kg to 
males and 610, 1,200, 2,390, 4,850, and 9,560 mg/kg to females) for 40 weeks. 
The results obtained were: 
No neoplasms or non-neoplastic lesions attributed to exposure to aspartame were observed in Tg.Ac 
mice.  This  model  is  usually  used  to  detect  papilloma  development  in  the  skin  following  dermal 
exposure;  forestomach  papillomas  may  also  develop  in Tg.AC  mice  following  oral  exposure.  No 
increase in either of these tumour types was seen following dosing with aspartame. Some male mice 
developed alveolar/bronchiolar adenomas, but these were not dose-dependent and were also seen in 
historical controls from the same mouse line. Sporadic salivary gland carcinomas were also observed   Review of data on the food additive aspartame 
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but  were,  again,  not  dose  related  and  had  previously  been reported in this line  following  dermal 
application of compounds.  
No neoplasms or non-neoplastic lesions attributed to exposure to aspartame were observed in p53
+/- 
mice; indeed, all the lesions reported in this line following a 9 month exposure protocol were non-
neoplastic (inflammatory infiltration of the salivary gland, atrophy of the adrenal cortex and adrenal 
subcapsular hyperplasia). 
The only adverse findings reported in Cdkn-/- mice are minimal to mild cytoplasmic vacuolization of 
periportal  hepatocytes  in  males  exposed  to  6,250,  25,000,  or  50,000  ppm  aspartame  and  mild 
nephropathy in high dose males; it was unclear whether these effects were dose-related. The Cdkn
-/- 
model is less well established than the Tg.AC and p53
+/- models, so any results obtained using this 
mouse line should be interpreted with caution. 
The overall conclusion drawn from this study was: “Under the conditions of this 9-month feed study, 
there was no evidence of carcinogenic activity of aspartame in male or female p53 haploinsufficient 
mice exposed to 3,125, 6,250, 12,500, 25,000, or 50,000 ppm” (NTP, 2005). However, the report 
notes that “Because this is a new model, there is uncertainty whether the study possessed sufficient 
sensitivity to detect a carcinogenic effect”. No firm conclusions are drawn from the results obtained in 
Tg.AC and Cdkn
-/- mice. 
It should be noted that this study was carried out according to FDA GLP regulations (21 CFR, Part 58) 
and  was  also  audited  retrospectively  on  submission  to  the  NTP  archives.  The  pathology  results 
(including all lesions potentially related to chemical administration) were subjected to peer reviewed 
by a Pathology Working Group, which confirmed that no brain neoplasms were present and noted the 
absence of non-neoplastic effects in any of the three strains tested (Long, 2002). Furthermore, its 
findings have been assessed by an expert reviewer (Swenberg, 2005), who concluded that the studies 
provide no evidence of carcinogenesis due to aspartame. 
This NTP study is the only reliable evidence concerning potential effects of aspartame on oncogenes 
and tumour suppressor genes. The only other study purporting to address changes in oncogene and 
tumour suppressor gene expression in response to aspartame is one in which CBA/CA mice were 
treated with aspartame (40, 200 or 2,500 mg/kg p.o.) for one week (Gombos, Varjas et al, 2007). Up 
regulation of c-myc, p53 and H-ras mRNAs, as detected by RNA dot blot analysis, in the lymph nodes 
is reported at all three doses. However, this study is unreliable because it is poorly described and 
pooled samples were used for analysis. In any case, effects on oncogene and tumour suppressor gene 
expression after one week’s exposure cannot be extrapolated to draw conclusions regarding possible 
molecular changes during tumour development in the long term. 
2.4.6.  Cancer concerns in humans 
Concern  about  the  possibility  that  saccharin  might  induce  bladder  cancer  has  sometimes  led,  by 
analogy,  to  similar  concerns  regarding  aspartame.  In  order  to  address  such  concerns,  the 
epidemiological data concerning potential links between artificial sweeteners and bladder cancer are 
summarised  in  Table  7.  None  of  these  studies  addresses  aspartame  directly;  most  of  them  were 
published before the approval of aspartame as a dietary sweetener and only four studies, one of which 
suggests a possible increase in cancer risk due to artificial sweeteners, have been published since 
1990.  The  majority  of  these  studies  indicate  no  additional  risk  associated  with  use  of  artificial 
sweeteners and none of them provide any direct evidence that aspartame is linked to bladder cancer. 
Additional concerns regarding possible carcinogenic effects of aspartame in humans were triggered by 
a paper published by Olney and colleagues  in 1996 (Olney, Farber et al, 1996). In this paper, a 
connection is postulated between increasing incidences of brain and spinal cord tumours based upon   Review of data on the food additive aspartame 
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an analysis of data from the NCI Surveillance, Epidemiology and End Results program. This program 
addresses cancer incidence in nine catchment areas across the USA, representing 10% of the US 
population. Site recodes representing meninges, spinal cord, cranial nerves or miscellaneous CNS 
tumours  (31040)  and  brain  (31010),  with  the  corresponding  histology  codes,  were  considered. 
Incidences for each year and tumour type were plotted. The authors interpret the resulting incidence 
curves as being biphasic (they are actually quite erratic, but with a distinct discontinuity between 1984 
and 1985). Interestingly, the curves for astrocytoma and glioblastomas are near mirror images of each 
other, possibly reflecting differences in diagnostic patterns between these tumour types. The incidence 
curve for anaplastic astrocytomas is more-or-less sigmoid and levels off after about 1989 after what is 
described as a “striking increase” in highly malignant astrocytic tumours in the mid to late 1980s. The 
authors suggest that this pattern of increase is associated with aspartame consumption following its 
approval in 1981 (and extended approval in 1983). They do not, however, present any consumption 
data.  Furthermore,  they  do  not  address  the  latency  of  brain  tumours  (Butchko,  1997):  tumours 
diagnosed in the mid to late 1980s would probably have arisen as a result of initiation and promotion 
events  taking  place  prior  to  the  approval  of  aspartame.  This  issue,  along  with  the  fact  that  the 
conclusions  drawn  are  compromised  by  the  ecological  fallacy,  has  been  highlighted  by  various 
commentators  (Ross,  1998;  Weihrauch  and  Diehl,  2004),  although  others  welcomed  the  study’s 
findings (Roberts, 1997). The same criticisms have been levelled against the claim that aspartame is 
temporally linked to an increase in the incidence of breast and prostate cancer (Schwartz, 1999). 
Others have pointed out that the change in apparent incidence of brain tumours is largely a function of 
improved diagnostic methods, including MRI, and the way in which the data are presented by Olney et 
al exaggerates the real, but relatively small, changes in incidence which have occurred (Levy and 
Hedeker, 1996). 
In an attempt to resolve the issue of possible brain cancer risk, data on aspartame consumption was 
collected from paediatric brain tumour patients and controls from 19 West Coast counties in the USA 
(Gurney, Pogoda et al, 1997). Patients were asked about consumption prior to diagnosis while controls 
provided information representing a similar time period. Cases (n=56) diagnosed with a primary brain 
tumour between 1984-1991 and aged ≥19 years when the study was conducted were matched for age, 
sex, year of birth and study site with controls (n=94) recruited by random dialling. Risk was also 
considered in relation to maternal aspartame consumption during pregnancy and breast feeding (49 
cases and 90 controls). The results indicated that case children were no more likely to have consumed 
aspartame, either from all sources (Odds Ratio (OR)=1.1) or from diet drinks (OR=0.9), than controls. 
In addition there was no suggestion of a dose response for age at first consumption, number of years of 
consumption or frequency of consumption and risk was not associated with maternal consumption 
during any part of pregnancy or breast feeding. These observations were considered unlikely to have 
been due to recall bias, although the possibility that exposure misclassification could have masked a 
true but weak effect was recognised. The authors conclude that “We found no evidence to support the 
hypothesis that consumption of aspartame is related to paediatric brain tumour occurrence” (Gurney, 
Pogoda et al, 1997), although the long latency of brain tumours and the associated possibility of long 
term effects of consumption are recognised. 
The question of aspartame intake and brain tumours was also considered as part of a study on mobile 
phone use in patients with malignant brain tumours diagnosed between 1994 and 1996 in the Uppsala-
Ӧnebro and Stockholm regions of Sweden (Hardell, Mild et al, 2001). Two controls per case (matched 
for age, sex and region) were drawn from population registers. The exposures considered were mobile 
phone use, medical x-rays and aspartame (assessed as soft drink consumption) in terms of years of 
intake, times per day/week and amount consumed per serving. The final number in the study was 425 
controls and 209 cases (136 malignant and 62 benign tumours; one patient had two tumours). The 
calculated Ors were: for all tumours, 1.24 (0.72-2.14) and for malignant tumours 1.70 (0.84-3.44). The 
discussion  states  that  “we  found  a  non-significantly  increased  risk  for  malignant  brain  tumours”,   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  68 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
although this is not included in the main conclusions of the study or in the abstract. Note that the 95% 
confidence intervals from both tumour classifications comfortably include an OR of 1.00. 
Further consideration of possible associations between self-reported consumption of aspartame and 
incident haematopoietic and brain cancers was undertaken as part of the NIH-American Association of 
Retired Persons (AARP) Diet and Health Study (Lim, Subar et al, 2006). Questionnaires were mailed 
to members of the AARP who were 50-71 years old and lived within one of eight selected study areas 
in  the  USA.  After  sifting,  473,984  responses  (285,079M/188,905F)  were  considered.  The  cancer 
outcomes  considered  were  lymphoid  and  non-lymphoid  tumours  (Hodgkin’s  and  non-Hodgkin’s 
lymphomas  and  multiple  myelomas),  gliomas,  meningiomas  and  neuromas/Schwannomas. 
Assessment  of  aspartame  consumption  focussed  on  consumption  via  cold  beverages  (sodas,  fruit 
drinks and iced teas), tea and coffee drinks (sachets) but not food. Frequency of consumption was 
classified in categories from “never” to “6+ times per day”. Daily consumption of aspartame was 
calculated assuming standard contents of aspartame but actual aspartame content of the beverages 
consumed was not verified. Individuals with high aspartame intakes were more likely to have a history 
of diabetes and be overweight (as assessed by BMI), but consumption of aspartame above 400-600 
mg/day was not associated with an increased risk of haematopoietic cancer (RR=0.98; 0.76-1.27), 
glioma (RR=0.73; 0.46-1.15) or glioblastoma (RR=0.64; 0.37-1.10). 
This study had a number of strengths, including size (allowing the inclusion of rare subtypes), data 
collection  prior  to  diagnosis  and  histological  confirmation  of  cases.  It  is  important  to  recognise, 
however, that the possibility of long term adverse effects of aspartame cannot be excluded on the basis 
of this study because the population addressed, being 50-71 years old in 1995-6, would not have been 
exposed to aspartame for more than, at the most, 15 years (Davis, Ganter et al, 2008). The study has 
also been criticised by the Truth in Labelling Campaign, which considered it unreliable because of the 
age of the participants, the use of beverage consumption as an indicator of aspartame intake, the 
relatively low levels of consumption reported and the variability between subgroups which, it claimed, 
would  have  obscured  any  effects  due  to  aspartame  (Samuels,  2007).  The  original  investigators’ 
response to this criticism was that beverage consumption does account for the majority of intake by 
consumers since the amounts of aspartame in foods and pharmaceuticals is relatively small, and that 
even in high level consumers no effects were observed (Lim, Hartge et al, 2007). 
Two recent papers (Bosetti, Gallus et al, 2009; Gallus, Scotti et al, 2007) have addressed the roles of 
artificial sweeteners in cancer risk in a network of case-control studies conducted between 1991 and 
2004 in various Italian regions. Numbers of cases per tumour type were 230 (gastric cancer) to 2569 
(breast cancer) and numbers of controls were 547 (gastric cancer) to 4154 (colon and rectum).  A 
structured questionnaire was used to estimate sweetener consumption in terms of sachets or tablets per 
week and sugar in terms of teaspoons per week. Risks for various tumour types were calculated 
against “all low calorie sweetener use”, “saccharin” and “other sweeteners”. The latter category was 
assumed  to  represent  mainly  aspartame.  Odds  ratios  (and  95%  confidence  intervals)  for  various 
tumour types vs. “other sweeteners” were as follows: 
Oral cavity/pharynx: OR=0.77 (0.39-1.53) 
Oesophagus: OR=0.77 (0.34-1.75) 
Colon: OR=0.90 (0.70-1.16) 
Rectum: OR=0.71 (0.50-1.02) 
Larynx: OR=1.62 (0.84-3.14) 
Breast: OR=0.80 (0.65-0.97)   Review of data on the food additive aspartame 
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Ovary: OR=0.75 (0.56-1.00) 
Prostate: OR=1.23 (0.86-1.76) 
Kidney: OR=1.03 (0.73-1.46) 
Gastric cancer: OR=0.86 (0.45-1.67) 
Pancreatic cancer: OR=1.16 (0.66-2.04) 
Endometrial cancer: OR=1.07 (0.71-1.61) 
Similar results were obtained when “all low calorie sweetener use” and “saccharin” were considered, 
and the investigators conclude that the original study (Gallus, Scotti et al, 2007) and the subsequent 
update (Bosetti, Gallus et al, 2009) provide no evidence that saccharin or other sweeteners (mainly 
aspartame) increase the risk of cancer at several common sites in humans. 
One additional study has addressed the link between aspartame consumption (as one of a number of 
lifestyle  factors)  and  risk  of  brain  tumours  (Cabaniols,  Giorgi  et  al,  2011).  This  study,  which 
considered the relationship between risk of malignant primitive brain tumours and medical history, 
private  habits  (including  aspartame  use)  and  psychological  stress,  was  conducted  in  the  western 
section of the Provence-Alpes-Côte d’Azur administrative region of France. Untreated cases of glioma 
(Grades II-IV) who were ≥18 years old when diagnosed in 2005 were included. Grade I was excluded 
because  this  is  primarily  a  paediatric  tumour  type.  Matched  controls  were  recruited  from  the 
neurosurgical unit of the same hospital. Lifestyle and personal history information was collected using 
standardised,  structured  questionnaires  completed  by  patients  or  family  members;  a  medical 
questionnaire  was  administered  by  and  occupational  physician.  Data  collected  included:  physical 
parameters; history of head trauma/surgery; smoking; alcohol consumption; vaccination history; and 
dietary habits (fruit and vegetable consumption, vitamin supplements, aspartame consumption and 
daily eating habits). Socioeconomic status and psychological stress were also assessed. Most of the 
factors considered had no discernible effect on risk; the OR for aspartame consumption more than 
once per week was 1.02 (0.57-1.85). The factors which did affect risk were a major life event within 5 
years (OR=1.90), a family history of cancer (OR=1.90), fruit and vegetable consumption more than 
once daily (OR=0.29) and skipping meals several times per week (OR=0.35). 
2.4.7.  Chronic oral toxicity in primates 
The only study addressing the chronic effects of aspartame on primates is a 52 week oral toxicity 
study in neonatal rhesus monkeys undertaken at the Primate Research Center, Madison, WI (Rao, 
McConnell et al, 1972). Starting in infancy, rhesus monkeys (Macaca mulatta) from full term normal 
pregnancies were dosed with aspartame (containing 0.2-1.0% DKP), which was mixed with Similac 
milk  formula  and  administered  four  times  daily.  Following  gradual  increases  in  the  doses 
administered, mean daily doses of 970 mg/kg/day (planned dose 1,000 mg/kg/day; 1M/1F), 3,010 
mg/kg/day (planned dose 3,000 mg/kg/day; 2M/1F) and 3,620 mg/kg/day (planned dose 4,000-6,000 
mg/kg/day; 2M) were attained. The actual duration of dosing ranged from 210-363 days. 
Survival was 100 % in all except the highest dose group; one monkey in this group died after 300 
days’ treatment. Food intake and growth rate were mildly reduced by treatment with aspartame. One 
low dose monkey, which had an apparent congenital abnormality,  was kept on the study but had 
reduced weight gain compared with other monkeys on the study. Haematology and clinical chemistry 
parameters  were  generally  unremarkable  in treated animals  except for increased  serum  [Phe]  and 
[Tyr], associated with increased urinary phenylketone levels, in medium and high dose groups after six 
months.   Review of data on the food additive aspartame 
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The main adverse effect observed in this study was that animals in both the medium and high dose 
groups started to experience grand mal seizures, the first such event occurring on day 218. Occurrence 
of seizures was associated with high serum [Phe]; similar convulsions occurred in monkeys fed L-Phe 
in  equimolar  quantities.  In  the  low  dose  group  no increase in serum  [Phe] was  observed and no 
seizures occurred. Intermittent seizures  occurred thereafter for the remainder of the study, usually 
occurring  during  handling.  Treatment  was  withdrawn  for  the  last  three  months  of  the  study;  no 
convulsions were observed during this period. 
All the medium and high dose monkeys in this study contracted Shigella infections during this study, 
and the data reassurance programme conducted by Searle rejected it on this basis (Rust, 1976). It 
should also be noted that the study included no control group; instead, historical control data were 
relied upon for comparison. Finally, no post-mortem observations were undertaken at the end of this 
study because the Principal Investigator died during the course of the study. 
2.4.8.  Summary 
The results of conventional chronic toxicity studies carried out in the 1970s did not indicate any 
significant neoplastic or non-neoplastic pathological effects in rodents dosed with aspartame via the 
diet. These studies were unsatisfactory in a number of ways, including the presence of infections 
requiring antibiotic treatment in one study, and they were subjected to detailed investigation by the US 
Bureau of Foods in the 1970s. The outcome of the investigation was that the studies were essentially 
reliable but that they were limited by a number of shortcomings in terms of diet preparation, protocol 
compliance and QA. Furthermore, when the studies were issued, concern was expressed regarding a 
possible excess of brain tumours in rats dosed with aspartame via the diet; however, further detailed 
examination  of  tissue  from  these  studies  did  not  indicate  any  treatment  related  effects  on  brain 
tumours.  
Three additional chronic toxicity studies (two in rats and one in mice) were recently reported by the 
ERF. In these studies, aspartame was administered from early life (in utero in one study) until the 
natural  death  of  the  animals.  Increased  incidences  of  a  variety  of  tumour  types  (including,  in 
particular, lymphomas and leukaemias) were reported in these studies, which have been the subject of 
intense controversy since the first one was published in 2005. The studies are difficult to interpret 
because the increased tumour incidences are close to those seen in control animals in other studies and 
there  is  evidence  that  the  animals  may  have  been  infected  with  the  organism  M.  pulmonis. 
Furthermore,  a  number  of  methodological  issues  call  these  studies  into  question.  These  include 
allowing  the  animals  to  die  naturally,  storing  the  carcasses  for  up  to  19  hr  before  performing 
necropsies, and fixing the tissues in ethanol rather than a conventional fixative such as 10% neutral 
buffered formalin (NBF) which would give better morphology. 
Overall,  the  available  chronic  toxicity  studies  do  not  indicate  any  overt  carcinogenic  effect  in 
experimental animals due to aspartame, but all the conventional studies are limited in various ways. 
These studies were subjected to more detailed review during the quality assessment of key studies 
identified by EFSA. Reassurance has recently been provided by a GLP-compliant study conducted by 
the NTP using transgenic mouse models. This indicated that aspartame had no carcinogenic effect in 
Tg.AC, P53
+/- or Cdkn2a
-/- mice dosed for 9 months via the diet. 
Concern regarding possible carcinogenic effects of aspartame has mainly focussed upon tumours of 
the bladder and brain. The issue of bladder carcinogenesis arose mainly by analogy with saccharin, 
which  is  known  to  induce  bladder  tumours  via  a  male  rat  specific  mechanism  involving  2-
microglobulin. A number of epidemiological studies were conducted in the between the 1970s and the 
1990s in an attempt to determine the relevance of these findings to humans; their results were variable 
but the majority did not indicate any increase in risk of bladder cancer in humans due to artificial   Review of data on the food additive aspartame 
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sweetener consumption. None of these studies addressed aspartame directly and many of them were 
carried out in populations diagnosed before aspartame entered the market. 
The issue of brain tumour induction by aspartame arose partly because of the suggestion of increased 
brain tumour incidence in chronic rat studies and partly following the publication of a paper stating 
that an increase in brain tumour incidence in the USA had coincided with the release of aspartame. 
Subsequent  epidemiological  studies  have  not  identified  any  association  between  brain  tumour 
incidence and use of aspartame; indeed, studies of artificial sweetener use in which risks associated 
with  saccharin  and  other  sweeteners  (presumed  to  represent  mainly  aspartame)  are  considered 
separately provide no evidence for an increased risk of any tumour type in humans. 
Treatment of rhesus monkeys with high doses of aspartame for the first year of life did not have any 
significant effect on biochemical parameters, but animals dosed with aspartame at doses above 3,000 
mg/kg/day experienced grand mal seizures beginning after about 30 weeks’ treatment. It is difficult to 
evaluate the significance of this finding because all the monkeys thus affected contracted a Shigella 
infection during the study, and it was rejected by the Searle data reassurance programme on this basis. 
2.5.  Reproductive and developmental toxicity 
Initial studies on the reproductive and developmental effects of aspartame and DKP were conducted 
by Searle and submitted as part of their original dossier. These studies focussed on rodents and rabbits, 
although some primate data were also generated. Other investigators began to pursue this issue in the 
1980s. 
2.5.1.  Effects on reproductive performance 
In the early 1970s, Searle undertook two studies of the reproductive effects of aspartame, one of which 
was followed up with a neonatal toxicity study in offspring from the F2 generation (Reno, 1971; Reno 
and Ferrell, 1972; Schroeder, Rao et al, 1972), and a similar study of DKP (Schroeder, Mitchell et al, 
1973b). 
The first of these, a two-generation study (Reno, 1971) was conducted in order to characterise the 
effects of aspartame on the reproductive performance of albino rats. Stratified randomisation by body 
weight was used to group albino Charles River CD rats which were dosed with aspartame over two 
generations. The planned doses of aspartame were 2,000 and 4,000 mg/kg, given to males (starting 
with n=12 per group) and females (n=24/treatment group) and adjusted weekly on the basis of body 
weight and food consumption. Prior to mating of the parental (P1) generation (at 90-100 days of age), 
rats were fed the appropriate diet for 9 weeks. During this period, actual intakes determined in weeks 4 
and 9 were 1,550 – 1,980 mg/kg/day and 3,120 – 3,830 mg/kg/day for the low and high dose groups, 
respectively. On birth of the F1A litters, general observations were carried out and the litters were 
reduced  to  10  pups/litter.  On  reaching  sexual  maturity,  10M  and  20  F  (19  controls)  from  each 
treatment group (P2) were interbred to produce the F2 generation. The F2A litters were reduced to 8 
pups/litter and allowed to grow to weaning, at which point 10 of each sex per group were necropsied 
and 20 organs were sampled for histopathological evaluation. 
A detailed evaluation of this study was undertaken as part of the quality assessment of key studies 
identified  by  EFSA,  below.  Briefly,  the  authors  report  all  parameters  to  be  comparable  between 
control and test groups except for body weight suppression at weaning among high dose pups, which 
was evident in both F1A and F2A generations. These offspring were also generally smaller than control 
pups. 
Offspring from this study were subjected to further evaluation at various times post-partum (Reno and 
Ferrell, 1972). At 24 h post-partum, 10 pups per group (2 per litter) were killed, gross necropsies were 
performed and tissues were preserved for histopathology. The same procedure was followed on post   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  72 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
natal days (pnds) 5, 15 and 21. In addition, samples were taken for haematological evaluation on pnds 
5, 15 and 21 and for clinical chemistry analysis on pnds 15 and 21. 
No stillbirths were observed among litters selected for this study; the appearance of all pups was 
normal at 24 hr, although 6 were subsequently lost through cannibalisation. No gross pathology was 
observed and clinical laboratory parameters were within their normal ranges except for a general 
reduction in white blood cell counts on pnds 15 and 21 (significant in males on pnd 15 and females on 
pnd  21).  No  histopathological  alterations  were  observed  in  the  liver,  heart  or stomach  but subtle 
histological changes (minimal to slight hypertrophy and vesiculation of nuclei in the tubules of the 
inner cortex) were observed in some kidney samples. These were not observed at pnd 28-30 in other 
offspring  from  the  original  study  and  were  not  believed  to  be  compound-related. The  conclusion 
drawn from this study, which is evaluated further below as part of the quality assessment of key 
studies identified by EFSA, was that treatment-related effects of a transient nature were unequivocally 
present at the 4,000 mg/kg/day dose level at 15 and 21 days of age, but these were not present at pnd 
28-30 in corroborative studies. 
The aim of a further study (Schroeder, Rao et al, 1972) was to characterise the effects of dietary 
administration of aspartame to male and female rats prior to mating and to pregnant females during the 
whole of gestation and lactation. Albino Charles River CD rats were dosed with aspartame from the 
age of 90 days and mated at age 160 days (M)/110 days (F). The planned doses of aspartame were 
2,000 and 4,000 mg/kg, given to males (n=14 per group) for 64 days and to females (n=48 controls, 
n=30/treatment group) for 14 days before mating. During the mating period dosing was by gavage; 
dietary treatment of the females continued throughout gestation and lactation. 
Half the pregnant females were sacrificed on pcd 13 for examination of the uterus and quantitation of 
live, dead and resorbed foetuses, while the remainder were allowed to proceed to natural delivery and 
lactation.  Examination  of  whole  litters  and  individual  neonates  was  conducted  and  ocular 
examinations were carried out once the offspring were sufficiently developed. The F1 offspring were 
inter-mated (avoiding brother-sister matings) to generate F2 litters, which were examined in the same 
way as soon as possible after delivery. 
Survival in this study was good (one male and two females died) and adverse effects on body weight 
were  generally  non-significant.  Food  consumption  was  generally  comparable  between  groups  but 
treated animals consumed more food during lactation. The doses actually consumed by females were 
as follows: 
Pre-mating: 2,017 and 4,430 mg/kg/day 
During gestation: 1,988 and 4,100 mg/kg/day 
During first 14 days’ lactation: 2,375 and 4,925 mg/kg/day 
During last 14 days’ lactation: 2,700 and 5,900 mg/kg/day 
No differences in conception rates, gestation periods, mating performance or fertility were observed 
between treated and control groups and no gross lesions were observed at hysterotomy. There were no 
significant differences in litter size or number of dead/viable pups although the offspring of aspartame-
treated dams tended to be larger than those of controls (only significant in one group). The survival of 
pups from aspartame-treated litters was better than that of controls, but this was attributed to unusually 
low survival in the control litters. Only one pup was found to be abnormal on gross examination, and 
no gross malformations were identified on pnd 14 or 21. A few superficial eye lesions were identified 
but these did not appear to be treatment related. No abnormalities were identified in the F2 generation 
study.   Review of data on the food additive aspartame 
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The  conclusion  from  this  study  was  that  aspartame  had  no  apparent  effects  on  maternal  sexual 
behaviour or fertility. The offspring of aspartame-treated dams showed excellent growth and survival 
to weaning and had unremarkable reproductive performance. 
The effects of DKP administered prior to mating and to females throughout gestation and lactation 
were also evaluated (Schroeder, Mitchell et al, 1973b). Albino Charles River CD rats were dosed with 
aspartame from the age of 90 days and mated at age 140 days (M)/105 days (F). The planned doses of 
DKP were 500, 1000 and 2000 mg/kg, given to males (n=14 per group) for 49 days and to females 
(n=60 controls, n=28/treatment group) for 17 days before mating and adjusted weekly on the basis of 
body weight and food consumption. During the mating period dosing was by gavage; dietary treatment 
of the females then continued throughout gestation and lactation. 
Half the pregnant females were sacrificed on pcd 14 for examination of the uterus and quantitation of 
live, dead and resorbed foetuses, while the remainder were allowed to proceed to natural delivery and 
lactation.  Examination  of  whole  litters  and  individual  neonates  was  conducted  and  ocular 
examinations were carried out once the offspring were sufficiently developed.  
Actual intakes of DKP by female rats were similar to those planned, averaging 450, 900 and 1800 
mg/kg/day over the whole study for low, medium and high groups respectively. Intakes did not vary 
markedly between pre-mating, gestation and lactation. Treatment had no apparent effect on parental 
survival, food consumption, mating performance, fertility or paternal body weights. Maternal body 
weight was unaffected by the low and medium doses of DKP but was significantly depressed in the 
high dose group on pcd 14 and pnds 14 and 21. Hysterotomy and litter examinations indicated that, 
apart from a decrease in the viable litter size in the highest dose group, all groups were comparable 
and no compound-related alterations, including ocular effects, were detected in offspring at birth or on 
pnds 4 and 21.  
The authors conclude that DKP had no adverse effects prior to mating or during mating, gestation or 
lactation and caused no foetal anomalies or changes in neonatal growth and development. 
2.5.2.  Embryotoxicity and teratogenicity 
During the early 1970s a large number of studies were carried out in an attempt to resolve the potential 
embryotoxic  and/or  teratogenic  effects  of  aspartame.  The  first  of  these  used  an  in  vitro  chicken 
embryotoxicity technique and provided no evidence of teratogenesis due to aspartame at doses of 0.25 
and 0.5 mg/egg (Jessup, 1970); the remainder used mammalian systems and are summarised in Table 
8. Three of these studies (Schroeder and McConnell, 1970; Vondruska, Schroeder et al, 1975a; 1975b) 
are evaluated in detail as part of the quality assessment of key studies identified by EFSA, below. 
In each of these studies, females were sacrificed just prior to delivery (for details, see Table 8) and the 
uterine horns were exposed and examined. Foetal swellings and resorptions were counted and foetal 
viability was determined visually on the basis of respiratory movements, skin colour and movement. 
Foetuses were removed and weighed, crown-rump weight was measured, and they were examined 
externally  and  prepared  for  the  assessment  of  visceral  irregularities  or  skeletal  abnormalities,  as 
follows: 
Foetuses for visceral examination were fixed in Bouin’s fixative then subjected to freehand sectioning 
of the head, thorax and abdomen by the Wilson method and evaluated using a dissecting microscope. 
Foetuses for skeletal evaluation were fixed in 80-95% ethanol. They were eviscerated, soft tissues 
were digested and the remaining skeletal preparations were cleared, stained using Alizarin Red S and 
stored in 100% glycerine.   Review of data on the food additive aspartame 
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In some (but not all) studies, ovaries, uteri and dead foetuses were preserved in 10% NBF for possible 
further evaluation. 
One general observation on these studies is that the studies in rats and mice seemed to give more 
interpretable results than those in rabbits. Problems were experienced in studies using rabbits because 
consumption tends to be reduced at high doses so that actual intakes often plateau at about 1,500 – 
2,000 mg/kg/day (see, for example, (Schroeder and McConnell, 1973)). Indeed, in one study the actual 
intake of the medium dose group was actually higher than that of high dose group (Schroeder, Rao et 
al, 1973b). Study reports tend to present findings according to the planned dose, and this has to be 
taken  into  account  when  interpreting  the  results  obtained.  In  at  least  one  study  (Schroeder  and 
McConnell, 1973), these suggest that treatment with aspartame induces foetal abnormalities in up to 
20% of litters, but the problems with food consumption make it difficult to determine whether this is 
an effect of aspartame itself or to reduced food consumption at higher doses of aspartame.  
Follow up studies provided some reassurance regarding this issue (Schroeder, Mitchell et al, 1973d; 
Trutter and Reno, 1973b); however, a further problem arose in that unusual major malformations were 
observed in one of these studies, one in a control foetus and one in the low dose group, and the 
incidence of defects in control offspring was high in the other study. A study was therefore conducted 
using the same diet, but without including any aspartame-treated groups (Schroeder, Mitchell et al, 
1974). As suspected, the suspect diet alone appeared to induce an unusually high incidence of major 
malformations in rabbit foetuses compared with a commercial control diet. This was attributed to an 
“unidentified factor” in the diet used in the previous studies. This finding means that the results of 
these studies (Reno, 1973; Schroeder, Mitchell et al, 1973d; Trutter and Reno, 1973b) cannot be relied 
upon for risk assessment purposes. 
Even  with  gavage  dosing  to  ensure  compound  intake,  problems  were  still  experienced  in  rabbit 
studies:  a  further  embryotoxicity/teratogenicity  study  (Schroeder,  Mitchell  et  al,  1973c),  was 
compromised by poor survival (attributed to problems with gavage dosing procedure) and  a poor 
conception rate (attributed to equivocal sexual maturity an marginal health status of the rabbits at 
insemination) which make it unreliable for risk assessment purposes. 
“Although major malformations were not evident in any foetuses from 19 control litters, examination 
of  external,  visceral  and  skeletal  structures  revealed  no  consistent  unusual  findings  among  test 
foetuses. Foetal skeletal evaluations revealed no trends towards greater or lesser development in the 
test groups as compared to the control group” (Reno, 1974) 
The  most  detailed  study  in  rabbits  (Vondruska,  Schroeder  et  al,  1975b)  compared  the  effects  of 
aspartame (500, 1,000 or 2,000 mg/kg/day p.o.) with those of Phe (820 mg/kg/day; 75% of the amount 
of Phe present in the top dose of aspartame) and Asp (1,100 mg/kg/day; 134% of the amount of Phe 
present in the top dose of aspartame). L-Asp and low/medium doses of aspartame and had no apparent 
adverse effects in this study,  but Phe, like high dose aspartame, reduced feed consumption from post-
insemination day (pid) 6 leading to body weight loss. There were more litters with large numbers of 
resorptions in the Phe group than the other dosing groups; this was considered consistent with the 
hypothesis that total nutritional intake during ad hoc feeding is inversely proportional to L-Phe intake 
and  that  abortion  or  resorption  occurs  as  a  response  to  nutritional  deprivation  under  these 
circumstances.  Mean  foetal  body  weight  and  croen-rump  distance  (CRD)  were  also  reduced  in 
response to either high dose aspartame or L-Phe. The number of tarsal and metatarsal ossification 
centres were reduced and there was an increase in total number of malformations in the L-Phe group 
(five  instances  of  umbilical  hernia  or  omphalocele  and  various  minor  malformations  including 
vertebral  defects  and  fused  or  split  sternebrae).  These  abnormalities  were  attributed  to  maternal 
nutritional deprivation rather than a compound-related effect, given that the statistically significant 
effects  produced  by  aspartame  were  similar  to  those  seen  in  rodents  following  severe  dietary   Review of data on the food additive aspartame 
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restriction. Phe and Asp also tested in this study, see text (Vondruska, Schroeder et al, 1975b). Further 
evaluation of this study will form part of Deliverable 4. 
2.5.3.  Effects on pregnant and lactating dams 
A series of three replicate studies was carried out in order to characterise the effects of aspartame on 
the pregnant rat and its offspring when administered via the diet (Schroeder, Rao et al, 1973a).  
In the first of these, female Charles River CD rats (aged 100 days at the start of mating) were mated 
with male rats of proven fertility and dosed with aspartame via the diet at planned doses of 2,000 or 
4,000 mg/kg/day from pcd 14 to 21 (n=24 per group). Females were observed and body weights and 
food consumption were recorded daily. Litters and individual neonates were examined as soon as 
possible after natural delivery and non-viable pups were examined, fixed in 10% formalin, macerated 
in 5% KOH, stained with Alizarin Red S and cleared in glycerine. Litter and neonatal examinations 
were repeated on pnds 4 and 21. 
Actual intakes in this study were 2,500 and 4,400 mg/kg/day during gestation and 3,600 and 6,800 
mg/kg/day during lactation. Maternal survival was 100%, gestation periods were normal and body 
weights were comparable during gestation but decreased in the high dose group at delivery and on 
pnds 7, 14 and 21. This reflected food consumption, which was comparable during gestation but 
reduced in treated groups during lactation. Mean litter size was comparable between controls and low 
dose groups but was increased in the high dose group, and there was a corresponding reduction in 
average pup weights at birth in the high dose group. Litter viability was comparable between groups. 
By pnd 21 pup weight in both treated groups was reduced relative to control values and pup survival 
was decreased in the high dose group on pnds 4 and 21. Thus, at the high dose level, the growth of 
dams was depressed during lactation and weaned litters contained fewer pups. 
No gross abnormalities were observed in this study but eye lesions were observed in the high dose 
group; these included incomplete eye opening (5/164 pups) and lens opacity (2/164). In order to 
evaluate this observation, the study was repeated twice (Schroeder, Rao et al, 1973d; 1973f). The 
group size in each of these studies was 30 per group and weaned pups were maintained on basal diet to 
the age of 12-15 weeks to allow complete ocular examinations to be conducted on pnd 28-44 and 97-
105. Actual intakes in these studies were 1,800/2,000 and 4,000/4,000 mg/kg/day during gestation and 
3,700/3,500 and 7,000/6,800 mg/kg/day during lactation and, as in the previous study, significant 
decreases in maternal body weight during lactation were associated with reduced neonatal growth, 
viable litter size and/or survival in one or both of the treated groups. However, no gross abnormalities 
were observed in viable pups and no biologically significant eye lesions were diagnosed at either pnds 
28-44 or pnds 87-105. 
In a follow up study  (Schroeder, Rao et al, 1973e), the effects of high doses of aspartame were 
compared with those of equimolar quantities of L-Phe and L-Asp. Female Charles River CD-1 rats 
(120 days old at the start of mating) were mated with males of proven fertility and fed aspartame, L-
Phe or L-Asp via the diet from, pcd 14 to weaning (28 ± 1 days’ exposure; n=30 per group). The doses 
administered  (up to 4.8%  in  the  diet)  led to actual  aspartame  intakes  of 4,000  mg/kg/day  during 
gestation  and  7,800  mg/kg/day  during  lactation;  L-Phe  intakes  of  1,800  and  4,200  mg/kg/day 
respectively; L-Asp intakes of 1,700 and 4,000 mg/kg/day, respectively; and (L-Phe + L-Asp) intakes 
of  2,100  +  1,800  mg/kg/day  and  4,600  +  3,900  mg/kg/day,  respectively.  Females  were  observed 
regularly during gestation. Litters and individual neonates were examined as soon as possible after 
natural delivery and non-viable pups were examined, fixed in 10% formalin, macerated in 5% KOH, 
stained with Alizarin Red S and cleared in glycerine. 
Maternal  body  weights  were  comparable  across  groups  during  gestation  but  were  reduced  in  the 
aspartame, L-Phe and (L-Phe + L-Asp) groups during lactation. Food consumption, however, was   Review of data on the food additive aspartame 
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comparable throughout the study. Maternal survival was similar in all groups (91-100%) and the 
duration of gestation was normal except for one female which died with on pcd 24 without giving 
birth. Mean litters size and viability were comparable in all groups and pup weights and survival were 
comparable at birth and on pnd 4; however, by pnd 21 pup body weight was reduced significantly in 
the aspartame group (and non significantly in the L-Phe and (L-Phe+L-Asp) groups and survival was 
reduced in the (L-Phe + L-Asp) group. No gross abnormalities were observed on pnd 0 or 4, but 
ringtail (necrosis) was present in four pups (3 control and 1 aspartame) on pnd 21. No biologically 
significant eye lesions were observed. The results of this study indicate that the effects of aspartame 
are similar to those of L-Phe, which, when dosed either alone together with L-asp, leads to depression 
of maternal body weight during lactation and a consequent reduction in pup survival and body weight 
at weaning. 
A further study of the reproductive effects of aspartame looked at the effects of ingested aspartame on 
lactation and on hormone levels in the blood and pituitary gland (Lennon, Metcalf et al, 1973). Pup 
weight gain was evaluated over pnds 6-12 in order to avoid effects due to the stress of birth or 
consumption of food at the end of lactation.  Charles River CD rats (60 days old at the start of mating) 
were allowed to breed and the resulting litters were culled to a maximum of 8 pups (4M and 4F per 
litter where possible). Dams of similar body weight were paired and randomised to test and control 
groups (6 pairs per group) in paired feeding design. Aspartame was administered via the diet (dietary 
concentrations were 1-14% w/w). Dam and pup body weights were recorded on pnds 6, 8, 10, 12, 16 
and 21. Effects on suckling-induced changes in serum and pituitary prolactin, follicle stimulating 
hormone and luteinising hormone were determined by radioimmunoassay (RIA) on pnds 13 and 21. 
At  termination,  mammary  glands  were  fixed  in  10%  formalin  and  prepared  for  histological 
examination. 
Actual mean intakes of aspartame in this study ranged from 1,900 – 9,100 mg/kg/day. These does 
caused  few  histological  changes  in  mammary  glands  although  mammary  gland  inactivation  was 
observed in 14% of dams. This was considered to be an effect of severe food restriction. There were 
slight increases in pup weight gain at concentrations up to 4% in the diet, but at 7.55 and 14% there 
was detrimental effect on food consumption, dam body weight and lactation leading to reduced body 
weight gain in the pups. Reduced pup survival was, however, only observed at the highest doses. 
Aspartame  administration  affected  prolactin  levels  (increased  in  the  serum  and  decreased  in  the 
pituitary, consistent with the stimulation of secretion from the pituitary), but did  not affect serum 
follicle stimulating hormone or luteinising hormone. A further study also indicated no marked effects 
of  aspartame  (100  or  300  mg/kg/day  for  10  days,  p.o.  as  a  corn  oil  suspension)  on  the  same 
gonadotrophins in either male or ovariectomised female Charles River COB
®CD
® Sprague Dawley 
rats (Mares and Berg, 1978). 
The  potential  effects  of  DKP  in  the  perinatal  and  postnatal  phase  of  rat  reproduction  were  also 
evaluated (Trutter and Reno, 1972a). Charles River CD-1 rats were mated to generate 80 pregnant 
females (n=20 per group) and dosed with DKP via the diet from pcd 14 to weaning. The planned doses 
of  DKP  were  500,  1,000  and  2,000  mg/kg/day  and  actual  intakes  were  670,  1,310  and  2,540 
mg/kg/day. All females were allowed to deliver naturally and litters were reduced to a maximum of 8 
pups for suckling. Females were observed regularly during gestation and offspring were examined at 
birth, frequently during suckling and at weaning. Stillbirths and dead pups were preserved in 10% 
NBF. Visceral examination was carried out on pups preserved in 10% NBF while pups for skeletal 
examination were stained with Alizarin Red S. Pup body weights were recorded on pnds 0, 4 and 21 
and females and weanling pups were discarded, except that control and high dose pups were kept alive 
until old enough for  ocular examination (carried out in high dose animals on pnds 40-42 and in 
controls on pnd 47-59). 
Maternal survival was 100% in this study and all maternal parameters measured were comparable 
across all treatment groups and controls. There was no evidence of any compound related effect on   Review of data on the food additive aspartame 
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gestational  index,  duration  of  gestation,  live  births,  litter  size,  pup  body  weight,  or  pup  growth, 
appearance and behaviour. Neither did weanling survival or the results of visceral, skeletal and ocular 
examinations reveal any treatment-related effects. 
2.5.4.  Primate studies 
The  Searle  dossier  on  aspartame  contains  a  compendium  of  fragmentary  data  on 
reproductive/developmental  parameters  in  primates,  (Rao  and  McConnell,  1975),  but  this  is  so 
incomplete as to be uninformative for purposes of risk assessment.  This was, however, followed up 
with a single formal study of the developmental effects of aspartame in infant macaques (Reynolds, 
Baumann et al, 1979). The results of studies on potential acute neurotoxic effects in neonatal monkeys 
(discussed in section 2.2.3, above), should also be noted.  
The single study mentioned above (Reynolds, Baumann et al, 1979) addressed the effects of aspartame 
on  infant  Macaca  arctoides  born  in  a  closed  colony  at  the  University  of  Illinois.  The  doses 
administered were 1,000, 2,000 or 3,000 mg/kg/day, and a group dosed with L-Phe (1,650 mg/kg/day, 
equimolar with the 3,000 mg/kg/day dose of aspartame) was also included. Infant monkeys were kept 
with their mothers for 1 week after birth and then caged individually and taught to take formula from a 
bottle. They were kept on a liquid diet for 270 days, although this was supplemented with one piece of 
fruit per day and a weekly vitamin sandwich once they were old enough to take solid food. After 270 
days the monkeys were gang housed and fed on monkey biscuits. 
The following analyses were conducted: 
Physical  measurements:  Body  weight  (weekly)  and  crown-rump  length,  crown-heel  length,  head 
circumference and developmental milestones (teething, vocalisation, alertness, tractability and general 
behaviour). 
Blood  analysis  (in  months  2,  4,  6,  8  and  9  of  treatment):  serum  electrolytes,  serum  osmolality, 
complete blood count, fasting glucose and amino acids. 
Urinalysis:  Labstix  (pH,  occult  blood  protein,  glucose,  ketones  and  bilirubin)  and  Phenistix 
(phenylketones). 
Electroencephalogram (EEG): 10% chloral hydrate-sedated monkeys were subjected to EEG analysis 
prior to and immediately at the start of treatment and repeated after 4 and 9 months’ treatment. A 
subset of monkeys (n=8) was tested again one month after cessation of treatment. 
The results of this study indicated that aspartame had no effect on the physical measurements taken. 
Water intake increased in response to aspartame (3,000 mg/kg/day) and L-Phe (1,650 mg./kg/day). 
This may have been associated with the taste of the additive-containing liquid diet (L-Phe is bitter 
while aspartame is sweet to monkeys). 
Blood chemistry and urinalysis were normal throughout dosing and did not differ between groups and, 
despite variability in the levels measured, fasting Phe levels were dose-related, reflecting intake of 
either aspartame or L-Phe itself. 
There  was  no  difference in  EEG  traces  between  treatment  groups, and the  EEG  recordings  were 
similar to those of human infants. No convulsions, seizures, shudders or any other abnormal behaviour 
was observed during the study and there was no evidence of induction of phenylketonuria or any 
neurological effects by aspartame.   Review of data on the food additive aspartame 
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This study provides some reassurance when compared with the chronic monkey study in which grand 
mal  seizures  were  observed  (Rao,  McConnell et  al,  1972).  It  should,  however,  be  noted that the 
conditions under which infant monkeys were  housed and treated would not be compliant with modern 
welfare standards. 
2.5.5.  Other investigations 
A limited number of studies addressing the reproductive and developmental effects of aspartame have 
been published in the peer-reviewed literature. These are summarised briefly below. 
The effects of aspartame on brain development and function in mouse neonates has been studied in 
terms  of  responsiveness  in  tests  of  surface  and  air  righting,  negative  geotaxis  and  visual  placing 
(Mahalik and Gautieri, 1984). Female CF-1 albino mice were mated and dosed with aspartame (1,000 
or 4,000 mg/kg/day p.o. in double distilled water) on pcds 15-18. They were then allowed to deliver 
normally and left undisturbed until the start of developmental testing. The tests used were visual 
placing (on pnd 17-15), surface righting (on pcd 4-12), air righting (on pnd 17-25) and negative 
geotaxis (on pnd 4-11). The only response for which a developmental delay was observed was visual 
placing. The paper states that this effect was dose-dependent, but only two doses of aspartame were 
tested  so  this  conclusion  cannot  be  drawn  from  the  data  presented.  The  authors  hypothesise  the 
possible  induction  by  aspartame  of  brain  dysfunction  which  cannot  be  detected  histologically; 
however, they admit that the effect was only noted at very high doses and that additional research 
would be required for verification. 
In a follow-up study (McAnulty, Collier et al, 1989), female CF-1 mice were dosed with a range of 
doses of aspartame (500, 1,000, 2,000 or 4,000 mg/k/day in aqueous 0.5% methylcellulose containing 
0.1% Tween 80; n=20 per group) on pcd 15-18. Physical parameters were recorded during suckling 
(pnd 0-21) and the following developmental parameters were assessed: eye opening; visual function, 
visual placing and midair righting reflex (from the day of eye opening); and surface righting reflex and 
negative geotaxis response (beginning on pnd 5). Aspartame had no adverse effects on the general 
condition of dams or offspring or on body weight/food consumption and there were no treatment-
related effects on litter size, viability, pup body weight, reproductive parameters, viability indices or 
physical/functional development. 
The effects of perinatal exposure to aspartame have also been assessed in a small study using rats 
(Yirmiya,  Levin  et  al,  1989).  Female  Sprague-Dawley  rats  were  dosed  with  aspartame  (8g/L  in 
drinking water, n=8) or water only (n=6) for 30 days before mating and during gestation. Pups were 
cross-fostered at birth (7 pups per litter) and weaned at pnd 21. Aspartame treatment continued in the 
offspring. Morphological development was similar between groups and there were no differences in 
body weights or the latencies of pinnae detachment, incisor eruption or eye opening between treatment 
groups. In terms of behavioural tests, there were no differences in negative geotaxis in the pups or in 
maternal retrieval of pups after separation and aspartame-treated rats actually perfumed better than 
controls in a radial arm maze test on pnd 30 (performances were similar on pnd 60). Thus, aspartame 
at the doses tested in this study had no effect on reflex or morphological development in rats, although 
further studies would be required to establish the existence of any beneficial effect. 
In another study in which female Sprague-Dawley rats were dosed with aspartame via the drinking 
water  from 12 days before conception to pnd 38, no effects were reported in response to exposure to 
either aspartame or L-Phe (Holder, 1989). In this study, the drinking water contained aspartame at 
0.007%, 0.036%, 0.18% or 0.9% (w/v). One group also received drinking water containing L-Phe at 
0.45%. Mating took place after 12 days’ exposure and dosing continued after completion of the 6-day 
mating period. Litters were culled to a maximum of 15 pups and pups were weaned at pnd 21. The 
developmental milestones noted were bilateral pinnae detachment and bilateral eye opening, while the   Review of data on the food additive aspartame 
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reflex  tests  conducted  were  surface  righting  reflex  and  negative  geotaxis,.  The  behavioural  tests 
conducted were maternal pup retrieval, radial arm maze test and milk maze test. 
The actual doses of aspartame consumed in this study were 14, 68, 347 and 1,614 mg/kg/day. The L-
Phe group consumed 835 mg/kg/day of L-Phe. There were no significant differences in maternal body 
weight or reproductive outcomes, and the weight gain of pups was similar between groups. Pups did 
not drink from water bottles before weaning but after weaning they consumed 32, 154, 836 or 3,566 
mg/kg/day while the L-Phe group consumed 1,795 mg/kg/day of L-Phe. No reflex or behavioural 
effects were noted due to either aspartame or L-Phe (Holder, 1989). 
The  effects  of  perinatal  exposure  to  aspartame  have  also  been  considered  at  the  level  of 
neurotransmission (Reilly, Debler et al, 1990; Reilly and Lajtha, 1995). Exposure of female Sprague-
Dawley rats to aspartame (500 mg/kg/day via the drinking water) throughout gestation and lactation 
had no effect on litter size or body weight of pups at birth or weaning. When neurotransmitter receptor 
binding was studied in pooled brain samples taken from 2-3 weanling rats, no effects on the binding 
characteristics of  2 adrenergic, dopamine D/D2 or 5-HT2 receptors were observed. In addition, there 
were no differences in dopamine, norepinephrine or 5-HT and their major metabolites, and plasma 
amino acid (Phe, Try, Asp, Glu) profiles were similar between aspartame-treated and control groups. 
However,  there  were  small  but significant  decrease in  brain levels  of  Phe,  Met,  Asp and  Glu  in 
aspartame-treated pups (Reilly, Debler et al, 1990).  
The observation  that  brain  levels  of  four  amino  acids  (Phe, Met,  Asp  and  Glu)  were  reduced  in 
response to aspartame was addressed in a follow-up study using the same dosing regimen. Aspartame 
was found to have no effect on glutaminergic receptor binding kinetics in the weanling cerebral cortex 
of hippocampus although levels of Glu were reduced slightly (by ~9-10%) in the cerebral cortex and 
hippocampus of aspartame treated rats, while the level of Asp was reduced by ~13% in the cerebral 
cortex only. These subtle changes were reversible following withdrawal of aspartame from pnd 21 to 
42 (Reilly and Lajtha, 1995). Overall, therefore, aspartame apparently had subtle or no effects on the 
neurotransmitter receptor binding kinetics and levels of amines representing several neurotransmitter 
systems in weanling rat brain, in agreement with previous studies by the same authors using adult rats 
(Reilly, Debler et al, 1989a; 1989b). 
Aspartame has been reported to have developmental effects in the guinea pig, which was chosen as a 
model because the majority of its brain development occurs in utero and also because the way it 
metabolises Phe is more like that of humans than rats (Dow-Edwards, Scribani et al, 1989). A dose of 
500 mg/kg/day was chosen for this study because this dose doubles Phe levels in pregnant female 
guinea pigs while more than doubling foetal levels. Virgin Duncan Hartley guinea pigs were given this 
dose of aspartame (p.o. in sesame oil) from pcd 1 to birth around pcd 65 and associational learning 
was assessed using the LiCl aversion test beginning on pnd 15. Aspartame did not significantly affect 
any of the standard indices of developmental toxicity measured: maternal weight gain, litter size, pup 
birth weights, gestational length, CRD, cranial width, maternal care or pup body weights on pnd 15. 
However, aspartame did appear to cause a defect in odour-associated learning; this was attributed to 
either an imbalance in amino acid profiles leading to disruption of central pathways involved in odour-
associative learning or possibly delayed development of the sense of smell. 
This stand-alone study is difficult to interpret: it is the only aspartame-related study in guinea pigs and 
the developmental test used has not been used in characterising the developmental effects of aspartame 
in other species. It is, therefore, of limited value for the purposes of risk assessment. 
2.5.6.  In vitro studies 
Aspartame was used in the validation of the FETAX (Frog Embryo Teratogenesis Assay – Xenopus) 
developmental  toxicity  assay,  a  Xenopus  laevis  blastula-based  assay  developed  as  a  proposed   Review of data on the food additive aspartame 
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replacement  for  mammalian  teratogenesis  assays 
(www.iccvam.niehs.nih.gov/methods/development/dev.htm). This assay involves the determination of 
the median lethal concentration (LC50) and median effective concentration (concentration inducing 
gross malformations in 50% of embryos; EC50). The (LC50/EC50) is then calculated, and compounds 
with a teratogenic index below 1.5 are considered to have low teratogenic potential. Aspartame had a 
low teratogenic index in the FETAX assay and was not considered to pose a teratogenic hazard on the 
basis of this assay (Bantle, Fort et al, 1990).  
A more recent study (Lau, McLean et al, 2006) made use of an in vitro mammalian system to examine 
the effects of mixtures of food additives. Inhibition of neurite outgrowth from differentiating mouse 
NB2a neuroblastoma cells, measured by light microscopy with image analysis (Neurite Outgrowth 
Explora Nova 1.00a), was used as an indicator of developmental neurotoxicity. Food additives were 
used at concentrations which had little or no effect individually ad interactions were evaluated using 
effect additivity and dose additivity models. Aspartame alone had an IC50 of 153   51.5  M for 
prevention of neurite outgrowth in the NB2a neuroblastoma cell line, but it had a synergistic effect 
with  quinoline  yellow:  a  combination  of  8.06    2.1  M  aspartame  with  0  M  quinoline  yellow 
produced 50% inhibition whereas simple additivity would predict that the total concentration required 
would be 138.6   48.6  M (P<0.01). When the potential involvement of the N-methyl-D-aspartate 
receptor was assessed using the non-competitive inhibitor CNS-1102, this compound was found to 
antagonise the effects of either aspartame or L-Glu, suggesting a possible involvement of the  N-
methyl-D-aspartate receptor in effects on neurite outgrowth. 
The discussion of this paper raises concerns regarding possible synergistic induction of developmental 
neuroticism by mixtures of food additives, including aspartame. It should, however, be noted that no 
synergistic cytotoxic effects were observed. It should also be noted that the presentation of this paper 
is somewhat unbalanced: its introduction cites several papers by Olney raising concerns about the 
potential excitotoxic effects of aspartame but does not present the subsequent evidence indicating that 
excitotoxicity is unlikely to be a cause for concern in reality. The authors do, however, admit that 
“mechanisms of synergistic toxicity have yet to be determined, and the implications of these data on 
developmental disorders remains to be investigated” (Lau, McLean et al, 2006). Furthermore, neurons 
would never be exposed to intact aspartame in vivo because aspartame is digested completely in the GI 
tract and does not enter the systemic circulation (let alone the brain), so these findings are unlikely to 
have significant implications in terms of risk assessment. 
2.5.7.  Reproductive effects in humans 
There is no direct evidence to indicate that aspartame has reproductive effects in humans; the results of 
a recent study (Halldorsson, Strom et al, 2010) are, however, important because of the concerns they 
have  raised  regarding  a  possible  association  between  maternal  soft  drink  consumption  during 
pregnancy and preterm delivery. 
The population addressed by this study was the Danish National Birth Cohort, comprising 91,827 
women. Participants were asked to complete a 4 week food frequency questionnaire around week 25 
of  pregnancy.  This  included  questions  about  consumption  of  soft  drinks,  subdividing  them  into 
carbonated or non-carbonated and sugar-sweetened or artificially sweetened. The primary outcome 
considered was preterm delivery (before week 37); preterm deliveries were sub-classified into late 
preterm (weeks 34-37), moderate preterm (weeks 32-34) and early preterm (before week 32). The 
primary analysis was for an association between sugar sweetened or artificially sweetened drinks and 
preterm delivery and the secondary analysis addressed the stability of the findings with respect to 
late/moderate/early preterm delivery and pre-pregnancy weight. Preterm deliveries were also separated 
into spontaneous and medically-induced deliveries.   Review of data on the food additive aspartame 
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Increased  consumption  of  soft  drinks  was  associated  with  lower  socioeconomic  status,  single 
motherhood,  smoking,  higher  BMI  and  greater  energy  intake.  There  was  no  association  between 
sugar-sweetened  carbonated  soft  drinks  and  preterm  delivery,  but  consumption  of  artificially 
sweetened soft drinks was strongly associated with preterm delivery. This was dose-dependent: the 
odds ratio for at least four servings per day vs. none was 1.78 (95% CI: 1.19-2.66), an association 
which was stronger than that for smoking. A similar, but less marked, effect was seen for consumption 
of artificially sweetened non-carbonated drinks (OR = 1.29; 1.05–1.59). This was not affected by 
correcting for gestational diabetes. 
In the secondary analysis, the highest dose groups were merged to give ORs for women consuming  1 
vs. no carbonated artificially sweetened soft drinks per day. The overall OR for this group was 1.38 
(1.15-1.65). A dose response was observed for late and moderate, but not early, preterm delivery. The 
findings were stable with respect to body weight, were not due to hypertension, and were similar for 
non-carbonated artificially sweetened soft drinks. They seemed to be driven primarily by medically 
induced rather than spontaneous preterm delivery. 
These results provide robust evidence for an increased risk of preterm delivery in women consuming 
large  quantities  of  artificially  sweetened  soft  drinks.  They  do  not,  however,  implicate  aspartame 
directly: the authors note that it is difficult to identify the sweeteners which might be responsible 
although  they  state  (without  providing  any  citation  in  support)  that  there  is  less  aspartame  and 
acesulfame K in non-carbonated soft drinks than in carbonated ones. The study is robust in that it is a 
prospective one in a large cohort, but it is observational and depends upon self-reported consumption. 
It should also be noted that respondents were not asked directly about aspartame consumption. The 
strengths of the study are recognised by industry commentators (Bursey and Watson, 2010), but they 
also note a number of limitations including failure to control for  diabetes and weight gain during 
pregnancy  as  possible  confounding  factors  and  use  of  beverage  consumption  as  an  estimate  of 
aspartame intake without taking into account other sources such as sweeteners added to coffee and tea.  
This  study  therefore  raises  general  concerns  regarding  possible  reproductive  effects  of  artificially 
sweetened soft drinks, particularly on medically induced preterm delivery, but it does not provide 
unequivocal evidence of an effect due to aspartame. In particular, as a prospective cohort study it 
could only demonstrate an association, not a cause and effect relationship.  
This point is noted by EFSA in a recent commentary on this paper (EFSA, 2011b; 2011a), which 
recognises that the study is of good quality but notes that further studies are required to confirm or 
reject the study findings and that these should take confounding factors into account. The suggestion 
by  the  study  investigators  that  the  adverse  effects  observed  could  be  due  to  aspartame-derived 
methanol  is  noted,  but  the  fact  that  no  evidence  is  produced  in  support  of  this  contention  is 
highlighted. 
2.5.8.  Summary 
The reproductive toxicity studies carried out prior to release did not indicate any adverse effects due to 
aspartame in mice, rats or rabbits. However, these studies were not conducted to modern standards 
(they predate the introduction of GLP regulations) and several of them are compromised by problems 
with  the  use  of  an  inappropriate  control  diet.  Dietary  studies  in  rabbits  also  proved  problematic 
because the rabbits failed to consume diets containing high doses of aspartame, so that the actual doses 
ingested did not correspond to those planned. There are no modern, GLP compliant studies addressing 
the reproductive toxicity of aspartame. 
Only  one  epidemiological  study  has  addressed  the  possible  reproductive  effects  of  aspartame  in 
humans. This study addressed preterm delivery and examined the effects of soft drink consumption 
thereon.  It  found  an increased  risk  of  preterm  delivery  in  women  who  frequently  ingested  either   Review of data on the food additive aspartame 
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carbonated or (to a lesser extent) non-carbonated diet drinks. This study did not address aspartame 
directly and it was subject to a number of confounding factors, but as a large, well-designed study its 
results merit careful consideration and further investigation. 
2.6.  Reported adverse effects in humans 
2.6.1.  Anecdotal reports 
Sporadic reports of adverse reactions to aspartame began to appear as brief items of correspondence in 
the  medical  literature  soon  after  its  market  entry  as  a  sweetener  and  have  continued  to  emerge 
sporadically ever since. Such reports attribute hypersensitivity reactions (Bohn, Buchner et al, 1997; 
Hill and Belsito, 2003; Jacob and Stechschulte, 2008; Kulczycki, 1986; Kulczycki, 1995; McCauliffe 
and Poitras, 1991; Novick, 1985; Roberts, 1996), headaches (Ferguson, 1985; Jacob and Stechschulte, 
2008; Johns and Gaull, 1986; Lipton, Lawrence et al, 1988; Watts, 1991), exacerbation/initiation of 
epilepsy (Eshel and Sarova-Pinhas, 1993; Walton, 1986; Wurtman, 1985) and various other ailments 
(Burkhart, 2009; Drake, 1986; Newman and Lipton, 2001; Robbins and Raymond, 1999; Roberts, 
1990; 2004; 2006; 2007a; 2007b; 2008; 2009) to aspartame. Such reports have always been open to 
criticism because of the possibility of confounding by medication and other disease factors as well as 
because individual cases cannot be used to derive cause and effect relationships (Geha, 1992b; Moser, 
1986; 1991). 
The FDA maintains passive surveillance of consumer complaints related to food additives, although it 
does not actively solicit such information. When 231 assessable complaints submitted prior to 1984 
were  evaluated  (Bradstock,  Serdula  et  al,  1986)  it  was  found  that  the  complainants  were 
predominantly female, white and aged 21-60 years. Their complaints were diverse in terms of the 
number  and  variety  of  symptoms  reported  and,  when  complaints  were  stratified  in  terms  of  the 
likelihood that the symptoms were actually related to aspartame exposure, the pattern was similar in 
all exposure groups except than none of the menstrual symptoms reported fell in the high probability 
group. Most of the symptoms reported were mild and common in the population and the investigators 
were unable to identify a specific constellation of symptoms related to aspartame exposure. However, 
the potential existence of particularly sensitive individuals could not be excluded. 
An alternative register of individuals reporting adverse reactions to aspartame was established in the 
1980s by Dr. Hyman Roberts, Palm Beach Institute for Medical Research, Florida, USA. This register 
has been reported on a number of occasions, most completely in 1988 (Roberts, 1988). The 1988 
report  presents  data  on  551  individuals  classified  as  “aspartame  reactors”;  these  include  391 
respondents to a national survey and 160 people contacted individually. The criteria for inclusion were 
a self-reported prompt improvement in signs and symptoms upon avoidance of aspartame-containing 
products and recurrence within hours or days upon rechallenge (although some refused to re-expose 
themselves). It should be noted that the majority of these individuals participated in response to an 
invitation which was sent to them with a questionnaire listing possible aspartame-related symptoms. 
This means that there was a strong element of suggestion involved; indeed, the investigator notes that 
some respondents believed they only had one reaction to aspartame until they answered the survey 
questionnaire.  
The following conditions are identified by Roberts as being “responsive” to aspartame: 
Visual, neurologic or bowel problems in diabetics, or diabetes gone “out of control”. 
Visual changes similar to those occurring in cataract, multiple sclerosis or toxic ambylopia. 
Confusion and memory loss suggestive of early Alzheimer’s disease, especially in 40-50 year olds.   Review of data on the food additive aspartame 
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Heavy/more frequent periods 
Eating disorders 
The discussion of this paper recognises that it is possible that the symptoms observed were only 
coincidentally associated with aspartame consumption and that double blind, placebo controlled trials 
(for  which  it  might  be  difficult  to  recruit  participants)  would  be  required  in  order  to  establish 
causation.  However,  it  does  nevertheless  recommend  inviting  “problem  patients”  to  abstain  from 
aspartame for several days or weeks. 
An update to the FDA passive surveillance programme in 1998 (Gray and Altekruse, 1998) considered 
6,629 reports of adverse reactions submitted between 1980 and 1997. The most frequent symptoms 
reported were: 
Headache: 1,909 reports (28.8%) 
Dizziness and problems with balance: 752 (11.3%) 
Altered mood quality/level: 686 (10.3%) 
Vomiting and nausea: 668 (10.0) 
Abdominal pain: 468 (7.0%) 
Change in vision: 378 (5.7%) 
Diarrhoea: 347 (5.2%) 
Other symptoms were reported by less than 5% of complainants. Of the 4,274 complaints which could 
be classified, 1,402 (32.8%) fell into the classification most likely to be associated with aspartame (i.e. 
symptoms which recurred on rechallenge and involved at least two aspartame-containing products). It 
was noted that the number of reported adverse reactions had declined over time after peaking in 1985 
and that only 15 adverse reactions were formally  reported in 1997. 
2.6.2.  Allergies and hypersensitivity 
Various reactions with allergic or hypersensitivity aetiologies have been linked to aspartame exposure; 
these commonly involve hives (Kulczycki, 1995) and urticaria (Kulczycki, 1986). Anecdotal reports 
of dermatitis occurring in response to aspartame have implicated aspartame-derived formaldehyde in 
the aetiology of the symptoms observed (Castanedo-Tardan, Gonzalez et al, 2009; Hill and Belsito, 
2003;  Jacob  and  Stechschulte,  2008);  however,  there  is  no  scientific  evidence  in  support  of  this 
mechanism. Aspartame is not always implicated in allergic responses: testing of patients with chronic 
urticaria as part of an investigation into the role of helicobacter pylori infections in this condition did 
not  identify  any  reactions  to  aspartame  among  50  patients  at  challenged  with  a  250  mg  dose  of 
aspartame (Wedi, Wagner et al, 1998) 
In  1992,  the  National  Institute  for  Occupational  Safety  and  Health  carried  out  a  health  hazard 
investigation at the Nabisco Brands Ltd Seville, Ohio branch where aspartame had been used since 
1983 (NIOSH, 1992). The investigation was initiated in response to a request from the United Food 
and  Commercial  Workers  Union.  The  investigation  included  an  evaluation  of  work  practices,  an 
assessment of employee exposure to airborne particles and medical evaluations. Aspartame exposure 
via inhalation ranged from below the limit of detection to 301  g/m3.  Employees were self-classified 
as cases if they reported developing two out of three key symptoms (chest tightness/shortness of 
breath/wheezing) or wheezing alone since starting employment at the facility. Controls were selected   Review of data on the food additive aspartame 
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at random from workers who did not report any symptoms. There was no difference between cases 
and controls in any of the various allergy-related parameters measured, including peak flow rate and 
skin  tests  for  aspartame  and  other  common  allergens,  although  two  employees  did  have  positive 
reactions to  other  chemicals  used at the  facility.  No  evidence  emerged  to suggest  that aspartame 
induced occupationally-related lower respiratory disorders and there was no association between the 
symptoms of asthma and exposure to aspartame, although the possibility of future development of 
aspartame allergies could not be excluded. 
Attempts to set up clinical trials to investigate potential hypersensitivity reactions to aspartame have 
been fraught with difficulty. It has invariably proved impossible to recruit the number of subjects 
planned, although it is impossible to know whether because there are few individuals who do actually 
perceive that they are hypersensitive or because of fears of severe reactions. This has meant that 
clinical trials on hypersensitivity reactions to aspartame tend to be small. 
Recruitment for the first such study, reported in 1991 (Garriga, Berkebile et al, 1991), was terminated 
after 32 months, at which point 61 people had responded to widespread advertising. The study was 
actually completed by 12 participants; five normal (1M/4F) and six atopic (2M/4F) volunteers also 
took part. Users of steroids, β-agonists and long-acting antihistamines were excluded. Participants 
were subjected to laboratory studies (skin prick testing, complete blood count, clinical chemistry, 
IgG/IgE  levels  and  plasma  histamine  levels)  prior  to  aspartame  challenge.  Antihistamines  were 
discontinued for 72 hr before challenge. Escalating doses of aspartame (0, 10, 100, 500, 1,000 and 
2,000  mg)  were  administered  under  single  blind  conditions.  The  placebo  used  was  lactose.  No 
reproducible reactions were observed among the 12 subjects who had reported hypersensitivity to 
aspartame or in either normal or atopic controls. The study investigators were unable to identify any 
individuals with reproducible reactions in whom the pathogenesis of aspartame sensitivity could be 
studied. 
Similar  problems  were  experienced  by  investigators  attempting  to  set  up  a  multicentre  study  to 
evaluate allergic reactions allegedly due aspartame consumption (Geha, 1992a; Geha, Buckley et al, 
1993).  The  original  plan  for  this  study  was  to  recruit  120  subjects  to  allow  detection  of  a  12% 
difference in the incidence of allergic reactions wit 80% power; however, despite extensive recruiting 
efforts over four years, only 21 individuals (4M/17F) were enrolled in the study. All the subjects who 
were  recruited  had  experienced  urticaria  and/or  angioedema  within  12  hours  of  ingesting  an 
aspartame-containing product; in 15 cases this had required medical attention and 12 subjects had 
received  treatment  with  epinephrine,  steroids  and/or  antihistamines.  Subjects  were  dosed  with 
aspartame or placebo according to a randomised, double-blind crossover design. The taste of the test 
material was concealed by swilling orange juice around the mouth before dosing. Increasing doses of 
50, 300 or 600 mg (3 per day) were administered on different days. The third dose on each day was 
accompanied by conversion products of aspartame (DKP and β-aspartame) or placebo. Of the 21 
subjects  tested,  17  had  no  allergic  reaction  during  the  study;  four  allergic  reactions 
(urticaria/angioedema) were detected, two after aspartame but not placebo and two after placebo but 
not aspartame. Three of these (including both after aspartame) only just met the diagnostic criteria. 
Thus, no relationship between aspartame and urticaria and/or angioedema could be documented in 
patients reporting a reaction to aspartame (Geha, Buckley et al, 1993). 
The  results  of  these  studies,  both  of  which  were  unable  to  demonstrate  an  allergenic  effect  of 
aspartame,  are  consistent with  those  of  a  small  study  (Szucs,  Barrett  et  al,  1986)  indicating  that 
aspartame  is  not  a  direct  mast  cell  secretagogue  in  the  mouse  mast  cell  line  PT18  or  in  human 
peripheral leukocytes in vitro. Aspartame did stimulate the proliferation of PT18 cells when added to 
cell culture medium at 2 mM over 9 days, but this effect was mimicked by addition of free Phe and 
Asp, suggesting that it was due to a nutrient supplementation effect rather than direct stimulation of 
cell turnover. There is also limited evidence that aspartame can stimulate leukotriene biosynthesis in   Review of data on the food additive aspartame 
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rat peritoneal macrophages in vitro (Hardcastle and Bruch, 1997), but the biological consequences of 
this observation (if any) are unclear. 
2.6.3.  Headaches 
In a study aimed at trying to resolve the issue of headache induction by aspartame, 40 subjects who 
had complained to Searle or the FDA of headache and neurological symptoms arising within 24 hours 
of  consuming  aspartame  were  investigated  in  a  study  at  Duke  University  Medical  Center,  North 
Carolina (Schiffman, Buckley et al, 1987). The hospital-based study was designed to detect a 33% 
difference in incidence of headache with 90% power. All participants were free of major medical 
problems were assessed by a neurologist as suffering from vascular headaches. The majority (70%) 
has either a personal or family history of allergy, but users of β-blockers and antihistamines were 
excluded.  
A clinical chemistry profile was taken prior to aspartame challenge, while skin prick allergy testing 
was carried out after completion of challenge testing. The protocol involved a five day study with 
challenges on days 3 and 5. Aspartame was administered via capsules as three doses of 10 mg/kg (at 
08.00, 10.00 and 12.00) to give a total of 30 mg/kg. The placebo was microcrystalline cellulose. 
Following dosing, headache incidence was monitored independently by the subject (on a scale of 0-
100) and the study investigator (mild/moderate/severe with note taken of other associated symptoms). 
Samples for further clinical chemistry analyses were taken at 07.45, 09.00, 11.00 and 16.00 on dosing 
days and also when headaches were reported. 
Headaches were reported by 26/40 participants during the study: eight with aspartame but not placebo, 
12 with placebo but not aspartame and six with both treatments. Overall, headaches were reported by 
35%  of  participants  following  dosing  with  aspartame  and  45%  following  placebo.  No  abnormal 
clinical chemistry findings were reported except that headaches were associated with elevated plasma 
norepinephrine (349.4 vs.251.2 pg/ml); this was also associated with increased blood pressure. Skin 
prick allergy testing results in this population was intermediate between those of a normal population 
and a group known to have allergies. 
This study has been criticised on the grounds that aspartame was administered via capsules (Lipton, 
Lawrence et al, 1988) and that it required participants to remain in hospital rather than living their 
normal lifestyle during exposure (Edmeads, 1988; Lipton, Lawrence et al, 1988). 
A further study aimed at clarifying the relationship between aspartame consumption and headaches 
addressed the effects of aspartame on frequency and intensity of migraine headaches during normal 
living (Koehler and Glaros, 1988). The subjects for the 13 week, double blind, randomised crossover 
study  met  the  criteria  for  migraine  established  by  the  1962  ad  hoc  committee  on  headache.  The 
inclusion  criteria  for  the  study  were:  medical  diagnosis  of  headache;  unmedicated  except  for 
analgesics; recurrent attacks separated by headache free periods; a history of 1-3 headaches over a 4 
week period; and a suspected relationship between migraines and aspartame consumption. Participants 
kept a record of headaches and diet over a 4 week baseline period and were then randomly assigned to 
receive either aspartame (300 mg capsules) or placebo (microcrystalline cellulose) four times daily for 
4 weeks. After a one week washout period they then took the other formulation. 
The study was completed by 11 participants. An increase in headaches was reported with aspartame 
compared with placebo; mean numbers of headaches experienced per dosing phase were 3.00 vs. 1.83 
when aspartame was taken first followed by placebo and 1.20 vs. 4.20 when placebo was taken first 
followed  by  aspartame.  There  was,  however,  no  change  in  the  frequency,  intensity,  duration  or 
symptoms of tension or unclassified headaches. Of the 11 participants, five (45%) experienced no 
change in migraines while six (55%) experienced an increased frequency of migraines with aspartame. 
No participant reported fewer headaches with aspartame.   Review of data on the food additive aspartame 
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This  study  was  so  small  that  it  is  difficult  to  interpret,  although  the  investigators  conclude  that 
“ingestion of aspartame by migraineurs caused a significant increase in headache frequency for some 
subjects”. It has also been criticised on the grounds of the lack of controls for confounding variables, 
because the effects observed were marginal (Schiffman, 1988) and on the basis that the statistical 
approach adopted was inappropriate (Amery, 1988). 
Another randomised double blind crossover study was conducted among individuals with self-reported 
headaches following ingestion of aspartame (Van den Eeden, Koepsell et al, 1994). The subjects, 
recruited by means of newspaper advertisements, were 18-65 years old, were not taking prophylactic 
medications  and  had  no  serious  medical  conditions.  They  were  asked  to  complete  a  baseline 
questionnaire in which they classified themselves as “very sure”, somewhat sure” or “not very sure” 
that their headaches were caused by aspartame. Unsurprisingly, given the wording of the invitation to 
participate, none of them reported that they did not know whether their headaches were caused by 
aspartame. 
The  study  design  involved  two  treatments  with  four  7-day  treatment  periods  over  38  days.  The 
sequence of treatments was randomised.  Aspartame was dosed at ~30 mg/kg/day in three daily doses 
via 300 mg capsules and subjects kept a diary to assess headache incidence in terms of time of onset, 
intensity (on a scale of 1-10) and associated symptoms. 
This study was compromised by a high drop-out rate, and the final data analysis addressed only 11 
subjects. The only subjects for whom there was evidence of a relationship between aspartame and 
headaches were those who were “very sure” that their headaches caused by aspartame; this group 
experienced about twice as many headaches while taking aspartame than on placebo (0.37 headache 
days  with  aspartame  vs.  0.18  with  placebo;  p<0.001).  The  findings  in  other  groups  were  non-
significant, and even in the “very sure” group there was no significant difference in the duration or 
intensity of their headaches, or in associated symptoms. The four migraine suffers in this study did not 
experience any adverse effects on their headaches in response to aspartame. 
The study has been criticised both on the grounds of its design (Schiffman, 1995) and because its 
results were unduly influenced by the effects observe in a single individual (Levy, Hedeker et al, 
1995; Schiffman, 1995). The latter criticism was accepted by the study investigators (Van den Eeden, 
McKnight et al, 1995), although they continued to defend the approach they had used. 
2.6.4.  Seizures 
In the late 1980s, concern began to be expressed regarding possible induction of seizures by aspartame 
and concerned physicians were invited to submit patients for further evaluation (Gaull, 1985), though 
with a very limited response (see below). 
By 1991, although there had been no documented cases of seizure due to aspartame, a number of 
anecdotal reports were in existence (Walton, 1986; Wurtman, 1985). In an attempt to clarify this issue, 
Searle undertook a clinical trial (reported in 1991 and published in 1995 (Rowan, Shaywitz et al, 
1995; Stargel and Tschanz, 1991). Its aim was to recruit 30 children and 30 adults who had reported 
experiencing seizures as a result of aspartame consumption; however, after a vigorous recruitment 
drive including writing personally to 159 potential participants it was only possible to recruit two 
children (aged 10 and 15 yr) and 16 adults (2M/14F; aged 20-70 yr), one of whom had been exposed 
occupationally, so recruitment was abandoned and the study was reported as it stood. This reduced its 
power, restricting it to being able to detect only a 46% incidence of seizures. 
All subjects were pre-screened by means of a detailed neurological history, neurological examination, 
drug history, physical examination, computerised tomography and EEG scans, routine haematology, 
clinical  chemistry  and  urinalysis.  They  were  then  assigned  in  the  order  of  enrolment  to  either   Review of data on the food additive aspartame 
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aspartame or placebo according to a computerised randomisation procedure. The study followed a 
double-blind, two-way crossover design in which the effects of aspartame (50 mg/kg divided into 3 
equal doses taken at 08.00, 10.00 and 12.00) were compare with those of placebo (microcrystalline 
cellulose (Avicel PH 102) + 0.9% aerosol. Aspartame and placebo days were separated by 24 hr. Each 
study period comprised a screening day (day 1), baseline days (days 2, 4 and 6) and treatment days 
(days 3 and 5). 
Neurological examinations were performed on days 1 and 6 of treatment; no additional neurological 
examinations were required because no symptomatic seizures occurred during the study. Abnormal 
EEGs  were  detected  on  non-treatment  days  in  13/18  subjects  and  computerised  tomography 
abnormalities were apparent in 6/18 subjects. In addition, one or more categories of neurological 
abnormalities were detected in 6/18 subjects (the study report does not indicate whether these were the 
same  six).  Continuous  EEG  recording  was  done  over  days  2-6  and  plasma  amino  acids  and 
anticonvulsants  were  assayed  daily  and  plasma  [Phe]  and  Phe/LNAA  ratios  increased  following 
aspartame administration, as expected. Adverse reactions were recorded regardless of their severity or 
relationship to test article administration. 
No seizures or adverse experiences were observed following aspartame consumption. Two subclinical 
seizures were identified during evaluation of the EEG traces after completion of the protocol; both 
occurred  during  sleep  and  after  consumption  of  placebo  but  before  exposure  to  aspartame.  No 
epileptiform activity was detected in 7 subjects over 5 days’ recording; in the remainder there was no 
difference in EEG profile between treatments. Eight adverse reactions, 4 of which were headaches, 
were recorded on placebo days. Overall, there was no difference in the pattern of EEG abnormalities 
between aspartame and placebo days. 
In 1992, the FDA reviewed 251 cases of epileptic seizure which had been reported as aspartame-liked 
via  their  passive  surveillance  system,  the  Adverse  Reaction  Monitoring  System  (Tollefson  and 
Barnard, 1992). Since adverse reactions involving seizure are classified as “severe”, all of these were 
investigated in detail by FDA field personnel. 
Of the 251 cases investigated, 124 fell into Group D under the FDA classification system for adverse 
reactions, meaning that the evidence suggested that they were either not associated with aspartame 
ingestion or were consistent with a pre-existing medical condition. Of the remaining 127 cases, 88 
(69%) had occurred in females and 82% of the 112 residents whose age was known were between 20-
59 years old, with a peak incidence in the 31-35 yr old age range, although 5 cases were observed in 
children aged 1-5 yr. When classified according to the likelihood that aspartame was involved in the 
adverse event recorded, 41/127 fell in Group A (most likely), 35/127 (28%) fell in Group B and 
51/127 fell in Group C. The event occurred within 12 hr of consuming aspartame in 82/127 (65%) 
cases; aspartame was considered unlikely to have been the cause in the other 45 (35%) because its 
component amino acids would have been cleared from the circulation  before the event occurred. The 
mean  amount  of  aspartame  consumed  was  1,088  mg/day  (range:  10-6,440  mg/day);  the  highest 
consumer exceeded the ADI for aspartame. On the basis of the evidence acquired, the FDA was 
“unable to determine whether the reported seizures and aspartame are not simply chance events”. No 
further scientific study was recommended on the basis of this information. 
The results of an attempt to  determine whether aspartame might exacerbate epilepsy in humans was 
also published in 1992 (Camfield, Camfield et al, 1992). In this study, 10 children (2M/8F) aged 
between 5.1 and 14.6 yr old who had recently been diagnosed with generalised absence epilepsy were 
studied on two consecutive days, shortly after diagnosis but before administration of medication. Their 
brain activity was monitored by means of 6--8 hr of ambulatory EEG recording. The protocol used 
was a randomised, double blind crossover trial in which the children were given either aspartame (40 
mg/kg in 250 ml orange juice consumed over 5 min) or placebo (orange juice sweetened with sucrose,   Review of data on the food additive aspartame 
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1/per 25 mg aspartame). Please note the use of orange juice, which has previously been shown to alter 
the amino acid profile observed after aspartame dosing, as a vehicle in this study. 
The endpoints considered were: number of spike-wave bursts corrected for recording time; duration of 
individual spike-wave bursts; and total duration of spike-wave bursts per hour of EEG recording. 
There were no differences in EEG during a pre-dosing baseline period, but the number of spike-wave 
bursts per hour was greater following aspartame than placebo in 7/10 patients and the mean length of 
spike-wave bursts was longer following aspartame than pace bi 8/10 patients. These findings were, 
however, not statistically significant. The total time in spike wave per hour also increased flowing 
aspartame compared with placebo in 8/10 patients, and when the results were combined for all 10 
patients this was statistically significant (p=0.028). 
These results, one of which just reaches significance, are difficult to interpret for a number of reasons. 
As of 1995, this was the only clinical study to have suggested that aspartame has an effect on seizures 
and it compared the effects of aspartame to a very short baseline period (1 hr) (Rowan, Shaywitz et al, 
1995). In addition, the only actual change observed was in the duration of spike-wave activity per 
hour; generalised spike wave discharges are seen on EEGs when children are experiencing absence 
seizures, but the amount of spike wave discharge is not related to the severity of the seizure, although 
longer-duration  spike  wave  discharge  events  tend  to  be  associated  with  greater  impairment  of 
consciousness and reaction time. It is important to note that in this study no assessment of clinically 
apparent unresponsiveness was undertaken, so that the EEG results presented cannot be linked to 
actual  seizure  events.  Furthermore,  the  findings  are  specific  to  absence  seizure,  which  are  not 
considered intrinsically hazardous, and cannot be extrapolated to other types of seizures. The fact that 
the study contradicts all other studies addressing aspartame and seizures, the potential confounding 
effects of the placebo sucrose) and the very short baseline time used for comparison of the EEG 
effects have led the conclusions of this study to be called into question (Shaywitz and Novotny, 1993). 
A further attempt to clarify the effects of aspartame on seizures and EEG activity during epilepsy was 
published in 1994 (Shaywitz, Anderson et al, 1994). The subject studies were 10 children aged 5-13 yr 
(5M/5F) who had experienced seizures of various kinds (including generalised convulsions, absence 
seizures and complex partial seizures) over a 1-6 yr period. Nine of them were taking antiepileptic 
medication. The protocol involved a 4-week randomised crossover study with 2 x 2 week dosing 
periods.  Aspartame  was  administered  via  300  mg  capsules  at  a  dose  of  34  mg/kg/day  and  the 
corresponding  placebo  capsules  contained  microcrystalline  cellulose.  On  test  days,  patients  were 
subjected to 24 hr 4-channel EEG recording and to a standard 21 lead EEG at the end of the 42 hr 
period. Blood samples were taken 30 min before and 1hr after dosing from amino acid profiling, 
methanol/formate analysis, clinical chemistry and antiepileptic drug estimation; urine was sampled 3hr 
post-dosing  for  the  measurement  of  monoamines  and  their  metabolites,  formate  and  creatinine. 
Throughout  the  stud,  seizures  and  behavioural  effects  were  documented  by  the  parents  using  the 
Conners Behaviour Rating Scales (for parents and teachers). Adverse events were documented using 
the Subjects Treatment Emergent Symptoms Scale (STESS). 
Of the nine children who completed both dosing periods, none had any clinical seizures during the 
study and there were no statistically significant differences in EEG between treatments. There were no 
statistically significant changes in clinical chemistry parameters, monoamines or their metabolites, and 
blood methanol levels were below the level of detection throughout the study. Plasma [Phe], however, 
did  increase  following  dosing  with  aspartame,  in  line  with  expectations.  Finally,  there  were  no 
differences in behaviour assessments and no adverse events were reported at any time during the 
study. 
Concern regarding a possible relationship between aspartame exposure and seizures led, in the 1980s 
and 1990s, to a number of studies of the effects of aspartame in various animal models of seizure   Review of data on the food additive aspartame 
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induction (Table 9). A few sporadic positive results were obtained, but the vast majority of these 
studies indicated neither pro- nor anticonvulsant effects due to aspartame. 
2.6.5.  Behavioural effects 
The suggestion that aspartame could have behavioural effects in children and adults has been raised 
repeatedly ever since aspartame was approved as a sweetener. 
Studies  which  can  provide  information  regarding  the  potential  behavioural  effects  fall  into  two 
categories: those which address aspartame as the primary test item and those which include aspartame 
as a non-nutritive control for the effects of other test items (e.g. sucrose). This latter type may provide 
useful information but it is often less complete than that from studies where aspartame is the primary 
focus. Where useful information can be gleaned from these studies they have been included in Table 
10 (Virkkunen, Kallio et al, 1994; Virkkunen, Rawlings et al, 1994). 
None of these studies indicates that aspartame has any effect on human behaviour; however, since 
most of them involved either single doses or short term administration of aspartame, it has been 
suggested  that  effects  might  still  be  observed  under  conditions  of  long  term  dosing  (Lapierre, 
Greenblatt et al, 1990) 
In order to try to resolve this issue, NutraSweet carried out a very detailed clinical trial reported in 
1993 (Schomer, Wurtman et al, 1993) and subsequently published in 1998 (Spiers, Sabounjian et al, 
1998). In this randomised, double blind placebo controlled three treatment crossover study, 51 healthy 
adults (26M/25F) were stratified by gender and then randomised to receive aspartame at either 15 
mg/kg/day  or  45  mg/kg/day  administered  as  a  combination  of  300  mg  capsules  and  aspartame 
sweetened Seltzer water (150 mg/300ml) in three equally divided doses at approximately 10.00, 15.00 
and 20.00. Apart from this, aspartame was excluded from the diet throughout the study but all subjects 
consumed sucrose (90 g/day) as a sweetened drink. Each treatment lasted for 20 days with an 8 day 
washout between treatment periods, and 48 subjects (24M/24F) completed the protocol. They were 
assessed by means of behavioural and cognitive tests (verbal learning, verbal attention span, spatial 
attention  span,  short/long  term  memory,  verbal  fluency,  response  set  alternation/inhibition,  motor 
response  set  alternation/inhibition  and  overall  cognitive  efficiency)  and  a  self  rating  mood  scale 
(rating tension, anger, depression, vigour, fatigue and confusion), vital signs, ECG and EEG. Amino 
acid profiles, insulin and glucose concentrations were measured in plasma. No statistically significant 
neuropsychological,  cognitive  or  behavioural  effects  were  observed  with  aspartame,  sucrose  or 
placebo and there were no differences in reported adverse effects between the three treatments. There 
were no treatment-related differences in EEG traces and no epileptiform abnormalities were detected. 
Plasma amino acid concentrations changed as expected in response to aspartame but remained within 
the normal postprandial range. 
Several acute behavioural studies of aspartame have been conducted in animals (Table 11). The only 
study indicating any effect due to aspartame was one suggesting a reduction in aggression in adult 
male Long-Evans rats dosed with aspartame i.p. (Goerss, Wagner et al, 2000). 
The route of administration may be a factor in determining subtle behavioural responses to aspartame 
in animal tests: one study has demonstrated effects in taste aversion and wheel running tests after i.p. 
injection but not after p.o. administration or voluntary consumption via the drinking water (Holder and 
Yirmiya, 1989). This difference may have been a function of different pharmacokinetics following 
administration via these routes. In particular, there was an increase in plasma [Asp] following i.p 
dosing which was not seen after either p.o. dosing or consumption via the drinking water. If this is the 
case, the effects observed following i.p. administration are unlikely to be relevant to humans since 
exposure is never likely to occur by i.p. or i.v administration under normal conditions of use. This 
caveat applies to several of the reported behavioural studies in animals (LaBuda and Hale, 2000;   Review of data on the food additive aspartame 
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Vitulli, McAleer et al, 1996), and in particular may compromise interpretation of the study in which 
effects on aggression in rats were reported (Goerss, Wagner et al, 2000). 
One subchronic study addressing the potential behavioural effects of aspartame was reported by Searle 
in 1972 (Potts, 1972). Weanling Long Evans rats (32M/32F per group) were dosed with aspartame 
(4.5% or 9% w/w in diet) or L-Phe (2.5% or 5.0% w/w in diet) via the diet for 13 weeks beginning on 
pnd 21. Their general posture, locomotion, behaviour, motor activity and external appearance were 
monitored before the  start  of  dosing  and regularly  throughout the  study.  Behavioural  testing  was 
carried out between days 66 and 87 of dosing.  The assessment methods used were activity cages for 
general motor activity and shuttle cages for learning behaviour. Motor activity (12M/12F rats) was 
scored three days before the behavioural assessment at times of 5, 30 and 60 min after being placed in 
activity cages. The behavioural test used was a conditioned avoidance response test using two-way 
shuttle  box.  The  conditioned  stimulus  was  a  five  second  tone  and  light  while  the  unconditioned 
response was an electrical shock to the foot. This response was measured in 20M and 20F rats from 
each group except for female controls (n=16). A non-discriminated avoidance test was also conducted. 
No adverse physical signs were observed in this study and no unequivocal effects on general activity 
levels were observed with either aspartame or L-Phe. The highest (equimolar) doses of aspartame and 
L-Phe produced a significant decrease in conditioned avoidance responses; this was also seen at the 
lower dose of L-Phe in females only, but not at the lower dose of aspartame. However, no effects were 
observed with either compound in the nondiscriminated avoidance test. Overall, aspartame had similar 
effects on behaviour when compared to equimolar L-Phe, with no evidence for either reduction or 
exacerbation of the effect when the dose was from aspartame rather than L-Phe itself. 
A  more  recent  study  (Christian,  McConnaughey  et  al,  2004)  addressed  the  question  of  whether 
aspartame administration over a four-month period might affect the memory of rats and if so, whether 
corresponding  changes  in  muscarinic  cholinergic  receptors  and  Na
+K
+ATPase  activity  might  be 
observed. Aspartame was administered via the drinking water at a dose of 250 mg/kg/day for four 
months. Body weight and food consumption were recorded. The rats were trained in a T-maze three 
times daily for 2 wk until they could consistently find a chocolate reward within 12 sec. Testing 
continued periodically throughout the treatment period. At the end of the study they were sacrificed, 
their brains were frozen at -70 C and membrane preparations were made from either whole brain 
tissue  or  individual  brain  areas.  Muscarinic  cholinergic  receptor  binding  was  determined  using  a 
radioligand binding assay in the presence of atropine (10-6 M) and ouabain-inhibitable Na
+K
+ATPase 
activity was measured enzymatically following incubation with 3.8 mM sodium dodecyl sulphate to 
unmask the activity. 
The results of the-maze test indicated that after 3-4 months, rats took measurably longer to find a 
reward in the T-maze than they did at the start of the study. After 90 days the time taken by treated 
animals was 18   4 sec compared with 10   1.4 sec in controls, and after 120 days it was 34   5 vs. 14 
 2 sec. This effect first became evident 60 days after the start of treatment, so these findings are not 
inconsistent with those of previous acute studies. There was a concomitant increase in muscarinic 
cholinergic  receptors  in  whole  brain  preparations  and  in  preparations  from  isolated  cortex, 
hypothalamus, hippocampus and cerebellum; however, the only change in Na
+K
+ATPase activity was 
an increase in the midbrain of aspartame treated animals (an area which had exhibited no change in 
muscarinic cholinergic receptor density). 
The implications of this observation are as yet unclear, but it does suggest the possibility of changes in 
memory following long term exposure to aspartame; however, it should be noted that the dose used 
(250 mg/kg/day) was very high relative to those to which humans are exposed.   Review of data on the food additive aspartame 
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2.6.6.  Summary 
Ever  since  its  release,  anecdotal  reports  have  attributed  numerous  adverse  effects  in  humans  to 
consumption of aspartame. The effects most commonly reported include hypersensitivity reactions, 
headaches,  seizure  induction  and  behavioural  changes.  However,  when  these  are  addressed  by 
properly designed clinical trials it usually proves impossible to detect any effect due to aspartame. 
Only sporadic effects in individual subjects are observed, and these occur in response to placebo at 
least as  often  as  in  response to aspartame.  Similarly,  when  effects  such as seizure  induction  and 
behavioural change are addressed in animal models the number of positive findings is well within the 
range expected by chance, although it should be noted that grand mal seizures were observed in 
monkeys treated with high doses of aspartame during the only chronic toxicity in primates. These 
seizures were attributed to high plasma [Phe] (similar effects were observed in response to equimolar 
doses of Phe) and to stress caused by handling. 
2.7.  Potentially vulnerable groups 
A number of subgroups within the population have the potential to be particularly vulnerable to the 
adverse effects of aspartame, if any. These include individuals with metabolic conditions and pre-
existing diseases. This section identifies these subgroups and evaluates the evidence for increased 
vulnerability. 
2.7.1.  Phenylketonurics 
Phenylketonurics represent a population subgroup with an obvious potential vulnerability to adverse 
effects from aspartame, and various commentators (Guttler and Lou, 1985; Koch, Schaeffler et al, 
1976;  McSherry,  1982)  note  that,  while  aspartame  had  no  apparent  adverse  effects  in  PKU 
homozygotes, the amount of Phe present in aspartame, even under normal conditions of consumption, 
is  large  enough  to  require  it  to  be  taken  into  account  when  planning  controlled  diets  for  the 
management of PKU. 
During the development of aspartame, several studies were undertaken to verify that the amount of 
Phe likely to be ingested by phenylketonurics would not cause adverse effects. These studies, which 
are  summarised  in  Table  12,  confirmed  that,  while  aspartame  intake  should  be  avoided  by 
phenylketonurics,  the  amount  which  might  be  ingested  inadvertently  would  be  unlikely  to  cause 
adverse effects even in PKU homozygotes.  
PKU carriers (heterozygotes) represent approximately 2% of the population, and often do not know 
that they carry the defective allele. During planning for the release of aspartame as a sweetener, 
concerns arose that their apparently normal Phe metabolism might be disturbed by the Phe content of 
aspartame  (Koch,  Peterson  et  al,  N/K-a)  and  that  this  might  result  in  damage  to  the  foetuses  of 
pregnant PKU heterozygotes and women with hyperphenylalaninaemia (Bhagavan, 1975; Freedman 
and Hilton, 1987; Levy, Waisbren et al, 1987; Lines, Stegink et al, 1981). 
The  results  of  studies  addressing  the  pharmacokinetics  of  aspartame-derived  Phe  in  PKU 
heterozygotes are summarised in Table 12. These indicated that, while PKU heterozygotes experience 
higher plasma [Phe] and slower clearance than normal individuals after a bolus dose of aspartame, the 
levels reached are well below those observed in well-controlled PKU homozygotes and do not fall in 
the range considered likely to induce toxicity. Indeed, the fact that aspartame is a convenient and well 
characterised way to administer a controlled dose of Phe has led to the proposal of an aspartame 
loading  test  for  the  identification  of  PKU  heterozygotes  and  there  is  evidence  to  suggest  that 
evaluation  plasma  [Phe]  under  fasting  conditions  and  after  an  aspartame  challenge  is  sufficiently 
sensitive  to  discriminate  between  moderate  and  severe  polymorphic  variants  of  phenylalanine 
hydroxylase (Da Silva, Carvalho et al, 2000; Silva, Pires et al, 1997).   Review of data on the food additive aspartame 
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In addition to the various studies addressing pharmacokinetics, one study has addressed the effects of 
aspartame on cognitive function, EEG and biochemical parameters in PKU heterozygotes (Trefz, de 
Sonneville et al, 1994). In this randomised, double blind, placebo-controlled crossover trial, adult 
PKU heterozygotes whose genotype had been confirmed by restriction fragment length polymorphism 
analysis were randomised to 12 weeks dosing with aspartame at either 45 mg/kg/day (9M/15F) or 15 
mg/kg/day (13M/12F), given via 300 mg capsules. The placebo was microcrystalline cellulose. Blood 
was  sampled  for  routine  haematology  and  blood  clinical  chemistry  during  weeks  -2,  12  and  24; 
urinalysis was also carried out. Computerised cognitive and neuropsychological test batteries were 
used and a non-computerised test for short term memory was also administered. Standardised EEGs 
were recorded in weeks -1, 12 and 24.  
No  changes  in  EEG  traces  were  identified  and  there  was  no  detectable  change  in  cognitive  or 
neuropsychological function during the study. Plasma [Phe] increased as expected within 1-3 hr after 
dosing at 45 mg/kg but not at 15 mg/kg, and this was reflected in the plasma Phe/Tyr and Phe/LNAA 
ratios; no effects on other amino acids, including Asp, were detected. There was no increase in the 
excretion of organic acids via the urine. No differences between aspartame and placebo in the pattern 
of mild adverse effects were noted, and no severe adverse effects were reported.  
There is no doubt that overt hyperphenylalaninaemia can have adverse effects on the foetal brain. In 
one rat study, for example, the addition of Phe to the diet of pregnant dams (strain not specified) at 
3.5% (duration of exposure not specified) led to a reduction in brain weight at birth compared with 
either controls or rats whose diet had been supplemented with Tyr at the same concentration (Lewis, 
Lyon et al, 1985). Furthermore, supplementation with Phe or Tyr adversely affected the subsequent 
performance  of  the  offspring  in  a  successive  discrimination  test,  though  not  in  a  simultaneous 
discrimination test, and the offspring of Phe treated dams exhibited more activity in an open field test 
than did those of Tyr treated or control dams. These rats had plasma [Phe] of approximately 300  M 
(120 – 600  M), which is within the range observed in female PKU heterozygotes given loading doses 
of aspartame; however, it is extremely unlikely that sustained exposure to such high levels of Phe 
would ever occur in human PKU heterozygotes. In this study a low concentration of aspartame (0.03% 
w/w) was added to the diet to mask the taste of the Phe, but this would not have been sufficient to 
effects observed, which were purely due to supplementation with Phe itself. 
2.7.2.  Glutamate-sensitive individuals 
During the development of aspartame as a sweetener there was concern that individuals who respond 
adversely  to  MSG  (so-called  “Chinese  Restaurant  Syndrome”)  might  also  be  hypersensitive  to 
aspartame, possibly as an effect of Asp released during the metabolism of aspartame. This was tested 
in 6 individuals who had previously reported an adverse reaction to MSG at 25 - 50 mg/kg (Stegink, 
Filer et al, 1979b; Stegink, Filer et al, 1981a). They were dosed with single doses of aspartame (34 
mg/kg in orange juice) or sucrose (1 g/kg) in a randomised, double blind, crossover design study with 
a washout period of 1 wk between treatments. Plasma amino acids were measured frequently for 4 hr 
after dosing and subjects (who did not have contact with each other during the study) were asked to 
note any adverse experiences. No symptoms of Chinese Restaurant Syndrome were reported during 
the study although one subject did report nausea after taking aspartame. There was no difference in 
plasma [Asp] between subjects in this study and previous normal controls; [Phe] and [Tyr] increased 
as  expected,  in  line  with  results  observed  previously  in  normal  subjects,  and  there  was  a  non-
significant increase in [Glu]. Effects on [Ala], [Pro] and branched chain amino acids were observed in 
all groups, probably as a consequence of using orange juice as a vehicle. 
2.7.3.  Obese individuals 
During  the  development  of  aspartame  it  was anticipated  that  obese  individuals,  particularly  those 
trying to lose weight, might be particularly heavy users, so three studies were conducted to determine 
whether their response to aspartame might differ from that of people having normal body weight.   Review of data on the food additive aspartame 
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A short term study was conducted in adults (n=95, aged 21-70) whose weight exceeded mean normal 
weight by >20% but who were otherwise healthy (Hoffman, McGinn et al, N/K). Persons having any 
abnormality in Phe metabolism, including PKU, were excluded. The study followed a randomised, 
double blind protocol in which aspartame was dosed via 300 mg capsules at increasing doses from 0.6 
to 8.1 g/day over a six week period. Participants were subjected to complete blood counts, urinalysis 
and clinical chemistry analysis, and plasma [Phe] and [Tyr] were determined regularly. Oral glucose 
challenge tests (with measurement of insulin and glucose) were conducted in weeks 3, 6 and during 
follow up. A complete ocular examination was carried out before and after the study. 
The dosing protocol was completed by 84 subjects (44 on aspartame and 40 on placebo). Both groups 
lost weight during the study but there were no differences in the extent of such loss between aspartame 
and placebo groups. Furthermore, no differences in clinical chemistry or response to glucose challenge 
were observed and there were no consistent differences between groups in plasma [Phe] and [Tyr]. No 
new ocular abnormalities developed during the course of the study. The main adverse effects observed 
were GI symptoms, mainly at the highest doses of aspartame (weeks 5 and 6). 
This study was continued as a 21 week study which included subjects who had completed the first 
dosing period (to give a total of 27 weeks’ exposure) and newly recruited subjects who were exposed 
for 21 weeks (Hoffman and Romano, N/K). Aspartame was administered to both groups at a constant 
dose of 1.8 g/day except for subjects who had been on placebo in the previous study, who stayed on 
placebo. Subjects were instructed to continue on their normal diet. Laboratory tests (as in the previous 
study) were conducted in weeks 12, 16, 20 and 21 after entry into this phase of the study. Urine 
samples were taken in weeks 0, 1, 10, 20 and 21. 
The study was completed by 105 participants (32 on placebo and 73 on aspartame). There was no 
significant  weight  change  during  the  study  in either  group.  No  biologically  important changes in 
clinical laboratory parameters were noted and there were no consistent differences in the response to 
an oral glucose challenge. Plasma [Phe] and [Tyr] were variable but no consistent differences were 
observed between placebo and aspartame groups. No ocular abnormalities were detected, there were 
no significant abnormalities in the final physical examinations and only GI tract effects similar to 
those  in  the  short  term  study  were  reported.  Overall,  then,  there  were  no  significant  differences 
between aspartame and placebo groups in any of the parameters evaluated. 
Concern that weight conscious young people might be particularly enthusiastic users of aspartame led 
to the initiation of a third study addressing toxicity in a group of young people who were actively 
engaged  in  a  weight  reduction  programme  (Knopp,  Brandt  et  al,  1976).  The  study  population 
comprised  55  individuals  aged  10-21  (93%  female),  the  majority  being  nursing  students  and  the 
remainder being paediatric referrals, who had a mean weight of 164.4 lb and were, on average, 33% 
overweight for their height. Diabetics were excluded. They participated in a randomised double blind 
trial in which aspartame (2.7 g/day) or lactose (placebo) was administered via gelatine capsules for 13 
weeks. They were assessed every 14 days and laboratory tests (clinical chemistry and haematology), 
plasma [Phe] and [Tyr] determinations and insulin and glucagon assays were carried out in weeks 0, 7 
and at the end of the study.  
There were no consistent differences between groups in terms of physical findings, weight loss or 
prescribed calorie intake and the side effects reported were similar to those observed previously: GI 
tract symptoms, menstrual changes (not unexpected in a group made up mainly of young women) and 
febrile illness. Aspartame had no effect on urinalysis results and no methanol was detected in the urine 
at  any  time  during  the  study.  There  was  no  significant  increase  in  plasma  [Phe]  or  [Tyr]  with 
aspartame treatment. Weight reduction caused a metabolic shift reflected in changes in insulin and  
glucagon levels, but aspartame had no effect on this.   Review of data on the food additive aspartame 
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2.7.4.  Diabetics 
The fact that aspartame is used as a sugar substitute means that diabetics represent another potentially 
susceptible subgroup within the population. Studies on aspartame tolerance by diabetics have therefore 
been carried out by the manufacturers (Searle and subsequently NutraSweet) before and during the 
marketing of aspartame as a sweetener. 
The first such study was conducted in Type I (insulin-dependent) diabetics aged 21-70 who were 
otherwise normal in terms of routine haematology, BUN, creatinine, T4 and bilirubin levels (Bleicher 
and  Stern,  N/K).  Aspartame  (1.8  g/day  via  capsules)  or  placebo  was  administered  for  13  weeks 
according to a double blind, randomised scheme. The study was completed by 77 subjects. There was 
no  evidence  of  changes  in  diabetic  control  in  either  group  and,  despite  variations  in  weight,  no 
consistent  gain  or  loss  of  weight  was  observed.  No  consistent  clinical  chemistry  findings.  Blood 
pressure,  pulse  and  EEG  traces  were  unaffected  by  treatment.  No  progression  of  existing  eye 
abnormalities was noted. 
The same report (Bleicher and Stern, N/K) also describes a study in Type II (non-insulin-dependent) 
diabetics. This part of the study was also published (Stern, Bleicher et al, 1976). Diabetes in these 
subjects (also aged 21-70) was being controlled by diet and medication; none of them was taking 
insulin The conduct of the study was the same as for the insulin-dependent group. This study was 
completed by 69 patients and again there was no consistent effect of treatment on diabetic control, 
mean weight, blood pressure, pulse or EEG trace. Clinical chemistry parameter varied among the 
study population but n new abnormalities developed during the study, and no significant changes in 
plasma [Phe] or [Tyr] were observed. No ocular changes were observed during the study. 
Another study addressing the effects of long term (18 weeks) treatment with aspartame in Type I and 
II diabetics is in existence (Nehrling, Kobe et al, 1985). The population investigated in this study had 
been stable for at least one month on maintenance therapy with fasting glucose levels  200 mg/dl. The 
randomisation procedure was blocked by weight to ensure approximately equal numbers of non-obese, 
moderately obese (115-130% ideal body weight) and very obese (130% ideal body weight) subjects in 
each group. Aspartame was administered at 2.7 g/day via capsules for 18 weeks, the placebo being 
corn starch. Baseline fasting and postprandial glucose levels and glycohaemoglobin were defined at 
two visits, separated by 1 wk, before the start of dosing. Further visits took place in weeks 3, 6, 9, 12, 
15, 17 and 18. During these visits subjects were questioned regarding adverse effects and blood was 
sampled in weeks 9, 17 and 18. 
The  study  was  completed  by  62  patients,  29  on  aspartame  and  33  on  placebo.  There  were  no 
differences between treatment groups in the parameters measured (glucose, glycohaemoglobin) and 
more adverse reactions were reported in the placebo group (21 reported by 14 subjects) than in the 
aspartame  group  (7  reported  by  6  subjects).  The  adverse  reactions  reported  included  headaches, 
constipation, sinus congestion, gastroenteritis and severe diarrhoea). 
The  effects  of  adding  sucrose  or  an  amount  of  aspartame  giving  equivalent  sweeteners  to  well 
controlled Type II diabetics has also been studied in 9 subjects (8M/1F)  who met the  diagnostic 
criteria  for  Type  II  diabetes  and  had  glycosylated  haemoglobin  levels  between  5.7  and  9.1% 
(Colagiuri, Miller et al, 1989). None of the subjects was being treated with insulin; 6 were taking 
sulphonylurea and the other 3 were being controlled by diet alone. The study was a randomised double 
bind crossover design in which sweetening agents were provided in sachets. One group added sucrose 
(45 g/day) to their diet in this way, the other added aspartame (162 mg/day). The crossover took place 
in week 6 or a 12 week study. The parameters assessed were body weight, glycosylated haemoglobin, 
total/LDL cholesterol, and triglycerides measured on study entry and at the end of each dosing period; 
carbohydrate tolerance and in vivo insulin action were evaluated at the same time points. Blood sugar 
was  self-monitored  as  normal.  There  was  no  significant  change  in  mean  body  weight  and  the   Review of data on the food additive aspartame 
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antidiabetic treatments received remained constant throughout the study. Furthermore, none of the 
measured  biochemical  parameters  changed,  either  in  response  to  sucrose  or  aspartame,  in  these 
patients. 
All three of these studies provided reassurance in terms of the absence of any effects of aspartame in 
diabetic control, both in Type I and Type II diabetics. 
Various studies have attempted to define the effects, if any, of acute doses of aspartame on glucose 
homeostasis. One of these (Okuno, Kawakami et al, 1986) addressed effects in controls (n=7, aged 31-
60 yr) and untreated diabetics (n=22) who were subdivided into three groups, with fasting blood 
glucose below 139 mg/dl (n=6, aged 18-64 yr), 140-199 mg/dl (n=8, aged 38-60 yr) or >200 mg/dl 
(n=8, aged 46-54 yr). After an overnight fast the subjects were dosed with aspartame (500 mg) or 
glucose (100 g) in water and plasma glucose, insulin and glucagon levels were monitored over 3 hr. 
There was a small but significant decrease in blood glucose after the aspartame challenge, but no 
change in insulin or glucagon. 
In a second arm of the same study (Okuno, Kawakami et al, 1986), 9 diabetics (3M/6F, aged 38-81 yr) 
with steady state glycaemic control on a prescribed energy intake diet were tested. Of these, 5 were 
taking insulin, one was taking oral medication and 3 were being controlled by diet alone. They were 
given a jelly cake containing 125 mg aspartame as dessert every day for 2 wk and subjected to an oral 
glucose tolerance test, complete blood count and liver/renal function tests 1 week before and after the 
dosing  period.  Fasting  a  postprandial  glucose  was  measured  twice  weekly  and  fasting  blood 
cholesterol, High density lipoprotein (HDL)-cholesterol and triglycerides weekly. This dosing regimen 
had no effect on the response to an oral glucose challenge or on fasting or postprandial glucose levels. 
No changes in standard clinical chemistry parameters, fasting blood cholesterol, HDL-cholesterol or 
triglycerides was observed. 
A further study on the effects of aspartame in Type II diabetics addressed effects on insulin and 
glucagon secretion in the fasting state and attempted to determine whether the sweet taste of aspartame 
increases insulin secretion in the absence of food (Horwitz, 1988; Horwitz, McLane et al, 1988). The 
study population comprised 12 normal subjects (12F, aged 28   8 yr) and 10 Type II diabetics (5M/5F 
aged 57   8 y). Note that the two groups are not well matched, although this did not seem to affect the 
outcome of the study in any obvious way. They were given single doses of cherry-flavoured Kool Aid 
with or without either aspartame (400 mg) r saccharin (135 mg) according to an open label crossover 
design. Plasma glucose, insulin and glucagon were measured for 3 hr following ingestion of each test 
beverage. Plasma glucose declined in both normal and diabetic subjects throughout the test period 
irrespective of treatment, presumably due to fasting, and there was no difference between treatments. 
Neither sweetener affected peak insulin concentrations in either diabetics or normal subjects (9.7, 11.1 
and 9.6  u/ml with placebo, aspartame and saccharin, respectively), although calculation of AUC for 
insulin  did  suggest  that  total  insulin  secretion  after  aspartame  was  greater  than  after  placebo  or 
saccharin (Horwitz, McLane et al, 1988); however, this was due to a reduction in secretion after the 
latter two beverages rather than an actual increase in response to aspartame.  Glucagon showed time-
to-time variation but no overall differences with treatment. Overall, neither aspartame nor saccharin 
had any direct effect on blood glucose homeostasis in fasting Type II diabetics or normal subjects. 
Similar results, indicating the lack of any effect of aspartame on glucose homeostasis, were reported in 
a  paper  which  include  both  a  clinical  study  and  a  study  in  streptozotocin-induced  diabetic  rats 
(Shigeta,  Yoshida  et  al,  1985). Their  human  study  (in Type  II  diabetics  admitted  to  hospital  for 
diabetic control) involved (i) oral glucose (75 g) and aspartame (225 mg) challenges administered 5 
days apart to 15 subjects and (ii) administration of an aspartame-sweetened diet containing 24-48 
mg/day aspartame for three days to Type II diabetics (n=20) and normal subjects (n=6), with fasting 
plasma glucose being measured before, 1 and 3 days after initiation of the diet. The same subjects   Review of data on the food additive aspartame 
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were also given jellies sweetened with 240 mg aspartame at 15.00 in addition to the diet, fasting blood 
glucose being measured before and afterwards. Aspartame did not have any  effect on glucose or 
insulin  levels  in  any  of  these  scenarios.  Similarly,  when  rats  were  made  diabetic  by  injecting 
streptozotocin (45 mg/kg i.v.) and subjected to oral glucose (1.5 g/kg) and aspartame (4.5 mg/kg) 
challenge tests, aspartame had no effect on glucose or insulin over and above those of streptozotocin. 
One subgroup which might be expected to have a particular vulnerability to adverse effects is diabetic 
patients with renal failure. This issue has been addressed in a study of 23 patients with chronic renal 
failure  who  were  receiving  maintenance  haemodialysis  (Gupta,  Cochran  et  al,  1989).  The  study 
involved two single doses of either aspartame (10 mg/kg via capsule) or placebo by a 3 week interval 
and followed  a randomised,  double-blind  crossover design.  Blood  was collected  1 and  2  hr after 
dosing and amino acid profiles were determined. Two adverse experiences were reported during the 
study: one patient experienced nausea and vomiting during the second dosing phase and one had a 
seizure (followed by full recovery) during the second dosing phase. In both cases the event occurred 
after  administration  of  placebo.  There  were  marked  subject-dependent  differences  in  amino  acid 
profiles in this population, but [Phe] and [Tyr] were consistently elevated (to levels which remained 
within the normal postprandial range) 1-2 hr after dosing with aspartame. Levels of Trp remained 
below the level of detection throughout the study. This study was considered to be reassuring with 
respect to the use of aspartame by diabetic subjects with chronic renal failure. 
2.7.5.  Alcoholic liver disease 
Patients with alcoholic liver disease are an obvious potential at-risk group for any compound which is 
taken orally. The question of any risk associated with the use of aspartame by alcoholics with liver 
disease was therefore addressed by NutraSweet in a study reported in 1991 (Mendenhall, 1991) and 
published in 1993 (Hertelendy, Mendenhall et al, 1993). 
The objectives of the study were to determine whether a single dose of aspartame (15 mg/kg) would: 
alter  clinical  and  biochemical  parameters  of  the  subjects  liver  disease;  produce  clinical  and/or 
biochemical changes of incipient or overt portal systemic encephalopathy; alter plasma amino acid 
profiles and/or alter the metabolic disposition of methanol and formate in the blood and urine. The 
subject o this study were 13 males aged 36-64 yr with a diagnosis of chronic stable alcoholic liver 
disease. The study followed an open-label randomised placebo controlled crossover design in which 
the  treatments  were:  300  ml  Kool  Aid  (placebo);  300  ml  Kool  Aid  plus  aspartame  (15  mg/kg); 
skimmed milk equimolar to the amount of Phe in 15 mg/kg aspartame. Blood samples were taken 
frequently up to 8 hr after dosing and analysed for plasma amino acids, blood formate/methanol, total 
bilirubin and liver enzymes were evaluated on treatment days. A Portal Systemic Encephalopathy 
Assessment (which measures changes in mental function), an EEG and urinalysis for formate and 
creatinine were carried out in the same days.  
The clinical chemistry results obtained upon entry to the study were consistent with the subjects’ 
diagnoses: Their AST, ALT and total bilirubin levels were, respectively, 81   48 IU/L (normal range 
5-40 IU/L), 59   43 IU/L (normal range 0-50 IU/L) and 1.4   1.1 IU/L (normal range 0.2 – 1.2 IU/L). 
These did not change in response to administrations of any of the test materials.  
Plasma [Phe] increased to slightly above the normal postprandial range (Cmax = 145.5   73.8  M) 
following aspartame treatment. This effect, which was not seen when Phe was administered in the 
form of skimmed milk because the need to digest the polypeptides in which it is contained slows down 
the release of Phe into the circulation, was associated with a corresponding drop in the branched chain 
amino acid/aromatic amino acid ratio, which has been implicated in portal system encephalopathy; 
however, no adverse experiences occurred after any of the treatments. In particular,  aspartame was 
not associated with clinical changes indicative of incipient or overt  portal system encephalopathy. 
One subject did develop dyspnoea and febrile illness during one of the washout periods, but this was   Review of data on the food additive aspartame 
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not  considered  to  be  related  to  dosing.  Liver  function  tests,  urinary  formate  and  blood 
formate/methanol did not change when aspartame was compared to either placebo or skimmed milk.  
The conclusion drawn was that “individuals with a diagnosis of stable chronic alcoholic liver disease 
can safely consume aspartame-containing beverages”. 
2.7.6.  Parkinson’s disease 
If  aspartame  did  have  an  effect  on  the  dopaminergic  signalling  system  of  the  brain,  this  would 
potentially  have  implications  for  patients  with  Parkinson’s  disease;  however,  only  one  study  has 
addressed this issue to date (Karstaedt and Pincus, 1993). This study focussed on Parkinson’s disease 
patients who were being treated with levodopa (n=18, aged 45-75; average duration of disease 4-30 
yr). All had been using levodopa for the same length of time. The patients were studied on two 
consecutive days and were dosed with aspartame (600 mg (n = 10) or 1200 mg (n=8) via capsules) 
alternating with placebo. The measurements taken were disability score (New York University scale), 
dyskinesia score (Abnormal Involuntary Movement Scale) and walking time. Plasma LNAAs and 
levodopa levels were determined. None of these parameters differed between the 600 mg dose of 
aspartame and control. After dosing with 1200 mg aspartame, plasma [Phe] peaked at 82.5  M (vs. 
57.2  M in controls) but no change in motor scores was observed. The discussion of this paper notes 
that LNAA levels above 900 M are associated with adverse effects; this level could be exceeded at 
very high levels of aspartame but not under normal conditions of use. The authors see no need for 
Parkinson’s disease patients to moderate their intake of aspartame. 
2.7.7.  Individuals suffering from mood disorders 
The final group which could, it has been claimed, be particularly vulnerable to the adverse effects of 
aspartame is that comprising individuals suffering from mood disorders such as depression. One study 
in the early 1990s (Walton, Hudak et al, 1993) set out to address this issue. Its aim was to recruit 40 
patients with a history of treatment for recurrent major depression but who were currently stable with a 
Brief Psychiatric Rating Scale of <6 at the time of the study. The study design involved a randomised 
crossover trial in which subjects took either placebo or aspartame (30 mg/kg/day) for 7 days with a 3 
day washout between dosing periods. Standard aspartame capsules were not available to the study 
investigator, so the aspartame used in this trial was bought in as pharmaceutical grade material (US 
Pharmacopeia Grade) and made up into capsules by a hospital pharmacy. 
During  dosing,  subjects  monitored  their  symptoms  using  a  checklist  provided  by  the  study 
investigator. The checklist identified a range of possible symptoms and subjects were invited to score 
them as: 0 – not present; 1 – mild (does not disrupt activities); 2 – moderate (controllable by education 
or other means) or 3 – severe (disrupts daily activities). The potential for suggestion in such a system 
should be noted. 
A wide range of symptoms was reported by subjects in this trial. These included a detached retina and 
a conjunctival haemorrhage (both during the placebo week), on the basis of which the study was 
terminated after completion by 8 patients (aged 24-60) and 5 controls (aged 24-56). Patients with 
depression reported increased scores and numbers of symptoms when taking aspartame as compared 
with placebo; this effect was not seen in controls. In particular, this group reported more headaches 
than the control group, although these did not differ between aspartame and placebo dosing periods. 
Symptoms were usually reported 2-3 days into a dosing period. 
This study has generated concerns regarding the potential toxicity of aspartame, but it cannot be relied 
upon for risk assessment purposes for a number of reasons: the aspartame used was not from the same 
source as any used in other trials; the method of eliciting reports of side-effects involved a strong 
element of suggestion; and the time at which adverse effects were reported is exactly when a lay 
person might expect to start to get side effects from a drug or chemical. The study was terminated on   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  98 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
the basis of adverse events, but neither of these happened during dosing with aspartame. Furthermore, 
the only thing the two reactions have in common is that both involved the eye, and no biologically 
plausible link to aspartame has been suggested for these effects (Butchko, 1994). 
2.7.8.  Summary 
With regard to potentially vulnerable groups, it is important to note that phenylketonurics (who have a 
genetic deficiency in phenylalanine hydroxylase activity) represent a known and well-characterised 
susceptible  subgroup  within  the  population.  They  need  to  restrict  their  intake  of  aspartame,  and 
aspartame-containing  products  are  required  to  carry  warning  labels  to  this  effect.  Controlled 
administration of single doses of aspartame to phenylketonurics has, however, provided reassurance 
that the ingestion of a small dose by these individuals is not hazardous. Furthermore, studies on PKU 
heterozygotes (“carriers”) have demonstrated that, while they exhibit higher plasma [Phe] peaks and 
slower clearance than controls following ingestion of aspartame, accumulation and long term effects 
are not observed. 
Other subgroups whose potential vulnerability to adverse effects following ingestion of aspartame has 
been investigated include MSG-sensitive individuals, the obese, diabetics, individuals with alcoholic 
liver disease, Parkinson’s disease sufferers and individuals with mood disorders. No untoward effects 
have been reported in any of these groups.    Review of data on the food additive aspartame 
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QUALITY ASSESSMENT OF KEY STUDIES  
The aim of the second phase of this project was to perform an in-depth scientific and quality assurance 
(QA)  assessment  of  fifteen  key  studies  from  the  study  reports  database  of  EFSA  and  the  first 
Ramazzini  Foundation  rat  carcinogenicity  study  (Soffritti  and  Belpoggi,  2005).  For  each  study, 
strengths and limitations as well as scientific soundness of the study were considered. This quality 
assessment was made with reference to good laboratory practice (GLP) and internationally recognised 
guidelines for similar studies, as far as possible and taking into consideration the date of the study. 
This  deliverable,  therefore,  comprises  a  detailed  review  of  fifteen  study  reports.  The  review  was 
conducted by: 
  Lesley Stanley, Eurotox Registered Toxicologist (overview and general toxicity) 
  Peter Millar, Pathologist (pathology) 
  Janice Birnie, Quality Assurance Consultant (QA and guideline compliance) 
In order to ensure a consistent approach to the review process, a proforma-based methodology was 
adopted. Proforma sections covering study details and QA were filled in for every primary study; for 
carcinogenicity studies, an additional section addressing pathology findings was also completed. Two 
of  the  study  reports  provided  were  pathology-related  follow  up  investigations;  for  these,  a  third 
proforma section was added to those already completed for the main study report. In total, therefore, 
13 proformas were completed and are appended to this report. Every study was reviewed by at least 
two team members; carcinogenicity studies were considered by all three reviewers. 
With respect to QA assessment, all study reports were assessed against current (as at 2012) GLP 
requirements, whether or not they claimed GLP compliance. Studies conducted in the USA were 
evaluated  against  FDA  GLP  guidelines;  non-US  studies  were  evaluated  against  Organisation  for 
Economic  Co-operation  and  Development  (OECD)  GLP  guidelines.  Further  assessment  against 
OECD protocol guidelines was carried out on a subset of reports at the discretion of the QA review 
team  member.  In  addition,  five  studies  were subjected to  an additional  QA check  addressing  the 
internal consistency of the report. 
The study reports were: 
1.  SC-18862: 106 Week Oral Toxicity Study In The Dog (E28) (Rao, Mauro et al, 1972). 
2.  SC-18862: Two Year Toxicity Study In The Rat. Final Report and Appendix (E33-4) (Reno, Ferrell et al, 1973a). 
3.  SC-18862: Lifetime Toxicity Study In The Rat. Final Report (E70) (Trutter, Reno et al, 1974). 
4.  SC-18862: 104 Week Toxicity Study In The Mouse. Final Report (E75) (Reno and Ferrell, 1974a). 
5.  SC-19192: 110 Week Toxicity Study In The Mouse. Final Report (E76) (Reno and Ferrell, 1974b). 
6.  SC-19192: 115 Week Oral Tumorigenicity Study In The Rat Volume I-II (E77-8) (Rao, Stejskal et al, 1974). 
7.  SC-18862: A Supplemental Study Of Dog Brains From A 106 Week Oral Toxicity Study (E86) (McConnell, 1973). 
8.  SC-18862 (Aspartame): A Supplemental Study Of Rat Brains From Two Tumorigenicity Studies (E87) (Reno, 
Ferrell et al, 1973b). 
9.  Histopathological Examination In A Carcinogenicity Study Of Sc-18862 In Slc:Wistar Rats. Final Report (UA04) 
(Iwata, 2006). 
10.  SC-18862: Evaluation Of Embryotoxic And Teratogenic Potential In The Rat (E5) (Schroeder and McConnell,   Review of data on the food additive aspartame 
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1970). 
11.  SC-18862: An Evaluation Of Embryotoxic And Teratogenic Potential In The Mouse (E89) (Vondruska, Schroeder 
et al, 1975a). 
12.  SC-18862: Toxicological Evaluation In The Neonatal Rat. Final Report (E9) (Reno and Ferrell, 1972). 
13.  SC-18862: Two Generation Reproduction Study – Rats. Final Report (E11) (Reno, 1971). 
14.  SC-18862: An Evaluation Of Embryotoxic And Teratogenic Potential In The Rabbit (E90)  (Vondruska, Schroeder 
et al, 1975b). 
15.  Report  on  Long-term  Carcinogenicity  Bioassays  to  Evaluate  the  Potential  Biological  Effects,  in  particular 
Carcinogenic, of Aspartame Administered in Feed to Sprague-Dawley Rats. Protocol No.: BT 6008 (Soffritti and 
Belpoggi, 2005). 
These studies may be categorised by study type, test item, sponsor and species as follows: 
Chronic toxicity/carcinogenicity: 
Aspartame: 
  Dog: Searle E28 (Rao, Mauro et al, 1972); follow up E86 (McConnell, 1973) 
  Mouse: Searle E75 (Reno and Ferrell, 1974a) 
  Rat: Searle E33-4, E70 (Reno, Ferrell et al, 1973a; Trutter, Reno et al, 1974);  
follow-up E87 (McConnell, 1973) 
  Rat: Ajinomoto (Iwata, 2006) 
  Rat:  European  Ramazzini  Foundation  of  Oncology  and  Environmental  Sciences  (ERF)  (Soffritti  and 
Belpoggi, 2005) 
DKP: 
  Mouse: Searle E76 (Reno and Ferrell, 1974b) 
  Rat: Searle E77-8 (Rao, Stejskal et al, 1974) 
Embryotoxicity/teratogenicity 
Aspartame 
  Mouse: Searle E89 (Vondruska, Schroeder et al, 1975a)   
  Rat: Searle E5 (Schroeder and McConnell, 1970)   
  Rabbit: Searle E90 (Vondruska, Schroeder et al, 1975b)   
Two generation reproduction study and neonatal toxicity 
Aspartame 
  Rat: Two generation: Searle E11 (Reno, 1971) 
        Neonatal toxicity in offspring E9 (Reno and Ferrell, 1972) 
Overall, the conclusions of the review team were as follows: 
  The studies conducted by or on behalf of Searle in the early 1970s were performed according 
to standards which were considered appropriate at the time; indeed, they were probably “state 
of the art” for the period. In order to provide a modern day perspective, the QA assessment 
conducted  in  this  review  evaluated  these  studies  against  current  (i.e.  as  at  2012)  GLP 
regulations and OECD guidelines. 
In general, no major deficiencies were identified but every study was found to lack certain key 
items that would exist in a GLP study and minor inconsistencies in data presentation were 
identified. It was not possible to confirm protocol objectives and any changes, as protocols for 
these studies were not provided. The main criticism made, which applies to all the Searle 
studies, was that they contain insufficient information to support adequate characterisation of 
the  test  item(s),  including  the  batch(es)  used,  and  for  the  duration  of  the  test  its  actual   Review of data on the food additive aspartame 
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concentration,  homogeneity  and  stability  in  the  diet  mix,  and  the  actual  concentrations 
consumed. 
Despite these caveats, the view of the review team is that these studies are adequate for use in 
risk assessment as long as their limitations are taken into account. 
  The study reported by the ERF (Soffritti and Belpoggi, 2005) has been the subject of intense 
controversy. This study is limited in a number of respects, but the most important concerns of 
the review team were that there are significant doubts about the pathology findings and that it 
claims compliance with GLP (and was carried out at a time when GLP regulations were in 
place in Italy) but lacks the necessary supporting documentation including Study Director 
identification, Study Director’s statement, QA Statement and information to support adequate 
characterisation  of  the  test  item  (batch(es)  used,  for  the  duration  of  the  test  its  actual 
concentration, homogeneity and stability in the diet, and the actual concentrations consumed).  
The opinion of the review team is that, before the results of this study are used for risk 
assessment, the pathology should be subjected to a comprehensive independent peer review 
and the whole study should be audited. 
  The study reported by Ajinomoto in 2006 (Iwata, 2006) was difficult to evaluate because it 
only contained further histopathological evaluation of an existing chronic toxicity study which 
was not included among the key studies. Internal evidence in the report strongly suggests that 
the study in question is that reported by Ajinomoto in 1981 (Ishii, Koshimizu et al, 1981); 
however, this identification cannot be made unequivocally because, while the 2006 report 
refers to a Sponsor’s study number (AP-104), the 1981 report does not have a study number. 
This being the case, the 2006 report has been reviewed as a stand-alone document rather than 
as  a  follow-up  study.  The  review  team  had  significant  concerns  regarding  this  study;  in 
particular: 
o  The provenance of the blocks used is unclear because of the issue of study origin 
raised above. 
o  No reference is made to the age of the paraffin blocks used, but if our identification of 
the parent study is correct, they would have been at least 25 years old. This could have 
significantly affected the quality of sections obtained, and should at least have been 
discussed in the report. 
o  Finally, and most importantly, the team pathologist has questioned the strain of rat 
used in this study. The report states that they were of the Slc:Wistar strain but the 
spectrum of lesions observed suggests that they were much more likely to have been 
of Fischer origin. This raises serious doubts about the origin of the samples and even 
whether the correct blocks were evaluated. 
The opinion  of  the  review  team,  therefore,  is  that  this study  should  not  be  used  for  risk 
assessment unless/until these issues are resolved. 
The following is a brief summary of the review team’s findings on individual studies. 
Chronic toxicity/carcinogenicity studies on aspartame: 
Searle E28 (Rao, Mauro et al, 1972); follow up E86 (McConnell, 1973): This study identified no 
chronic toxicity in dogs at doses up to 4,000 mg/kg/day administered daily via the diet. Its relevance to 
risk assessment may be summarised as follows:   Review of data on the food additive aspartame 
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Study design 
and power 
Small study: 5 dogs per sex per group. 
  Control groups same size as treatment groups 
Three dose levels plus control 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used 
  Purities of individual batches not indicated 
Compound administered daily in controlled doses 
High standard of fixation of key tissues 
Relevance of 
the study  Provides chronic toxicity data from a non-rodent species 
Adequacy of 
data sets 
No intercurrent deaths 
Good range of endpoints measured 
  Lack of some data specified at week 78; unlikely to have affected outcomes 
Good tissue accountability 
Data sources  Commercial study report, pre-GLP (1972) 
Comments 
  This was a small study, but it seems to have been conducted to a high standard. It provides 
reassurance concerning lack of toxicity in a non-rodent species. 
  Brain sections from this study were evaluated independently by two general pathologists  and a 
comparative neuropathologist . The experts agreed that in this study “ependymal neoplasms were not 
present, nor was focal ependymal proliferation a notable concern in treated animals” though they did 
raise issues regarding sample quality and labelling.  
  Both the original study and the follow up investigation were included in the UAREP authentication review 
in 1978. No major issues were raised. 
Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Searle  E75  (Reno  and  Ferrell,  1974a):  This  study  does  not  indicate  any  chronic  toxicity  or 
carcinogenic effect due to aspartame when administered to mice via the diet at doses up to 4,000 
mg/kg/day. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
Adequate size: 36 per sex per group 
  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus control 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet. 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intake close to that planned. 
No issues with histopathology findings. 
Relevance of 
the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of 
data sets 
Poor survival to termination: 25-42% per group. 
Laboratory investigations only performed on a subset of mice. 
Number of clinical chemistry analyses limited by volume of obtainable from mice and lack of 
suitable microanalytical methods at the time. 
Range of tissues sampled was state of the art for the date the study was conducted.  
  Modern guidelines would recommend the inclusion of additional tissues.   Review of data on the food additive aspartame 
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Poor tissue accountability 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
  This study was included in the UAREP authentication review in 1978. No major issues were raised. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in 
risk assessment as long as its limitations are taken into account. 
Searle E33-4 (Reno, Ferrell et al, 1973a); follow-up E87 (McConnell, 1973). This study does not 
indicate overt toxicity or carcinogenic effects due to aspartame when administered to rats via the diet 
at doses up to 4,000 mg/kg/day for two years. Reduced survival was observed in females at 8,000 
mg/kg/day. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
Adequate size: 40 per sex per group 
  Control groups: 60 per sex to enhance statistical power 
Four doses levels plus control 
  Allows some characterisation of dose response 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used; DKP content of each batch specified. 
Calculated compound intake within 10% of that planned. 
  No justification for dose escalation in highest dose group. 
Two outbreaks of infection during the study; neither appears to have impacted on the overall 
study conclusions.  
Possible issues with procedure for dealing with decedents did not preclude histopathological 
evaluation. 
No issues with pathology conduct or interpretation 
Relevance of 
the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of 
data sets 
Intercurrent clinical chemistry analysis undertaken, but only on 5 rats per group 
Some results excluded from analysis without providing a justification 
Good tissue accountability 
Range of tissues sampled was state of the art for the date the study was conducted, although 
modern guidelines recommend the inclusion of additional tissues. 
Evaluation of brain and urinary bladder was comprehensive even by today’s standards. 
Some data missing from report 
Data sources  Commercial study report, pre-GLP (1973) 
Comments 
  This study (original study and follow up investigation) was included in the UAREP authentication review 
in 1978. They found the history of the study difficult to follow, but raised no significant issues with the 
data recording and interpretation. 
  Brain sections from this study and study E70 were evaluated independently by two general pathologists  
and a comparative neuropathologist . The conclusion from this follow-up investigation was that there 
was no evidence of an intracranial tumorigenic effect due to aspartame although brain tumour 
development did seem to be related to treatment in one of the two studies. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in 
risk assessment as long as its limitations are taken into account. 
Searle E70 (Trutter, Reno et al, 1974); follow-up E87 (McConnell, 1973). This study does not indicate 
chronic toxicity or carcinogenic effects due to aspartame when administered to mice via the diet at 
doses of 2,000 or 4,000 mg/kg/day. Its relevance to risk assessment may be summarised as follows:   Review of data on the food additive aspartame 
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Study design 
and power 
Adequate size: 40 per sex per group 
  Control groups: 60 per sex to enhance statistical power 
Two dose levels plus control 
  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used; DKP content of each batch specified. 
No evidence to confirm that compound was administered throughout parental 
gestation/lactation; calculated compound intake by offspring close to that planned. 
Good tissue accountability 
Detailed description of sampling method for histopathology. 
Range of tissues sampled was state of the art for the date the study was conducted, although 
modern guidelines recommend the inclusion of additional tissues. 
Evaluation of brain and urinary bladder was comprehensive even by today’s standards. 
No issues with pathology conduct or interpretation 
Relevance of 
 the study 
Lifetime bioassay in a standard laboratory rodent species; acts as a follow up to two-generation 
reproductive toxicity study (E11) 
Adequacy of 
data sets 
Intercurrent clinical chemistry analysis undertaken, but only on 5 rats per group 
Range of tissues sampled was state of the art for the date the study was conducted, although 
modern guidelines recommend the inclusion of additional tissues. 
Data sources  Commercial study report, pre-GLP (1974) 
 
Comments 
  This study provides information regarding the effects of aspartame when administered in utero as well 
as throughout postnatal life. 
  This study was included in the UAREP authentication review in 1978. No major issues were raised. 
  Brain sections from this study and study E33-4 were evaluated independently by two general 
pathologists and a comparative neuropathologist . The conclusion from this follow-up investigation was 
that there was no evidence of an intracranial tumorigenic effect due to aspartame although brain tumour 
development did seem to be related to treatment in one of the two studies. 
  This study would not be considered fully compliant with the current OECD Guideline for carcinogenicity 
testing (Number 451), but the guideline was not in place when the study was conducted. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in 
risk assessment as long as its limitations are taken into account 
ERF (Soffritti and Belpoggi, 2005). This study is difficult to interpret because of the issues of potential 
infection, unusual diagnostic criteria applied and lack of supporting laboratory data. In particular, the 
report contains evidence of high levels of chronic infection and external commentators have suggested 
that it was compromised by infection with M. pulmonis. Quite apart from the undesirability of there 
being so much evidence of chronic infection in the animals on study the effects of these findings on 
incidences of the putative treatment-related findings in the nasal cavities, lungs and kidneys need to 




Large study: 100-150 animals per sex per treatment group 
  Control group same size as individual treatment groups. 
  This makes the study unbalanced in that controls only represented 300/1800 (16.7%) 
of rats. 
Six dose levels plus controls   Review of data on the food additive aspartame 
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  This should have allowed the characterisation of dose responses, but actual intakes 
are not specified in the report. 
Data quality 
Study claims GLP compliance, but this could not be verified. 
  Report contains a number of deviations from GLP requirements. 
Report lacks information on batches of test item used, purity etc. 
Actual compound intakes not reported. 
Report contains evidence of chronic infection during the course of the study. 
Serious concerns regarding pathology diagnoses and interpretation. 
Relevance  of 
the study 
Provides information as to the effects of aspartame when administered to the end of the natural 
lifespan, but difficult to compare with conventional two-year bioassays. 
Adequacy  of 
data sets 
No laboratory investigations conducted, and minimal in life observations. 
Large quantity of descriptive information on tumour incidence, but difficult to interpret. 
Data sources  Privately funded study report. Claims GLP, but without supporting evidence. 
Carried out at time when GLP and OECD Guidelines were in place. 
Comments 
  This study has been the subject of intense controversy and lacks many features specified by 
OECD Guideline 451, which was in place at the time the study was conducted. 
  A subset of slides (chosen by ERF) was shown to a group of NTP pathologists, but it is not clear 
whether any of their recommendations were acted on. 
  The most important concerns of the review team were: 
o  The study claims compliance with GLP (and was carried out at a time when GLP regulations 
were in place in Italy), but lacks the necessary supporting documentation. 
o  There are significant doubts about the pathology findings.  
  The opinion of the review team is that, before the results of this study are used for risk assessment, the 
pathology should be subjected to a comprehensive independent peer review and the whole study should 
be audited. 
Ajinomoto (Iwata, 2006). It is difficult to draw any conclusions from this study because of the lack of 
information  regarding  the  conduct  of  the  original  study.  The  study  provided  no  evidence  of 
carcinogenic effects due to aspartame at dosed up to 4,000 mg/kg/day. The results suggest increased 
mineralisation  of  the  renal  pelvis  in  males  at  2,000-4,000  mg/kg/day  and  in  females  at  4,000 
mg/kg/day, but this was not associated with transitional cell hyperplasia and is not considered to be of 
toxicological significance. Its relevance to risk assessment may be summarised as follows: 
Study  design 
and power 
The limited information in the study report indicates that the samples analysed were from a 
study having a group size of 60M/60F per group. 
  The control groups were of the same size as the treatment groups. 
  It is not clear whether this included all the samples from the original study. 
Three doses plus control 
  This would allow limited evaluation of doses responses. 
Data quality 
Report clearly states that this was a non-GLP study. 
  Study was conducted at a time when OECD GLP guidelines were in place. 
  It would not be fully compliant if assessed against GLP requirements. 
Tissue dissection and fixation procedures are not described. 
  If tissues are 25 years old, as implied, tissue quality could be an issue. 
The provenance of the tissues could not be verified. 
  The samples do not appear to be from the strain specified. 
Peer review of histopathology findings mentioned in Methods but outcome not reported. 
Relevance  of 
the study 
Potentially provides information on histopathological changes in response to aspartame in an 
additional strain of rat. 
Adequacy  of  Reports histopathology on a subset of samples from an original study which could not be   Review of data on the food additive aspartame 
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data sets  identified unequivocally. 
Wide ranging list of tissues examined 
  However, some recommended tissues were not examined: peripheral nerve, skeletal 
muscle, skin, eyes and spinal cord 
No in life observations or laboratory investigations. 
Data sources  Commercial study report, non-GLP (2006) 
Comments 
  This document reports further histopathological evaluation of a previous chronic toxicity study which was 
not included in the list of key studies identified by EFSA. The samples examined in this study were from 
a previous 104 week carcinogenicity study, identified as Sponsor’s study number AP-104. They appear 
to be the main group samples from the two year bioassay reported by Ishii (1981); however, that report 
does not carry a Sponsor’s study number so it is impossible to be sure that it was the source of the 
samples used here. This being the case, the 2006 report has been reviewed as a stand-alone document 
rather than as a follow-up study. The review team had significant concerns regarding this study; in 
particular: 
  The provenance of the blocks used is unclear because of the issue of study origin raised above. 
  No reference is made to the age of the paraffin blocks used, but if our identification of the parent study is 
correct, they would have been at least 25 years old. This could have significantly affected the quality of 
sections obtained. 
  Finally, and most importantly, the team pathologist has questioned the strain of rat used in this study. 
The report states that they were of the Slc:Wistar strain but the spectrum of lesions observed suggests 
that they were much more likely to have been of Fischer origin. This raises serious doubts about the 
origin of the samples and even whether the correct blocks were evaluated. 
  The  recommendation  of  the review  team,  therefore,  is  that  this study  should  not be used  for  risk 
assessment unless/until these issues are resolved. 
Chronic toxicity/carcinogenicity studies on DKP: 
Searle  E76  (Reno  and  Ferrell,  1974b).  This  study  does  not  indicate  any  chronic  toxicity  or 
carcinogenic  effect  due  to  DKP  when  administered  to  mice  via  the  diet  at  doses  up  to  1,000 
mg/kg/day. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
Adequate size: 36 per sex per group 
  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus control 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intake close to that planned. 
No issues with pathology conduct or interpretation 
Relevance of 
the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of 
data sets 
Laboratory investigations only performed on a subset of mice. 
Number of clinical chemistry analyses limited by volume of obtainable from mice and lack of 
suitable microanalytical methods at the time (noted by UAREP). 
Poor survival to termination: 20-39% per group 
Tissue accountability better than for concurrent study (E75) 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
  This study was included in the UAREP authentication review in 1978. This noted a discrepancy between 
the survival data in the study report and the outcome of re-analysis, and also observed an unusually high   Review of data on the food additive aspartame 
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incidence of statistically significant differences in control values between this study and E75, which was 
carried out concurrently. No histopathology issues were raised. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Searle  E77-8  (Rao,  Stejskal  et  al,  1974).  This  study  does  not  indicate  any  overt  toxicity  or 
carcinogenic effect due to DKP when administered to rats via the diet at doses up to 3,000 mg/kg/day, 
although body weight was affected at the highest doses administered. The impact of several outbreaks 
of  infectious  disease  on  the  study  outcome  is  not clear.  Its  relevance  to  risk  assessment  may  be 
summarised as follows: 
Study design 
and power 
Adequate size: 36 per sex per treatment group 
  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus controls 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Purity of DKP batches used not specified. 
Calculated compound intake within “roughly 10%” of that planned. 
Study compromised by outbreaks of infectious disease: see Section 2. 
No issues with pathology conduct or interpretation 
Relevance of 
the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of 
data sets 
Significant number of animals died from infection and/or lost to histology due to severe autolysis 
Intercurrent clinical chemistry analysis undertaken, but only on 6 rats per group.  
Detailed description of sampling method for histopathology. 
Some clinical chemistry values missing 
No table of necropsy findings in report 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which 
concluded that it was authentic. It is also covered in the Bressler Report (Bressler, 1977), which 
identifies various issues in relation to quality but does not draw clear conclusions regarding its 
authenticity. A further FDA review notes the absence of terminal clinical chemistry analysis from the 
study report (FDA, 1976). 
  This study would not be considered fully compliant with the current OECD Guideline for carcinogenicity 
testing (Number 451), but the guideline was not in place when the study was conducted. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in 
risk assessment as long as its limitations are taken into account 
Embryotoxicity/teratogenicity studies on aspartame: 
Searle E89 (Vondruska, Schroeder et al, 1975a). This study does not indicate any clear cut effects on 
maternal, litter or foetus parameters due to aspartame when administered to mice via the diet at doses 
up to 4,000 mg/kg/day. The report provides no clear explanation for the increased incidence of split 
sternebrae observed. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
≥32 dams per group mated 
  ≥200 foetuses per group examined for visceral abnormalities 
  ≥ 200 foetuses per group examined for skeletal malformations 
Three dose levels plus control   Review of data on the food additive aspartame 
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Rationale for some data manipulations is unclear 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) 
including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No details of diet preparation provided. 
Calculated compound intake up to 35% higher than planned. 
Report lacks information on why some data are missing (“ND= no data”  flagged for some 
maternal values), nor discuss the impact of these omissions. 
Relevance of 
the study  Evaluation of embryotoxicity and teratogenicity in a standard laboratory rodent species. 
Adequacy of 
data sets 
Maternal survival 100%. 
Limited in life observations; no laboratory investigations . 
No explicit description of visceral observations. 
Not clear how incidence of major malformations was calculated for comparison with background 
incidences. 
Data sources  Commercial study report, pre-GLP (1975) 
Comments 
  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
  The study report was peer reviewed by an external consultant. 
  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which 
concluded that it was authentic. It is also covered in the Bressler Report (Bressler, 1977), which 
identifies a failure of blinding in the foetal examination and a lack of documentation but does not draw 
clear conclusions regarding its authenticity. No substantive issues were raised in the review of Collins 
(Collins, 1978). 
  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in 
risk assessment as long as its limitations are taken into account. 
Searle E5 (Schroeder and McConnell, 1970). This study does not indicate any clear cut effects on 
maternal, litter or foetus parameters due to aspartame when administered to rats via the diet at doses 
up to 4,000 mg/kg/day. The significance of the observed differences in ossification of the cervical 
vertebral centra is not clear. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
≥24 dams per group (30 initially  mated) 
  ≥100 foetuses per group examined for visceral abnormalities 
  ~ 200 foetuses per group examined for skeletal malformations 
Two dose levels plus control 
  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) including 
the batch(es) used and ongoing analysis in diet 
No information provided regarding purity of test item. 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intakes close to those planned. 
Fixation in 95% ethanol would have made embryo preparations fragile 
Relevance of 
the study  Evaluation of embryotoxicity and teratogenicity in a standard laboratory rodent species. 
Adequacy of  Limited in life observations; no laboratory investigations.   Review of data on the food additive aspartame 
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data sets  Some inconsistencies and omissions noted. 
Lack of individual data for some parameters. 
No necropsy observations on ovaries and uteri. 
Data sources  Commercial study report, pre-GLP (1970) 
Comments 
  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which noted that 
the visceral samples were no longer available for review but concluded that the study was authentic. It is 
also covered in the Bressler Report (Bressler, 1977), which identifies a failure of blinding in the foetal 
examination and a lack of documentation but does not draw clear conclusions regarding its authenticity. 
  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Searle E90 (Vondruska, Schroeder et al, 1975b). This study indicated clear cut effects on maternal, 
litter and foetus parameters due to aspartame when administered to rabbits by gavage at a dose of 
2,000 mg/kg/day, though not at lower doses. These effects may not have been due to a direct effect of 
aspartame itself, but they still represent a consequence of dosing, even if the mechanism involved is 
indirect. Its relevance to risk assessment may be summarised as follows: 
Study design 
and power 
Large study: 50 dams per group 
  Number of foetuses per group examined varied (75-339) 
Three dose levels plus control, also L-Phe and L-Asp groups 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) including 
the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Compound administered daily in controlled doses. 
Report lacks information on why some data are missing (“ND= no data” flagged for some maternal 
values), nor discuss the impact of these omissions. 
Relevance of 




Limited in life observations; no laboratory investigations  
High incidence of resorptions, abortions and premature deliveries reduced number of foetuses 
available for examination. 
Detailed terminal analysis of dams and surviving foetuses 
Data sources  Commercial study report, pre-GLP (1975) 
Comments 
  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
  The study was compromised by a severe adverse effect on food consumption at the highest dose 
administered. Gavage dosing also affected food consumption in all groups. 
  The study report was peer reviewed by an external consultant. 
  This study was included in the UAREP authentication review in 1978. Some discrepancies were noted, 
along with the limitations of the rabbit as a model for this kind of study. No substantive issues were raised 
in the review of Collins (Collins, 1978). 
  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted.   Review of data on the food additive aspartame 
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  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Two generation reproduction and neonatal toxicity studies on aspartame: 
Searle E11 (Reno, 1971). This study does not indicate any clear cut effects on reproductive parameters 
due to aspartame when administered to rats via the diet at doses up to 4,000 mg/kg/day over two 
generations, but the range of parameters evaluated is very limited. Its relevance to risk assessment may 
be summarised as follows:   
Study design 
and power 
12 males and 12 females per treatment group for first round of breeding 
Two dose levels plus control 
  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) including 
the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No evidence to confirm that compound was administered throughout gestation and lactation; 
calculated intakes variable, up to 22.5% lower than planned. 
No inconsistencies noted, but very few data presented 
Relevance of 
the study 




Limited in life observations; no laboratory investigations. 
No histological evaluation. 
Superficial evaluation of reproductive parameters; lacks in depth analysis. 
Small number of F1A offspring examined due to poor survival and need to populate P2 generation 
and lifetime toxicity study. 
Some maternal and litter data not reported. 
Data sources  Commercial study report, pre-GLP (1971) 
Comments 
  This study provides very limited information given the potential importance of the study.  
  This study was included in the UAREP authentication review in 1978. The study findings were agreed and 
the reviewers noted that the study exhibited fewer problems and discrepancies than other studies. 
  This study would not be considered fully compliant with the current OECD Guideline for 2-generation 
reprotox testing (Number 416), but the guideline was not in place when the study was conducted. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Searle E9 (Reno and Ferrell, 1972). The histological changes seen in the kidney in this study appear 
to be consistent with normal histological processes during postnatal development. There is evidence of 
an effect of treatment at pnd 15-21, but this is transient and appears to have resolved by pnd 28-30. Its 
relevance to risk assessment may be summarised as follows: 
Study design 
and power 
Small number of F2A offspring from two generation study (20M/20F) examined at weaning. Follow 
up evaluation of pups from other F2A litters (10 per sex per group) at pnd 28-30. 
Two dose levels administered to dams, plus control 
  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
  Insufficient information to support adequate characterisation of the test item(s) including 
the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No evidence to confirm that compound was administered to dams throughout gestation and   Review of data on the food additive aspartame 
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lactation. 
Relevance of 
the study  Provides information on effects on weanling rats of administration of aspartame to dams. 
Adequacy of 
data sets 
Limited laboratory investigations undertaken. 
Wide range of tissues sampled, but only histology reported is on kidney, liver, heart and stomach. 
  Only 13-20 tissues per sex per group examined for initial litters selected 
Supplementary analysis of pups from other F2A litters (10 per sex per group) at pnd 28-30. 
Information in study report is sketchy. 
Data sources  Commercial study report, pre-GLP (1972) 
Comments 
  Since aspartame undergoes complete hydrolysis in the GI tract, it is extremely unlikely that pups were 
exposed to intact aspartame via the milk, although they could have been exposed to high levels of L-Phe 
derived from the aspartame in their dam’s diet. The pups could also have been exposed to aspartame 
itself if they started to consume solid diet as well as milk during the suckling period. 
  This study was included in the UAREP authentication review in 1978. The review notes one significant 
technical error, but this did not materially affect the outcome of the study. The panel agreed with the 
histology findings. 
  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Overall, the opinion of the review team is that the studies conducted by or on behalf of Searle in the 
1970s can be used in risk assessment if their limitations are taken into account, but issues relating to 
the ERF and Ajinomoto studies require resolution before they are relied upon. Specifically: 
  The  ERF  study  should  be  subjected  to  independent  audit;  its  pathology  findings  should 
undergo a comprehensive independent peer review. 
  The Ajinomoto study should be authenticated with respect to the identity of the original study 
to which it relates; in particular, the genetic background of the rats used in this study should be 
confirmed. 
The team notes that the only two generation reproductive toxicity study, while without major quality 
issues, is limited with respect to procedures carried out, parameters measured and outcomes reported. 
Reassurance would be provided by conducting another two generation study according to current 
OECD guidelines. 
DISCUSSION 
The approved use of aspartame is as a dietary sweetener; as such, the only route by which consumers 
are exposed to this compound is via ingestion (although other routes may become relevant in the 
occupational setting). 
Following  oral  exposure,  aspartame  undergoes  hydrolysis  catalysed  by  esterases  and  dipeptidases 
leading to release of its individual components (Asp, Phe and methanol). This may occur either in the 
lumen of the GI tract or within intestinal mucosal cells; either way, it is the individual components 
which undergo absorption. Intact aspartame is not detected in the systemic circulation, and aspartame 
therefore has an effective oral bioavailability of zero. 
Two  of  the  three  components  of  aspartame  (Asp  and  methanol)  are  cleared  rapidly  from  the 
circulation.  Under  some  circumstances  (e.g.  when  aspartame  is  ingested  in  the  absence  of 
carbohydrates)  Asp  is  briefly  measurable  in  the  plasma  following  ingestion,  but  under  normal 
conditions of use Asp is rapidly metabolised and excreted predominantly in expired CO2, although a   Review of data on the food additive aspartame 
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small proportion may be incorporated into proteins. Even after ingestion of large doses of aspartame, 
blood methanol levels usually remain below or very close to the limits of detection.  
The effective pharmacokinetics of aspartame are therefore those of its Phe component. Plasma [Phe] 
usually peaks about 60 min after ingestion and is then cleared from the circulation over a period of 
about 2-3 hr depending on the dosing regiman used. If repeated high doses are administered (e.g. at 2 
hr intervals), Phe may accumulate and reach a plateau after about 6 hr; however, levels invariably 
return  to  background  following  overnight  abstinence.  The  ultimate  fate  of the  Phe  component  of 
aspartame is incorporation into proteins. 
The potential physiological consequences of exposure to aspartame-derived Phe are a function of its 
effects on the Phe/LNAA ratio. It has been suggested that changes in this ratio could affect the uptake 
of other LNAAs via the BBB leading to changes in neurotransmitter levels  in key brain regions; 
however,  no  consistent  changes  in  neurotransmitter  levels  either  in  whole  brain  or  specific  brain 
regions have been identified following exposure of rodents to aspartame, even at high doses. In this 
context, a species difference in the metabolism of Phe should be noted: rodents have much higher 
hepatic phenylalanine hydroxylase activity than do humans. Rodents therefore metabolise aspartame-
derived Phe rapidly to form Tyr, so that dosing with aspartame leads to an increase in plasma [Tyr] 
and the Tyr/LNAA ratio, whereas in humans the main effect observed is on plasma [Phe] itself and on 
the Phe/LNAA ratio. 
No significant acute or subchronic toxicity has been observed in animal models even at the highest 
doses  of  aspartame  which  could  reasonably  be  administered,  and  humans  given  high  doses  over 
periods of up to 27 weeks have reported no significant adverse effects. Early concerns that aspartame 
might cause neurotoxicity in neonates and infants were not substantiated by subsequent experimental 
data. 
There is no evidence to indicate that aspartame is genotoxic, either in vitro (with or without metabolic 
activation) or in vivo. Occasional marginal positive results have been reported, but such results only 
occur sporadically and do not indicate any particular cause for concern. 
The results of conventional chronic toxicity studies carried out in the 1970s did not indicate any 
significant neoplastic or non-neoplastic pathological effects in rodents dosed with aspartame via the 
diet. These studies were unsatisfactory in a number of ways, including the presence of infections 
requiring antibiotic treatment in one study, and they were subjected to detailed investigation by the US 
Bureau of Foods in the 1970s. The outcome of the investigation was that the studies were essentially 
reliable but that they were limited by a number of shortcomings in terms of diet preparation, protocol 
compliance and QA. Furthermore, when the studies were issued, concern was expressed regarding a 
possible excess of brain tumours in rats dosed with aspartame via the diet; however, further detailed 
examination  of  tissue  from  these  studies  did  not  indicate  any  treatment  related  effects  on  brain 
tumours.  
Three additional chronic toxicity studies (two in rats and one in mice) were recently reported by the 
ERF. In these studies, aspartame was administered from early life (in utero in one study) until the 
natural  death  of  the  animals.  Increased  incidences  of  a  variety  of  tumour  types  (including,  in 
particular, lymphomas and leukaemias) were reported in these studies, which have been the subject of 
intense controversy since the first one was published in 2005. The studies are difficult to interpret 
because the increased tumour incidences are close to those seen in control animals in other studies and 
there  is  evidence  that  the  animals  may  have  been  infected  with  the  organism  M.  pulmonis. 
Furthermore,  a  number  of  methodological  issues  call  these  studies  into  question.  These  include 
allowing  the  animals  to  die  naturally,  storing  the  carcasses  for  up  to  19  hr  before  performing 
necropsies, and fixing the tissues in ethanol rather than a conventional fixative such as 10% NBF 
which would give better morphology.   Review of data on the food additive aspartame 
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Overall,  the  available  chronic  toxicity  studies  do  not  indicate  any  overt  carcinogenic  effect  in 
experimental animals due to aspartame, but all the conventional studies are limited in various ways. 
These studies were subjected to more detailed review during the quality assessment of key studies 
identified by EFSA. Reassurance has recently been provided by a GLP-compliant study conducted by 
the NTP using transgenic mouse models. This indicated that aspartame had no carcinogenic effect in 
Tg.AC, p53
+/- or Cdkn2a
-/- mice dosed for 9 months via the diet. 
Concern regarding possible carcinogenic effects of aspartame has mainly focussed upon tumours of 
the bladder and brain. The issue of bladder carcinogenesis arose mainly by analogy with saccharin, 
which  is  known  to  induce  bladder  tumours  via  a  male  rat  specific  mechanism  involving  2-
microglobulin. A number of epidemiological studies were conducted in the between the 1970s and the 
1990s in an attempt to determine the relevance of these findings to humans; their results were variable 
but the majority did not indicate any increase in risk of bladder cancer in humans due to artificial 
sweetener consumption. None of these studies addressed aspartame directly and many of them were 
carried out in populations diagnosed before aspartame entered the market. 
The issue of brain tumour induction by aspartame arose partly because of the suggestion of increased 
brain tumour incidence in chronic rat studies and partly following the publication of a paper stating 
that an increase in brain tumour incidence in the USA had coincided with the release of aspartame. 
Subsequent  epidemiological  studies  have  not  identified  any  association  between  brain  tumour 
incidence and use of aspartame; indeed, studies of artificial sweetener use in which risks associated 
with  saccharin  and  other  sweeteners  (presumed  to  represent  mainly  aspartame)  are  considered 
separately provide no evidence for an increased risk of any tumour type in humans. 
The reproductive toxicity studies carried out prior to release did not indicate any adverse effects due to 
aspartame in mice, rats or rabbits. However, these studies were not conducted to modern standards 
(they predate the introduction of GLP regulations) and several of them are compromised by problems 
with  the  use  of  an  inappropriate  control  diet.  Dietary  studies  in  rabbits  also  proved  problematic 
because the rabbits failed to consume diets containing high doses of aspartame, so that the actual doses 
ingested did not correspond to those planned. There are no modern, GLP compliant studies addressing 
the reproductive toxicity of aspartame. 
Only  one  epidemiological  study  has  addressed  the  possible  reproductive  effects  of  aspartame  in 
humans. This study addressed preterm delivery and examined the effects of soft drink consumption 
thereon.  It  found  an increased  risk  of  preterm  delivery  in  women  who  frequently  ingested  either 
carbonated or (to a lesser extent) non-carbonated diet drinks. This study did not address aspartame 
directly and it was subject to a number of confounding factors, but as a large, well-designed study its 
results merit careful consideration and further investigation. 
Ever  since  its  release,  anecdotal  reports  have  attributed  numerous  adverse  effects  in  humans  to 
consumption of aspartame. The effects most commonly reported include hypersensitivity reactions, 
headaches,  seizure  induction  and  behavioural  changes.  However,  when  these  are  addressed  by 
properly designed clinical trials it usually proves impossible to detect any effect due to aspartame. 
Only sporadic effects in individual subjects are observed, and these occur in response to placebo at 
least as  often  as  in  response to aspartame.  Similarly,  when  effects  such as seizure  induction  and 
behavioural change are addressed in animal models the number of positive findings is well within the 
range expected by chance, although it should be noted that grand mal seizures were observed in 
monkeys treated with high doses of aspartame during the only chronic toxicity in primates. These 
seizures were attributed to high plasma [Phe] (similar effects were observed in response to equimolar 
doses Phe) and to stress caused by handling. 
With regard to potentially vulnerable groups, it is important to note that phenylketonurics (who have a 
genetic deficiency in phenylalanine hydroxylase activity) represent a known and well-characterised   Review of data on the food additive aspartame 
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susceptible  subgroup  within  the  population.  These  individuals  need  to  restrict  their  intake  of 
aspartame,  and  aspartame-containing  products  are  required  to  carry  warning  labels  to  this  effect. 
However, controlled administration of single doses of aspartame to phenylketonurics has provided 
reassurance  that  the  inadvertent  ingestion  of  a  small  dose  by  these  individuals  is  not  hazardous. 
Furthermore, studies on PKU heterozygotes (“carriers”) have demonstrated that, while they exhibit 
higher plasma [Phe] peaks and slower clearance than controls following ingestion of aspartame, no 
accumulation or long term effects are observed. 
Other population subgroups whose potential vulnerability to adverse effects following ingestion of 
aspartame has been investigated include MSG-sensitive individuals, the obese, diabetics, individuals 
with alcoholic liver disease, Parkinson’s disease sufferers and individuals with mood disorders. No 
untoward effects have been reported in any of these groups.  
There is no consistent evidence that aspartame has adverse effects, either in healthy individuals or in 
potentially  susceptible  groups,  under  normal  conditions  of  use.  Phenylketonurics  are  the  only 
individuals who need to regulate their intake of aspartame for health reasons, and they are supported in 
doing this by clear labelling of aspartame-containing products. 
The studies conducted by or on behalf of Searle in the early 1970s were performed according to 
standards which were considered appropriate at the time; indeed, they were probably “state of the art” 
for the period. In order to provide a modern day perspective, the QA assessment conducted in this 
review evaluated these studies against current (i.e. 2012) GLP regulations and OECD guidelines. 
In general, no major deficiencies were identified but every study was found to lack certain key items 
that would exist in a GLP study and minor inconsistencies in data presentation were identified. It was 
not possible to confirm protocol objectives and any changes, as protocols for these studies were not 
provided. The main criticism made, which applies to all the Searle studies, was that they contain 
insufficient information to support adequate characterisation of the test item(s), including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
Despite these caveats, the view of the review team is that these studies are adequate for use in risk 
assessment as long as their limitations are taken into account. 
The  study  reported  by  Soffriti  (Soffritti  and  Belpoggi,  2005)  has  been  the  subject  of  intense 
controversy. The most important concerns of the review team were that it claims compliance with 
GLP but lacks supporting documentation and that there are significant doubts about the pathology 
findings. The opinion of the review team is that, before the results of this study are used for risk 
assessment, the pathology should be subjected to a comprehensive independent peer review and the 
whole study should be audited. 
The study reported by Ajinomoto in 2006 (Iwata, 2006) was difficult to evaluate because it only 
comprises  histopathological  re-evaluation  of  a  previous  study  which  could  not  be  identified 
unequivocally. The review team had significant concerns regarding this study and took the view that it 
should not be used for risk assessment unless/until these issues are resolved. 
Overall, the opinion of the review team is that the Searle studies can be used in risk assessment if their 
limitations  are  taken  into  account,  but  issues  relating  to  the  Ajinomoto  and  ERF  studies  require 
resolution before these studies can be relied upon. The team notes that the only two generation study, 
while  without  major  quality  issues,  has  serious  limitations.  Reassurance  would  be  provided  by 
conducting another two generation study according to current OECD guidelines.   Review of data on the food additive aspartame 
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A huge amount of evidence already exists regarding the potential adverse effects of aspartame, both in 
animal models and in humans, and most of this is reassuring. Overall, the opinion of the review team 
is that the studies conducted by or on behalf of Searle in the 1970s can be used in risk assessment if 
their limitations are taken into account, but issues relating to the ERF and Ajinomoto studies require 
resolution before they are relied upon. Specifically: 
  The  ERF  study  should  be  subjected  to  independent  audit;  its  pathology  findings  should 
undergo a comprehensive independent peer review. 
  The Ajinomoto study should be authenticated with respect to the identity of the original study 
to which it relates; in particular, the genetic background of the rats used in this study should be 
confirmed. 
The team notes that the only two generation reproductive toxicity study, while without major quality 
issues, is limited with respect to procedures carried out, parameters measured and outcomes reported. 
Reassurance would be provided by conducting another two generation study according to current 
OECD guidelines. 
There  are,  therefore,  two  areas  in  which  the  existing  data,  while  still  essentially  reassuring,  are 
compromised by issues of methodology and QA: 
The original chronic toxicity studies conducted by Searle and the more recent studies carried out by 
the ERF have created vigorous debate regarding possible carcinogenic effects due to aspartame. The 
recent NTP studies in transgenic mice, which were conducted to the highest possible standards, are 
reassuring; however, the team agrees with Huff and LaDou (Huff and LaDou, 2007) that a GLP-
compliant 2-year bioassay conducted by an organisation such as the NTP would help to resolve the 
issue of carcinogenicity once and for all. 
The reproductive toxicity studies conducted by Searle in the 1970s, while essentially reassuring, were 
conducted to the standards current at the time and beset by technical difficulties. In particular, there is 
only one two-generation reproductive toxicity study in the dossier  (Reno, 1971) and this falls some 
way short of modern requirements. A modern, GLP compliant reproductive toxicity study conducted 
according to the appropriate guidelines would, it is to be hoped, confirm the lack of any embryotoxic, 
teratogenic  or  reproductive  effect  due  to  aspartame.  Such  further  data  would  provide  further 
reassurance, especially in the light of the recent epidemiological findings reported by Halldorsson et 
al. (Halldorsson, Strom et al, 2010).   Review of data on the food additive aspartame 
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LITERATURE SEARCH TEMPLATE 
Contract number and title: CT/EFSA/ANS/2011/03 
Contractor:      Dr Lesley Stanley 
Search details:    Search of published literature 
OBJECTIVE: A documented complete and exhaustive search of the published literature that could contribute directly or indirectly to 
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NLM/PubMed 
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5023 references 




Free text  62 
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Sweetening agents  MESH  3493 
(sweeten*) and (artificial 
or intens*)  Free text  968 
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Toxseek/Pubmed 
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exported to 
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references  Deleted papers with the words “taste”, “caries” or “dental” in title 
Deleted general commentaries on oral health, food intake/obesity, diabetes, bladder cancer, 
food/pharmaceutical formulation, alcohol consumption. 
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Tier I: Selection by category  Action  Yes  No  Reason for rejection 
Unpublished study reports  All go to Stage II assessment  131     N/A (N.B. Includes some documents in more than one volume) 
Documents from national authorities  Select for further consideration on basis of relevance  78     N/A 
Primary research papers  Select for further consideration on basis of relevance  509     N/A 
Secondary sources: <10 years old  Select for further consideration on basis of relevance  50     N/A 
Epidemiology of bladder cancer and artificial sweeteners  Tabulate results based on information in abstracts?  37     Do not address aspartame itself, but are a topic of public concern 
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Secondary sources: <10 years old  Aspartame toxicity/interpretation of toxicology studies  16  34  Chosen on basis of direct relevance 
Documents from national authorities  FDA documents  12  7  Superceded/already considered 
   NIEHS/EPA/NTP/NIOSH evaluations  5  0  N/A 
   JECFA evaluations (to be handled by EFSA)  0  12  Being handled by EFSA 
   EFSA/SCF evaluations (to be handled by EFSA)  0  6  Being handled by EFSA 
   UK FSA/COT/COC evaluations  5  16  More than  10 years old/Being handled by EFSA 
   Evaluations from other national authorities  2  13  Being handled by EFSA 
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   Behavioural effects  17  0  N/A 
   Adverse reactions in humans  12  0  N/A 
   Vulnerable groups  25  0  N/A 
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Table 1. Regional effects on neurotransmitters in the brain 
        Effects observed   
Animals  Dose and route  Duration  Brain regions 
examined  5-HT and 5-HIAA  Dopamine  Norepinephrine  Catecholamine 




p.o. as 10% 
suspension 
in 0.5% CMC 
Single dose, 
sacrificed 




No change  No change  No change  No change 
No changes detected by either 
biochemical or electrochemical 
methods. Plasma and brain 
[Phe] and [Tyr] increased as 
expected. Ref: (Perego, De 
Simoni et al, 1988). 




p.o. as suspension 




after 30, 60, 






No change in 5-HT; 
slight reduction in 5-
HIAA in hypothalamus 
No change  No change 
No change 
except for 
DOPAC in pons 
medulla 
Animals with NT levels below 
limit of detection ignored. F344 
generally had higher NT levels 
than Sprague Dawley. Ref: 








200 – 300  
mg/kg 
p.o. or i.p.  
as slurry in saline 
Single dose, 
sacrificed 
















Phe/LNAA and Tyr/LNAA ratios 
increased by oral aspartame as 
in other studies. Ref: 












No change  No change  No change  No change 
Plasma and brain amino acid 
levels unchanged after 30 days’ 
dosing. No effect on aminergic 
receptor kinetics. Refs: (Reilly, 







p.o. in corn oil  
Single dose, 
sacrifice 






cortex, midbrain  









levels within expected levels for 
male CD-1 mice. Ref: 
(Coulombe and Sharma, 1986). 





No change  No change  No change 
Changes seen after 30 days 
differed from those after an 
acute dose. Ref: (Sharma and 
Coulombe, 1987).   Review of data on the food additive aspartame 
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Table 2. Acute toxicity studies on aspartame and DKP  
(a) Aspartame 
  Animals  Route  Dose range  Outcome  Comments and reference(s) 
Oral           
Rat  Male Sprague Dawley, Charles River 
(n=6 per group) 
p.o. as 15-25% suspension 
in 1% Tween 80 
Up to 
5000 mg/kg 
No deaths within 7 days 
at any dose 
Motor and behavioural activities 
unremarkable. Ref: (Andress, Martinez 
et al, 1973b) 
Mouse  Male Sprague Dawley, Schmidt Ha/ICR  
(n=2 or 6 per group) 
Rabbit  Male New Zealand White Luenberg 
(n=1 or 3 per group) 
Intraperitoneal           
Rat  Male Sprague Dawley, Charles River  
(n=6 per group)  i.p. in aqueous solution  Up to 2033 mg/kg 
No deaths within 7 days 
at any dose 
Motor and behavioural activities 
unremarkable. Ref: (Andress, Martinez 
et al, 1973b)  Mouse  Male Sprague Dawley, Schmidt 11a/ICR  
(2 or 6 per group) 
i.p. as 2% aqueous 
suspension  Up to 1000 mg/kg 
 
(b) DKP 
  Strain  Route  Dose range  Outcome  Comments and reference(s) 
Oral           
Rat  Male Sprague Dawley, Charles River 
(n=6 per group)  p.o. as 15-17.5% 
suspension in 1% Tween 80 
(aqueous 2% suspension 
for low doses) 
Up to 5000 mg/kg  No deaths within 7 days 
at any dose 
Motor and behavioural activities 
unremarkable. Ref: (Andress, Martinez 
et al, 1973a) 
Mouse  Male Sprague Dawley, Schmidt Ha/ICR 
(n=2 or 6 per group) 
Rabbit  Male New Zealand White Luenberg 
(n=1 or 3 per group) 
Intraperitoneal           
Rat  Male Sprague Dawley, Charles River 
(n=6 per group)  i.p. as 2% aqueous 
suspension 
Up to 1562 mg/kg 
No deaths within 7 days 
at any dose 
Motor and behavioural activities 
unremarkable. Ref: (Andress, Martinez 
et al, 1973a)  Mouse  Male Sprague Dawley, Schmidt 11a/ICR 
(n=2 or 6 per group)  Up to 1577 mg/kg 
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Table 3. Effects of single oral doses of aspartame on biochemical parameters in humans 
Topic  Characteristics  Dose  Samples 
taken 
Analyses 






no history of 
diabetes mellitus, 
bone disorders, or 
renal calculi 
(4M/3F) 
Aspartame, 250 mg; 
Glucose, 75 g 
in 250 ml H2O 
Blood every 
30 min; urine 
hourly. 
Study 







No change in glycaemia or insulin 
release; serum and urinary calcium 
increased (30 min); serum phosphate 
decreased; urinary calcium increased; 
no effect on urinary phosphorus or 
oxalate. 
Effects of glucose in line with expectations. Effects 
quite subtle, but with possible implications in terms of 
renal calculi, osteoporosis if verified. Note, however, 
than no sustained elevation in urinary calcium was 
observed in a study of 108 subjects dosed at 75 
mg/kg/day for 6 months. Refs: (Leon, 1999; Nguyen, 










Aspartame, 165 mg 
Solution in water, taken on 
empty stomach 
Blood up to  








Blood glucose and plasma insulin did 
not deviate from normal ranges in 
response to sweeteners or water. No 
evidence of insulin release in response 
to sweeteners. No physiologically 
significant changes in blood glucose. 
Other sweeteners (acesulfame K, cyclamate, 
saccharin) administered at equal sweetening 
intensity. No evidence that aspartame disturbs 






22-32 yr (8M/8F) 
Aspartame, 534 mg 
Asp, 242 mg 
Phe, 300 or 1000 mg 
Gelatine capsules or saline 
solution  consumed with a test 
meal 
Blood every 
15 min, 30 
min before to 








Aspartame did not affect prolactin, 
cortisol, growth hormone, insulin or 
glucose differently from other 
treatments 
No side effects. Prolactin increased after Phe (1000 
mg); cortisol and insulin declined after all treatments; 
growth hormone not affected by any meal. No 
endocrine disturbance in response to doses of 
aspartame similar to those in 1L diet beverage. Refs: 




Average BMI = 
20.6; aged 20-25 
yr (3M/7F) 
Sucrose, 50 g; 
Aspartame 80 mg 
In chocolate drink, 400 ml 








Blood glucose increased by 50% after 
sucrose, 12% after aspartame. Insulin 
increased to same extent after both 
drinks. Β-endorphin increased more 
after aspartame than after sucrose 
(p<0.02). 
Authors suggest possible effect of aspartame on 
peripheral β-endorphin release, thought to be due to 
effect on glucose homeostasis or direct effect of 
aspartame rather than a sensory effect of food. 
Authors speculate that stimulation of insulin in the 
absence of carbohydrate could lead to glucose stress 
leading to release of β-endorphin. Refs: (Melchior, 






patients; aged ≥18 
yr (25M/25F) 
Randomised, two-
site, single blind 
Aspartame (n=24); Sucrose 
(n=26) (doses not specified). 
2x 45 ml doses the night before 
colonoscopy. 






No significant differences in Na+, K+, 
BUN, creatinine, BUN/creatinine. 
Increased phosphorus in aspartame 
group, possibly due to enhancement of 
phosphorus uptake due to aspartame 
Main endpoint was quality of colonoscopy 
preparation; serum analytes were secondary 
endpoints. This was not a toxicity study but it provides 
an indication of the lack of effects of aspartame on 
clinical chemistry parameters in patients requiring   Review of data on the food additive aspartame 
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controlled trial  mixed with drink for palatability.  or its constituent amino acids.  colonoscopy. Refs: (Chamberlain, Balart et al, 2007). 
Table 4. Subacute toxicity studies on aspartame and DKP  
(a) Aspartame 
Strain  Dose range   Duration  Outcome  Comments and reference(s) 
Oral         
“Young” purebred beagles, 7.2 – 
13.2 kg (2M/2F per group) 
5/125 mg/kg/day 
via gelatine capsules  8 weeks  100% survival; variable pattern of 
body weight loss/maintenance/gain 
No consistent haematology, clinical chemistry or urinalysis findings; no 
consistent ocular findings; no gross pathology; no consistent effects on 
organ weights; no cytopathological changes. Refs: (Jessup and Shott, 
1969). 
Via diet         
Charles River CD rats, 7 wk old 




within 10% of planned 
4 weeks 
100% survival; no unequivocal effect 
on body weight or food consumption 
except decreased consumption in 
high dose females, wks 2-3. 
No adverse physical/behavioural changes; no treatment-related 
pathological changes except for clear, viscous fluid coating intestinal 
mucosa in treated rats. N.B. only examined 5 controls and all high dose 
animals; remaining animals were discarded. Refs: (Rao, Martinez et al, 
1972b). 
Charles River CD rats, sexually 
mature (10M/10F per group). 
Group allocation by stratified 
randomisation 
5/125 mg/kg/day 
via diet  8 weeks  100% survival; no unequivocal effect 
on body weight or food consumption 
No signs of systemic toxicity or pharmacological effects. No treatment 
related changes in haematology or urinalysis; increased terminal blood 
sugar at 125 mg/kg/day but no other significant changes in clinical 
chemistry. Organ weights unaffected except for increased liver/body 
weight ratio in high dose males. No histopathological findings except 
bile duct hyperplasia/pericholangitis in all groups. 
Refs: (Jessup and Voelker, 1969). 
Charles River CD rats, weanlings 
(5M/5F per group) 
9:100 ratio in diet (aspartame) 
5:100 ratio in diet (Phe)  9 weeks 
Two deaths; one control male, one 
aspartame-treated male. Relative 
food consumption comparable 
between groups. No treatment-related 
effect on terminal body weight. 
No physical/behavioural abnormalities; no significant treatment related 
changes in haematology, clinical chemistry, urinalysis; no treatment-
related changes in organ weight or pathological observations. Reduced 
body weight gain in treated groups, both compounds and both sexes; 
less marked in females than males. Refs: (Hemm, Rao et al, N/K) 
Ha/ICR mice, 7 wk old (5M/5F per 
group) 
Planned: 2,000/4,000,/10,000 
mg/kg/day via diet; 
Actual: 3,000/5,000/13,000 
mg/kg/day 
4 weeks  100% survival; no unequivocal effect 
on body weight or food consumption 
No adverse physical/behavioural changes; no treatment-related 
pathological changes except for clear, viscous fluid coating intestinal 
mucosa in treated mice. N.B. only examined 5 controls and all high dose 
animals; remaining animals were discarded. Refs: (Rao, Martinez et al, 
1972a).   Review of data on the food additive aspartame 
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(b) DKP 
Strain  Dose range  Duration  Outcome  Comments  
Oral         
Charles River CD rats, 11 wk 
old (10M/10F per group) 
1000 mg/kg/day 
p.o. as 5% aqueous suspension 
Daily for 
2 weeks 
100% survival; no unequivocal effect 
on body weight 
No physical/behavioural changes; no treatment related changes in 
haematology, clinical chemistry, urinalysis; no treatment-related 
pathological changes. Refs: (Rao, Mauro et al, 1971). 
Ha/ICR mice, 4 wk old (10M 
per group) 
1000 mg/kg/day 
p.o. as 5% aqueous suspension 
Daily for 
2 weeks 
100% survival; no unequivocal effect 
on body weight 
No physical/behavioural changes; no treatment related changes in 
haematology, clinical chemistry, urinalysis; no treatment-related 
pathological changes. Refs: (Rao, Martinez et al, 1971) 
Via diet         
“Young” Charles River CD rats, 
(5M/5F per group) 
1,000/2,000/4,000/6,000 
mg/kg/day via diet; 
actual consumption  
within 5% of planned 
5 weeks 
100% survival; reduced body weight 
in high dose females due to reduced 
food consumption. 
No physical/behavioural changes; no dose-related changes in 
haematology, clinical chemistry, urinalysis; no dose-related changes in 
organ weight or treatment-related pathological changes. Evidence of 
colonic parasites, mild chronic bronchitis and mild chronic inflammation 
of liver and bile ducts. Refs: (Rao, Staunton et al, 1972) 
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Table 5. In vivo genotoxicity of aspartame 
(a) Aspartame 
Animals  Dose and route  Method  In life observations  Outcome  Comments and reference(s) 
Young male albino 
Holtzmann rats (10 per 
group) 
400/800/1,200/1,600 
mg/kg/day for 5 days  
p.o. (vehicle not stated) 
Chromosome aberration test in 
spermatogonia and bone 
marrow. Counted 500 
spermatogonia, 500 bone 
marrow spreads per group 
(does not specify per rat). 
None 
No difference in aberration 
frequency between control 
and any dose of aspartame. 
Positive controls: triethylenemelamine (single 
dose, 0.5 mg/kg i.p.), cyclohexamine (10, 50 
mg/kg/day). Latter showed no increase in 
aberration frequency. Ref:  (Bowles and 
Jessup, 1970) 
Male Purina CD rats, ~ 8 
wk old (10 per group) 
500/1,000/2,000/4,000 
mg/kg/day for 5 days  
p.o. as 10% suspension 
in 1% Tween 80 
Chromosome aberration test in 
bone marrow. Counted 500 cell 
spreads per group (50 per rat). 
No compound-related in vivo 
effects. 4 intercurrent deaths, 3 in 
controls. Weight loss in all except 
positive control groups. 
No compound-related effects 
on chromosomal aberration 
frequency. 
Positive control: triethylenemelamine (single 
dose, 0.5 mg/kg i.p.) induced 10x more 
chromosomal aberrations than in vehicle 
controls. Ref: (Reno and Bowles, 1972a) 
Male Purina CD rats, ~ 
12 wk old (10 per group) 
500/1,000/2,000/4,000 
mg/kg/day in three 
doses per day for 5 day  
p.o. as 10% suspension 
in 1% Tween 80 
Host-mediated assay carried 
out following final dose on day 5 
using S. typhimurium (3x108 
colony forming units) histidine 
auxotrophic strain G46 
No evidence of compound related 
morbidity. Food consumption 
reduced in two highest dose 
groups but no effect on body 
weight 
Slight increase in mutation 
frequency (2.46 fold) at 
highest dose, but non 
significant and not dose-
related. Authors conclude no 
biologically meaningful effect 
on mutation frequency. 
Recovery of viable indicator organisms was 
suboptimal but considered adequate for 
interpretation. Positive control: 
dimethylnitrosamine (single dose, 100 mg/kg 
i.p.); mutation frequency was 8.19 fold greater 
than in vehicle control. Ref: (Reno and Good, 
1972b) 
Sprague-Dawley Ha/ICR 
random bred Swiss 
mice, male, 5-6 weeks 
old (10 per group) 
1,000/2,000/4,000/8,000 
mg/kg/day for 5 days  
p.o. as 10-15% 
suspension in 1% Tween 
80 
Host-mediated assay carried 
out following final dose on day 5 
using S. typhimurium histidine 
auxotrophic strain G46. 
All groups except positive controls 
lost weight but no difference in 
terminal body weight or food 
consumption.  Intercurrent deaths 
due to dosing errors. 
No increase in mutation 
frequency with aspartame 
compared with vehicle 
controls. 
Positive control: methylazoxymethanol (30 
mg/kg, single dose, p.o.) yielded significant 
increase in mutation frequency. Ref: (Bost, 
1974) 
Charles River CD rats; 
proven males ~ 160 
days old, virgin females 
90-135 days old (15 per 
group) 
2,000 mg/kg (M only) 
p.o. as 10% suspension 
in 1% Tween 80 
Dominant lethal assay, weekly 
presentation of new females for 
8 wk.  
No effect on growth of males, 
mating ability, fertility or 
ovarian/uterine data except for 
sporadic effects on corpora lutea 
and foetal swellings.  
No evidence of dominant 
lethal effect. No increase in 
foetal deaths (50.0% vs. 
48.5% in controls) 
Positive control: methyl methane sulphonate 
(single dose, 25 mg/kg i.p.); females mated to 
these males exhibited significant increase in 
foetal deaths (68%). Ref: (Schroeder, Rao et 
al, 1973c) 
Charles River CD rats : 
proven males ~ 160 
days old, virgin females 
90-135 days old (15 per 
2,000 mg/kg (M only) 
p.o. as 10% suspension 
in 1% Tween 80 
Dominant lethal assay, weekly 
presentation of new females for 
8 wk.  
No effects on body weight. Two 
deaths in negative control males. 
Mating ability, pregnancy rates 
comparable in controls and treated 
No evidence of dominant 
lethal effect; no decrease in 
fertility or increase in foetal 
deaths. 
Positive control: methyl methane sulphonate 
(single dose, 25 mg/kg i.p.) significantly 
increased early foetal death rate. Ref: 
(Schroeder, Mitchell et al, 1973f)   Review of data on the food additive aspartame 
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group)  animals (87.9 vs. 83.4%). 
 
(b) DKP 
Strain  Route  Method  In life observations  Outcome  Comments and reference(s) 
Male Purina CD rats, ~ 8 
wk old (10 per group) 
250/500/1,000/2,000 
mg/kg/day for 5 days 
p.o. as 10% suspension 
in 1% Tween 80 
Chromosome aberration test in 
bone marrow. Counted 500 cell 
spreads per group (50 per rat). 
One intercurrent death, no 
compound related in life effects. 
Weight loss in all except positive 
control groups. 
No compound related effects 
on chromosome aberration 
frequency. 
Positive control: triethylenemelamine 
(single dose, 0.5 mg/kg i.p.). Aberration 
frequency 20-50x that in vehicle controls. 
Ref: (Reno and Bowles, 1972b) 
Male Purina CD rats, ~ 
12 wk old (10 per group) 
250/500/1,000/2,000 
mg/kg/day in 
3 doses/ day for 5 days 
p.o. as 10% suspension 
in 1% Tween 80 
Host-mediated assay carried 
out following final dose on day 5 
using S. typhimurium (3x108 
colony forming units) histidine 
auxotrophic strain G46 
Two intercurrent deaths, both in 
high dose group. One low dose rat 
died as indicator organisms 
injected. Weight loss and reduced 
food consumption in all except 
positive control groups. 
No significant increase in 
mutation frequency with DKP 
(ratio to vehicle control was 
0.6-2.12 fold and not dose-
related).  
Recovery of viable indicator organisms was 
suboptimal but considered adequate for 
interpretation. Positive control: 
dimethylnitrosamine (single dose, 100 
mg/kg i.p.); mutation frequency was 18.53 
fold greater than in vehicle control. Ref: 
(Reno and Good, 1972a) 
Sprague-Dawley Ha/ICR 
random bred Swiss nice, 
male, 5-6 weeks old. (10 
per group) 
1,000/2,000/4,000/8,000 
mg/kg/day for 5 days 
Host-mediated assay carried 
out following final dose on day 5 
using S. typhimurium histidine 
auxotrophic strain G46. 
Reduced survival at highest dose: 
30% at 8,000 mg/kg/day, 
associated with severe diarrhoea 
and dehydration. Loss of body 
weight in all except positive 
control group, no difference in 
body weight or food consumption 
between DKP and negative 
controls.  
No increase in mutation 
frequency with DKP 
compared with vehicle 
controls. 
Positive control: methylazoxymethanol (30 
mg/kg, single dose, p.o.) yielded significant 
increase in colony count and mutation 
frequency. Several animals showing 
adverse effects did not survive injection of 
indicator organisms. Ref: (Bost and Stolt, 
1974) 
Charles River CD rats; 
proven males ~ 160 
days old, virgin females 




p.o. as 5% suspension 
in 1% Tween 80 
Dominant lethal assay, weekly 
presentation of new females for 
8 wk.  
Rate of growth during mating 
period was comparable in all 
groups. No deaths in DKP group. 
Overall week by week pregnancy 
rates similar between DP and 
controls. 
No effect on fertility or mating 
ability. No evidence of 
dominant lethal effect foetal 
deaths comparable between 
DKP and control groups 
throughout mating period. 
Same controls as in companion study. 
Refs: (Schroeder, Mitchell et al, 1973f; 
Schroeder, Mitchell et al, 1973e).  
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Table 6. Chronic toxicity studies on aspartame and DKP  
(a) Aspartame 
Strain  Dose (planned)  In life observations  Neoplastic  Non-neoplastic  Comments and reference(s)  
Charles River CD 
rats.  
Control: 60M/60F; 
Test: 40M/40F per 
dose; group 
allocation by stratified 
randomisation to give 
homogeneous 








for 104 weeks 
 
No unusual in life observations. Respiratory 
symptoms observed in all groups throughout 
study. Growth suppressed in high dose 
groups; food consumption reduced in these 
group wks 1-52. Reduced survival in high 
dose females; other groups comparable. No 
consistent changes in clinical chemistry 
parameters in weeks 13, 26, 52 or 104. No 
compound-related effects in ocular 
examination. 
No increase in probability of 
tumour formation (any 
tumour, mammary tumour, 
mammary carcinoma, 
benign only or any 
malignant tumour) in any 
group. 
No biologically significant changes 
in organ weights. Relative kidney 
weight increased in three highest 
dose groups (male); associated 
with renal pigment deposits 
whose incidence was dose-
dependent and with focal 
hyperplasia of renal pelvic 
epithelium/tubular degeneration in 
highest dose males. 
High dose group increased from 
6,000 to 7,000 mg/kg/day in 
week 16 and to 8,000 mg/kg/day 
in week 44; actual consumption 
within 10% of that planned. Lots 
used contained varying amounts 
of DKP up to a maximum of 
1.5%. Five brain neoplasms 
observed, all in treated groups. 
Ref: (Reno, Ferrell et al, 1973a) 
Charles River CD 
weanling rats from 
two generation 
reproductive toxicity 
study (Reno, 1971). 
Control: 60M/60F 







for 104 weeks. 
 
No unusual in life observations. Respiratory 
symptoms observed in all groups throughout 
study, attributed to chronic murine 
pneumonia Growth suppressed in high dose 
group males; food consumption reduced in 
this group wks 1-52. Survival was 
comparable in all groups. No consistent 
changes in clinical chemistry parameters in 
weeks 6, 13, 26, 52 or 104. No compound-
related effects in ocular examination. 
No increase in probability of 
tumour formation (any 
tumour, mammary tumour, 
mammary carcinoma, 
benign only or any 
malignant tumour) in any 
group. 
No biologically significant changes 
in organ weights. Hepatic 
hyperplastic nodules seen at 
higher frequency in treated 
females than controls; attributed 
to an unusually low incidence in 
controls rather than a treatment 
effect. 
Parents treated at same dose 
from before mating to weaning. 
Actual intakes were 1,990/3,980 
mg/kg/day. Lots used contained 
varying amounts of DKP up to a 
maximum of 1.5%. Nine brain 
neoplasms observed; considered 
unrelated to treatment, dose, sex. 
Ref: (Trutter, Reno et al, 1974) 
CD-1 HAM/ICR Swiss 
mice, 28 days old at 
start of treatment. 
Control: 72M/72F 
Test: 36M/36F per 
dose; group 
allocation by stratified 
randomisation to give 
homogeneous 







for 104 weeks. 
No unusual in life observations. No 
compound-related effects in ocular 
examination. Rate of body weight gain was 
similar in all female groups but was slightly 
reduced in male treatment groups compared 
with controls. Males at low and high 
treatment levels consumed less than the 
other male groups. Survival in all treatment 
groups was similar to that of controls. No 
consistent changes in haematological or 
clinical chemistry parameters in weeks 5, 
10, 20, 23, 40, 60 or 104. 
No increase in probability of 
tumour formation (any 
tumour, benign only, any 
malignant tumour, primary 
lung tumour, 
lymphoreticular cell tumour, 
any vascular tumour) in any 
group. No primary 
intracranial tumours 
reported although four brain 
metastases were observed. 
No treatment-related non-
neoplastic changes in any organ 
or tissue.  
Actual intakes were 
1,020/2,010/4,303 mg/kg/day. 
Lots used contained 0.8-1.2% 
DKP. Ref: (Reno and Ferrell, 
1974a)   Review of data on the food additive aspartame 
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Strain  Dose (planned)  In life observations  Neoplastic  Non-neoplastic  Comments and reference(s)  
Golden Syrian 
hamsters, 20 days 
old at start of study. 
Control: 70M/70F 









intended to be 
for 104 weeks; 
terminated after 
46 weeks due to 
infection. 
No unequivocal compound related in life 
observations. Food consumption and body 
weight gain comparable between control 
and treated groups. No differences between 
control and treated groups in haematology 
(weeks 13, 26, 46) or clinical chemistry 
(weeks 26, 46).  
No compound-related 
histopathological alterations 
reported. No tissue masses 
or neoplastic changes 
reported in hamsters dying 
during the treatment period. 
No treatment-related effects on 
organ weights. No compound-
related histopathological 
alterations reported. Acute GI 
inflammation associated with 
incidental disease. 
Dose escalation used for highest 
dose group: 6,000 mg/kg/day 
weeks 1-14; 8,000 mg/kg/day 
weeks 15-18; 10,000 mg/kg/day 
weeks 19-22; max dose to end of 
study. Actual intakes were within 
15% of that planned except 
highest dose group (8,300 
mg/kg/day). Lots used contained 
<1% DKP. Entire hamster colony 
infected with an unidentified 
disease causing diarrhoea; 
resembled “Wet tail”. Caused 
unusually high mortality rate in all 
groups and led to termination of 
study at week 46. Refs: (Rao, 
Mauro et al, 1972d; 1972a; Rao, 
Mauro et al, 1972c) 
Purebred Beagle 
dogs, 5 months old at 
start of dosing 






for 106 weeks 
No unusual in life observations; survival 
100% in all groups. No compound related 
variations in food consumption or body 
weight gain, although occasional erratic 
decreases in food consumption occurred in 
control and treated dogs. First ocular 
examination at 24 wk revealed bilateral 
cataract in two dogs; not known whether this 
was treatment-related, but thought to be 
congenital. No biologically meaningful 
treatment related haematology/clinical 
chemistry findings. 
None noted in original study 
report.  
No statistically significant 
variations in organ weights. No 
dose or sex-related non-
neoplastic pathology.  
Actual intakes as planned Lots 
used contained ≤1% DKP. No 
increase in serum L-Phe levels 
during treatment, but sporadic 
increases in urinary 
phenylketones in high dose dogs. 
Ref: (Rao, Mauro et al, 1972b). 
Follow up study (McConnell, 
1973) on brains from all 40 dogs 
did not reveal any brain 
neoplasms. 
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(b) DKP 
Strain  Dose (planned)  In life observations  Neoplastic  Non-neoplastic  Comments and reference(s) 
Charles River CD 
rats, 4 wk old at start 
of study. 
Control: 72M/72F; 













for 115 weeks 
No unusual in life observations. No 
compound-related decrease in survival 
rates. Body weights reduced in high dose 
groups (M and F) in later stages and 
periodically at lower doses. Food intake not 
consistently affected. Decreased serum 
cholesterol in high dose animals from day 
42/92 (F/M) onwards and decreased urinary 
pH on ≥1 occasion in all treated female 
groups; otherwise no biologically meaningful 
changes in haematology or clinical 
chemistry. No compound-related effects in 
ocular examination. 
In no instance was the 
adjusted tumour incidence 
of any of the tumour types 
analysed (any tumour, 
benign only, any malignant 
tumour, any mammary 
tumour, benign mammary 
tumour, malignant 
mammary tumour, any 
pituitary tumour) 
significantly higher than that 
of the respective controls. 
No unusual tumours were 
encountered. 
No biologically meaningful 
compound-related variation in 
organ weights. There was no 
treatment-related non-neoplastic 
histopathology in any organ or 
tissue, and no unusual non-
neoplastic lesions were observed. 
Actual intakes were within 10% of 
those planned. Two transient 
unidentified infectious diseases 
occurred during the study; these 
affected control and treated rats 
equally. Reduced urinary pH may 
have been associated with 
presence of acidic DKP 
metabolites in urine. Ref: (Rao, 
Stejskal et al, 1974) 
CD-1 HAM/ICR Swiss 
mice, 28 days old at 
start of treatment. 
Control: 72M/72F; 
Test: 36M/36F per 
dose; group 
allocation by body 
weight for each sex to 
give homogeneous 







for 110 weeks 
No unusual in life observations. Mean 
survival poor (20-40%), but not affected by 
treatment. No differences in body weight 
gain during first year despite significantly 
reduced food consumption in males at all 
three doses of DKP. No consistent 
treatment related haematology/clinical 
chemistry findings in weeks 5, 10, 20, 40 or 
60. No compound-related effects in ocular 
examination. 
In no instance was the 
adjusted tumour incidence 
of any of the tumour types 
analysed (any tumour, 
benign only, any malignant 
tumour, primary lung 
tumour, lymphoreticular 
tumour, vascular tumour) 
significantly higher than that 
of the respective controls. 
No unusual tumours were 
encountered. 
No consistent non-neoplastic 
alterations attributable to 
compound treatment were 
observed. 
Actual intakes were within 1% of 
planned doses. The DKP used in 
this study was assumed to be 
100% pure. One primary brain 
tumour identified in a control 
female. Secondary 
lymphoreticular tumours detected 
in brain and urinary bladder from 
small numbers of mice at all dose 
levels. Ref: (Reno and Ferrell, 
1974b)   Review of data on the food additive aspartame 
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Table 7. Epidemiology of bladder cancer in relation to artificial sweetener use
8 
Primary aim 
of study  Study type  Location  Diagnosis  Number of 
subjects 
Effect of 


















Increased risk with occupational exposure, 
cigarette smoking applied to all grades and 
stages. Increased risk with history of bladder 
stones, urinary tract infections. No effect due 
to coffee consumption, family history. 
Part of the National Bladder Cancer Study. Ref: 








258 cases  No effect 
Improved five year survival associated with 
drinking habits, green tea consumption.  
Alcohol consumption conferred improved 
prognosis: RR=0.46 (0.26-0.79). No effect due 
to smoking, hair dye use, consumption of 
coffee, black tea, green tea, cola. 













Decreased risk with increasing consumption of 
vitamin C (F; p=0.03) and green vegetables 
(M; p=0.02). Inverse association with 
consumption of regular ground coffee (F; 
p=0.02). No effect due to tea. 
Cases identified between 1977 and 1985. Ref: 











Cigarette smoking, p<0.001; alcohol intake, 
p<0.001; Turkish coffee, p=0.01; Use of 
artificial fertilisers/insecticides p<0.01; 
“Unspecified chemical substances” p<0.001. 


















Mild increase in risk with cholesterol 
consumption, history of diabetes (OR=1.65, 
p=0.019) 
Association with diabetes was not linked to use of 
artificial sweeteners or to insulin, other medications or 
low calorie foods. Ref: (Risch, Burch et al, 1988) 
Wide  Case- Spain  Bladder  406 cases  Increased  Cigarette smoking; History of urologic disease;  Concludes that aetiology is multifactorial. Ref: (Bravo, 
                                                 
8 This table is based upon online abstracts because the publications considered do not address aspartame directly and most of them are no longer (or were never) available online in full text 
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Primary aim 
of study  Study type  Location  Diagnosis  Number of 
subjects 
Effect of 
sweeteners   Other exposures considered  Comments and reference(s) 
ranging  control  cancer  (353M/53F)  Occupational risk; Low water consumption; 
Family history of cancer; Coffee drinking 










(453M/53F)  Not stated  No effect due to beer, wine, spirits. 
High risk of bladder cancer associated with 
consumption of wine mixed with “gaseosa” 
(carbonated water with artificial sweeteners). 














Occupation, passive smoking, coffee 
consumption, high BMI, diabetes, high blood 
pressure. 
Took steps to avoid confounding due to smoking. 








761 cases  No effect  Occupational exposure, cigarette smoking, 
coffee consumption did not affect risk. 
No effect on recurrence rate n patients diagnosed 









173 controls  No effect 
Cigarette smoking: OR=2.4 (1.5-4.0); 
phenacetin use: OR=6.5 (1.5-59.2); history of 
131Iuptake procedure: OR=3.7 (1.4-11.0). No 
effect due to occupational history, family 
history, history of bladder infections. 
Women aged 20-49 years in 1975-1980. Cases 
consumed more coffee than controls (p<0.05). Ref: 
(Piper, Matanoski et al, 1986) 
Occupational 
exposure  Cohort  USA  Bladder 
cancer  1385 subjects  No effect 
Occupational exposure: OR=4.3 (1.8-10.3). No 
effect due to cigarette smoking, coffee 
consumption, use of phenacetin, decreased 
intake of vitamin A or prior employment in high 
risk occupations. 
Workers potentially exposed to carcinogenic aromatic 
amines. Cumulative incidence of bladder cancer 
determined from death certificates, interviews with 
urologists and screening programme. Ref: (Schulte, 




control  Japan  Bladder 
cancer 
293 cases; 
589 controls  No effect 
Increased risk with cigarette smoking (Males 
RR=1.89 (1.15-4.00); females RR=3.53 (1.71-
7.27). Risk also increased with cocoa 
consumption in males but not with coffee. 
Reduced risk with consumption of black/green 
tea (F) and fruit juice (M). 
Relative risk for artificial sweetener use “was below 1”. 



















(RR=1.1)  None 
Conducted in 1978 as part of National Bladder Cancer 
Study. Compared use of artificial sweeteners in 
hospital and population control series. Proportion of 
artificial sweetener users higher in hospital based than 
population controls. Relative risks based on hospital   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  168 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food 
Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is subject. It may 
not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the 
authors. 
Primary aim 
of study  Study type  Location  Diagnosis  Number of 
subjects 
Effect of 
sweeteners   Other exposures considered  Comments and reference(s) 
tract  controls  controls were therefore lower than those based on 
population controls. Hospital controls considered more 





















Study ran from 1979 to 1981. No effect of either 
cyclamate or saccharin. Ref: (Moller-Jensen, Knudsen 




control  USA  Bladder 
cancer  Not stated  Increased 
Increased risk with cigarette smoking, 
occupation, history of urinary tract infections. 
No effect due to consumption of coffee, 
alcoholic and non-alcoholic beverages, hair 
dye use, family history or history of diabetes 
mellitus, bladder stones or pelvic irradiation. 
A significantly greater number of cases began drinking 
artificially sweetened beverages at an earlier age, 
drank artificially sweetened beverages for a greater 
number of years and consumed a greater number of 
glasses of artificially sweetened beverages compared 
















No effect  None 
Populations with extensive use of artificial sweeteners 
30-40 years before study date. Main sugar substitute 













No effect  None mentioned  Some associations seen in subgroups, could have 

















Among men, RR was 0.8 (0.6-1.1) in those who had 
used dietetic beverages and 0.8 (0.5-1.1) in those who 
had used sugar substitutes. Among women, the 
corresponding relative risks were 1.6 (0.9-2.7) and 1.5 













No effect  No interaction with tobacco smoking. 
No effect for use of artificial sweeteners or diet 
beverages. Consumption of artificial sweeteners and 
diet beverages strongly reflected socioeconomic 










Cigarette smoking: ORs = 3.9 (M) and 2.4 (F). 
Increased risk with: occupational exposures; 
Positive association with use of artificial sweeteners, 
particularly saccharin. Re-evaluation of artificial   Review of data on the food additive aspartame 
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Primary aim 
of study  Study type  Location  Diagnosis  Number of 
subjects 
Effect of 
sweeteners   Other exposures considered  Comments and reference(s) 





p=0.009  coffee consumption; water from private 
supplies. No additional risk with hair dyes (F), 
phenacetin (M), nitrites, beverages other than 
coffee, fiddlehead greens. 
sweetener data confirmed a significant risk in males 
and a dose response relationship” Refs: (Howe, Burch 
et al, 1977; Howe, Burch et al, 1980; Howe and Burch, 
1981) 
Various  Case-






No effect  Increased with cigarette smoking, occupational 
exposure, and coffee consumption. 
Study conducted between 1969 and 1974. Ref: 




















control  Canada  Bladder 
cancer  Not stated  No effect 
No association with occupation. Heavy 
smoking increased risk (ORs = 6.37M/4.36F). 
No effect due to tea or coffee; cola, alcohol 
increased risk in male smokers. 
Ref: (Morgan and Jain, 1974) 
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Table 8. Embryotoxicity/teratogenicity studies on aspartame and DKP  
(a) Aspartame 
Animals  Dose and 
route  Duration  Observations in dams  Observations in offspring  Comments and reference(s) 
Charles River 




group; first 24 






Mated at 100 days 
old; dosed from 
pcd 6-15; sacrificed 
on pcd 20 
No maternal mortality; no treatment-related 
effects on body weight, but decreased mean 
food consumption in high dose group. No 
lesions of ovary or uterus. Mean litter size, 
foetal weight, CRD similar in all groups. No 
non-viable foetuses; similar incidence of 
resorptions 
No external irregularities in 315 control, 
295 low dose or 294 high dose foetuses. 
Visceral abnormalities in 1/114, 1/108 and 
1/107 foetuses from control, low and high 
dose groups, respectively. No skeletal 
abnormalities. 
Actual intakes were 1,985 and 4,094 mg/kg/day. 
Incidence of unossified cervical centra similar to 
historical controls in all groups except in controls, 
where it was unusually low. Not thought to be 
















sacrificed on pid 
28. 
Mean body weights comparable among groups 
but food consumption markedly reduced at 
highest dietary concentration. Food 
consumption in high dose group increased 
sharply on return to normal diet. No effects on 
mean litter size, foetal resorption rate, sex 
distribution, CRD. 
Mean foetal body weight reduced in 
highest dose group. Treatment associated 
with serious congenital anomalies in ~20% 
of litters/8% of total offspring. Number of 
“normal” litters: control 10/10; low dose 
11/13;  high dose 8/10. Anomalies 
observed in abnormal litters were cleft 
palate, microstomia and syn/oligodactyly.  
Actual intakes were 1,880 and 1,870 mg/kg/day. 
Authors suggest that effects were a consequence of 
reduced maternal food consumption. Actual doses 
consumed by the two aspartame groups were similar, 
but the results are presented according to planned 
dose. Ref: (Schroeder and McConnell, 1973) 
New Zealand 
White rabbits, 









dosed from pid 6-
18; sacrificed on 
pid 28. 
Maternal survival: control 100%; low dose 97%; 
high dose 90%. Conception, premature delivery 
rate, body weight and food consumption during 
gestation comparable between control and 
treated groups. No marked effect of treatment 
on in utero litter size, resorption rates, foetal 
sex distribution, CRD. 
Mean foetal body weight comparable 
between groups. External soft tissue 
examinations “unremarkable”: major 
malformations in 1 foetus per group, minor 
malformations in 4 high dose foetuses 
from 2 litters. Novel major malformations 
in one control and one low dose foetus. 
Actual intakes were 1,100 and 1,900 mg/kg/day. 
Lower dose follow up; controls pair-fed with high dose 
group from pid 6-18. This time actual intakes were as 
planned. Novel major malformations in two foetuses 
thought to be due to problems with diet used; results 














dosed from pid 6-
18; sacrificed on 
pid 29. 
One maternal death in high dose group; 
gestation lengths comparable except for one 
premature delivery in high dose group. 
Conception rates: control 96%; low dose 81%; 
high dose 77%. Body weight changes 
comparable in treated groups, reduced in pair-
fed controls. Food consumption decreased in 
No compound related effects on 
uterine/litter data. Major malformations in 
5/153 control offspring, 3/100 in low dose 
group, 4/121 in high dose group. Affected 
2-3 litters in each group. Not compound-
related. 
Actual intakes were 1,380 and 2,360 mg/kg/day. 
Controls pair-fed with high dose group from pid 6-24. 
Suspect diet was used in this study, so results cannot 
be relied upon. Ref: (Trutter and Reno, 1973b).   Review of data on the food additive aspartame 
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Animals  Dose and 
route  Duration  Observations in dams  Observations in offspring  Comments and reference(s) 














dosed from pid 6-
18; sacrificed on 
pid 29/30. 
Pregnancy rate: control 12/15; low dose 13/15; 
medium dose 10/15; high dose 12/15. No 
findings from gross necropsies. Means daily 
food consumption was reduced in treated 
groups, especially at highest dose level. No 
meaningful differences in implantation, 
resportion sites, number, weight or length of 
live/dead foetuses. 
Gross abnormalities : control 4/88; low 
dose 4/118; medium dose (actual highest) 
8/63; high dose 0/115. Visceral 
abnormalities: control 0/29; low dose 2/51; 
medium dose (actual highest) 0/27; high 
dose 0/45. Skeletal abnormalities: control 
1/53; low dose 1/61; medium dose (actual 
highest) 4/31; high dose 0/56. 
Abnormalities did not appear to be dose 
related. 
Actual intakes were 670/1,350/1,160 mg/kg/day. 
These did not match planned doses; actual intake of 
medium dose group was higher than that of high 
dose group. Groups are referred to according to 
planned dose. At end of study some low/medium 
dose animals received high dose diet due to shortage 
of appropriate diets. Suspect diet was used in this 
study, and control/test animals received different 















dosed from pid 6-
19; sacrificed on 
pid 28. 
Maternal survival and body weight not affected 
by treatment. Food consumption suppressed in 
high dose group at pid 6 and 10. Conception 
rates similar between groups. Abortions only 
seen in high dose group (2/12 litters). In utero 
litter size was decreased in the group with the 
highest actual intake.  
Foetal viability in surviving litters, foetal 
sex distribution, foetal body weight and 
CRD not affected by treatment. No 
external, soft tissue or skeletal 
abnormalities induced by aspartame 
treatment at actual doses up to 1,450 
mg/kg/day. 
Actual intakes were 840/1,450/1,260 mg/kg/day. 
These did not match planned doses; actual intake of 
medium dose group was higher than that of high 
dose group. Groups are referred to according to 
planned dose Treatment curtailed in some animals 
due to shortage of appropriate diet but high dose 
animals did receive appropriate diet for entire study. 
Ref: (Schroeder, Rao et al, 1973b). 
New Zealand 
White rabbits, 















dosed from pid 6-
18; sacrificed on 
pid 28. 
Maternal survival suboptimal: control 67%; 
treated 69%. Poor conception rate: 4/8 controls, 
10/25 surviving treated females were pregnant 
at terminal sacrifice. Body weight comparable 
between groups. 
Could only evaluate 4 control litters (29 
foetuses) and 8 treated litters (65 
foetuses). Litter size, foetal weight 
unexceptional. No significant 
morphological aberrations noted. 
Controls pair-fed with aspartame group. Poor survival 
attributed to problems with gavage dosing procedure, 
poor conception to equivocal sexual maturity, 
marginal health status. No 
embryotoxicity/teratogenicity, but this study is 
unreliable due to the problems experienced. Ref: 


















dosed from pid 6-
18; sacrificed on 
pid 28/29. 
Maternal survival of controls 23/24 vs. 60/72 in 
treated group. Conception rates similar 
between groups. Both groups lost body weight 
during study, regained by treated animals. No 
compound related effects on maternal 
appearance at gross necropsy. Implantation 
and number of live/dead foetuses similar 
between groups. Number of resorption sites 
Mean weight of live foetuses greater in 
treated group; thought to be due to food 
restriction in controls rather than an effect  
of treatment. No apparent abnormalities 
associated with treatment: external: 
control 8/134, treated 23/236; visceral 
control 8/66, treated 12/113; skeletal 
control 1/68, treated 17/123. 
Controls pair fed with group having lowest 
consumption in previous 24 hr. Poor survival in 
treated group attributed to respiratory infection and 
problems with gavage dosing procedure. Some 
evidence for increased skeletal development/ 
ossification in treated animals, thought to be a 
function of nutrition rather than compound related. No 
discernible teratogenic effect but possible slight   Review of data on the food additive aspartame 
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Animals  Dose and 
route  Duration  Observations in dams  Observations in offspring  Comments and reference(s) 
increased in treated animals compared with 
concurrent/historical controls. 
embryotoxicity manifesting as an increased 






















dosed from pid 6-
18; sacrificed on 
pid 29. 
Maternal survival: control 91%; low dose 86%; 
high dose 88%. Abortions in 3 control dams 
and premature delivery in one control, one low 
dose. Conception rates control 96%; low dose 
86%; high dose 81%. Mean body weights 
comparable across test groups; control body 
weight suppressed due to pair feeding. Mean 
food consumption decreased in both treatment 
groups. No compound related effects on 
implantation, resorption, number of live/dead 
foetuses, findings at gross necropsy. 
No dose related effect on foetal body 
weight. Incidence of major malformations: 
control 0/19 (0/19 litters); low dose 1/198 
(1/24 litters); high dose 7/343 (6/45 litters). 
Controls pair-fed with high dose group. Authors do 
not consider that this study indicates embryotoxicity 




















dosed from pid 6-
18; sacrificed on 
pid 28. 
Reduced feed consumption in high dose group 
from pid 6 leading to body weight loss, 
significant from pid 13 onwards. Most marked in 
females which later aborted (usually on pid 18-
21). 
Mean foetal body weight and CRD 
reduced in high dose group. Number of 
tarsal and metatarsal ossification centres 
reduced at highest dose, also increased 
incidence of 13th rib and reduced sterna 
ossification. Increase in total number of 
malformations in high dose group (3 cleft 
palate, various minor malformations 
including vertebral defects and fused or 
split sternebrae). No abnormalities in low 
and medium dose groups. 
Abnormalities attributed to maternal nutritional 
deprivation rather than a compound-related effect, 
given that the statistically significant effects produced 
by aspartame were similar to those seen in rodents 
following severe dietary restriction. Phe and Asp also 












Mated at ~70 days 
old; dosed from 
pcd 6-15; sacrificed 
on pcd 18 
No effects on maternal survival, conception 
rates, maternal body weight changes, food 
consumption, incidence of abortion or 
premature delivery, mean litter size or number 
of resorptions per litter. 
No effects on mean foetal body weights, 
CRDs, number of major malformations 
and skeletal variants. 
Actual intakes were 1,400/2,700/5,700 mg/kg/day. 
Note that actual intakes were greater than planned. 
Ref: (Vondruska, Schroeder et al, 1975a). 
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(b) DKP 
Animals  Dose and 
route  Duration  Observations in dams  Observations in offspring  Comments and reference(s) 
Charles River 
CD rats, 95±5 
days old at 







Mated at 100 days 
old; dosed from 
pcd 6-16; sacrificed 
on pcd 20 
Maternal survival, conception rates, food 
consumption and body weight changes 
generally comparable between control and 
treated groups. Mean number of foetuses per 
pregnant dam comparable between groups. 
Mean number of resorptions significantly 
reduced in high dose group, attributed to 
unusually high numbers in the control group. 
Sex distribution, foetal body weight and 
CRDs similar across all groups. No 
evidence of embryotoxicity or treatment-
related anatomical alterations in any 
group. 
Actual intakes “closely approximated” those 




















dosed from pid 6-
18; sacrificed on 
pid 28/29. 
Maternal survival: control 15/21; low dose 
17/21; medium dose 15/21; high dose 2/21. 
Conception rates similar for control, low and 
medium dose groups (81-93%); one of two 
surviving high dose animals was pregnant. No 
unusual in life observations in females. Overall 
group mean body weight changes were similar 
in control, low and medium dose groups; food 
consumption decreased slightly in low and 
medium dose groups, markedly in surviving 
high dose female. No compound related 
effects on implantation, resorption rates or 
numbers of live/dead foetuses in low and 
medium dose groups. 
No significant differences in foetal body 
weight or CRD. No consistent skeletal 
abnormalities, visceral defects or changes 
in developmental rate observed. 
Maternal fatalities were associated with 
development of large gastric boluses 
comprising a granular white material (thought to 
be DKP) and hair. Ref: (Trutter and Reno, 
1972d). 
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(c) Aspartame plus DKP, 3:1 ratio 
Animals  Dose and 
route  Duration  Observations in dams  Observations in offspring  Comments and reference(s) 
Adult Charles 
River CD rats 






Mated as adults; 
dosed from pcd 6-
14; sacrificed on 
pcd 19 
No compound-related in life or necropsy 
findings. Mean body weights similar in all 
groups. Food consumption by test groups 
exceeded that of controls throughout study. No 
compound-related effects on implantation, 
resorption rates or mean number of live/dead 
foetuses per litter. 
Group mean body weight and CRD in high 
dose offspring were greater than those of 
controls but within normal range. No 
consistent unusual observations on 
external, visceral or skeletal examination.  
Actual intakes 970/2,010/3,040 mg/kg/day.  No 
evidence of embryotoxic or teratogenic effects. 




















dosed from pid 6-
18; sacrificed on 
pid 28/29. 
No compound-related in life or necropsy 
findings. Maternal survival: Control 16/20; low 
dose 8/20, medium dose 11/20, high dose 
8/20. Pregnancy rates at term were 82-100%. 
Generated 14 control, 7 low dose, 9 medium 
dose and 8 high dose litters. Mean body 
weights in low dose animals were similar to 
those in controls, remained constant in 
medium dose and declined in high dose 
animals. Food consumption decreased in all 
groups, especially at higher doses. No 
compound-related effects on implantation or 
mean number of live/dead foetuses per litter. 
Medium and high dose offspring had lower 
body weights and shorter CRD than 
controls, low dose animals. No consistent 
unusual findings in external, visceral or 
skeletal examinations or trends towards 
greater or lesser development in treatment 
groups compared with controls. 
Intercurrent deaths thought to be due to dose 
aspiration or respiratory disease. No evidence 
of embryotoxic or teratogenic effects. Ref: 
(Trutter and Reno, 1972b). 
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Table 9. Effects of aspartame on seizure induction in animal models 











p.o. in 0.5% CMC 
Single bolus dose 





at various doses 
i.p./p.o. Induces 
tonic-clonic 
seizures within 5 
min of dosing 
Median effective dose 
(ED50) for metrazol 
Aspartame had no 
statistically significant effect 
on ED50 for metrazol. 
Number of rats having 
convulsions increased in 
response to aspartame 
(750-1,000 mg/kg).  
Aspartame given as a single bolus dose to 
fasted animals reduced ED50 from 65.9 to 
50.7 mg/kg (n/s). Phe had same effect in 
terms of increasing number of rats having 
convulsions in response to metrazol. Ref: 
(Guiso, Caccia et al, 1988) 
Single bolus dose 
to fed animals; 
three divided 
doses; via diet 
overnight 
Aspartame had no effect 
when given to fed animals, 
in three divided doses or via 
diet overnight. 
Effect seems to be a function of 
overloading the system with a bolus dose 
after fasting; not relevant to normal use. 




or 120 nmol). 
Electrodes implanted 
surgically 3-5 days 
before experimentation. 
Seizures detected by 
EEG. Correct placement 
of electrodes and 
injection needles 
confirmed histologically 
at end of study. 
No effect due to either 
aspartame or equimolar 
Phe 
Ref: (Guiso, Caccia et al, 1988) 
Electrical 
stimulation via ear 
clip electrodes. 
Current which causes 
hind leg tonic extension 
in 50% of animals. 
No effect due to either 
aspartame or equimolar 
Phe 
Ref: (Guiso, Caccia et al, 1988) 













p.o. in tap water 
In random order 











Myoclonic response to 
photic simulation 
Neither aspartame nor Phe 
(at doses of 50-450 mg/kg) 
had any pro- or 
anticonvulsant effect in 
baboons, despite elevated 
plasma [Phe] and 
Phe/LNAA ratios. 
Baboons are particularly susceptible to 
manipulation of brain monoamine levels; 
provides a model considered to 
correspond to primary generalised 
epilepsy in man. Plasma amino acid 
profiles in this study were consistent with 
this. Maximal increase in Phe/Tyr ratio was 
from 1.39 (pre-treatment) to 24.7 (4 hr 
after aspartame at 1,000 mg/kg). Ref:   Review of data on the food additive aspartame 
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Aim of study  Animals  Dose   Duration  Seizure induction  Assessment of effect  Observations  Comments and reference(s) 













(n=24 per group) 
p.o. 
vehicle not stated  Single dose; 
Pentylenetetrazol 
administered 1 h 
after aspartame 
Pentylenetetrazol 
(65 mg/kg s.c.)  
Fraction of animals 
developing clonic 
seizures 
Significant increase at 
1,000 and 2,000 mg/kg in 
number of mice convulsing 
in response to 
pentylenetetrazol 
High doses of aspartame were chosen in 
order to shift amino acid ratio in brain in 
favour of Phe. Ref: (Pinto and Maher, 
1988) 
1,000 mg/kg  Pentylenetetrazol 
(50-75 mg/kg s.c.) 
ED50 for 
pentylenetetrazol 
ED50 reduced from 66 (64-
68) to 59 (56-63) mg/kg by 
aspartame, 1,000 mg/kg 
Note that confidence intervals almost 
overlap. Effect blocked by Val (1,000 
mg/kg) suggesting it was associated with 
uptake of LNAA (Phe?) across BBB. Ref: 






administered 1 h 
after aspartame 
Fluorothyl applied 
to gauze pad as 




Time to first clonic 
seizure, with loss of 
upright posture 
Aspartame (1,000 – 2,000 
mg/kg) reduced time of 
fluorothyl exposure required 
to induce seizures. At 2,000 
mg/kg time was 339 sec vs. 
510 without aspartame. 
Effect replicated by treatment with 
equimolar Phe but not Asp or methanol. 
Blocked by Val (1,000 mg/kg). Ref: (Pinto 
and Maher, 1988) 
1,000 mg/kg 
Single dose,  30, 
60 or 120 min or 
24 hr before 
fluorothyl 
exposure 
Effects observed after 30, 
60 or 120 min but not after 
24 hr. 





















each dose of 
aspartame 
Generalised clonus with 
loss of righting reflex 
following administration 
of pentylenetetrazol at 
ED50 
Aspartame had no effect on 
ED50 for pentylenetetrazol, 
also did not affect number 
of mice exhibiting seizures 
when exposed to 
pentylenetetrazol at ED50. 
Also measured amino acid in blood and 
brain, neurotransmitters in brain. Increases 
in plasma [Phe] and [Tyr], modest 
reductions in brain 5-HT and 5-HIAA 1 hr 
after aspartame. No effect on 
norepinephrine or dopamine in whole brain 

















infusion started 1 
hr later 
Theophylline 
infused i.v. as 
aminophylline (40 
mg/ml) at 0.051 
ml/min; infusion 
CSF and aortic blood 
sampled. Total infused 
dose, serum and CSF 
[theophylline], required 
to induce maximal 
Neither aspartame not 
affected any of these 
parameters 
Theophylline has been shown to induce 
severe seizures in humans. Aspartame 
had no effect on theophylline-induced 
seizures at a dose previously shown to 
potentiate seizure induction by metrozol.   Review of data on the food additive aspartame 
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Aim of study  Animals  Dose   Duration  Seizure induction  Assessment of effect  Observations  Comments and reference(s) 
stopped at time of 
maximal seizures.  











1000 mg/kg p.o. 
in isotonic saline 
+ Tween 80 




Electrical stimulation or 
pentylenetetrazol 1-2 hr 
after first dose  
Aspartame had no effect on 
rate of stimulation induced 
by stimulation of the 
prepyriform cortex, number 
of animals developing 
seizures after electric shock 
or frequency/duration of 
seizure activity after 
pentylenetetrazol. 
Seizure models used: Kindling via bipolar 
electrode implanted unilaterally in right 
deep prepyriform cortex (2s train of 50 Hz 
biphasic square wave current, 1 ms in 
duration) until Stage 5 seizure occurred; 
electroshock via ear clip electrode at 60, 
65, 70 or 75 mA current, 50 Hz, 1 msec 
pulse interval for total duration of 1 sec; 
induction of seizures by 35, 40, 45 or 
50mg/kg pentylenetetrazol. Ref: (Tilson, 
Thai et al, 1989) 
1000 mg/kg p.o. 
in isotonic saline 
+ Tween 80 
Twice daily for 14 
days 
Electrical stimulation 2 hr 
after each dose or hourly 
on day after end of 
dosing 
Aspartame had no effect on 
rate of kindling at 90 days of 




1,000 mg/kg p.o. 
in isotonic saline 
+ Tween 80 
pnd 3-10  Stimulation twice daily 
until seizures produced 
1,000 mg/kg p.o. 
in isotonic saline 
+ Tween 80 
pnd 21-35  Stimulation twice daily 















p.o. as a slurry n 
dH2O 
Kindled 2 wk after 
surgery. Single 
dose; stimulated 
1 hr later 
Kindled by daily 
application of  
1 sec train of 
biphasic pulses 




threshold, behaviour and 
duration. 
Aspartame had no effect on 
any measure in this study 
Surgical implantation of bipolar electrode 
aimed at the basolateral amygdala or 
ventral hippocampus. Amygdala has 
lowest kindling threshold of any structure 
in rat brain and should be susceptible even 
to subtle effects. Could not detect any 
effect in either this or the hippocampus 
model. (Cain, Boon et al, 1989)   Review of data on the food additive aspartame 
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mg/kg p.o. in 
mice and rats 





sacrificed 1 hr 
later 
Metrozol 
administered i.p.  
1 hr after dosing 
with test 
compound(s);  
Effect on response to 
metrazol administered at 
ED50; response 
considered positive if 
tonic-clonic seizure 
occurs within 5 min of 
dosing 
Proconvulsant effect 
previously observed in rat 
replicated, but no effect in 
mice or guinea pigs 
DBA/2J mice are susceptible to audiogenic 
seizures. The species difference observed 
did not seem to be due to transport of Phe 
and/or Tyr into the brain. (Diomede, 
Romano et al, 1991) 














sacrificed 1 hr 
later 
Metrozol 
administered i.p.  
1 hr after dosing 
with test 
compound(s) 
Effect on ED50 of 
metrozol 
At 500 g/kg, Tyr protected 
against seizures induced by 
Phe but not aspartame; at 
1,000 mg/kg also protected 
against aspartame 
induction. 
Dosed with/without Tyr (500 or 1,000 
mg/k); compared with Phe (500 mg/kg) 
with/without Tyr. Aspartame increased 
[Tyr]/[Phe] ratio in plasma but not in brain, 
but as there was no vehicle treated control 
group this is difficult to evaluate. Ref: 
















p.o. in 0.5% 
methylcellulose 
Single dose; 





GEPR-9 exhibit  
tonic extensor 
convulsions in 
response to sound 
stimulation  
Quantified in terms of 
Audiogenic Response 
Score and latency from 
onset of acoustic 
stimulation to start of 
running and to clonic or 
tonic convulsions. 
No effect on  audiogenic 
seizures due to single 
doses up to 2,000 mg/kg or 
subchronic dosing at up to 
863 mg/kg/day 
Only change in brain norepinephrine or 
dopamine was an increase in both strains 
at doses  500 mg/kg. Decreased 5-HT in 
hypothalamus of GEPR-3 at 1,000/2,000 
mg/kg. Amino acid profiles similar to those 
in other rat strains. (Dailey, Lasley et al, 
1991)  















p.o. in 0.5% 
methylcellulose/ 
0.1% Tween 80 
Single dose 
sacrificed 1 hr 
later 
Supramaximal 
electric shock (150 
mA for 2 sec via 
ear clip electrode).  
Induction of full tonic 
extensor seizures. 
No statistically significant 
changes in extension/ 
flexion ratios at any dose in 
non-epileptic rats or GEPR 
rats of either line. 
Both [Phe] and [Tyr] increased as exacted 
in response to aspartame. Brain transport 
ratios also increased at higher doses, as 
expected. No effect on pharmacokinetics 











750 mg/kg p.o. 
as suspension in 
sesame oil 







Latency to onset of 
forelimb clonus; tonic 
seizures with loss of 
posture; time between 
these endpoints. 
No effect on gestation 
length, litter size, birth 
weight or parameters at pnd 
30. No effect on clonic or 
tonic seizure threshold or 
time between endpoints. 
Guinea pig considered good model 
because most brain development occurs in 
utero. Gavage dosing of dams caused 
increased seizure threshold in offspring 
regardless of material administered 
(Sperber, Moshé et al, 1995).   Review of data on the food additive aspartame 
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1000 mg/kg p.o. 
in 0.5% CMC 
Single dose; 





Effect of aspartame on 
ED50. Also assessed 
spontaneous locomotor 
activity in open field test 
No  effect  on  spontaneous 
locomotor  activity  or  
seizure  threshold,  but 
subacute dosing decreased 
anticonvulsant  efficacy  of 
ethosuximide  and  valproic 
acid (seizure threshold) and 
of  phenytoin  (generalised 
tonic-clonic seizures). 
Also measured brain [epinephrine], 
[norepinephrine], [Asp], [Phe], [Glu] and 
[GABA]. Subacute aspartame decreased 
levels of epinephrine and norepinephrine 
in brain and partially antagonised effects of 
anticonvulsants on brain amino acids.  
Effects on anticonvulsant activity not due 
to changes in pharmacokinetics of 
anticonvulsants themselves (Helali, El-
Kashef et al, 1996) 
100  mg/kg/day 
p.o. in 0.5% CMC   14 days 
Table 10. Behavioural effects of aspartame in humans 
(a) Children 
Aim of 
study  Subjects  Aspartame 






challenge trial in 8 
children (6M/2F) 
aged 5-13 yr 
believed by their 
parents to react 












3 doses of each 
test item, 
separated by 48 
hr. 
Vital signs; motor activity 
(actometer); cognitive tests; 
observation measures;  
behaviour ratings 
No evidence of any 
effects 
  * noted to be an additional source of 
fructose at 11 mg/100 ml.  “The 
individual subject data from these two 
studies provide scant data for any 
effect of sucrose on behaviour, and 
none at all for aspartame”. Ref: 






challenge trial 18 
children (9M/9F) 
aged 3.5-5.3 yr with 
no known history of 
hypoglycaemia, 
diabetes or “allergic” 
reactions to sugar 
(167 mg) in 
apple juice* 






Parent’s Target Behaviour 
Checklist; Teacher’s Target 
Behaviour Checklist; 
behavioural observations; 
motor activity (actometer); 
cognitive test measures 
Sucrose had minimal 
effects, but aspartame 






blind challenge trial 
30 boys aged 2-6 yr; 
30 mg/kg in 
lemon 
flavoured 
Sucrose 1.75 mg/kg 
Glucose 1.75 mg/kg 





assessment; motor activity 
(actometer); Conners Ten 
Acute sugar loading did 
not increase aggression 
or activity in preschool 
Assessments carried out in laboratory 
and at home. Actometer assessment 
suggested slightly reduced motor   Review of data on the food additive aspartame 
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Aim of 
study  Subjects  Aspartame 












Item Scale of impulsiveness, 
restlessness and inattentive 
behaviour 
children; any behavioural 
effects of aspartame 
were either extremely 
subtle or absent. 
activity following aspartame, but this 
was not evident to observers. Ref:  






crossover study; 20 
children aged 9-10 
34 mg/kg in 









to amino acid 
content 
Single dose at 
10.30; observed 
until 12.30. Two 
sessions 
separated by at 
least 1 day 
Conditional associative 
learning task; Children’s 
Depression Inventory; State-
Trait Anxiety Inventory; 
arithmetic test; motor activity 
(actometer); behaviour 
assessed by video. 
No effect on learning 
task, arithmetic test, 
mood, motor activity or 
observed behaviour. 
Motor activity varied with time but not 
treatment. In second experiment, 
motor movement was less frequent 
after sucrose than aspartame. Ref: 
(Saravis, Schachar et al, 1990) 
Double blind 
crossover study; 20 
children aged 9-10 
9.7 mg/kg in 
Kool Aid 
Sucrose, 1.75 g/kg 














trial; 15 children 
aged 5-13 (11M/4F) 
with attention deficit 
disorder 
34 mg/kg/day 




2 weeks; tested 
after 1 week 
Matching Familiar Figures 
test; Wisconsin Card Sorting 
Test; Children’s Checking 
Task; Airplane Test. Parents 
assessed behaviour using 
Conners Behaviour Rating 
Scales, Multigrade Inventory 
for Teachers. Adverse 
effects recorded using 
STESS. 
No effect on cognitive or 
behavioural status 
Condition not medicated during study 
period. Mean dose of aspartame was 
29.2-41.9 mg/kg/day. No effect on 
urinary excretion of monoamines or 
their metabolites. This study has been 
criticised on the grounds that the 
group size used was too small to 
detect an effect due to aspartame. 
Refs: (Krohn, 1994; Shaywitz, 





Controlled diet study 
23 children aged 6-
10, reported to 
respond adversely to 








2.  Low in 
sucrose, high 
in aspartame; 
3. Low in 
None 









Paediatric Behaviour Scale; 
ADDH Comprehensive 
Teachers’ Rating Scale; 
Behaviour Symptom 
Checklist; Paediatric 
Assessment of Mood; Paired 
Associate Learning; 
Wisconsin Card Sorting 
Test; Continuous 
Performance Test; Grooved 
No effect on behaviour 
or cognitive function. 
Mean dose of aspartame was 38   13 
mg/kg/day. This study has been 
debated intensely, but more with 
reference to the effects of sugar than 
aspartame. One child carrying a 
polymorphic variant of L-aspartyl-L-
phenylalanine hydrolase exhibited 
some deficits in attention tests. 
Plasma [Phe] and [Asp] were within 
normal ranges and AspPhe did not   Review of data on the food additive aspartame 
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Aim of 
study  Subjects  Aspartame 
treatment  Other treatments  Duration  Assessment of effects  Observations  Comments and reference(s) 
sucrose, high 
in saccharin 
Pegboard test, Static 
Steadiness Test; Timed 
reading and mathematics 
test; motor activity; 
structured behavioural 
observations. 
accumulate in plasma. Refs: 
(Schoenthaler, Samuels et al, 1994; 
Stegink, Lindgren et al, 1995; 
Wolraich, Lindgren et al, 1994) 
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study  Subjects  Aspartame 







blind crossover trial; 
10 adults (6M/4F) 
without history of 
mental illness, 
substance abuse, 
seizure disorder or 
aspartame 
intolerance 
15 mg/kg via 
capsules. 
Taken after 










and 12, 24 hr 
after dosing. 
Mood, cognition and reaction 
time; arithmetic and digit 
symbol substitution test; 
mood, sedation and 
autonomic disturbances on 
100 mm analogue rating 
scale; information acquisition 
and recall 
Aspartame did not cause 
significant changes in 
mood, cognition, 
reaction time or memory 
in normal, healthy 
volunteers. There was 
no difference between 
aspartame and placebo 
in occurrence of 
headaches or hunger. 
Note co-administration of orange juice 
which could affect amino acid profiles 
following dosing. Amino acid profiles 
were as expected for dose 
administered. Ref: (Lapierre, 






12 adults (8M/4F), all 
current aviation 
pilots 











Ethanol to produce 
blood level of 0.1% 
(single dose only, 
on test days) 
Single dose; 
assessment 
after 45 min 
SPARTANS cognitive test 
battery, v1.0. Tests 
perceptual-motor abilities, 
spatial awareness, working 
memory, attentional 
performance, multitasking, 
risk taking, processing 




with aspartame.  
Ethanol (positive control) caused 
decrements in psychomotor and 
spatial abilities. Ref: (Stokes, Belger 
et al, 1991) 
Counterbalanced, 










sample 90 min 
after dosing on 
test days. 
SPARTANS cognitive test 
battery, v2.0. 
No deleterious effects on 
performance. Minor but 
statistically significant 
improvements in 3/47 
tasks. 
Plasma [Phe] increased as expected. 
Improved performance could have 
been a practice effect. Ref: (Stokes, 
Belger et al, 1994) 
   Review of data on the food additive aspartame 
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Table 11. Behavioural effects of aspartame in animal models 
Aim of study  Animals  Dose and route  Other 








Up to 1,000 
mg/kg 
p.o.in isotonic 
saline + Tween 
80 or 0.5% CMC 
(i.p.in one study) 
None 
Acute and up to 
14 days. Tested 2 
hr after last dose 
Motor activity; acoustic startle 
response to 110 db, 200 ms, 8 kHz 
tone; step-through passive 
avoidance test; two way active 
avoidance test; spatial navigation in 
Morris water maze. 
No effect on sensorimotor 
functioning in any of these 
tests. No effect on behaviour of 
rats with neurotoxicant-induced 
lesions of hippocampus. 
Stereotaxic surgery used to create 
hippocampal lesions by injection of 
colchicine into two rostrocaudal sites. 
Destroys granule cells and mossy 
fibres in dentate gyrus. Ref: (Tilson, 
























testing 1 hr after 
dosing 
Spontaneous behaviour assessed 
over 15 min in clear box with two 
partitions. Two rats (one treated, 
one control) per test placed on 
either side of partition, able to see 
and smell each other. Behaviour 
analysed by computer. 
No behavioural alteration 
detected at any dose of 
aspartame, L-Phe or L-Tyr.  
Use of computerised pattern 
recognition system to improve analysis 
of spontaneous behaviour. Positive 
control significantly affected number of 
behavioural inititations and time spent 
in walking, turning and head turning.  
Ref: (Mullenix, Tassinari et al, 1991) 
Behavioural 
thermoregulation: 











i.p. in saline9 
None 
Single dose; 
tested once a 
week, alternating 
test and vehicle 
(32 sessions) 
Skinner box test, rats had to press 
a lever for warmth.  
No effect on rate of lever 
pressing 
Rats were trained to press a lever to 
receive food. Aspartame did not seem 
to produce a lowered hypothalamic set 
point when injected i.p. Ref: (Vitulli, 















minimum of one 
day between test 
days. 
Aggression test conducted between 
09.00 and 13.00: response to 
intruder in home cage; latency to 
first attack; number of attacks over 
next 20 min. 
Aspartame significantly 
increased latency to first attack 
and reduced number of bites. 
Number of rats engaging in 
aggressive attacks: vehicle, 
11/11; 200 mg/kg 10/11; 400 
mg/kg 8/11; 800 mg/kg, 6/11. 
Neurochemical parameters measured 
following same dose of aspartame; 5-
HT and 5-HIAA elevated in striatum at 
all doses tested.  No change in 
dopamine, DOPAC or homovanillic 











i.p. in water6 
None 
Single dose. 
Ethanol  (1.6 g/kg) 
dosed 30 min later 
Behavioural tests using open field 
and plus maze, 5min each 
No effect on anxiety-related 
behaviour. No interaction 
between ethanol and 
aspartame. 
Ref: (LaBuda and Hale, 2000) 
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Table 12. Effects of aspartame in individuals who are homozygous or heterozygous for PKU 
Topic  Characteristics  Dose  Duration  Samples taken  Analyses 








12 year old male (1) 
15 year old female (1) 
PKU homozygotes (2): 
14 year old males on 
low Phe diets 
Aspartame: 34 mg/kg 
L-Phe: 19 mg/kg 
in 180 ml orange 
juice10. Standardised 
diet prescribed for 72 







Blood taken at  
t = 0, 1, 2, 4, 8, 
24, 48, 72 hr; 3 x 
8hr urine before 
and after each 
dose, also 48 and 







No change in urinary output of Phe and 
metabolites. No significant change in 
plasma Tyr but significant increase in 
plasma Phe*. No nausea, emesis or other 
signs or symptoms Blood and urine results 
all normal. No methanol detected in blood 
or urine. 
*Differs between study report (states 
no difference in plasma Phe) and 
published version (quoted here). 
Refs: (Koch, Schaeffler et al, 1976; 
Koch and Shaw, N/K; Koch, N/K) 
Effects of 








(1M/4F, aged 11, 16, 
17, 21, 23) 
184 mg as Diet Coke. 






Blood sampled at 




No significant increase in plasma [Phe] or 
[Tyr] over baseline in either normal subjects 
or PKU homozygotes. 
Aim of study was to determine 
whether inadvertent consumption of 
a can of diet coke might have an 
adverse effect in PKU patients. Ref: 









200 mg In cherry 
flavoured Kool Aid, 












Aspartame administered at this dose with 
or without carbohydrate did not affect 
plasma [Phe] in normal subjects or PKU 
patients (1500   230  M in PKU vs. 54.8   
8.5  M in controls). No change in 
Phe/LNAA ratio. 
Two part balanced crossover study. 
Carbohydrate, with or without 
aspartame, reduced plasma 
branched chain amino acids leading 
to an increase in the Phe/LNAA 
ratio. Any changes observed in this 
study were due to the carbohydrate 
administered, not to aspartame. Ref: 
(Wolf-Novak, Stegink et al, 1990) 









PKU Hets (n=14) 
 
10 mg/kg in cherry 






taken before and 




Pre-treatment [Phe] and Phe/LNAA levels 
elevated in PKU and non-PKU mild 
hyperphenylalaninaemia, not in PKU hets. 
Aspartame increased plasma [Phe] and 
Phe/LNAA in controls and PKU Hets but 
not in PKU and non-PKU mild 
hyperphenylalaninaemia. No serious 
adverse effects noted, but one severe 
Increased Phe/LNAA in PKU reflects 
inability to metabolise Phe to Tyr 
because of deficiency in 
phenylalanine hydroxylase. Small 
dose of aspartame did not 
accentuate hyperphenylalaninaemia 
n PKU and non-PKU mild 
hyperphenylalaninaemia. Ref: 
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Topic  Characteristics  Dose  Duration  Samples taken  Analyses 
conducted  Outcome  Comments and reference(s) 
headache after ingestion of test dose.  (Caballero, Mahon et al, 1986) 




Normal adults (n=8, 
4M/4F) 
Obligate PKU hets 
(n=6; 3M/3F) 
10 mg/kg in cherry 
flavoured Kool Aid  Single dose.  
Blood samples 
taken frequently 




No effects on plasma [Asp], [Glu], [Gln], 
[Asn], branched chain amino acids. Plasma 
[Phe] peaked at t=30 min (121   20.8  M 
in PKU hets vs. 67.3   7.5  M in controls). 
Returned to baseline by t=120 min, but 
baseline higher in PKU hets (90.4   17.1 
M vs. 50.9   8.2  M). Plasma Phe/LNAA 
also increased and remained above 
baseline at t=120 min. 
Balanced crossover design. Study at 
4 mg/kg n normal subjects only also 
reported in this paper. Ref: (Stegink, 
Wolf-Novak et al, 1987) 
Effects on 
plasma and 




Healthy adult females 
(n=4) 
Obligate PKU hets 
(n=4) 
Aged 20-28 yr 
34 mg/kg in 240 ml 





up to t = 240 min 
[Phe] in plasma 
and 
erythrocytes 
Plasma [Phe] did not exceed normal limits 
in healthy individuals or obligate PKU hets. 
Peaked at t = 60 then rapidly returned to 
near pre-dosing values. No clinical signs or 
symptoms observed. 




loading at 34 
mg/kg on 
plasma and 
red cell amino 
acids in PKU 
heterozygotes 
Healthy adults (n=12; 
6M/6F) 
Obligate PKU hets 
(n=8) 
34 mg/kg in 300 ml 
cold orange juice7  Single dose 
Blood samples 
taken frequently 





No significant changes in plasma [Asp], 
[Glu], [Gln] or [Asn] during 4 hr after dosing. 
Plasma [Phe] rose 15-120 min after dosing, 
peaked sooner in  normal controls than 
PKU-hets. Cmax in PKU-hets was 160.2   
22.5 vs. 111   24.9  M in controls. Small 
increase in [Tyr] in normal subjects, not in 
PKU-hets. 
[Ala] and [Pro] increased in both 
groups and plasma branched chain 
amino acids decreased, probably 
due to use of orange juice vehicle. 
Results consistent with rapid 
metabolism of aspartame to Phe in 
PKU-hets, with slow clearance of 
resulting Phe. Levels of Phe in PKU-
hets did exceed normal postprandial 
limits, but only by a small amount. 
Ref: (Stegink, Filer et al, 1979f) 
Healthy adults (n=22 
12M/10F) 
Obligate PKU hets 
(n=12, all F) 
34 mg/kg in 250 ml 
cold orange juice7  Single dose 
Blood samples 
taken frequently 





Plasma [Asp] [Glu], [Gln] and [Asn] 
unchanged in both groups. Cmax in PKU-
hets was 151   46.7 vs. 108   322  M in 
controls. Mean plasma [Phe] was higher in 
PKU Hets at all time points. Plasma [Phe] 
in PKU hets did exceed the normal range at 
Tmax. Plasma [Tyr] rose in normals but not 
Follow up study to increase 
numbers.  One “normal” subject had 
an amino acid profile consistent with 
being an unidentified PKU Het. Ref: 
(Stegink, Koch et al, 1981)   Review of data on the food additive aspartame 
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Topic  Characteristics  Dose  Duration  Samples taken  Analyses 
conducted  Outcome  Comments and reference(s) 
in PKU hets, consistent with the deficiency 
in phenylalanine hydroxylase in PKU hets. 
Effects of 
aspartame 
loading at 100 
mg/kg on 
plasma and 
red cell amino 
acids in PKU 
hets 
Healthy adults (n=6; 
3M/3F) 
Obligate PKU hets 
(n=5) 
100 mg/kg in 500 ml 
cold orange juice7 




up to t = 6 hr 
Plasma amino 
acid profiles 
Plasma [Asp] increased slightly* (p=0.02)*; 
slight increase in [Asn] (p<0.02)*; plasma 
[Glu], and [Gln] unchanged. Plasma [Phe] 
was slightly, but significantly, higher in PKU 
hets than normals at t=0; increased in both 
30-90 min after dosing; Cmax greater in PKU 
hets than normal subjects (417   233  M 
vs. 200   60  M); reflected in AUC. 
Plasma [Tyr] rose in both groups but to a 
greater extent in normal subjects, 
consistent with a deficiency in 
phenylalanine hydroxylase in PKU hets. 
*Differs between study report (states 
no difference in plasma [Asp] or 
[Asn]) and published version (quoted 
here). [Ala] and [Pro] increased in 
both groups, probably due to use of 
this vehicle. Plasma [Phe] exceeded 
the normal range in PKU hets, but 
the levels attained were much lower 
than those in PKU homozygous 
children (up to 6,000  M). Ref: 
(Stegink, Filer et al, 1978; Stegink, 










PKU hets (11M/12F) 
85  mol/kg as 5% 










Blood sampled at 
t = 0, 1, 3, and 8 
hr. 
Amino acids 
High protein meal alone had minimal 
effects on blood [Phe] and Phe/LNAA ratio 
in PKU hets or controls. When aspartame 
was co-administered with the high protein 
meal there was a slight increase in plasma 
[Phe], peaking in PKU hets at t=3 hr (153   
21  M) and in controls at t=1 hr (95   7 
M). Corresponding effect on Phe/LNAA 
ratio. 
Peak levels in PKU hets were 
slightly above normal postprandial 
levels. Phe/LNAA ratios remained 
below those in individuals with mild 
hyperphenylalaninaemia. Ref: 
(Curtius, Endres et al, 1994)   Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  187 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food 
Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is subject. It may 
not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the 
authors. 
Topic  Characteristics  Dose  Duration  Samples taken  Analyses 
conducted  Outcome  Comments and reference(s) 
Effects of 3 
consecutive 
doses in PKU 
hets 
PKU hets (n=6; 
3M/3F) 
30 mg/kg in 240 ml 











frequently up to 6 
hr after dosing 
Plasma amino 
acids 
[Phe] increased after each 10 mg/kg dose; 
did not return to baseline between doses, 
so accumulated over dosing period. 
Corresponding changes in plasma 
Phe/LNAA ratio. Other amino acids not 
affected. With single dose, no effects on 
plasma [Asp] or [Glu]; [Phe] peaked at t = 
45 min (197   21.5  M). Single dose 
generated higher Phe/LNAA and greater 
AUC than divided dose. 
Pharmacokinetics following a single 
dose exhibits a sharper, higher peak 
of Phe than the same dose when 

















for 8 hours 
Blood taken at 30 
min intervals for 9 
hr and at t=24 hr. 
Also at t=0,4,8 
and 24 hr for 
methanol/ 
formate. Urine 
collected -8 to 0, 









Plasma [Phe] increased 30 min after each 
dose, did not return to baseline between 
doses, levelled off after 6 doses; 
corresponding increase in Phe/LNAA ratio. 
Slight elevation in [Tyr], other amino acids 
unaffected. No effect on blood 
methanol/formate or urinary formate. 
Aspartame did not increase [DKP] (below 
limit of detection, 4  M) but direct 
administration of DKP did lead to increase 
in plasma and urine. DKP did not affect 
methanol/formate levels. No adverse 
effects reported. 
Randomised open label placebo-
controlled crossover study. 
Maximum [Phe] was within normal 
postprandial range. Limit of 
detection for methanol was 0.35 
mg/dl and for formate 0.02 mg/dl. 
Ref: (Burns, W.W. et al, 1987b); 
(Stegink, Filer et al, 1990) appears 







Natural parents of 
PKU offspring, aged 
21-45 (n=65) 
Continued in 52 
subjects 
Aspartame from 0.6 
to 8.1 g/day. 
L-Phe from 0.34 – 
4.55 g/day via 













for 21 weeks 













Phe; EEG in 
No consistent clinical chemistry 
abnormalities, no effects on glucose 
challenge tests; [Phe] and [Tyr] remained 
within normal limits throughout the study 
and varied to same extent in aspartame 
and placebo groups with no clinically 
relevant differences between groups. No 
abnormal urinary metabolites detected. No 
difference in adverse experiences between 
aspartame and placebo groups. 
Randomised double blind placebo-
controlled study. There were 
differences in absolute values of 
parameters between study centres, 
but these were not considered to 
compromise the interpretation of the 
results. One abnormal EEG trace 
was identified in a subject taking 
placebo in the short term study, but 
it had resolved by the end of the 
study. This study provides no   Review of data on the food additive aspartame 
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Topic  Characteristics  Dose  Duration  Samples taken  Analyses 
conducted  Outcome  Comments and reference(s) 
  random subset 
of subjects. 
evidence of differences in 
aspartame handling between PKU 
hets and normal individuals. Refs: 
(Koch, Peterson et al, N/K-a; Koch, 
Peterson et al, N/K-b); subset of 
patients/results published separately 
(Koch, Shaw et al, 1976)   Review of data on the food additive aspartame 
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Appendix 5: Key Study Review Proformas 
 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Document identification: 
Title  SC-18862: 106 Week Oral Toxicity Study in the Dog 
(Pathology-Toxicology Project No. 855S70) 
Authors  Rao, K. S., Mauro, J., McConnell, R. G.  Date  1972 
Study Type  Chronic Toxicity  Dossier #  E28 
Purpose of study: 
“…to evaluate the safety of multiples of the anticipated daily human intake, and to induce and define such adverse 
effects as might occur only at prodigious multiples of such intake.” 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Up to 1% DKP (SC-19192)* 
Lot # (s) 
74050, 75010, 75040B, 75070A, 75080A, 75080B, 75090A, 75090B, 75100B, 
75120, 75130A, 75130B, 75140C, 75150B, 76030A, 76040D, 76060A, 56082B, 
56147B, 56117A, 56117B, 56067A, 56067B, 56147C. 
*Mean consumption of DKP was calculated from analytical data for the lots of aspartame used. Maximum intake 
of DKP was 42 mg/kg/day in high dose animals from weeks 76-100. 
Animals: 
Species:  Dog  Strain:  Beagle 
Source:  Not stated  Age/weight:  5 months (150-160 days at 
start of treatment) 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration   
Formulation procedure 
Incorporated into 200g diet daily on individual basis. Mixed with 200-300 ml tap water 
and presented at 09:00; usually consumed within about 2 hr. 
•  Another 200 g basal diet was presented once the dosing mixture was fully 
consumed. Residual diet was weighed about 4 hr later and total diet 
consumption calculated for the day. 
•  No diet was provided from 16.00 to 09.00 the next morning. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry 
Dogs housed in individual cages 
Animal quarters air conditioned; temperature set at 72￿C 
Fluorescent lighting; 14 hr light/10 hr dark cycle 
Water available ad libitum; food intake regulated as described above. 
Diet  Powdered KASCO basal dog diet (raw meal form) (Agway Inc., USA) 
Minimisation of bias  Animals separated according to sex and assigned individual cages by a standard 
randomisation procedure. 
Blocking of groups 
5 x 8 dog housing groups; two replicate groups of each sex. 
•  Within each housing group, two dogs received each of the four treatments. 
•  Results were pooled across the two housing groups 
Number per group  5M/5F per group  Acclimatisation  5 weeks 
Start of dosing  At 150-160 days of age  Duration  106 weeks CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Planned doses 
0 (control) 
1, 000 mg/kg/day 
2, 000 g/kg/day 






Basis for dose selection 
Multiples of 0, 33, 67 and 133 times, respectively, the anticipated maximum daily 
human intake, based on the estimated maximum daily intake of 30 mg/kg/day by a 
27 kg child. 
Dose correction  None indicated 
Comments  It is not clear from the report whether or when daily doses were corrected for body 
weight. 
In life procedures: 
General observations 
Daily for survival. General 
observations weekly at 
time of weighing. 
Clinical chemistry  
Blood collected via jugular 
puncture in weeks -1, 4, 8, 
14, 26, 52, 78, 106 
Food consumption  Daily.  Haematology 
Blood collected via jugular 
puncture in weeks  -2, 0, 4, 
8, 14, 26, 52, 78, 106 
Body weight  Weekly for first 8 weeks; 
“periodically” thereafter.  Urinalysis 
Spontaneously voided 
urine samples collected in 
weeks -2, 0, 2, 4, 8, 14, 
26, 52, 78, 106. 
Ocular examinations  Weeks 24, 30, 37, 52, 80, 
104/105  Other 
Signs of systemic 
pharmacological or 
toxicological effects noted 
at time of weighing “and 
whenever warranted”. 
Comments  None 
Procedure for intercurrent deaths: 
Time to necropsy  N/A  Parameters recorded  N/A 
Tissues sampled  N/A 
Comments  N/A 
Termination procedures: 
Termination method  Animals fasted overnight, selected at random and sacrificed by intravenous sodium 
pentobarbital administration. 
Time to necropsy  Immediate (see below)  Parameters recorded   
External assessment  None described 
Necropsy procedure 
Animals fasted overnight, selected at random and sacrificed by intravenous 
administration of sodium pentobarbital. 
Preliminary fixation of eyes, brain and pituitary achieved by immediate injection of 
NBF via the carotid artery following bilateral transection of the jugular veins. 
•  Both eyes immediately removed and suspended in formalin fixative. 
Animals necropsied immediately. 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Tissues sampled 
Entire organs or tissue blocks sampled from: 
Stomach 


















Lymph node (pectoral and mesenteric) 
Nerve (sciatic) 
Brain and cervical spinal cord 
Bone with marrow (costal) 
Bone marrow plug and smear (femoral) 




*weighed fresh  
**Brain and cervical spinal cord suspended in formalin fixative. Fixed brain was 
sectioned at 8 levels and examined grossly under low magnification; subsequently, 
3 coronal sections (at the level of the optic chiasma, mammillary body and trapezoid 
body) of brain and a transverse section of sciatic nerve were examined 
microscopically after Luxol fast blue-PAS-haematoxylin staining. 
Representative blocks of the above fixed tissues from all dogs were embedded in 
paraffin, sectioned and stained with H&E. 
•  Additional tissue blocks from heart, liver, kidney, adrenal and sciatic nerve 
were routinely frozen in liquid nitrogen, stored at -125￿F until sectioned by 
cryostat, and stained for lipid with Sudan IV. 
•  Air-dried smears of femoral marrow were stained with Giemsa stain and 
stored for subsequent use as required. 
Fixation  Cold NBF 
except for pituitary  Storage conditions  Not stated 
Comments  Concentration of NBF is not specified. 
Statistical procedures: 
Data manipulation 
Results were pooled across the two housing groups to give averages for 5 animals 
per sex. Standard errors were calculated as pooled mean squares over treatment 
groups over time and for both sexes 
•  Except for autopsy organ weights  where the two sexes gave separate 
error estimates 
Certain measurements were log-transformed prior to statistical evaluation in order to 
improve the approximation of the data to the Gaussian error distribution. 
•  Means reported for transformed measurement are geometric rather than 
arithmetic means 
Statistical tests used 
Student’s t-test 
•  Level of statistical significance = 5% 
Many of the tables also show Least Significant Differences to aid in comparison of 
results by inspection. 
•  These are based on pooled within-group mean squares assuming 5 control 
and 5 treated dogs per comparison 
•  They appear once in the table below the earliest set of means for the given 
variable 
•  The same Least Significant Difference value applies to all the other 
comparison values for this variable, for both sexes 
The report states that the t-test allows for missing values but the Least Significant 
Difference values assume fixed numbers, so the agreement between t test CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
significance and Least Significant Difference is close but not exact. 
For log transformed data, Least Significant Differences are quoted as % of the 
smaller of the two means being compared, thus adjusting for the fact that additive 
differences in the log transformed scale become multiplicative ratios when returned 
to the original scale of measurement. 
•  Variables treated in this way were clinical chemistry determinations, 
prothrombin time and activated PTT, body weights and organ weights. 
Statistical tests were not performed in the case of differential white blood cell counts 
except for differential PMN values. 
Results of in life observations: 
General observations 
Survival was 100%. 
Physical examination findings were “unremarkable”. 
•  There were no changes in motor or behavioural activity or general physical 
appearance. 
•  “Limited neurological examination data revealed no remarkable changes in 
either control or treated dogs” 
•  All dogs remained in good health, appeared to be active and showed normal 
behaviour throughout study. 
Food consumption 
No consistent compound-related variations. 
•  Occasional erratic decreases in food consumption were observed in control 
and treated dogs, particularly after 52 weeks’ treatment. 





Haematocrit (micro method) 
Haemoglobin (cyanmethaemoglobin) 
Total RBC count (Coulter counter) 
Total WBC count (Coulter counter)* 
Differential WBC count (smear)** 
Prothrombin time (Tilt tube method) 
Activated partial prothrombin time 
*week -1 instead of week -2 






Glucose (not on day 547) 
Ketones (not on day 547) 
Bilirubin 
Microscopic sediment 
Urobilinogen (not on days 92, 734) 
Phenylketones 















Serum lipoprotein electrophoresis 
Free fatty acids (wk 106) 
Ornithine carbamyl transferase 
Serum protein electrophoresis 
Total serum protein 
 
There were no biologically meaningful changes in haematological parameters. 
•  Transient differences reaching statistical significance were frequently 
present, especially in red cell parameters. 
o  Haemoglobin, haematocrit and total red cell count were consistently 
lower in high dose males during the first year of the study only. 
There was no evidence of treatment related changes in serum biochemistry profiles. 
•  Transient sporadic significant differences in several parameters were 
observed. Most values remained within normal limits; no consistent dose-
related pattern was evident. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Outcomes: 
Terminal body weights  There were no statistically significant variations in organ weights. 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
No statistically significant changes in organ weights were detected. 
Post-mortem gross and microscopic findings were unremarkable. 
•  No indication of compound-related alterations was present.  
•  The commonest lesions observed were incidental inflammatory conditions such 
as interstitial inflammation of the lung, pyelitis and slight focal chronic 
inflammation of the kidney, GI tract, liver and prostate. 
Results of lipid staining in high dose animals: 
•  All adrenal slides were positive in the cortex 
•  All kidney sections were positive in distal convoluted tubule except for four 
male dogs 
•  All heart and liver sections were negative. 
Neoplastic lesions  None reported 
Comments 
The methods section states that Sudan IV staining was carried out on cryosections 
whereas the results sections reports results with Oil Red O. This is unlikely to have 
had consequences in terms of the interpretation of the study since Sudan IV and Oil 
Red O are both red dyes used for staining neutral lipid. Oil Red O is generally 
reckoned to give a more intense colour and has largely replaced Sudan IV. 
 
There was no increase in serum L-Phe levels during the 106 week treatment period. 
No meaningful changes in urinary parameters were observed. 
Except that a significant increase in urinary excretion of phenylketones (in 
spontaneously voided urine) was observed in some high dose dogs at weeks 2, 4 
and 26 of treatment but at 8, 14, 52, 78 and 106 weeks all high doses were negative 
in this respect. 
Ocular examinations 
No consistent treatment-related changes were observed. 
•  Eye lesions of variable nature were observed in 6 control, 5 low dose, 3 
medium dose and 8 high dose animals but were generally similar between 
control and treated animals. 
•  However, when the initial ocular examination was performed in Week 24, 
two dogs (one medium dose, one high dose) exhibited bilateral anterior 
subcapsular and nuclear cataracts. 
o  These dogs were litter mates; the cataracts were therefore 
believed to be congenital in origin and unrelated to treatment. 
o  The lesions were of a type which is often congenital and they did 
not progress during the remainder of the study. 
o  A subsequent pup from the same parent dogs also exhibited 
cataract. 
•  There were no pretreatment eye examinations in this study, so it is not 
clear when the observed cataracts developed. 
Other  Survival rate 100% in all groups. 
Comments  The Results section mentions the outcome of “limited neurological examinations”, 
but there is no reference to these in the Methods section. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Conclusions: 
Authors’ conclusions 
“It is concluded that continuous dietary administration of SC-18862, at daily intake levels of 1, 2, and 4 g/kg, to 5 
month old Beagle dogs of both sexes for 106 consecutive weeks causes no biologically meaningful alterations in 
body weight, food consumption, physical examination, clinical laboratory examinations or post-mortem gross and 
microscopic findings”. 
Reviewer’s comments 
This study identified no chronic toxicity in dogs at doses up to 4,000 mg/kg/day administered daily via the diet. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  Not evaluated 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP check 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data)  
•  No location of archiving data 
•  No Study Director (although report author) 
•  No start/finish dates 
•  Possible lack of a description of all circumstances that may have affected the quality or integrity of the 
data 
o  No mention of the lack of insulin and phenylalanine data for week 78 – reason why and impact 
•  Noted during check that results section (p 14) states no significant variations in bodyweight although 
table flags a continuous significant difference for males)  
Not possible to confirm protocol objectives and any changes, as protocol not provided 
Commentary: 
General comments 
No significant issues were identified during the review of this study. Its findings are generally reassuring, giving no 
indication of toxicity in beagles dosed with aspartame for two years. Cataracts were observed in two dogs, but 
these seem to have been congenital.  
Strengths and limitations of study 
Strengths: 
•  Provides information in a non-rodent species 
•  Sent to a leading comparative neuropathologist for verification of brain findings 
•  Exceptional standard of fixation of brains 
Limitations: 
•  Small study – only 5 dogs per group. Reasonable given cost and size of test animals, but limits statistical 
power. 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). A number of errors and discrepancies were identified, but it was considered that none of 
these would have affected the results by more than 10%. Two differences in histopathological diagnosis were 
notes, but these were not considered to be biologically significant. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Small study: 5 dogs per sex per group. 
•  Control groups same size as treatment groups 
Three dose levels plus control 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used 
•  Purities of individual batches not indicated 
Compound administered daily in controlled doses 
High standard of fixation of key tissues 
Relevance of the study  Provides chronic toxicity data from a non-rodent species 
Adequacy of data sets 
No intercurrent deaths 
Good range of endpoints measured 
•  Lack of some data specified at week 78; unlikely to have affected outcomes 
Good tissue accountability 
Data sources  Commercial study report, pre-GLP (1972) 
Comments 
•  This was a small study, but it seems to have been conducted to a high standard. It provides reassurance 
concerning lack of toxicity in a non-rodent species. 
•  Brain sections from this study were evaluated independently by two general pathologists  and a 
comparative neuropathologist . The experts agreed that in this study “ependymal neoplasms were not 
present, nor was focal ependymal proliferation a notable concern in treated animals” though they did 
raise issues regarding sample quality and labelling.  
•  Both the original study and the follow up investigation were included in the UAREP authentication review 
in 1978. No major issues were raised. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
Document identification: 
Title  SC-18862: 106 Week Oral Toxicity Study in the Dog 
(Pathology-Toxicology Project No. 855S70) 
Authors  Rao, K. S., Mauro, J., McConnell, R. G.  Date  1972 
Study Type  Chronic Toxicity  Dossier #  E28 
Purpose of study: 
“…to evaluate the safety of multiples of the anticipated daily human intake, and to induce and define such adverse 
effects as might occur only at prodigious multiples of such intake.” 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
Standard species Laboratory Beagles 
Please comment on the choice, age and health status of the animals used. 
The animals appeared to remain healthy throughout the study 
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes   
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
Regular daily checks for survival and, prior to initiation of treatment and at each body weight measurement, 
checks for general health.  
No decedents in the study.  
Infusion fixation of brain, eyes and pituitary gives better fixation than standard methods. 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No comments 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
Please add comments on tissue sampling and preservation 
Additionally infusion fixation of brain, eyes and pituitary gland. 
Procedures were better than standard for brain 
                                                             
1 Please delete as applicable CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Tissue accountability was good 
Not possible to comment on quality without viewing the slides but fixation, sectioning and staining of brain and 
sciatic nerve were exceptional when compared to most routine studies  
Pathology findings: 
Please give your expert opinion on the findings reported 
No grading system was used for the histopathological findings just a descriptive phrase or sentence. Most of the 
findings consisted of minor chronic inflammatory changes described as ‘focal collections of a few mononuclear 
cells’. 
Lens calcification was the microscopic diagnosis for the cataracts observed in-life 















Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Section 3: Follow up studies 
Document identification: 
Title  SC-18862: A Supplemental Study of Dog Brains from a 106 Week Oral Toxicity Study 
(P-T No. 855S70) Project No. 1226 
Authors  McConnell, R. G.  Date  1973 
Study Type  Follow up – further histopathological evaluation  Dossier #  E86 
Follow up from: 
Title  SC-18862: 106 Week Oral Toxicity Study in the Dog  
(Pathology-Toxicology Project No. 855S70) 
Authors  Rao, K. S., Mauro, J., McConnell, R. G.  Date  1972 
Study Type  Chronic toxicity  Searle Dossier #  E28 
Purpose of study: 
Reason for follow up  Response to a request for further microscopic examination of brains 
Aim of follow up study  “…to ensure than any lesion present was detected and accurately diagnosed”. 
Additional procedures performed: 
Animals sampled: 
10 low dose dogs 
10 medium dose dogs 
1 high dose dog 
Tissues analysed:  Brain 
Procedure: 
Brain sections were evaluated independently by two general pathologists  (Drs. Mauro 
and Dugan; Microscopy for Biological Research, Ltd.) and a comparative 
neuropathologist  (Dr. J.R.M. Innes; Flow Laboratories, Rockville, Md.). The wording of 
the reports from these experts differs slightly, but they agree that in this study 
“ependymal neoplasms were not present, nor was focal ependymal proliferation a 
notable concern in treated animals”. The pathologists did, however, raise issues 
regarding sample quality and labeling. 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
Please add comments on tissue sampling and preservation 
Any discrepancies in initial sampling were corrected by Dr Innes 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Dr Innes was a very well-respected neuropathologist and co-author of Comparative Neuropathology. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 3: Follow up studies 
Pathology findings: 
Please give your expert opinion on the findings reported 
An exhaustive examination of the brain for neoplastic and non-neoplastic findings showed no treatment-related 
changes. 
General comments: 
Please add any other comments on this study 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). No significant pathological lesions were noted (Unattributed, 1978c). 
Reviewer Details: 
Name: Peter Millar  Date: April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
FDAGLP report content 
 
Page 1 of 1 
Study Identifier  01 1972 (E28) 
Study Title  SC-18862: 109 Week Oral Toxicity Study in the Dog 
  Y  N  Comment 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  Protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  Purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and substrain, age, and 
procedure used for identification. 







A description of the dosage, dosage regimen, route of 
administration, and duration.  √     
A description of all circumstances that may have affected the 
quality or integrity of the data.    √  (1) 
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    (not named 
as SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√    (2) 
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.    √   
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √  Presume N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) No mention, for example of the lack of insulin and phenylalanine data for week 78 – 
reason why and impact 
(2) Noted during check that results section (p 14) states no significant variations in 
bodyweight although table flags a continuous sig difference for males 
Report GLP content check by/date: J Birnie 11 –19 April 2012 
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Document identification: 
Title  SC-18862: 104-Week Toxicity Study in the Mouse 
(P-T No. 984H73) Final Report 
Authors  Reno, F.E., Ferrell, J.F.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E75 
Purpose of study: 
“…to evaluate and characterize the effects of long term dietary feeding of SC-18862 in ICR Swiss albino mice”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  0.8 -1.2% DKP* 
Lot # (s)  76050A (1.2% DKP), 56047B (0.9%), 76040C (1.0%), 56057C (1.0%), 56057D 
(1.0%), 56627-1 (0.8%) 
*Intake of DKP was approximately 10, 20 and 40 mg/kg/day for the three treatment groups during the study. 
Animals: 
Species:  Mouse  Strain:  Albino 
CD-1 (HAM-ICR Swiss) 
Source:  Charles River, USA  Age/weight:  28 days old at start of 
dosing (12-22 g) 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration  Not stated 
Formulation procedure  Aspartame was incorporated into the basal diet on a w/w basis and thoroughly mixed 
in a twin-shell Patterson Kelley blender. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry  Mice housed individually in elevated wire mesh cages 
Food and water provided ad libitum. 
Diet  Wayne Laboratory Chow 
Minimisation of bias  Stratified randomisation by body weight for each sex; animals were arranged into 
four groups to give a homogeneous distribution of weights between groups. 
Blocking of groups  None indicated 
Number per group 
72M/72F controls 
35-37M/F* per test group 
*some mis-sexing at start 
Acclimatisation  Not stated 










based on data to wk 100 
Basis for dose selection  None provided 
Dose correction  Adjusted according to body weight changes: weekly in weeks 0-4; fortnightly weeks 
5-12; every four weeks from week 13-100. 
Comments  See QA comments. 
No justification is provided for the doses selected. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
In life procedures: 
General observations 
Daily for survival; general 
observations at time of 
weighing 
Clinical chemistry   At termination only 
Food consumption 
Weekly in weeks 0-4; 
fortnightly weeks 5-12; 
every four weeks from 
week 13-100. 
Haematology 
Mixed arteriovenous blood 
samples (0.25 ml) taken by 
segmental amputation of 
tail in weeks 5,10, 20, 23, 
40, 60 (6 mice per sex per 
group) and 104 (majority of 
surviving mice) 
Body weight 
Weekly in weeks 0-4; 
fortnightly weeks 5-12; 
every four weeks from 
week 13-100. 
Urinalysis  At termination only 
Ocular examinations 
In weeks 4 (earliest point 
at which eyes were 
mature enough for 
examination), 20, 40, 
60 and 104. 
Other 
Observed for signs of 
toxicity and 
pharmacological effects 
and for development of 
palpable tissue masses. 
Comments  None 
Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  Terminal body weight 
Tissues sampled 
Necropsy performed under supervision of staff pathologist; representative tissues 
preserved unless precluded by autolysis. 
•  Presumably the same as those taken in planned necropsies, but this is not 
stated. 
Tissues examined: 
•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
•  Some carcasses showing advanced autolysis were placed into fixative 
whole after the abdominal and thoracic cavities had been opened and 
inspected. 
Comments  It is not clear to what extent autolysis was a problem in the analysis of decedents. 
Termination procedures: 
Termination method  Sodium pentobarbital anaesthesia followed by exsanguination. 
Time to necropsy  Presumably immediate  Parameters recorded  Body weight 
Organ weights 
External assessment  Tissues of the major body cavities were examined, as well as skin and the internal 
and external aspects of the GI tract. 
Necropsy procedure 
Necropsy performed under supervision of staff pathologist. 
Terminal blood samples (1.25 ml) taken by arterial puncture of abdominal aorta. 
•  Clinical chemistry analyses conducted on serum from terminal blood 
samples were BUN, ALT, and ALP. 
•  Frozen serum samples from a representative number of mice per group 
were sent to the sponsor for determination of L-phenylalanine. 
Individual urine samples (0.15 ml) collected by evacuation of urinary bladder at 
necropsy; analysed for phenylketones and by microscopic examination of sediment. 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Tissues sampled 
Tissues sampled at necropsy: 

















Mesenteric lymph node,  







Mammary gland (R4, 5) 
Bone (rib junction) 
Bone marrow (femoral) 
Skeletal muscle 
Nerve (Brachial plexus) 
Usual and unusual lesions 
     *weighed fresh 
     **weighed after fixation 
Histopathological examination was performed on all unusual or usual gross lesions 
from all animals at each treatment level, plus microscopic examination of 20-27 
grossly unremarkable organs from all control and 4,000 mg/kg/day dose animals 
and roughly 2/3 and 1/3 of animals at 2,000 and 1,000 mg/kg/day, respectively.  
•  Actual numbers of tissues analysed listed in report (Figure B, attached) 
In particular, 
•  Brain tissue was examined such that five coronal sections representing the 
major neuroanatomical areas of the brain were evaluated; two sections per 
block were examined thus providing a total of 10 brain sections per mouse. 
•  After gross examination of hemisected fixed bladder, four transverse 
bladder sections cut at 50 mM intervals were examined microscopically. 
All wet tissues, embedded tissues and mounted tissue sections were retained by 
Hazleton Laboratories. 
Fixation  10% NBF  Storage conditions  Not stated 
Comments  None 
Statistical procedures: 
Data manipulation  Not described 
Statistical tests used 
Bartlett’s test for a preliminary test of homogenicity of variances relating to rates of 
body weight change (compared by method of Rao), food consumption, terminal 
body weights, organ weights, organ weight/body weight ratios.  
•  Analysis of variance Scheffe’s method of paired comparison when 
variances were homogeneous. 
•  Two sample t-test when variances were not homogeneous 
Survival rates after 100 wk compared by the method of Sachs 
•  A life-table technique was used to calculate the proportion of mice 
surviving the period in treated and control groups 
•  The two survival rates were compared by the t-test 
Clinical laboratory data were compared by the t-test. 
Tumour incidence (adjusted) was calculated by the method of Sachs, involving a 
life-table approach and survival rates. 
•  Control and treated adjusted tumour incidences were then compared by 
the t-test. 
The level of significance for all tests was set at 5%. 
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Results of in life observations: 
General observations 
No evidence of effects on physical appearance or behaviour of animals. 
Use of the life-table technique indicated that survival in each of the treatment groups 
was comparable to that of controls. 
•  Mortality was ≤50% after 18 months. 
•  Mortality increased during the last 6 months of the study due to 
spontaneous disease. 
•  Mean survival to week 100 was 25-42%. 
Nine mice were lost during the study and were excluded from statistical analysis: 
•  Seven escaped, two were accidentally killed 
Food consumption 
During the first year of the study, food consumption tended to be slightly suppressed 
in all treatment groups. 
•  This was only significant in males at 1,000 and 4,000 mg/kg/day. 
•  Food consumption was generally lower in treated mice during the second 
year of the study, but this was not evaluated statistically. 
Growth 
Rates of body weight gain for female mice were comparable across all groups. 
•  Body weight gains in treated males were significantly lower than in controls 
during the first year of the study. 
•  The difference at Week 52 was not greater than 3%, therefore this finding 
was not considered biologically meaningful. 
•  Male body weights during Year Two were comparable across groups. 
Laboratory tests 
Haematology tests carried out during the study (on six mice per group) were: 
o  Haematocrit 
o  Haemoglobin 
o  Erythrocyte count 
o  Total WBC count  
o  Differential WBC count  
o  Prothrombin time (wks 5, 10, 40, 60) 
No alterations attributable to treatment were observed. 
•  Random fluctuations were occasionally observed but the values remained 
within normal limits. 
•  Haematocrit test carried out on week 20 gave unexpected results 
•  The test was repeated in week 23, resulting in normal values. 
Ocular examinations 
There was no evidence of any compound-related ocular effect. 
Principal findings at necropsy included corneal opacities and cataracts, tending to 
occur more frequently in controls and at 1,000 mg/kg/day than at higher doses. 
Other 
Signs commonly observed in laboratory mice observed in a few animals during the 
first 18 months of the study and with increasing frequency during the last 6 months: 
o  Hunched appearance 
o  Sores and/or desquamation on the tail and other parts of the body 
o  Localised alopecia 
o  Bloated appearance 
o  Stained fur 
o  Eye cloudiness, redness and/or discharge 
o  Protruding vagina and/or vaginal discharge in females 
•  Incidences were similar in treated and control animals. 
Palpable nodules, swollen areas and wart-like skin lesions were seen in 7/144 
control and 7/216 treated mice (mainly males). 
•  Incidence was much lower than in rat studies (E70, E33-4) 
Comments  Poor survival may have compromised interpretation of this study. 
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Outcomes: 
Terminal body weights 
Terminal body weights were unremarkable for each of the treated groups. 
The following statistically significant changes in terminal organ weights were noted: 
  Dose (mg/kg/day) 
  1,000  2,000  4,000 
Thyroid/BW ratio  › (M/F)     
Heart/BW ratio      › (F) 
Prostate/BW ratio  ﬂ (M)  ﬂ (M)   
 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Gross observations at necropsy failed to reveal consistent changes in any organs or 
tissues that could be attributed to compound administration. 
•  Gross necropsy findings comprised incidental findings common in mice of 
this age and strain. 
Histopathological examination revealed no evidence of any treatment-related non-
neoplastic changes in any organ or tissue. 
Lesions which were observed but not considered to be treatment-related included: 
•  Deposits of amyloid in thyroid, adrenal, myocardium, spleen, liver, kidney, 
gastric mucosa, pancreas, small intestine, lymph nodes and testes 
•  Minimal deposits in cerebral hemispheres 
•  Hyperplasia of the outer adrenal cortex/capsule 
•  Pigment deposition and cortical hypertrophy in the adrenal 
•  Mild focal nonsupporative myocarditis 
•  Vascular changes in a few animals 
•  Components of chronic pulmonary disease 
•  Extramedullary haematopoiesis in the spleen 
•  Occasional signs of hepatitis 
•  Chronic kidney disease complex 
•  Nematodiasis in the large intestine 
•  Hypospermatogenesis and mineralisation of seminiferous tubules 
•  Small foci of mononuclear cell accumulation in the bladder 
•  Incidental salivary gland alterations 
•  Dilatation of uterine glands and uterine hyperplasia  
•  Follicular ovarian cysts 
None of the changes observed were considered to be treatment-related. 
Neoplastic lesions 
In no instance in either sex at any of the treated levels was the adjusted tumour 
incidence of any of the types of tumours analysed significantly higher than that of 
the respective controls. 
•  Tumour types considered: 
o  Any tumour 
o  Only benign tumour 
o  Any malignant tumour 
o  Primary lung tumour 
o  Lymphoreticular tumour 
o  Vascular tumour CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Sporadic reductions in adjusted tumour incidences were observed in males; there 
were no statistically significant changes in adjusted tumour incidence in females. 
A detailed evaluation of brain tissues to determine the presence or absence of 
intracranial neoplasms was performed on all survivors and non-survivors for which 
suitable tissues were available. 
•  No primary intracranial tumours were observed. 
•  Brain metastases from other primary sites were observed in four mice. 
Close inspection of the urinary bladder identified “large, neoplastic appearing 
epithelial cells” in two males (one at 1,000 mg/kg//day and one at 4,000 mg/kg/day). 
•  No other evidence of primary neoplasia was observed in the bladder. 
•  Metastatic lymphosarcoma and reticulum cell sarcoma were observed in 
tissues including the bladder in two controls (both females) and two mice at 
4,000 mg/kg/day (1M/1F). 
Other  
Terminal blood chemistry data did not indicate any compound-related alterations. 
•  BUN and ALT levels tended to be high in all groups, but ALP values were 
generally within normal limits 
Hepatic phenylalanine hydroxylase activity was elevated in one mouse per sex at 
4,000 mg/kg/day but was otherwise unremarkable. 
Results of terminal urinalysis were unremarkable. 
Comments 
Laboratory investigations only performed on a subset of mice. 
Number of clinical chemistry analyses limited by volume of obtainable from mice 
and lack of suitable microanalytical methods at the time. 
Conclusions: 
Authors’ conclusions 
“Thus, SC-18862 administered to the mouse for 104 weeks in the diet at dosage levels of 1, 2 and 4 g/kg/day 
exhibited no adverse effects regarding survival rate nor did it produce any convincing evidence of an effect with 
respect to the incidence of neoplasms or with regard to non-neoplastic changes in any organ or tissue” 
Reviewer’s comments 
This study does not indicate any chronic toxicity or carcinogenic effect due to aspartame when administered to 
mice via the diet at doses up to 4,000 mg/kg/day. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  Not conducted 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP Check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No location of archiving data 
•  No Study Director (although report author) 
•  No reported method of identification. Animals were house singly but not mentioned how tissues/samples 
were identified. There was a concurrent study for some of the time, see 05 below 
Not possible to confirm protocol objectives and any changes, as protocol not provided. 
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Commentary: 
General comments 
Interpretation of this study would have been facilitated by the provision of a summary table combining tumour 
incidences in decedents and animals included in the terminal sacrifice; however, the study seems to be of good 
quality for the date when it was carried out. 
Strengths and limitations of study 
Strengths: 
•  Inclusion of a large control group to assist in evaluation of statistical significance 
•  Range of tissues sampled was state of the art for the date the study was conducted, although modern 
guidelines recommend the inclusion of additional tissues. 
Limitations: 
•  Laboratory investigations only performed on a subset of mice. 
•  Number of clinical chemistry analyses limited by volume of obtainable from mice and lack of suitable 
microanalytical methods at the time. 
•  Poor tissue accountability 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). The panel noted that examination of individual mice for palpable masses was actually 
performed more frequently than the protocols specified (Unattributed, 1978b). They recognised that the fluid filled 
swellings observed in mice from time to time can regress spontaneously. There were some issues with the 
histopathological diagnoses, but overall no statistical or biological evidence for tumour induction was found. Some 
problems with sample autolysis were noted, but these did not significantly affect the histology results. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Adequate size: 36 mice per sex per group 
•  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus control 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intake close to that planned 
No issues with histopathology findings 
Relevance of the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of data sets 
Poor survival to termination: 25-42% per group 
Number of clinical chemistry analyses limited by volume of obtainable from mice and 
lack of suitable microanalytical methods at the time. 
Range of tissues sampled was state of the art for the date the study was conducted.  
•  Modern guidelines would recommend the inclusion of additional tissues. 
Poor tissue accountability 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
•  This study was included in the UAREP authentication review in 1978. No major issues were raised. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
Document identification: 
Title  SC-18862: 104-Week Toxicity Study in the Mouse 
(P-T No. 984H73) Final Report 
Authors  Reno, F.E., Ferrell, J.F.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E75 
Purpose of study: 
“…to evaluate and characterize the effects of long term dietary feeding of SC-18862 in ICR Swiss albino mice”. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains for long term studies. 
Please comment on the choice, age and health status of the animals used. 
The histopathological findings encountered were representative of the range of spontaneous pathology seen in 
this mouse stain with high incidences of amyloid deposition, spindle cell hyperplasia in the adrenal gland and 
chronic kidney disease. 
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes   
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
No record of time from death to necropsy in the report but presumably appropriate. 
Necropsy procedures fine as documented 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No unusual findings and no significant differences in incidence. However, assessment was made difficult by the 
absence of a summary table which combined the incidences in decedents and terminal sacrifice animals. 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
                                                             
1 Please delete as applicable CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Please add comments on tissue sampling and preservation 
The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was conducted 
but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, Harderian glands, 
parathyroid glands, skin, thymus and trachea. 
Tissue accountability was poor in this study: It was noted that 13% of the males and 11% of the females were lost 
to histopathological examination due either to escapes or autolysis. This included 27% of high dose males and 
11% high dose females. In addition there was a poor tissue harvest of some of the smaller tissues including the 
gall bladder, thyroid glands, prostate gland and pituitary e.g. only 11/32 pituitary glands were examined in the 
highest dosage group females. 
Although brain and urinary bladder was subjected to rigorous examination it was noted that only 68% of high dose 
male and 69% of female bladders were submitted for examination  
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  ?Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Without seeing the slides it is impossible to comment on the quality of the sectioning, tissue placement, staining 
etc. were consistent across the groups 
Pathology findings: 
Please give your expert opinion on the findings reported 
From the summary tables the findings appear to have been consistently reported.  
As with the rat study the absence of a summary table giving the combined incidences of non-neoplastic findings in 
all the animals made interpretation difficult. 
In view of the special interest shown in the brain and urinary bladder two findings are worth further comment:  
First in the brain the very small mineral deposits were reported in the cerebral hemispheres that from the 
description given are consistent with spontaneous bilateral mineralisation of the lateral thalamus – a common 
age-related change seen in several mouse strains and of no toxicological significance.  
Secondly in the urinary bladder two ‘small submucosal collections of rather large, neoplastic-appearing epithelial 
cells classified as carcinoma were noted in sections of the urinary bladder from one low level male and one high 
level male’. This description suggests a more likely diagnosis to be the so-called submucosal mesenchymal 
tumour or decidual reaction seen spontaneously particularly in Swiss mice. 
I have no criticism of the study pathologist’s interpretation of the findings. 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Page 1 of 1 
Study Identifier  04 1974 (E75) 
Study Title  SC-18862: 104-Week Toxicity Study in the Mouse  
  Y  N  Comment 
below 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √     
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  Protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  Purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √  No reported 
ID method (1) 
A description of the dosage, dosage regimen, route of 





A description of all circumstances that may have affected the 
quality or integrity of the data.  √     
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    (not named 
as SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.  √  √  Only 
specimens 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √  Presume N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) No reported method of identification. Animals were house singly but not mentioned how 
tissues/samples were identified. There was a concurrent study for some of the time, see 05 
Report GLP content check by/date: J Birnie 11-19 April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Document identification: 
Title  SC-18862: Two-year Toxicity Study in the Rat. Final Report 
(P-T No. 838H71) 
Authors  Reno, F.E., Ferrell, J.F., Busey, W.M.  Date  1973 
Study Type  Chronic toxicity  Dossier #  E33-4 
Purpose of study: 
“…to evaluate and characterize the effects of long term ingestion of SC-18862 in albino rats”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Up to 1.5% DKP*  
Lot # (s)  See Table 1A, attached 
*Maximum intake of DKP was about 80 mg/kg/day in high dose group during last 60 weeks of study. 
Animals: 
Species:  Rat  Strain:  Albino, Charles River CD 
Source:  Not stated  Age/weight:  75-108 g (M) 
80-102g (F) 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration  Not specified 
Formulation procedure  Aspartame was incorporated into the basal diet on a w/w basis and thoroughly mixed 
in a twin-shell Patterson Kelley blender. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry  Rats were housed individually in elevated wire mesh cages. 
Food and water were available ad libitum. 
Diet  Purina Laboratory Chow 
Minimisation of bias 
Stratified randomisation by body weight for each sex; animals were placed into five 
groups taking into account the differences in body weight so that a homogeneous 
distribution of body weight was obtained within groups. 
Blocking of groups  None indicated 
Number per group  60M/60F controls 
40M/40F per test group  Acclimatisation  Not specified 
Start of dosing  Not specified  Duration  104 weeks 
Planned doses 
0 (control) 
1, 000 mg/kg/day 
2, 000 mg/kg/day 
4,000 mg/kg/day 
8,000 mg/kg/day 
Actual intakes  Within 10% of those 
planned.  
Basis for dose selection  None provided 
Dose correction 
Individual body weights and individual food consumption were calculated3x/week in 
Weeks 0-4; 2x/week in Weeks 5-13 and weekly in Weeks 14-26; fortnightly in Weeks 
26-52; monthly from Weeks 53 to termination. Doses adjusted after each weighing.  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
In life procedures: 
General observations 
Daily for mortality; 
general observations at 
time of weighing. 
Clinical chemistry  
Mixed arteriovenous blood 
samples (2 ml) taken by 
segmental amputation of 
tail; weeks 13, 26, 52, 104.   Food consumption 
See Dose Correction 
section, above 
Haematology 
Body weight  Urinalysis 
Collected overnight in 
metabolism cages in 
weeks 13, 26, 52, 104; 
samples pooled by group 
and sex. 
Ocular examinations 
At initiation and in weeks 
42, 52 and 104 
 
Other 
Records were kept of 
incidence, time of 
appearance, location, size 
and changes in palpable 
lesions. 
Comments  None 
Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  Terminal body weight 
Tissues sampled 
Necropsy performed under supervision of staff pathologist; representative tissues 
preserved unless precluded by autolysis. 
•  Presumably the same as those taken in planned necropsies, but this is not 
stated. 
Tissues examined: 
•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
Comments  It is not clear to what extent autolysis was a problem in the analysis of decedents. 
Termination procedures: 
Termination method  Sodium pentobarbital anaesthesia followed by exsanguination. 




•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
Necropsy procedure 
Necropsy performed under supervision of staff pathologist 
Terminal blood samples (10 ml) taken by arterial puncture of abdominal aorta. 
Clinical chemistry analyses conducted on serum from terminal blood samples: 
Fasting blood sugar 
BUN 













Some details are missing from the report: see QA comments. 
No justification is provided for the doses selected. 
Top dose group was increased from 6,000 to 7,000 mg/kg/day in Week 16 and from 
7,000 to 8,000 mg/kg/day in Week 44; this dose escalation is not explained. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Statistical procedures: 
Data manipulation  Not described 
Statistical tests used 
Life-table technique for survival 
t-test for clinical laboratory data 
Analysis of variance, or F-test at 5% probability level for remaining criteria 
Preliminary tests (where applicable) by methods of Bartlett, Rao, Scheffe, Sachs 
and Fisher-Behrens (modified t-test) 
Life-table technique for probability of tumour formation 
Results of in life observations: 
General observations 
No effects on the physical appearance and behaviour of animals were observed. 
Survival during the first 18 months of the study was comparable in all groups. 
•  Male survival was comparable between treated and control groups, but 
slightly higher in treated groups (38% in controls; 53% at 8,000 mg/kg/day) 
•  Survival was reduced in females at 8,000 mg/kg/day (25 vs. 47%) 
Food consumption 
Food consumption during Year One were significantly lower than controls in 
•  Males at 8,000 mg/kg/day 
•  Females at 4,000 mg/kg/day and 8,000 mg/kg/day. 
Food consumption was not evaluated after week 52 of the study, but the above 
pattern appeared to be maintained. 
Comparison of the nutrient intakes of control and doses animals indicated that 
•  Basal diet contained 24% crude protein and 66% carbohydrate 
Tissues sampled 
Tissues sampled at necropsy: 

















Lymph node, mesenteric 
Urinary bladder (see note below) 







Bone marrow (sternum) 
Skeletal muscle with peripheral nerve 
Mammary gland 
Usual and unusual lesions 
 
*weighed fresh 
**weighed after fixation 
Histopathological examination was performed on all unusual or usual gross lesions 
from all animals at all treatment levels, plus microscopic examination of 20-25 
grossly unremarkable organs from all control, 4 and 8 g/kg/day animals and from 
“roughly one-fourth of the animals at the two lowest treatment levels”. 
•  Actual numbers of tissues analysed listed in report (Figure A, attached) 
•  Special attention was paid to urinary bladder: after gross examination of 
the fixed hemisected bladder, four intermittent transverse bladder sections 
were examined microscopically from each rat in the study. 
•  Two sections examined from brain, from cerebrum and cerebellum. 
All preserved/embedded tissues and stained tissue sections retained at Hazleton 
Laboratories. 
Fixation  10% NBF  Storage conditions  Not stated. 
Comments  None  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  At 8,000 mg/kg/day aspartame, the diet contained approximately 21% 
crude protein and 56% carbohydrate 
•  These intakes were considered sufficient to meet the maintenance and 
growth requirements of the rats. 
Growth 
Growth rates for groups dosed at 1,000 mg/kg/day, 2,000 mg/kg/day and 4,000 
mg/kg/day were comparable with those of controls. 
•  At 8,000 mg/kg/day, growth rates of treated males and females were 
significantly lower than in controls to varying extents throughout the Year One. 
•  Body weights during Year Two are not discussed in the report. 
Laboratory tests 





Total WBC count  
Differential WBC count  
Serum clinical chemistry: 
Fasting blood sugar 
BUN 














•  On pooled samples from 5M/5F 
per group, monthly 
 
N.B. The same rats were not necessarily used for both haematology and clinical 
chemistry. Pooled urine samples were analysed. 
Haematology data indicated no compound related effects.  
•  All values were within normal limits. 
Clinical chemistry data indicated no consistent, statistically significant alterations. 
•  Random fluctuations reaching statistical significance were sporadically 
observed, but the values generally remained within normal limits. 
Results of urine analysis were generally unremarkable throughout the study. 
Ocular examinations 
There was no indication of a compound-related effect in ocular examinations. 
Gross changes observed included 
•  Ocular discharge which was occasionally bloody in appearance 
•  Reddened eyelids 
•  Lacrimation 
•  Squinting, protruding and pale eyes 
Other 
Respiratory signs noted at a low to moderate incidence in all groups during the first 
year of the study and with increasing incidence during the second year: 
•  Wheezing 
•  Rapid or laboured breathing 
•  Nasal discharge, sometimes bloody in appearance. 
•  Reddened eyelids 
•  Hunched posture 
Typical signs of aging observed during the second year of the study: 
•  Roughening and staining of the fur 
•  Sores on the tail, legs, paws and body (particularly in males) 
•  Alopecia on the legs and body (particularly in females) 
Palpable nodules, tissue masses and wart-like skin lesions were seen in up to 20% 
of male rats and up to 62.5% of females.  
•  These could be single or multiple in individual rats and often regressed 
spontaneously; sometimes similar lesions appeared elsewhere in same rat. 
Comments  None CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Outcomes: 
Terminal body weights 
The following statistically significant changes in terminal organ weights were noted; 
none of these are likely to have significant biological consequences: 
 
  Dose (mg/kg/day) 
  1,000   2,000  4,000  8,000 
Terminal BW        ﬂ (M) 
Thyroid weight      ﬂ (F)  ﬂ (M/F) 
Heart weight        ﬂ (M) 
Liver/BW ratio  ﬂ (M)       
Kidney/BW ratio    › (M)  › (M)  › (M) 
Adrenal weight        ﬂ (F) 
Testes/BW ratio      › (M)   
Uterus/BW ratio    › (F)  › (F)   
 
 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Gross necropsy findings comprised incidental findings commonly found in laboratory 
animals of this age and sex.  
•  There were no consistent gross alterations in any organs or tissues that 
could be attributed to treatment with aspartame. 
No effects were observed in brain, pituitary, spinal cord, peripheral nerve, thyroid, 
adrenal, salivary gland, skin, skeletal muscle, heart, liver, lymph node, bone 
marrow, stomach, small intestine, large intestine, uterus, vagina, mammary gland, 
testis and urinary bladder. 
The following lesions were identified but not believed to be treatment related: 
•  Nodular adrenal hyperplasia (present in all animals). 
•  Adrenal angiectasis in the majority of females 
•  Focal myocardial fibrosis in most animals 
•  Components of chronic murine pneumonia complex  in most animals 
•  Minimal/mild bile duct proliferation and pericholangitis 
•  Chronic interstitial nephritis with related epithelial and tubular changes 
•  Focal pancreatic fibrosis and mild atrophy 
•  Focal accumulation of brown, non-birefringent pigment in gastric mucosal 
epithelium, occasionally associated with areas suggestive of early focal 
necrosis (mainly found in animals found dead or sacrificed in extremis) 
•  Occasional inflammatory lesions of the bladder (1-3 animals per group) 
•  Splenic extramedullary haematopoiesis in all groups. 
•  Minimal/slight endometriosis and fibrosis of uterine wall. 
•  Ovarian cystic follicles increased in treated animals. 
•  Slight/moderate seminal vesicle atrophy, mildly increased at high doses. 
•  Acute and chronic prostatitis, seen more often in treated animals. 
•  Focal pancreatic fibrosis, mild atrophy and nodular hyperplasia of the 
pancreas, primarily at 8 g/kg/day. 
•  Mild dacroadenitis and pulmonary pneumocyte hyperplasia in surviving CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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females at 8,000 mg/kg/day. 
A brown, non-birefringent renal pigment deposit was present in the cortical tubular 
and pelvic epithelium of male survivors and non-survivors at all treatment levels.  
•  This was observed in: 
o  7/59 controls 
o  1/28 at 1,000 mg/kg/day 
o  10/30 at 2,000 mg/kg/day 
o  19/40 at 4,000 mg/kg/day 
o  29/40 at 8,000 mg/kg/day 
•  The pigment was identified as iron-containing haemosiderin by use of 
Gomori’s iron stain. 
•  At 8,000 mg/kg/day, pigment deposition was associated with: 
o  focal hyperplasia (11/40 vs. 5/59 controls) 
o  tubular degeneration (16/40 vs. 0/59 controls) 
•  Neither renal function nor longevity was adversely affected. 
Neoplastic lesions 
All tissue masses observed at necropsy were examined and described 
microscopically and a diagnosis made. 
•  In most cases a single section of each tumour was examined. 
Tumour incidence was analysed statistically employing a life-table technique. 
•  Tumour types considered: 
o  Any tumour 
o  Mammary tumour 
o  Mammary carcinoma 
o  Only benign tumours 
o  Any malignant tumours 
•  In no instance in either sex at any of the test levels was the probability of 
tumour formation of any of the types of tumour analysed significantly higher 
than that of the respective controls.  
•  No significant change in probability was seen in females. 
•  Two significant reductions in probability were observed in males: 
o  For any tumour at 2,000 mg/kg/day 
o  For any malignant tumour at 8,000 mg/kg/day 
Specifically, no compound-related bladder lesions were observed. 
Other 
Frozen serum samples from 5M/5F control and 8,000 mg/kg/day rats were sent to 
the sponsor for determination of L-phe. 
•  Serum [L-Phe] was reduced in males at 4,000 mg/kg/day and 8,000 
mg/kg/day 
Comments  None 
Conclusions: 
Authors’ conclusions 
“Thus, SC-18862 administered to rats for two years lacks an adverse effect on the incidence of neoplasms at all 
ingestion levels in both sexes, lacks an adverse effect on the survival rate at ingestion levels of 4 g/kg/day or less, 
and produces no convincing evidence of treatment-related, non-neoplastic changes in any organ or tissue 
examined, except possibly the renal changes in higher treatment levels of male survivors as listed above”. 
Reviewer’s comments 
This study does not indicate any overt toxicity or carcinogenic effect due to aspartame when administered to rats 
via the diet at doses up to 4,000 mg/kg/day for two years. Reduced survival was observed in females at 8,000 
mg/kg/day.  
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  Not conducted CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
Commentary: 
General comments 
The animals suffered from an outbreak of sialodachryoadenitis in the first year and chronic murine pneumonia in 
the second year. This was probably a fairly common occurrence in studies conducted at this time but would be 
considered evidence of poor husbandry nowadays. Neither infection appeared to have impacted on the overall 
study conclusions.  
The only non-neoplastic effect which appeared to be treatment related was deposition of haemosiderin in the 
renal pelvis. This was, in some cases, associated with epithelial hyperplasia and tubular degeneration, but no 
functional consequences were observed. For further information, see section 2. 
Typically CD rats have high incidences of pituitary and mammary tumours and before the introduction of dietary 
improvements high incidences of chronic progressive nephropathy.  
There were noticeably lower incidences of animals bearing mammary or pituitary tumours in the highest dosage 
group.  This was probably a consequence of the significant reduction in food consumption and body weight gain 
seen in treated animals. Given today’s knowledge of the tumour lowering effects of reduced body weight and food 
consumption the question arises as to whether or not the degree of change in the latter two parameters would 
have affected other tumour profiles and if it would have been prudent to have extended the examination to all 
tissues in the lower dosage groups.  
Interpretation of this study would have been facilitated by the provision of a summary table combining tumour 
incidences in decedents and animals included in the terminal sacrifice. 
Strengths and limitations of study 
Strengths 
•  The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was 
conducted but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, 
Harderian glands, parathyroid glands, skin, thymus and trachea. 
•  Evaluation of brain and urinary bladder was comprehensive even by today’s standards. 
•  Brain sections evaluated independently by two general pathologists  and a comparative 
neuropathologist. 
Limitations 
•  No justification for dose escalation in highest dose group 
QA comments 
GLP check 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No Study Director (although report author) 
•  No location of archiving data 
•  No rationale for 2x dose increases 
•  The rationale for the limited results and some results excluded from statistical analysis is not clear  
(compare food consumption with biochemistry for example)  
•  Possible lack of a description of all circumstances that may have affected the quality or integrity of the 
data: 
o  Impact of diseases that affected the mortality rate during year 2 on study objectives/outcome 
hasn’t been discussed 
o  Could not find results of the monthly fasting phenylketone results, nor mention of how fasting 
affected bodyweight data. 
Not possible to confirm protocol objectives and any changes, as protocol not provided CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  Laboratory investigations only performed on 5 rats per group 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). The review team found it difficult to follow the history of the study because of a lack of 
tracked protocol amendments and because the study seemed to have evolved over time. The documentation of 
this process is described as “vague” (Unattributed, 1978b). However, transcriptional errors between the raw data 
and study report were noted to be rare and the correlation between clinical observations, gross necropsy and 
microscopic observations was assessed as “quite satisfactory”. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Adequate size: 40 per sex per group 
•  Control groups: 60 per sex to enhance statistical power 
Four doses levels plus control 
•  Allows some characterisation of dose response 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used; DKP content of each batch specified. 
Calculated compound intake within 10% of that planned. 
•  No justification for dose escalation in highest dose group 
Two outbreaks of infection during the study; neither appears to have impacted on the 
overall study conclusions.  
Possible issues with procedure for dealing with decedents did not preclude 
histopathological evaluation. 
No issues with pathology conduct or interpretation 
Relevance of the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of data sets 
Intercurrent clinical chemistry analysis undertaken, but only on 5 rats per group 
Some results excluded from analysis without providing a justification 
Good tissue accountability 
Range of tissues sampled was state of the art for the date the study was conducted, 
although modern guidelines recommend the inclusion of additional tissues. 
Evaluation of brain and urinary bladder was comprehensive even by today’s 
standards. 
Some data missing from report 
Data sources  Commercial study report, pre-GLP (1973) 
Comments 
•  This study (original study and follow up investigation) was included in the UAREP authentication review 
in 1978. They found the history of the study difficult to follow, but raised no significant issues with the 
data recording and interpretation. 
•  Brain sections from this study and study E70 were evaluated independently by two general pathologists  
and a comparative neuropathologist . The conclusion from this follow-up investigation was that there was 
no evidence of an intracranial tumorigenic effect due to aspartame although brain tumour development 
did seem to be related to treatment in one of the two studies. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Document identification: 
Title  SC-18862: Two-year Toxicity Study in the Rat. Final Report 
(P-T No. 838H71) 
Authors  Reno, F.E., Ferrell, J.F., Busey, W.M.  Date  1973 
Study Type  Chronic Toxicity  Dossier #  E33-4 
Purpose of study: 
“…to evaluate and characterize the effects of long term ingestion of SC-18862 in albino rats”. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains used in long-term bioassays for which historical control data is readily 
available. Typically CD rats have high incidences of pituitary and mammary tumours and before the introduction of 
dietary improvements high incidences of chronic progressive nephropathy.  
Please comment on the choice, age and health status of the animals used. 
The animals suffered from an outbreak of sialodachryoadenitis in the first year and chronic murine pneumonia in 
the second year. This was probably a fairly common occurrence in studies conducted at this time but would be 
considered evidence of poor husbandry nowadays. Neither infection appeared to have impacted on the overall 
study conclusions.  
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes   
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
Animals were examined for mortality once per day. 
Procedures for dealing with animals found dead are not detailed in the report e.g. time to necropsy; whether 
refrigerated or whole body opened and placed in fixative. However, although autolysis (no severity grade given) 
was noted in many of the decedents’ tissues none were classed as sufficiently autolytic to preclude meaningful 
histopath. 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No significant differences in incidence between controls and treated were noted and there were no unusual 
findings. However, assessment was made difficult by the absence of a summary table which combined the 
incidences in decedents and terminal sacrifice animals. 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
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Please add comments on tissue sampling and preservation 
The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was conducted 
but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, Harderian glands, 
parathyroid glands, skin, thymus and trachea. 
Full protocol list of tissues was confined to the control and highest dosage groups except for brain and urinary 
bladder which were examined in all animals.  
Tissue accountability was good in this study 
It was noted that the brain and urinary bladder were subjected to a very comprehensive examination even by 
today’s standards. 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Without seeing the slides it is impossible to comment on the quality of the sectioning, tissue placement, staining 
etc. were consistent across the groups. 
Pathology findings: 
Please give your expert opinion on the findings reported 
Examination of the summary revealed a range of findings that one would expect to be present in this strain of rat. 
No synonyms were noted in any of the tissues. 
As might be expected some of the tumour nomenclature was outdated e.g. ‘Reticulum cell sarcoma’, 
‘lymphosarcoma’ and ‘hyperplastic nodule’. 
Assessment of non-neoplastic findings was made difficult by the absence of a summary table that combined the 
incidences in decedent and terminal sacrifice animals. 
There were noticeably lower incidences of animals bearing mammary or pituitary tumours in the highest dosage 
group.  This was probably a consequence of the significant reduction in food consumption and body weight gain 
seen in treated animals. Given today’s knowledge of the tumour lowering effects of reduced body weight and food 
consumption the question arises as to whether or not the degree of change in the latter two parameters would 
have affected other tumour profiles and if it would have been prudent to have extended the examination to all 
tissues in the lower dosage groups.  
I agreed with the study pathologist’s overall conclusions and considering the date when it was conducted I have 
no significant criticisms of its conduct. 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Document identification: 
Title  SC-18862 (Aspartame): A Supplemental Study of Rat Brains from Two Tumorigenicity 
Studies (P-T Nos. 838H71 and 892H72) Project No. 1227 
Authors  Reno, F.E., Ferrell, J.F., Innes, J. R. M.  Date  1973 
Study Type  Follow up – further histopathological evaluation  Dossier #  E87 
Follow up from: 
Title  SC-18862: Two-year Toxicity Study in the Rat. Final Report. (P-T No. 838H71) 
Authors  Reno, F.E., Ferrell, J.F., Busey, W.M.  Date  1973 
Study Type  Chronic toxicity  Searle Dossier #  E33-4 
Purpose of study: 
Reason for follow up 
Suggestion that “a more comprehensive microscopic surveillance of brain tissue (all 
major neuroanatomical areas) from all treated and control rats on the study would 
provide more reliable data on the actual incidence of [brain] tumors” 
Aim of follow up study  To examine brains from study 838H71 (E-33-4) in more detail and to compare the 
findings in brains from that study to those in study 892H72 (E70). 
Additional procedures performed: 
Animals sampled:  440 rats from 838H71 
280 rats from 892H72  Tissues analysed:  Brain 
Procedure: 
Microscopic examination of eight carefully selected coronal (whole brain) tissue 
specimens per rat. 
Brain sections were evaluated independently by two general pathologists  (Drs. 
Mauro and Dugan; Microscopy for Biological Research, Ltd.) and a comparative 
neuropathologist  (Dr. J.R.M. Innes; Flow Laboratories, Rockville, Md.).  The 
outcome of this investigation was as follows: 
•  In the first study (E33-4), 12 neoplasms affecting the brain were identified. All 
were in aspartame-treated rats; incidence seemed to be treatment-related but 
not dose- or sex-related. The overall incidence of brain tumours in this study 
(across all groups) was 2.7%. 
•  No additional brain tumours were identified in brains from the second study 
(E70) but the nine tumours identified in the original study report were 
confirmed. The incidence of tumours in this study appeared to be random. The 
overall incidence of brain tumours in this study (across all groups) was 3.2%. 
The conclusion from this follow-up investigation was that there was no evidence of an 
intracranial tumorigenic effect due to aspartame although brain tumour development did 
seem to be related to treatment in one of the two studies. 
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Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes1   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
Please add comments on tissue sampling and preservation 
No comments 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Again an exhaustive examination employing one of the leading neuropathologists of the time 
Pathology findings: 
Please give your expert opinion on the findings reported 
I agree with the overall conclusion. It illustrates the difficulty in ascribing treatment-relationship to low incidence 
tumours that have not been seen in controls. Lucky they had two studies to examine. 
General comments: 
Please add any other comments on this study 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). Various unequivocal neurological neoplasias were identified (Unattributed, 1978c): these 
were principally primary gliomas. Astrocytomas, which were generally well differentiated but infiltrative and 
sometimes massive, predominated. Oligodendrogliomal and ependymal lesions were also identified, and 
contiguous pituitary tumours were noted in some cases. There was no significant difference in the incidence of 
any of these tumours in relation to sex, treatment or dose. 
Reviewer Details: 
Name: Peter Millar  Date: April 2012 
Reviewer Details: 
Name: Lesley Stanley  Date: 24-Apr-12 
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Study Identifier  02 1973 (E33-4)   
Study Title  SC-18862: Two-Year Toxicity Study in the Rat  
  Y  N  Comment 
Name and address of the facility performing the study and the dates 
on which the study was initiated and completed.  √     
Objectives and procedures stated in the approved protocol, including 
any changes in the original protocol.    √  protocol not provided 
Statistical methods employed for analyzing the data.  √    (1) 
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  purity  not reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √ 
No reported ID 
method, however 
animals were housed 
individually 
A description of the dosage, dosage regimen, route of administration, 
and duration.  √   
No reported analyses 
of feed 
(4) 
A description of all circumstances that may have affected the quality 
or integrity of the data.    √  (2) (3) 
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    Project manager. 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√  √  (3) 
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report are 
to be stored.  √  √  Not for data 
The statement prepared and signed by the quality assurance unit as 
described in 58.35(b)(7): to be included with the final study report 
which shall specify the dates inspections were made and findings 
reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.  √    Project manager 
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or corrected 
and the reasons for the correction or addition, and shall be signed 
and dated by the person responsible. 
  √  Presume N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) The rationale for the limited results and some results excluded from statistical analysis is not 
clear  (compare food consumption with biochemistry for example)  
(2) Impact of diseases that affected the mortality rate during year 2 on study objectives/outcome 
hasn’t been discussed 
(3) Could not find results of the monthly fasting phenylketone results, nor mention of how fasting 
affected bodyweight data. 
(4) No rationale for 2x dose increase 
Report GLP content check by/date: J Birnie 11-19 April 2012 
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Document identification: 
Title  SC-18862: Lifetime Toxicity Study in the Rat 
(P-T No. 892H72) Final Report 
Authors  Trutter, J.A., Reno, F.E., 
Ferrell, J.F., Busey, W.M.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E70 
Purpose of study: 
“…to evaluate and characterize the effects of SC-18862 in the albino rat exposed to the compound or its 
constituent moieties transplacentally throughout gestation, and via maternal milk and the dry diet mixture during 
lactation. Treatment was then continued for the ensuing 104 weeks post-weaning”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  0.4 - 1.5% DKP* 
Lot # (s) 
75100B (1.2% DKP), 5-280D (0.6%), 75110 (1.0%), 75160C (1.3%), 75150A (1.2%), 
76020A (0.8%), 76020B (0.8%), 56070 (0.5%), 76080A (0.4%), 56040A (1.5%), 
75170B (1.2%), 76050A (1.2%), 56047B (0.9%), 76040C (1.0%), 56057C (1.0%), 
56057D (1.0%), 56627-1 (0.8%) 
*intake of DKP was about 20 and 40 mg/kg/day for low and high dose groups, respectively. 
Animals: 
Species:  Rat  Strain:  Derived from Charles 
River CD albino line 
Source:  F1A weanling rats from 
two generation study  Age/weight: 
Weanlings 
Males: 40-140 g 
Females: 29-128 g 
Comments:  
See comments on two generation study (E11); other offspring from that study also 
used for neonatal toxicity study (E9). 
The widest weight range at the start of the study was among controls; weights listed 
above are for the control groups; the other two groups fell within these ranges. 
Formulation: 
Route of administration  Via diet  Concentration   
Formulation procedure  Aspartame was incorporated into the basal diet on a w/w basis and thoroughly mixed 
in a twin-shell Patterson Kelley blender. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry  Rats were housed individually in elevated wire mesh cages. 
Food and water were available ad libitum. 
Diet  Purina Laboratory Chow (nitrate levels 38-56 ppm; nitrite levels from 2.0-3.3 ppm) 
Minimisation of bias 
120 control, 80 low dose and 80 high dose F1A weanlings equally divided by sex 
were picked at random from the total population available, which was as follows: 
  P1 generation dietary level (mg/kg/day) 
  0  2,000  4,000 
F1A weanlings available  163  198  156 
F1A litter distribution  21  22  23 
The remaining F1A weanlings were used as the P2 generation of the two-generation 
reproduction study (E9) CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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In life procedures: 
General observations 
Daily for survival. General 
observations made at 
time of weighing. 
Clinical chemistry   Mixed arteriovenous blood 
samples (2 ml) taken by 
segmental amputation of tail 
from 5 rats per sex per group 
in weeks 6, 13, 26, 52,104.  Food consumption 
Weekly in weeks 0-26; 
fortnightly in weeks 27-
52; every four weeks for 
remainder of study 
Haematology 
Body weight 
Weekly in weeks 0-26; 
fortnightly in weeks 27-
52; every four weeks for 
remainder of study 
Urinalysis 
Collected overnight from 5 
rats per sex per group in 
metabolism cages in weeks 
6, 13, 26, 52, 104; samples 
pooled by group and sex. 
Ocular examinations  At 2 weeks of age and in 
weeks 52 and 104  Other 
Incidence, time of 
appearance, location, size 
and change in character of 
palpable tissue masses were 
recorded. 
Comments  None 
Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  Terminal body weight 
Tissues sampled 
Necropsy performed under supervision of staff pathologist; representative tissues 
preserved unless precluded by autolysis. 
•  Presumably the same as those taken in planned necropsies, but this is not 
stated. 
Tissues examined: 
•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
Comments  It is not clear to what extent autolysis was a problem in the analysis of decedents. 
 
Blocking of groups  None specified 
Number per group 
60M/60F controls from 
concurrent F1A litters 
40M/40F per test group 
Acclimatisation  Study started at weaning 
Start of dosing 
P1 generation treated for 
60 days before mating 
and during gestation and 
lactation; offspring treated 
from weaning. 
Duration  104 weeks 
Planned doses  2,000 mg/kg/day 
4,000 mg/kg/day  Actual intakes  Low dose: 1,990 mg/kg/day 
High dose: 3,980 mg/kg/day 
Basis for dose selection  None given 
Dose correction 
Doses corrected at time of weighing 
•  Weekly in weeks 0-26; fortnightly in weeks 27-52; every four weeks for 
remainder of study 
Comments 
Parental gametes provided by treated animals; weanlings used had been exposed 
transplacentally and during suckling. After weaning, feeding with aspartame 
continued throughout lifespan (104 weeks). 
No justification is provided for the doses selected. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Termination procedures: 
Termination method  Sodium pentobarbital anaesthesia and exsanguination 




•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
Necropsy procedure 
Necropsy performed under supervision of staff pathologist 
Terminal blood samples (10 ml) taken by arterial puncture of abdominal aorta. 
•  Clinical chemistry analyses conducted on serum from terminal blood 
samples (5 rats per sex per group): 
Fasting blood sugar 
BUN 














•  Frozen serum samples from 5M/5F control and 8,000 mg/kg/day rats were 
sent to the sponsor for determination of insulin 
•  Urinary homogentisic acid determined at termination in individual samples 
from 5 rats per sex per group.  
Tissues sampled 
Tissues sampled at necropsy: 
Brain 
Pituitary 














Lymph node, mesenteric 
Urinary bladder 






Bone (rib junction) 
Bone marrow (femur) 
Peripheral nerve (brachial plexus) 
Skin 
Mammary gland 
Usual and unusual lesions 
Bone marrow smears 
*weighed fresh 
**weighed after fixation 
Histopathological examination was performed on all unusual or usual gross lesions 
from all animals at each treatment level, plus microscopic examination of 20-25 
grossly unremarkable organs from all control and treated animals. 
Tissue samples examined histopathologically are listed in Text Figure A (attached). 
In particular, the following were examined microscopically: 
•  One section from left lobe; entire liver preserved 
•  One longitudinal hemisection from one kidney; each kidney hemisected 
•  A single longitudinal section through one lobe of the thyroid 
•  A single longitudinal or frontal block through the mid-ventricles and atria of 
the heart 
•  Single longitudinal sections of the adrenal, eye, ovary and testis 
•  Two longitudinal sections of each hemisphere of the bladder were cut at 
approximately 50 mM intervals. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  Eight coronal sections representing major neuroanatomical areas of brain. 
Frozen liver samples from five rats per sex per group were analysed for 
phenylalanine activity. 
Bone marrow smears obtained from each animal killed by design were retained for 
possible future reference. 
All preserved/embedded tissues and stained tissue sections were retained at 
Hazleton Laboratories. 
Fixation  10% NBF  Storage conditions  Not specified 
Comments  Laboratory investigations were only performed on a subset of rats. 
Statistical procedures: 
Data manipulation  Not described 
Statistical tests used 
Life-table technique for survival 
t-test for clinical laboratory data 
Analysis of variance, or F-test at 5% probability level for remaining criteria 
Preliminary tests (where applicable) by methods of Bartlett, Rao, Scheffe, Sachs 
and Fisher-Behrens (modified t-test) 
Life-table technique for probability of tumour formation 
Results of in life observations: 
General observations 
There was no evidence of effects on the physical appearance or behaviour of rats. 
Survival assessed by the life-table technique revealed that survival after 104 weeks 
was comparable to controls for both treated groups. 
•  Mortality in all groups was low during the first 18 months of the study 
•  Mortality increased during the last six months of the study, mainly due to 
spontaneous disease 
Food consumption 
Food consumption at 2,000 mg/kg/day in both sexes and in females at 4,000 
mg/kg/day were comparable with those of controls. 
•  Food consumption in males at 4,000 mg/kg/day was significantly reduced 
Growth 
Growth rates at 2,000 mg/kg/day in both sexes and in females at 4,000 mg/kg/day 
were comparable with those of controls. 
•  Growth rates in males at 4,000 mg/kg/day were significantly reduced 
Laboratory tests 





Total WBC count  
Differential WBC count  
Serum clinical chemistry: 
Fasting blood sugar 
BUN 














•  On pooled samples from 5M/5F 
per group, monthly 
 
N.B. The same rats were not necessarily used for both haematology and clinical 
chemistry. Pooled urine samples were analysed except at termination, when 
individual samples were used. 
Haematology data indicated no compound related effects. 
•  Occasional statistically significant differences were observed but the values 
measured were within normal limits. 
Clinical chemistry data indicated no consistent, statistically significant alterations. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  Random fluctuations reaching statistical significance were sporadically 
observed, but the values generally remained within normal limits. 
Results of urine analysis were generally unremarkable throughout the study. 
•  No urinary phenylketones or homogentisic acid were detected. 
Ocular examinations 
There was no indication of a compound-related effect in ocular examinations. 
Gross changes observed included 
•  Ocular discharge which was occasionally bloody in appearance 
•  Reddened eyelids 
•  Lacrimation 
•  Squinting, protruding, cloudy or pale eyes 
Other 
The incidences of common signs, including infectious disease and signs of aging, 
were comparable between control and treated animals. They occurred with 
gradually increasing frequency as the age of the animals increased and included: 
•  Hunched appearance 
•  Desquamation of the tail 
•  Sores on the tail and other parts of the body 
•  Localised alopecia on the extremities and body 
•  Stained fur 
•  Soft faeces 
•  Wheezing and laboured respiration, particularly in males 
Palpable nodules, tissue masses and wart-like skin lesions were seen in up to 18% 
of male rats and up to 48% of females.  
•  These could be single or multiple in individual rats and often regressed 
spontaneously; sometimes similar lesions appeared elsewhere in same rat. 
•  They were seen at the highest frequency in control rats 
Comments  None 
Outcomes: 
Terminal body weights 
The following statistically significant changes in terminal organ weights were noted: 
  Dose (mg/kg/day) 
  2,000  4,000 
Thyroid weight  › (F)   
Thyroid/BW ratio  › (F)   
Heart weight  ﬂ (M)  ﬂ (M) 
Heart/BW ratio  ﬂ (M)  ﬂ (M) 
Liver weight  › (F)  › (F) 
Prostate/BW ratio    › (M) 
There were no associated histopathological findings to indicate that these changes 
were compound related; they were considered to be of little biological significance. 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  See results summarised throughout this proforma. 
F2 generation  N/A 
Non-neoplastic lesions 
There were no compound-related changes in any organs or tissues.  
•  Gross necropsy findings comprised incidental findings common in rats of 
this age and strain. 
Palpable nodules, tissue masses and wart-like skin lesions were seen in some rats.  
•  These often regressed spontaneously; sometimes similar lesions appeared CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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elsewhere in same rat. 
There were no histopathological findings in brain, spinal cord, eye, salivary gland, 
thyroid, lung, small intestine, large intestine, lymph node, peripheral nerve, skin, 
testis, prostate, seminal vesicle, vagina, bone, bone marrow, mammary gland. 
Hepatic hyperplastic nodules were observed as follows: 
  Incidence of hepatic hyperplastic nodules 
  Non-survivors  Survivors  
  Males  Females  Males  Females 
0 (control)  2/25  0/28  5/22  2/29 
2,000 mg/kg/day  1/20  3/23  2/20  7/16 
4,000 mg/kg/day  1/18  1/20  4/22  6/20 
•  This finding was not considered compound related because the incidence 
in untreated females was unusually low (historical incidence 24%). 
•  Other hepatic lesions were observed in both control and treated groups: 
o  Bile duct proliferation 
o  Non-suppurative pericholangitis 
o  Periportal fibrosis (seen more frequently in controls than treated 
females) 
Renal changes were also observed. These tended to be more severe in males than 
females and included: 
•  Dilatation of renal tubules 
•  Intratubular pigmentation and protein deposition 
•  Non-suppurative interstitial nephritis associated with glomerulosclerosis 
and epithelial regeneration 
•  Cortical pigmentation 
•  Focal mineralisation 
o  The incidence of the latter two findings was increased in treated 
animals compared with controls but these differences were not 
considered to be meaningful. 
  Cortical pigmentation  Focal mineralisation 
  Survivors  Non-survivors  Survivors 
  Males  Females  Females  Females 
0 (control)  3/21  6/29  4/29  1/28 
2,000 mg/kg/day  6/20  7/16  4/16  4/23 
4,000 mg/kg/day  5/22  9/19  9/19  7/20 
Other non-neoplastic lesions detected in both control and treated rats included: 
•  Changes attributable to chronic murine pneumonia 
•  Pigment deposition and extramedullary hematopoiesis in the spleen 
•  Focal gastritis, mucosal ulceration and pigmentation 
•  Focal pancreatic acinar atrophy 
•  Follicular/paraovarian cysts 
•  Ovarian atrophy 
•  Endometritis, dilatation of uterine glands 
•  Occasional minor histological changes in the bladder, including the 
presence of urinary calculi 
•  Pituitary chromophobe hyperplasia and cysts involving pars distalis 
•  Nodular hyperplasia of the adrenal cortex and adrenal angiectasis 
•  Focal myocarditis, fibrosis and mineralisation 
Lesions identified with low incidence and not believed to be treatment-related were: 
•  Pancreatic focal acinar atrophy (M) 
•  Ovarian atrophy (F) 
•  Submucosal mononuclear infiltration involving urinary bladder (M) CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Neoplastic lesions 
All tissue masses observed at necropsy were examined and described 
microscopically and a diagnosis rendered. 
•  In most cases, a single section of each tumour was examined. 
Tumour incidence was analysed statistically by sex employing an actuarial (life-
table) technique. 
•  Tumour types considered: 
o  Any tumour 
o  Mammary tumour 
o  Mammary carcinoma 
o  Only benign tumours 
o  Any malignant tumour 
•  In no instance in either sex at any of the test levels was the probability of 
tumour formation of any of the types of tumour analysed significantly higher 
than that of the respective controls.  
•  The probability of benign tumour formation in males at 4,000 mg/kg/day 
was significantly lower than that in control males. 
•  Nine brain neoplasms were identified, a total incidence of 9/272 (3.3%). 
o  These comprised: 
§  Four astrocytomas in controls (3M/1F) 
§  Two astrocytomas at 2,000 mg/kg/day (1M/1F) 
§  One ependymoma at 2,000 mg/kg/day (M) 
§  One astrocytoma at 4,000 mg/kg/day (M) 
§  One meningioma at 4,000 mg/kg/day (F) 
o  Their incidence was random with respect to treatment, dose and sex. 
Other 
Hepatic phenylalanine hydroxylase activity was determined from five rats per sex 
and group at termination. 
  Hepatic phenylalanine hydroxylase activity 
(mM Tyrosine/g/30 min 
0 (control)  1.36 ± 0.39  1.24 ± 0.54 
2,000 mg/kg/day  3.21 ± 0.42 
(p ≤ 0.05)  1.21 ± 0.46 
4,000 mg/kg/day  3.13 ± 1.35 
(p ≤ 0.05) 
2.52 ± 0.92 




There is evidence of non-neoplastic hepatic and renal changes in this study but 
these are dismissed as being non-meaningful. 
The toxicological significance of the increased hepatic phenylalanine hydroxylase 
activity observed in treated animals, if any, is unclear. 
Great effort was devoted to the search for brain tumours in this study, although no 
significant increase in incidence was found. This makes the section on tumour 
incidence appear somewhat unbalanced. 
Conclusions: 
Authors’ conclusions 
“Thus, rats exposed to 2 or 4 grams/kg/day of SC-18862 and/or its metabolic products throughout the full prenatal 
period by placental transfer, throughout the nursing period via maternal milk and/or dry diet, and post-weaning for 
104 weeks by direct dietary administration, exhibited no adverse effects regarding survival rate or incidence of 
neoplasms, nor did they exhibit convincing evidence of treatment-related, non-neoplastic changes in any organ or 
tissue of either sex.” 
Reviewer’s comments 
This study does not indicate any chronic toxicity or carcinogenic effect due to aspartame when administered to 
rats via the diet at doses of 2,000 or 4,000 mg/kg/day. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  Yes  
Justification for Internal Quality Review:  This study used offspring from the two-generation reproduction 
study which was also subjected to additional QA review 
QA comments 
GLP Check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of  the test item(s) including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in 
the diet mix, and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No location of archiving data 
•  No Study Director (although report author) 
•  No reported method of identification.  
Not possible to confirm protocol objectives and any changes, as protocol not provided 
OECD Guideline check: 
Test item: similar to above. The guideline also calls for a CoA for the test item which was not present. No mention 
of quality of water, bedding (e.g. content/contaminant analyses). Some individual data not reported. No BMD, 
NOAL or LOAEL determination.  
Per the report the animals are F1A weanlings from parents which continued to receive test material during mating 
and throughout gestation and nursing. From the 2-generation study report: Project 700-239 there’s no information 
to show that test diet was administered beyond the end of mating. 
Supplementary Check: 
A small sample of items were cross-checked for internal consistency: 
•  No mention of the organs with a high incidence of autolysis in decedents (e.g. kidney)  
•  The relevance of parameters other than tumours isn’t discussed – e.g. significant compound-related 
increase in liver phenylalanine hydroxylase activity  
•  Text table with incidence of intracranial neoplasms (p53) doesn’t include a Group 1 female 
metastatic adenocarcinoma (this is listed in Table 9 and in Figure 6); it hasn’t been attributed to 
another organ – “primary site not identified”. 
•  The level of significance of bodyweight differences is not reported 
•  No mention of how food was deprived for fasting parameters 
Commentary: 
General comments 
This study made used of F1A offspring from the two-generation reproduction study (E11). 
The increased renal mineralisation observed in treated animals does not represent a toxicological effect. 
Interpretation of this study would have been facilitated by the provision of a summary table combining tumour 
incidences in decedents and animals included in the terminal sacrifice. 
Strengths and limitations of study 
Strengths 
•  This study provides follow up information on offspring from the two generation reproduction study (E11) 
•  The report provides a detailed description of the tissue sampling methods used for histopathology. 
•  The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was 
conducted but modern recommendations would require a few additional tissues. 
•  Evaluation of brain and urinary bladder was comprehensive even by today’s standards. 
•  Brain sections were evaluated independently by two general pathologists  and a comparative 
neuropathologist. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Limitations 
•  No evidence to confirm that compound was administered throughout gestation and lactation. 
•  Laboratory investigations only performed on 5 rats per group. 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). The panel agreed that the histology findings in this study revealed no aspartame-related 
lesions (Unattributed, 1978c). Some discrepancies were noted, but the agreement between the raw data and the 
study report was generally good. Overall, there was no evidence of toxicologically significant changes. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Adequate size: 40 per sex per group 
•  Control groups: 60 per sex to enhance statistical power 
Two dose levels plus control 
•  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Large number of different batches used; DKP content of each batch specified. 
No evidence to confirm that compound was administered throughout parental 
gestation/lactation; calculated compound intake by offspring close to that planned. 
Good tissue accountability 
Detailed description of sampling method for histopathology. 
Range of tissues sampled was state of the art for the date the study was conducted, 
although modern guidelines recommend the inclusion of additional tissues. 
Evaluation of brain and urinary bladder was comprehensive even by today’s 
standards. 
No issues with pathology conduct or interpretation 
Relevance of the study  Lifetime bioassay in a standard laboratory rodent species; acts as a follow up to two-
generation reproductive toxicity study (E11) 
Adequacy of data sets 
Intercurrent clinical chemistry analysis undertaken, but only on 5 rats per group 
Range of tissues sampled was state of the art for the date the study was conducted, 
although modern guidelines recommend the inclusion of additional tissues. 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
•  This study provides information regarding the effects of aspartame when administered in utero as well as 
throughout postnatal life. 
•  This study was included in the UAREP authentication review in 1978. No major issues were raised. 
•  Brain sections from this study and study E33-4 were evaluated independently by two general 
pathologists  and a comparative neuropathologist . The conclusion from this follow-up investigation was 
that there was no evidence of an intracranial tumorigenic effect due to aspartame although brain tumour 
development did seem to be related to treatment in one of the two studies. 
•  This study would not be considered fully compliant with the current OECD Guideline for carcinogenicity 
testing (Number 451), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Document identification: 
Title  SC-18862: Lifetime Toxicity Study in the Rat 
(P-T No. 892H72) Final Report 
Authors  Trutter, J.A., Reno, F.E., 
Ferrell, J.F., Busey, W.M.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E70 
Purpose of study: 
“…to evaluate and characterize the effects of SC-18862 in the albino rat exposed to the compound or its 
constituent moieties transplacentally throughout gestation, and via maternal milk and the dry diet mixture during 
lactation. Treatment was then continued for the ensuing 104 weeks post weaning”. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains used in long-term bioassays for which historical control data is readily 
available. Typically CD rats have high incidences of pituitary and mammary tumours and before the introduction of 
dietary improvements high incidences of chronic progressive nephropathy. 
Please comment on the choice, age and health status of the animals used. 
The animals appear to have kept good health throughout 
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes   
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
Animals examined once per day for mortality.  Procedures for dealing with animals found dead are not detailed in 
the report e.g. time to necropsy; whether refrigerated or whole body opened and placed in fixative. However, 
although autolysis (no severity grade given) was noted in many of the decedents' tissues none were classed as 
sufficient autolytic to preclude meaningful histopath. 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No significant differences in incidence between controls and treated animals and no unusual findings 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
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Please add comments on tissue sampling and preservation 
The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was conducted 
but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, Harderian glands, 
parathyroid glands, skin, thymus and trachea. 
Full protocol list of tissues was confined to the control and highest dosage groups except for brain and urinary 
bladder which were examined in all animals. 
N.B. In this study several of the paired organs e.g. kidneys, adrenals, eyes had only one section examined. 
Tissue accountability was good in this study 
It was noted that the brain and urinary bladder were subjected to a very comprehensive examination. 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Without seeing the slides it is impossible to comment on the quality of the sectioning, tissue placement, staining 
etc. were consistent across the groups. 
Pathology findings: 
Please give your expert opinion on the findings reported 
No significant criticisms of the interpretation. The diagnoses appeared to be sensible, consistently reported and 
the range was that which would be expected with this strain. 
Interpretation of necropsy findings and non-neoplastic findings is made difficult by the absence of tables giving the 
overall incidences and the pathologist’s text referring to changes in survivors or non-survivors rather than all the 
animals. 
I agreed with the study pathologist’s overall conclusions and considering the date when it was conducted I have 
no significant criticisms of its conduct. 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Document identification: 
Title  SC-18862 (Aspartame): A Supplemental Study of Rat Brains from Two Tumorigenicity 
Studies (P-T Nos. 838H71 and 892H72) Project No. 1227 
Authors  Reno, F.E., Ferrell, J.F., Innes, J. R. M.  Date  1973 
Study Type  Follow up – further histopathological evaluation  Dossier #  E87 
Follow up from: 
Title  SC-18862: Lifetime Toxicity Study in the Rat. Final Report  (P-T No. 892H72) 
Authors  Trutter, J.A., Reno, F.E., 
Ferrell, J.F., Busey, W.M.  Date  1974 
Study Type  Chronic toxicity  Searle Dossier #  E70 
Purpose of study: 
Reason for follow up 
Suggestion that “a more comprehensive microscopic surveillance of brain tissue (all 
major neuroanatomical areas) from all treated and control rats on the study would 
provide more reliable data on the actual incidence of [brain] tumours” 
Aim of follow up study  To examine brains from study 838H71 (E-33-4) in more detail and to compare the 
findings in brains from that study to those in study 892H72 (E70). 
Additional procedures performed: 
Animals sampled:  440 rats from 838H71 
280 rats from 892H72  Tissues analysed:  Brain 
Procedure: 
Microscopic examination of eight carefully selected coronal (whole brain) tissue 
specimens per rat. 
Brain sections were evaluated independently by two general pathologists  (Drs. 
Mauro and Dugan; Microscopy for Biological Research, Ltd.) and a comparative 
neuropathologist  (Dr. J.R.M. Innes; Flow Laboratories, Rockville, Md.).  The 
outcome of this investigation was as follows: 
•  In the first study (E33-4), 12 neoplasms affecting the brain were identified. All 
were in aspartame-treated rats; incidence seemed to be treatment-related but 
not dose- or sex-related. The overall incidence of brain tumours in this study 
(across all groups) was 2.7%. 
•  No additional brain tumours were identified in brains from the second study 
(E70) but the nine tumours identified in the original study report were 
confirmed. The incidence of tumours in this study appeared to be random. The 
overall incidence of brain tumours in this study (across all groups) was 3.2%. 
The conclusion from this follow-up investigation was that there was no evidence of an 
intracranial tumorigenic effect due to aspartame although brain tumour development did 
seem to be related to treatment in one of the two studies. 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
Please add comments on tissue sampling and preservation 
No comments 
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Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Again an exhaustive examination employing one of the leading neuropathologists of the time 
Pathology findings: 
Please give your expert opinion on the findings reported 
I agree with the overall conclusion. It illustrates the difficulty in ascribing treatment-relationship to low incidence 
tumours that have not been seen in controls. Lucky they had two studies to examine. 
General comments: 
Please add any other comments on this study 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). Various unequivocal neurological neoplasias were identified (Unattributed, 1978b): these 
were principally primary gliomas. Astrocytomas, which were generally well differentiated but infiltrative and 
sometimes massive, predominated. Oligodendrogliomal and ependymal lesions were also identified, and 
contiguous pituitary tumours were noted in some cases. There was no significant difference in the incidence of 
any of these tumours in relation to sex, treatment or dose. 
Reviewer Details: 
Name: Peter Millar  Date: April 2012 
Reviewer Details: 
Name: Lesley Stanley  Date: 25-Apr-12 
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Study Identifier  03 1974 (E70) 
Study Title  SC-18862: Lifetime Toxicity Study in the Rat 
  Y  N  Comment 
below 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √     
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  Protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  Purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and substrain, age, and 
procedure used for identification. 
√  √  No reported 
ID method 
A description of the dosage, dosage regimen, route of 
administration, and duration.  √     
A description of all circumstances that may have affected the 
quality or integrity of the data.    √   
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√  √  Not actually 
SD 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.  √  √  Only 
specimens 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √   
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
None 
Report GLP content check by/date: J Birnie 19 April 2012 
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Study identifier  03 1974 (E70) 
Study Title  SC-18862: Lifetime Toxicity Study in the Rat 
*OECD Guideline no: 451 Carcinogenicity Studies 
 
*§    Y  N  Comment 
17 
Analytical information on the nutrient and dietary contaminant levels 
should be generated periodically, at least at the beginning of the 
study and when there is a change in the batch used, and should be 
included in the final report  
  √   
17  Analytical information on the drinking water used in the study should 
similarly be provided    √   
39  Individual animal data should be provided for all parameters 
evaluated    √   
39  Additionally, all data should be summarised in tabular form showing 
for each test group:       
  the number of animals at the start of the test  √     
  the number of animals found dead during the test or killed for 
humane reasons and the time of any death or humane kill  √  √ 
No time of 
death for early 
decedents 
 
the number showing signs of toxicity, a description of the signs of 
toxicity observed, including time of onset, duration, and severity of 
any toxic effects 
√  √  No tables for 
clinical signs 
   the number of animals showing lesions, the type of lesions and the 
percentage of animals displaying each type of lesion  √  √  No tables for 
clinical signs 
39 
Summary data tables should provide the means and standard 
deviations (for continuous test data) of animals showing toxic effects 
or lesions, in addition to the grading of lesions 
√  √  No tables for 
clinical signs 
40 
Historical control data, if evaluated, should be submitted from the 
same laboratory and relate to animals of the same age and strain 
generated during the five years preceding the study in question 
  √  No reference 
41 
When applicable, numerical results should be evaluated by an 
appropriate and generally acceptable statistical method. The 
statistical methods and the data to be analysed should be selected 
during the design of the study. Selection should make provision for 
survival adjustments, if needed. 
     
42  The test report should contain the following information: 
  Test substance:        
  physical nature, purity, and physicochemical properties    √  No purity. 
  identification data  √     
  source of substance  √     
  batch number  √     
  certificate of chemical analysis    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)    √  N/A 
  Test animals        
  species/strain used and justification for choice made  √    Comment (1) 
  number, age, and sex of animals at start of test  √     
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test    √  Individual data 
not present 
  Test conditions:       
  rationale for route of administration and dose selection  √     
  when applicable, the statistical methods used to analyse the data  √     
  details of test substance formulation/diet preparation  √     
  analytical data on achieved concentration stability and homogeneity 
of the preparation  √  √  No stability nor 
homogeneity 
  route of administration and details of the administration of the test 
substance  √     CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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  for inhalation studies, whether nose only or whole body    √  N/A 
 
actual doses (mg/kg body weight/day), and conversion factor from 
diet/drinking water test substance concentration (mg/kg or ppm) to 
the actual dose, if applicable 
√     
  details of food and water quality  √  √  Nitrates/ 
nitrites in feed 
  Results (summary tabulated data and individual animal data should 
be presented)       
  general       
  survival data  √  √  No individual 
data 
  body weight/body weight changes  √  √  No individual 
data 
  food consumption, calculations of food efficiency, if made, and water 
consumption, if applicable  √  √ 
No individual 
data; no food 
efficiency 
  toxicokinetic data if available    √  N/A 
  opthalmoscopy (if available)  √    Only 
abnormalities 
  haematology (if available)  √     
  clinical chemistry (if available)  √     
  clinical findings       
  signs of toxicity  √  √  No individual 
data 
  Incidence (and, if scored, severity) of any abnormality  √  √  No individual 
data 
  nature, severity and duration of clinical observations (whether 




  necropsy data       
  terminal body weight  √  √  No individual 
data 
  organ weights and their ratios, if applicable  √  √  No individual 
data 
  necropsy findings; incidence and severity of abnormalities  √  √  Not severity 
  histopathology       
  non neoplastic histopathological findings  √     
  neoplastic histopathological findings  √     
  correlation between gross and microscopic findings    √   
  detailed description of all treatment-related histopathological findings 
including severity gradings  √     
  report of any peer review of slides    √  N/A 
  statistical treatment of results, as appropriate  √     
  discussion of results, including  √     
  discussion of any modelling approaches    √   
  dose-response relationships  √     
  historical control data    √   
  consideration of any mode of action information    √   
  BMD NOAL or LOAEL determination    √   
  relevance for humans  √     
  conclusions       
Comments: 
(1)  Per the report the animals are F1A weanlings from parents which continued to receive test material 
during mating and throughout gestation and nursing. From the 2-generation study report: Project 700-
239 there’s no information to show that test diet was administered beyond the end of mating. 
Report content QA check by/date: J Birnie 18-19 April 2012 
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Study ID  03 1974 (E70 
Study Title  SC-18862: Lifetime Toxicity Study in the Rat 
Internal Consistency  
 
A small sample of items were cross-checked for internal consistency: 
 
§  No mention of the organs with a high incidence of autolysis in decedents (e.g. kidney)  
§  The relevance of parameters other than tumours isn’t discussed – e.g. significant 
compound-related increase in liver phenylalanine hydroxylase activity  
§  Text table with incidence of intracranial neoplasms (p53) doesn’t include a gp 1 
female metastatic adenocarcinoma (this is listed in Table 9 and in Figure 6 it hasn’t 
been attributed to another organ – “primary site not identified”) 
§  The level of significance of bodyweight differences is not reported 
§  No mention of how food was deprived for fasting parameters 
Information relating to the test item  
  
No purity, stability, homogeneity, analyses. 
Other comment 
 
Per the report the animals are F1A weanlings from parents which continued to 
receive test material during mating and throughout gestation and nursing. From the 
2-generation study report: Project 700-239 there’s no information to show that test 




J Birnie 19 April 2012 
 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 




Report on Long-term Carcinogenicity Bioassays to Evaluate the Potential Biological 
Effects, in particular Carcinogenic, of Aspartame Administered in Feed to Sprague-
Dawley Rats. Protocol No.: BT 6008 
Authors  Soffritti, M., Belpoggi, F.  Date  2005 
Study Type  Chronic toxicity  Dossier #  N/A 
Purpose of study: 
(1) to assess the qualitative-quantitative carcinogenic effects of [aspartame] administered at different doses in 
feed to Sprague-Dawley rats for their life-span 
(2) in the event of a positive result, to identify the target organs of the carcinogenic effects, the type of tumours 
observed and their precursors, and other pathological affects relevant to public health. 
Test Item: 




Lot # (s)  None provided: “Food grade”; produced by NutraSweet , obtained from Giusto 
Faravelli SpA, Milan, Italy 
Animals: 
Species:  Rat  Strain:  Sprague Dawley 
Source:  Bred in house at CMCRC  Age/weight:  4-5 weeks old 
Comments:   This study is difficult to compare with other studies because of use of an in house 
strain of rats. 
Formulation: 








Formulation procedure  Not specified 
Confirmatory analysis 
Concentrations and stability of aspartame in diet were evaluated at the start of the 
experiment. 
•  Method used was infrared absorption spectroscopy 
•  A sample of the aspartame used, identified by batch number and date of 
production, is held at -70￿C. 
Comments  See QA comments 
Study design: 
Animal husbandry 
Rats housed in groups of 5 in makrolon cages (41 x 25 x 15 cm) with stainless steel 
tops and a shallow layer of white wood shavings as bedding. 
•  Kept in rooms designated exclusively to the experiment 
•  Temperature maintained at 23 – 2￿C 
•  Relative humidity 50-60% 
•  12 hr light/dark cycle 
Food was provided ad libitum. 
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During the experiment, health of the animals was monitored 3x daily, 6 days/week  
•  Twice daily on Sundays and public holidays 
•  Animals considered ill or moribund were signalled to the veterinarian or 
chief of pathology, who determined whether the rodent required isolation. 
•  A patrol to detect and collect dead rats was performed 4 x daily 
Drugs were not used 
•  In the event of infection, animals were isolated and maintained under 
continuous observation 
The experiment was conducted according to the Italian law regulating use of animals 
for scientific purposes (Decreto Legislativo 116, 1992). 
•  All animals were examined monthly by the veterinarian and by the Local 
Veterinary Service, in line with this legislation 
Diet 
Corticella-type pelleted diet from Labatorio Dottori Piccioni 
•  Analysed for nutritive components and possible pollutants 
o  Pesticides 
o  Metals 
o  Compounds with oestrogenic activity 
o  Nitrosamines 
o  Aflatoxins 
•  Used within2 months of the date of production 
Drinking water was analysed periodically to identify the possible presence of 
pollutants (bacteria and chemicals). 
•  Values were always within the acceptable ranges (not specified) 
Minimisation of bias 
Rats were weaned at 4-5 weeks of age, identified by ear punch and “randomised in 
order to have no more than one male and one female from each litter in the same 
group”. 
Blocking of groups  None specified 
Number per group 
150M/150F controls 
150M/150Fat 80 
          to 2,000 ppm 
100M/100F at 10,000 
          to 100,000 ppm 
Acclimatisation  3-4 weeks 
(from age 4-5 wk to 8 wk) 
Start of dosing  8 weeks of age  Duration  To natural death 
Planned doses  Dose per body weight not 
specified  Actual intakes  Not specified 
Basis for dose selection 
To simulate a assumed daily intake by humans of 
•  5,000 mg/kg body weight 
•  2,500 mg/kg body weight 
•  500 mg/kg body weight 
•  100 mg/kg body weight 
•  20 mg/kg body weight 
•  4 mg/kg body weight 
Dose correction  None described 
Comments  See QA comments 
In life procedures: 
General observations  2, 3 or 4 times daily  Clinical chemistry   None specified 
Food consumption 
Water/food consumption 
monitored per cage for 
50M/50F per group, 
weekly for first 13 wk and 
fortnightly weeks 14-110. 
Haematology  None specified CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Body weight 
Weekly for first 13 wk, 
fortnightly weeks 14-110 
then every 8 weeks. 
Urinalysis  None specified 
Ocular examinations  None specified  Other 
Macroscopic clinical 
examination weekly for 
first 13 wk and fortnightly 
thereafter. 
Comments  Only limited in life observations were undertaken; really just surveillance of survival 
Procedure for intercurrent deaths: 
Time to necropsy 
Up to 16 hr; carcasses 
stored at 4￿C until 
necropsy. 
Parameters recorded  Not specified 
Tissues sampled 
Upon natural death, rats underwent complete necropsy. 
•  All animals were necropsied as soon as possible after death 
•  See procedure below 
Comments 
The report states that all rats were necropsied within 16 hr of death, but from the 
timings given a rat dying just after 12.00 on a weekend would be left for at least 20 hr 
before necropsy. 
Termination procedures: 
Termination method  N/A (natural death) 
Time to necropsy 
Up to 16 hr; carcasses 
stored at 4￿C until 
necropsy. 
Parameters recorded   
External assessment  Not described 
Necropsy procedure 
Upon natural death, rats underwent complete necropsy. 
•  All animals were necropsied as soon as possible after death 
•  Necropsies performed 8.00-19.00, Mon-Fri and 08.00 – 12.00 Sat/Sun 
•  Rats were necropsied within 16 hr of death 
•  A qualified pathologist performed or supervised the necropsies 
Data recorded: 
•  Date and presumed hour of death 
•  Identification number and sex of animal 
•  Identification of technician retrieving carcass 
•  Identification of person carrying out necropsy 
Examined: 
•  External surfaces and all orifices 
•  Internal and external aspects of all hollow organs 
•  Cranial cavity 
•  External surfaces of brain and spinal cord 
•  Nasal cavities and paranasal sinus 
•  Neck and associated tissues 
•  Thorax 
•  Abdomen 
•  Pelvis 
•  Muscular and bone carcass 
o  Bones fixed in 10% formalin, decalcified with 10% 
formaldehyde/20% formic acid in water. 
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Tissues sampled 
Any organ or tissue with pathological lesions 
Skin and subcutaneous tissue 
Mammary gland 
Brain (3 sagittal sections) 
Pituitary gland 










Lung and mainstem bronchi 
Heart 
Diaphragm 














Interscapular brown fat pad 
Lymph nodes*** 
*Five sections, with oral and nasal cavities and external and internal ear ducts. 
** Four levels: duodenum, ileum, jejunum, rectum) 
***subcutaneous, mediastinal, mesenteric and those near to neoplasms, even if 
apparently normal. 
Following fixation: 
•  Trimmed according to SOP (not provided) and embedded in paraffin 
•  Sectioned at 3-5 mM 
o  Multiple sections taken from macroscopic lesions and metastases 
•  Stained routinely with haematoxylin and eosin 
Immunohistochemical stains: 
•  S100 for malignant Schwannomas 
•  Chromogranin A for olfactory neuroblastomas 
Tissues examined by junior and senior in house pathologists 
•  Some lesions also shown to an NIEHS Pathology Working Group 
Fixation  70% ethanol except 
bones (see above)  Storage conditions  All specimens retained; 
conditions not stated 
Comments 
The report states that all rats were necropsied within 16 hr of death, but from the 
timings given a rat dying just after 12.00 on a weekend would be left for at least 20 hr 
before necropsy. 
Use of 70% ethanol as a fixative is likely to cause dehydration and shrinkage of 
tissues. Ethanol does not give good morphology and is usually only used for fixation 
of tissues intended for immunohistochemical analysis of antigens which would be 
damaged by formaldehyde. It is not commonly used as a fixative when preparing 
tissues for H&E staining. 
Statistical procedures: 
Data manipulation 
“Multiple tumours of different type and site, of different type in the same site, of the 
same type in bilateral organs, of the same type in the skin, in the subcutaneous 
tissue, and in mammary glands, or at distant sites of diffuse tissue (i.e. bones and 
skeletal muscle) were plotted as single/independent tumours. Multiple tumours of 
the same type in the same tissue or organ, apart from those mentioned, were 
plotted only once” 
Statistical tests used 
Cochran-Armitage trend test for linear trends in tumour incidence 
Poly K-test 
•  Survival-adjusted quantal response modification of the Cochran-Armitage 
test which takes survival into account. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Results of in life observations: 
General observations 
No evident behavioural changes were observed among treated animals compared 
with controls. 
No difference in survival between male groups 
•  Decreased survival in female controls starting at 104 weeks of age. 
Food consumption 
Food consumption reduced at 100,000 ppm. 
•  In control males, food consumption dropped towards the end of the study; 
there was no apparent further reduction at low doses of aspartame 
•  In females, reduced consumption was dose-related 
No differences in water consumption 
•  Except for a slight decrease in intake after week 72 at highest dose in both 
sexes. 
Growth  No substantial differences in mean body weight except at highest dose 
•  Slight decrease in males and females at 100,000 ppm 
Laboratory tests  None reported 
Ocular examinations  None reported 
Other  None reported 
Comments  In life observations were very limited; really just surveillance for survival 
Outcomes: 
Terminal body weights  Not discussed 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Acute and chronic inflammatory processes in lungs and kidneys 
•  High incidence of bronchopneumonia in control and treated rats 
•  Considered to be related to “the spontaneous death of animals” 
For details of all non-neoplastic changes observed, see Table 10 (attached) 
Neoplastic lesions 
Parameters evaluated: 
•  General pathological lesions, both macroscopic and microscopic 
•  Types of tumours and tumour precursors 
•  Number of benign and malignant tumours and tumour precursors for each 
tumour-bearing animal 
•  Number of malignant tumours per 100 animals 
•  Number and percentage of animals bearing different types of tumours and 
tumour precursors 
•  Latency time of benign and malignant tumours and tumour precursors 
Apart from the increased incidence of specific preneoplastic and neoplastic lesions 
related to treatment, the spectrum of neoplastic lesions observed in all groups was 
considered by the authors to be typical of the colony from which they came. 
Lesions considered to be aspartame-related were: 
•  Total benign tumours 
o  Significant positive trend in females (p ≤ 0.05) 
o  Significant in males at 10,000 ppm only (p ≤ 0.01) compared with 
controls 
•  Total malignant tumours 
o  Significant positive trend in males (p ≤ 0.05) and females (p ≤ CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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0.01) 
o  significant increase in incidence in females at 50,000 ppm only (p 
≤ 0.01) compared with controls 
•  Preneoplastic and neoplastic lesions of: 
o  Olfactory epithelium 
§  Significant positive trend in males and females (p ≤ 0.01) 
§  Statistically significant increase in males and females at 
all doses above10,000 ppm (p ≤ 0.01); in males also at 
400 ppm. 
§  Hyperplasia characterised by increased thickness of 
epithelium 
§  Sparse adenomas were observed among treated males 
and females but not among controls. 
§  One case of olfactory neuroblastoma was observed in a 
female treated at the highest dose; this was positive for 
Chromogranin A by IHC 
o  Renal pelvis 
§  A dose related increase in incidence of dysplastic 
hyperplasias and papillomas of the transitional cell 
epithelium of the renal pelvis and ureter was observed in 
females (significance not stated). 
§  There was a positive trend in incidence of carcinomas in 
females (p ≤ 0.05) compared with controls 
§  The incidence was significantly higher at 100,000 ppm 
than in controls (p ≤ 0.05) 
§  Carcinomas were also observed in males at all doses 
above 2,000 ppm. 
§  In females, combined incidence of dysplastic lesions and 
carcinomas showed a significant positive trend (p ≤ 0.01) 
§  The increase in incidence was statistically significant at 
all doses above 10,000 ppm (p ≤ 0.01) and at 2,000 ppm 
(p ≤ 0.05). 
§  The carcinomas are described as invading the papilla 
and kidney parenchyma with various levels of extension, 
the cells being of transitional type. The presence of 
mitotic figures is noted.  
o  Bladder 
§  Sparse preneoplastic and neoplastic lesions of the 
transitional epithelium were observed in treated animals 
but not controls. 
§  Transitional cell carcinomas were observed in two males 
at 10,000 ppm and one female at 2,000 ppm. 
•  Malignant tumours of the brain 
o  The following are reported in treated animals: 
§  10 gliomas 
§  1 medulloblastoma 
§  1 meningioma 
o  There was no evidence for a dose relationship 
•  Malignant Schwannomas of peripheral nerves 
o  These were diagnosed on the basis of S100 positivity 
§  There was a positive trend in males (p ≤ 0.05). 
§  Nine malignancies were observed in treated females 
(various doses) but not in controls 
o  The most frequent sites of origin were cranial nerves (72%) and 
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o  Local soft tissue invasion was observed 
o  Metastases were observed in three males at 100,000 ppm 
§  Two metastasised to submandibular lymph nodes 
§  One to lung and liver 
o  Histologically these tumours are described as Antoni B. 
•  Lymphomas and leukaemias 
o  Haemolymphoreticular neoplasias occurred with 
§  Significant positive trend in males (p ≤ 0.05) and females 
(p ≤ 0.01) compared with controls 
§  Increased incidence was positive in females at all doses 
(p ≤ 0.01 or p ≤ 0.05). 
o  Most frequent types observed were 
§   Lympho-immunoblastic lymphoma, mainly involving lung 
and mediastinal/peripheral lymph nodes 
§  Histiocytic sarcomas/monocytic leukaemias involving 
mainly thymus, lung, liver, spleen, nodes and blood 
vessels 
o  The authors state that: “The differential diagnoses were based on 
the morphological criteria followed in our laboratory for several 
decades and are in line with the guidelines of the International 
Classification of Rodent Tumours (IARC, 1993)”. 
The following historical control incidences are noted: 
•  Excluding studies using groups of ≤100 per sex (total of 1934F/1945M) 
  Males  Females 
Olfactory neuroblastoma  0.1% (0.0-1.8%)  0.1% (0.0-1.8%) 
Transitional cell carcinomas 
of renal pelvis, ureter  None observed  None observed 
Transitional cell carcinomas 
of bladder  None observed  None observed 
Malignant Schwannomas 
of peripheral nerves  0.5% (0.0-2.0%)  0.1% (0.0-1.0%) 
Lymphomas  
and leukaemias  20.7% (8.0-30.9%)  12.4% (7.0-
18.4%) 
•  Including studies using groups of ≤100 per sex (total of 2265F/2274M): 
  Males  Females 
Olfactory neuroblastoma  0.1% (0.0-1.8%)  0.1% (0.0-1.8%) 
Transitional cell carcinomas 
of renal pelvis, ureter  None observed  0.04% (0.0-1.0%) 
Transitional cell carcinomas 
of bladder  None observed  None observed 
Malignant Schwannomas 
of peripheral nerves  0.4% (0.0-2.0%)  0.1% (0.0-2.0%) 
Lymphomas 
and leukaemias  20.6% (8.0-30.9%) 13.35 (4.0-25.0%) 
 
Comments  See pathology comments 
Conclusions: 
Authors’ conclusions 
“The mega-experiment performed in our laboratory on APM administered with feed to Sprague-Dawley rats from 8 
weeks-old until natural death has shown for the first time the multipotential carcinogenic effects of this compound. 
In fact, the results indicate that APM causes in our experimental conditions: 1) an increased incidence of 
malignant tumour-bearing animals with a positive significant trend in males (p≤0.05) and in females (p≤0.01), 
particularly in the females treated at 50,000 ppm (p≤0.01); 2) in females, dysplastic lesions and carcinomas of the 
renal pelvis and ureter combined, show a significant positive trend (p≤0.01) and a statistically significant increase CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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in those treated at 100,000 (p≤0.01), 50,000 (p≤0.01), 10,000 (p≤0.01), 2,000 (p≤0.05) and 400 (p≤0.05) ppm; 3) 
a positive significant trend in both males (p≤0.05) and females (p≤0.01) and a statistically significant increase of 
the incidence of lymphomas-leukaemias in females treated at the doses of 100,000 (p≤0.01), 50,000 (p≤0.01), 
10,000 (p≤0.05), 2,000 (p≤0.05) and 400 (p≤0.01) ppm; and 4) an increased incidence of malignant 
Schwannomas of the peripheral nerves with a positive trend in males (p≤0.05).” 
Reviewer’s comments 
This study is difficult to interpret because of the issues of potential infection, unusual diagnostic criteria applied 
and lack of supporting laboratory data. In particular, the report contains evidence of high levels of chronic infection 
and external commentators have suggested that it was compromised by infection by M. pulmonis. Quite apart 
from the undesirability of there being so much evidence of chronic infection in the animals on study the effects of 
these findings on incidences of the putative treatment-related findings in the nasal cavities, lungs and kidneys 
need to borne in mind in the overall assessment. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP check: (Note that GLP regulations were current in Italy at the time of the study) 
Study claims compliance with GLP but there is no Study Director, Study Director’s Statement, QA Statement, 
without which a study could not claim compliance. Also Archivist doesn’t appear to be sufficiently independent.  
Test Item: there is insufficient information to support adequate characterisation of the test item including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
It is not clear what was provided to peer reviewers: histopath results? + slides? + ,macroscopic results?  Results 
of peer review are not included nor referenced. There is no information on the extent that peer review confirmed 
original results. 
OECD Guideline check: 
Test item: similar to above. The guideline also calls for a CoA for the test item which was not present in Volume 1 
There are a lot of other data missing that would be expected according to OECD guidelines, perhaps these are 
present in Volume II. 
•  N.B. Contents of Volumes 2-8 checked by LAS; they contain individual data and statistical analysis of 
terminal data. 
•  During this check it was noted that the terminal data analyses are headed “Terminal Sacrifice at 105 
weeks” although the rats were actually allowed to live out their natural lifespan. This discrepancy seems 
to have been due to the use of NTP terminal data analysis software without customisation. 
Commentary: 
General comments 
The study report indicates that the test item and diet were subjected to various analyses; however, the 
acceptability criteria applied are not defined within the report and the analytical results are not presented. This 
makes it difficult to draw conclusions about the quality and consistency of the materials used. 
A subset of slides (chosen by ERF) was shown to a group of NTP pathologists, but it is not clear whether any of 
their recommendations were acted on. 
The possible Mycoplasma pulmonis infection identified by external commentators (see below) could have 
influenced the study’s outcomes. 
Strengths and limitations of study 
Strengths: 
•  Lifetime exposure and large number of animals per group conferred on this study the potential to be 
sensitive to low incidence effects; 
Limitations: CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  The study report claims GLP compliance, but no supporting evidence is provided. 
•  The study lacks many of the features specified by OECD Guideline 451, which was in place when the 
study was conducted. 
•  No batch details or analytical information on the test item is provided. 
•  The rats used were from an in house colony, making it difficult to compare the results with those of 
studies using animals from commercial sources. 
•  The rats were allowed to die naturally, meaning that there was the potential for autolysis prior to 
necropsy. 
•  The tissues were fixed with 70% ethanol, which could have adversely affected the quality of the histology 
sections. 
•  A wide range of tissues was analysed, but various recommended tissues were omitted. 
•  Non-standard statistical procedures were used. 
Opinions of other commentators 
A subset of slides from this study was shared with an NTP Pathology Working Group in 2004 (Hailey, 2004). The 
lesions for review were selected by Dr Belpoggi of the ERF. This was technically not a peer review as the use of 
its results and discussion were at the discretion of Dr. Belpoggi and the ERF, also because the Working Group did 
not have the power to alter diagnoses, only to pass comment. The findings of the Working Group were as follows: 
•  Cases diagnosed as mammary adenocarcinoma were generally considered by the Working Group to be 
fibroadenomas. 
•  The malignant Schwannomas were generally confirmed, although some Working Group members 
preferred the term sarcoma (not otherwise specified). 
•  There were queries over the exact diagnosis of the neuroblastomas 
•  Of 17 brain lesions examined, 15 of which were neoplastic, most were confirmed although some were 
thought to represent gliosis. It was difficult to classify these tumours according to subtype due to 
autolysis, so general terms such as glioma or mixed glioma were preferred by the Working Group rather 
than astrocytoma or oligodendroglioma. 
•  The diagnosis of lymphocytic or histiocytic neoplasm was generally confirmed; these lesions are not 
usually subdivided by the NTP, but in general the ERF classifications were accepted. 
•  All lesions diagnosed as atypical hyperplasia and neoplasia of the transitional epithelium of the renal 
pelvis were reviewed. The Working Group generally agreed with the descriptions recorded, but 
considered that the hyperplasia observed was not atypical and was usually secondary to inflammation. 
•  The Working Group agreed with 50% of the diagnoses of squamous cell carcinoma of the ear duct and 
oral cavity, but identified the remainder as hyperplasias. 
The potential implications of this and other ERF studies have led to intense stakeholder debate (Abdo, Camargo 
et al, 2007; Abegaz and Soffritti, 2007; Magnuson, Williams et al, 2008; Manuppello, Willett et al, 2008; Mead, 
2006) as well as calls for the NTP to conduct its own bioassay on aspartame (Huff and LaDou, 2007). An expert 
reviewer, noting the inconclusive nature of the findings and the questions surrounding diagnosis, has called for a  
fully blinded peer review of the aspartame study by board-certified pathologists, with particular emphasis on the 
need for expect consideration of the lymphomas and leukaemias observed (Swenberg, 2005). 
This study was reviewed by EFSA in a statement issued in 2006 (EFSA, 2006). The statement noted that the 
lifetime exposure and large number of animals per group conferred on this study the potential to be sensitive to 
low incidence effects; however, its flaws (including high background incidence of chronic inflammation of the lungs 
and other vital organs and tissues together with uncertainty regarding the diagnosis of some tumour types) called 
its findings into question. The EFSA Panel concluded that the increased incidence of lymphomas and leukaemias 
was unrelated to aspartame (and fell within the range observed previously in controls) and that the preneoplastic 
and neoplastic lesions of the renal pelvis were treatment-related but not relevant to humans. They considered that 
the reported changes in total tumour incidence did not provide evidence of carcinogenic potential and that a full 
peer review would be required in order to evaluate the malignant Schwannoma findings. They noted the incidence 
of brain tumours in aspartame-treated groups but did not consider them treatment-related given that no dose 
response was observed, commenting that the lack of an apparent dose response for tumour incidence would be 
remarkable if the effect was really treatment-related, given the wide range of doses tested. 
The FDA also conducted an evaluation of the study, reaching the conclusion that “...FDA finds no reason to alter 
its previous conclusion that aspartame is safe as a general purpose sweetener in food” (FDA, 2007). 
Soffriti  et al  (Soffritti, Belpoggi et al, 2007) note that not all CMCRC/ERF studies show high incidences of CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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lymphoma/leukaemia: the background incidence in previous studies is 20.6% (8.0-30.9%) in 2,265 males and 
13.3% (4.0-25.0%) in 2,274 females. This represents data from studies  conducted over a 20 year period, and the 
comment has been made that a comparison with studies conducted over the preceding 5 years would have been 
more relevant because of possible genetic drift within rat colonies (COC, 2006). Other investigators have reported 
lymphomas and leukaemias to be a common neoplastic lesion in aging untreated Sprague-Dawley rats following 
exposure to two different basal diets (Nakazawa, Tawaratani et al, 2001). 
Comments on this study in the review of Magnuson et al (Magnuson, Burdock et al, 2007) note the same QA 
issues raised in this proforma, including deviations from OECD Guideline 451 and the fact that GLP compliance 
could not be confirmed. Various problems with animal husbandry, including crowded cage conditions and the 
housing of treatment groups in different rooms are identified; the lack of characterization of the diet and test item 
is also noted. The lack of haematology data is also identified as a serious limitation of the study, especially given 
that lymphomas and leukaemias are among the key lesions reported. Inconsistencies in the statistical analysis are 
also highlighted. In general, a tendency to over diagnosis of various types of lesion is criticized. 
There has been intense debate over the last 3-4 years regarding the possibility that the apparent high incidence of 
lymphomas/leukaemias in ERF rat carcinogenicity studies was a consequence of infection by the organism M. 
pulmonis. A detailed evaluation of ERF studies was carried out and reported in 2008 by the National Center for 
Environmental Assessment (EPA) (Caldwell, Jinot et al, 2008). This considered that the assays conducted by the 
ERF were generally consistent with GLP and NTP studies with regard to both conduct and outcome, but noted 
differences in the rat strain used (inbred Sprague Dawley from an in house colony vs. Fischer 344), study length 
and approach to reporting lymphomas and leukaemias. The reviewers considered that it was difficult to compare 
the incidence of haemolymphoreticular tumours between ERF and NTP studies because of the different reporting 
formats used, but that the diagnostic classifications were comparable, at least for lymphomas. They did not 
believe that the leukaemias observed in ERF studies were due to chronic infection, noting the lack of specific 
evidence for M. pulmonis infection in the ERF colony as well as the fact that a link between M. pulmonis infection 
and lymphoma induction was not established (there is a link with hypertrophy and metaplasia but not neoplastic 
transformation; also noted by Schoeb et al (see below) and remarking that the assays in which high incidences of 
lymphomas/leukaemias were observed were on chemicals which had metabolites, including methanol, in 
common. This concluded that: “An examination of the bioassays used by the ERF and NTP shows that the ERF 
bioassay program produces credible results, consistent with those of NTP” and that “The study length and rat 
strain used by the ERF may explain why lymphomas/leukaemias in ERF bioassays have not always been 
reproduced in NTP or similar bioassays”. These commentators did not, therefore, consider that M. pulmonis 
infection was a likely explanation of the results obtained. 
Other commentators do not accept this evaluation, noting the lack of testing for mycoplasma infection at the ERF, 
the high background rate of lymphoma and leukaemia in the colony used and the fact that the incidence of these 
tumour types in the aspartame and methyl tert-butyl ether (MTBE) studies conducted at the ERF was within the 
range of previous control values (Goodman, Beyer et al, 2009). Schoeb et al, for example, consider it highly likely 
that the rats in the ERF bioassays were infected with M. pulmonis characterised by accumulation of lymphocytes 
and plasma cells in the lung (Schoeb, McConnell et al, 2009a; Schoeb, McConnell et al, 2009b; Schoeb and 
McConnell, 2011a; 2011b) and that this was the likely cause of the bronchopneumonia observed in rat ERF 
studies. They believe that ERF bioassays are confounded by M. pulmonis disease, which is characterised by 
epithelial hyperplasia and metaplasia progressing to bronchiectasis, bronchiolectasis and pneumonia, and that the 
disease lesions were misdiagnosed as lymphomas. They also consider that the olfactory epithelial lesions 
observed in ERF studies are typical of M. pulmonis disease, which can be acquired from the dam during suckling 
and affects the nasal passages as well as the middle ears, larynx, trachea, bronchia and bronchioles. The 
hallmark of M. pulmonis disease is accumulation of lymphocytes and plasma cells, particularly around the bronchi, 
bronchioles and adjacent vessels. The accumulating cells include many immature and proliferating lymphoid cells 
and the resulting accumulations can resemble dysplastic and neoplastic lesions.  
The conclusion of Schoeb et al, based upon tabulation of the results from the aspartame, MBTE and methanol 
bioassays conducted by ERF, is that the pulmonary localisation of the tumours observed, as well as their 
pleiomorphic morphology which is atypical of lymphomas, make it likely that these assays were compromised by 
M. pulmonis disease and that the disease lesions were misdiagnosed as lymphomas. They note the apparent 
high incidence of lymphoma in control rats in ERF studies, although they also recognize that increased detection 
because of the increased length of the assays compared with conventional bioassays and/or inadvertent 
development of a susceptible subline of rats by the ERF are possible explanations which cannot be excluded. 
They do not, however, consider that pulmonary lymphoma induction is a likely consequence of infection with M. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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pulmonis. They recommend further evaluation of slides, including respiratory tract sections, from ERF studies and 
testing of samples for M. pulmonis. Caldwell et al, however, maintain their position that M. pulmonis infection was 
not responsible for the tumours observed (Caldwell, Jinot et al, 2009). It is interesting, in the light of this 
discussion, to note that the ERF rat colony is conventionally maintained and that the mouse study, which used 
SPF animals, did not indicate a carcinogenic effect due to aspartame. 
Another commentary by the same authors (Schoeb and McConnell, 2011a) notes the content of a court 
deposition indicating the presence of antibodies to “mycoplasma” in ERF rats. It also notes that the distribution of 
lesions in the lymph nodes and spleen is no more consistent with lymphoma than  M. pulmonis disease. It 
concludes that “…it cannot be ascertained whether lesions diagnosed as pulmonary lymphoma were caused by 
chemical exposure, by M pulmonis, or by an interaction of the two” and recommends that “For these reasons, we 
strongly believe that no regulatory agency should include the reported induction of lymphoma in these bioassays 
in cancer risk assessments unless such effects can be verified”. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Large study: 100-150 animals per sex per treatment group 
•  Control group same size as individual treatment groups. 
•  This makes the study unbalanced in that controls only represented 300/1800 
(16.7%) of rats. 
Six dose levels plus controls 
•  This should have allowed the characterisation of dose responses, but actual 
intakes are not specified in the report. 
Data quality 
Study claims GLP compliance, but this could not be verified. 
•  Report contains a number of deviations from GLP requirements. 
Report lacks information on batches of test item used, purity etc. 
Actual compound intakes not reported. 
Report contains evidence of chronic infection during the course of the study. 
Serious concerns regarding pathology diagnoses and interpretation. 
Relevance of the study  Provides information as to the effects of aspartame when administered to the end of 
the natural lifespan, but difficult to compare with conventional two-year bioassays. 
Adequacy of data sets  No laboratory investigations conducted, and minimal in life observations. 
Large quantity of descriptive information on tumour incidence, but difficult to interpret. 
Data sources  Privately funded study report. Claims GLP, but without supporting evidence. 
Carried out at time when GLP and OECD Guidelines were in place. 
Comments 
•  This study has been the subject of intense controversy and lacks many features specified by OECD 
Guideline 451, which was in place at the time the study was conducted. 
•  A subset of slides (chosen by ERF) was shown to a group of NTP pathologists, but it is not clear whether 
any of their recommendations were acted on. 
•  The most important concerns of the review team were: 
o  The study claims compliance with GLP (and was carried out at a time when GLP regulations 
were in place in Italy), but lacks the necessary supporting documentation. 
o  There are significant doubts about the pathology findings.  
•  The opinion of the review team is that, before the results of this study are used for risk assessment, the 
pathology should be subjected to a comprehensive independent peer review and the whole study should 
be audited. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
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Document identification:  
Title 
Report on Long-term Carcinogenicity Bioassays to Evaluate the Potential Biological 
Effects, in particular Carcinogenic, of Aspartame Administered in Feed to Sprague-
Dawley Rats. Protocol No.: BT 6008 
Authors  Soffritti, M., Belpoggi, F.  Date  2005 
Study Type  Chronic toxicity  Dossier #  N/A 
Purpose of study: 
(1) to assess the qualitative-quantitative carcinogenic effects of [aspartame] administered at different doses in 
feed to Sprague-Dawley rats for their life-span (2) in the event of a positive result, to identify the target organs of 
the carcinogenic effects, the type of tumours observed and their precursors, and other pathological affects 
relevant to public health. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1  No1 
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains used in long-term bioassays for which historical control data is readily 
available. 
Please comment on the choice, age and health status of the animals used. 
Table 10 gives the distribution of the ‘phlogistic’ changes. There was a very high incidence of inflammatory 
changes across all the groups e.g. bronchopneumonia was observed in 77-95% of animals, pyelonephritis in 37-
83% and ‘encephalic abscesses’ and ‘meningitis’, presumably secondary to severe middle ear infection, in 6.5-
20% and 7.3-19% respectively. 
Quite apart from the undesirability of there being so much evidence of chronic infection in the animals on study 
the affects of these findings on incidences of the putative treatment-related findings in the nasal cavities, lungs 
and kidneys need to borne in mind in the overall assessment (see below).  
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate? 
•  3 x day six days a week and 2 x day Sundays and holidays 
Yes   
Was the timing of planned sacrifices (if any) appropriate? 
•  All animals died spontaneously 
Yes   
Was the time from death to necropsy appropriate? 
•  16 hours maximum  Yes   
Please add comments on the necropsy procedures used 
No indication of autolysis in the animals was present in the report. Notwithstanding the procedures for monitoring 
ill-health it would be reasonable to assume that some of the animals had a degree of autolysis given that they 
were all allowed to die spontaneously. 
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Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
Not discussed or presented in the report 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes?   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate? 
•  Yes but unusually tissues were fixed in 70% alcohol 
Yes   
Please add comments on tissue sampling and preservation 
The list of protocol organs included the nasal cavities, larynx, pharynx, diaphragm, middle ear with cranium, 
tongue, Zymbal’s gland and brown fat but a number of recommended tissues were missing e.g. aorta, bone 
(femur and/or sternum) with bone marrow, caecum, colon, eyes, peripheral nerve, seminal vesicles, skeletal 
muscle and spinal cord.  
70% alcohol is an acceptable fixative but tends to make tissue hard and brittle and produce a reddish eosinophilic 
stain 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
The reported methods are appropriate but section and stain quality could not be assessed 
Pathology findings: 
Please give your expert opinion on the findings reported 
 
I have several concerns regarding the pathology diagnoses and the interpretation: 
 
1.  Upper Respiratory Tract: Hyperplasia of the olfactory epithelium particularly as characterized in this 
report as ‘increased thickness of the epithelium’ is part and parcel of chronic inflammation in the nasal 
cavities. Given the high incidence of inflammatory changes in the respiratory tract I would need some 
convincing to consider the hyperplastic lesions and even the small number of adenomas seen as 
treatment-related rather than secondary to chronic inflammation. 
2.  I don’t believe, given the number of rats on study, that the presence of one ‘olfactory neuroblastoma’ is 
particularly notable. 
3.  Lymphomas and leukaemias: I note that ‘the most frequent type of hemolymphoreticular neoplasias 
observed in the experiment were ‘lymphoimmunoblastic lymphomas, mainly involving lung and 
mediastinal nodes’. It is my experience that lymphomas occurring only in the lung are extremely rare and 
I note that in the recent EPA sponsored review of the methanol study conducted at the Ramazzini 
Institute only four out of the sixty-four lymphomas of the lung, diagnosed by the institute pathologists, 
were confirmed by the PWG; most were considered to be severe lymphoplasmacytic infiltrates due to 
chronic inflammation. 
4.  Renal pelvis and ureter: The criteria for use of the terms ‘dysplastic hyperplasia’ and ‘dysplastic 
papilloma’ and which findings constitute a pre-neoplastic lesion should be explained. From the Table 16 
it appears that the overall incidences of hyperplasia and/or papilloma in controls although greater in 
some of the treated groups are not statistically significantly different from control. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
5.  The statistical significance attained by the inter-group differences in malignant Schwannomas is based 
upon very low incidences and the level of significance attained is also low (p<0.05). I wonder if this is an 
exact p value or asymptotic value. In view of this and the absence of a similar change in females I would 
be inclined to believe this is a false positive finding which given the number of end points examined is not 
unreasonable. 
6.  A number of the incidences of tumours appear unusually high e.g. the number of 
osteoma/osteosarcomas is very high across all the groups particularly in the cranial cavity. Might this be 
a misdiagnosis of reactive bone changes associated with chronic middle ear infection? Also the number 
of cholangioma/cholangiosarcomas is rather high. 
7.  The positive trends reported for overall incidences of animals bearing a benign tumour and those bearing 
a malignant tumour are largely dependent upon pairwise comparisons in the lower dosage groups. There 
is no clear indication of an increase in overall tumour incidence with dosage. 
8.  No indication of ‘cause of death’ is given in the summary tables which since the animals were allowed to 
die spontaneously might have provided useful information. 
9.  I’m not sure that the poly-k-test is appropriate for a long-term study such as this. I think a Peto analysis 
would be more appropriate 
In my opinion before the results of this study are used for safety assessment the pathology should be subjected to 
a comprehensive independent peer review. 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Study Identifier  15 Dr Soffritti Volume 1 
Study Title 
Report on long-Term carcinogenicity Bioassays to evaluate the Potential 
Biological effects, in particular carcinogenic, of Aspartame administered 
in feed to SD rats. Protocol BT6008 
 
  Y N  Comment 
General 
Reports of Principal investigators or scientists involved in the study 
should be signed and dated by them    √  No peer 
report 
The final report should be signed and dated by the Study Director to 
indicate acceptance of responsibility for the validity of the data. The 
extent of compliance with the with principles of GLP should be 
indicated 
  √ 
Has a claim 
of GLP, but 
no SD 
Corrections and additions to a final report should be in the form of 
amendments. Amendments should be signed and dated by the 
Study Director 
  √  N/A 
Reformatting of the final report to comply with the submission 
requirements of a national registration or regulatory authority does 
not constitute a correction, addition or amendment to the final 
report. 
  √  N/A 
Identification of the study, the test item and the reference item 
A descriptive title  √     
Identification of the test item by code or name (IUPAC, CAS etc)  √  √  No batch 
Identification of  any reference item by name    √  N/A 
Characterisation of the test item including purity, stability, and 
homogeneity   √  √  (1) 
Information concerning the sponsor and the test facility 
Name and address of the sponsor  √     
Name and address of the test facilities and test sites involved 
√   
Although not 
clear what 
was done at 
each site 
Name and address of the study director 
  √ 
Has a claim 
of GLP, but 
no SD 
Name and address of any principal investigator(s) and phase(s) of 
the study delegated, if applicable    √  (2) 
Name and address of scientists having contributed reports to the 
final report     √  (3) 
Dates 
Experimental starting and completion dates  √     
Statements 
A QA programme statement listing the types of inspections made 
and their dates, including the phase(s) inspected, and the dates any 
inspection results were reported to management and to the SD and 
PI(s), if applicable. This statement would also serve to confirm that 
the final report reflects the raw data.  
  √ 
Has a claim 
of GLP but no 
QAS 
Description of Materials and Test methods 
Description of materials and methods used  √     
Reference to OECD test guideline or other test guideline or method    √   CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD GLP report content 
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Results 
A summary of results  √     
All information and data required by the study plan      (4) (5) 
A presentation of the results, including calculations and 
determinations of statistical significance   √     
An evaluation and discussion of the results and, where appropriate, 
conclusions  √  √  (5) (6) 
Storage 
The location(s) where the study plan, samples of test and reference 





Organisation for Economic Co-operation and Development: 
ENV/MC/CHEM (98)17: OECD Principles on Good laboratory Practice, as revised 
Comments: 
(1) Although there is reported testing of stability and concentrations at the start, it is not 
stated how this relates that this relates to the duration of the test. No testing of 
homogeneity – in fact it is not clear how the medicated feed was made – if existing 
diet was in pellet form were these ground and mixed with APM, or did the facility 
manufacture medicated pellets?  
(2) At the time of the study guidance indicates that a study with a GLP claim should be 
conducted as a multi-site study 
(3) Not clear what was provided to peer reviewers: histopath results? + slides? + 
macroscopic results?  Results of peer review not included nor referenced not 
acknowledged if/that they confirmed the original pathologist 
(4) Not possible to assess without the study plan. 
(5) Section 1.7 states that animals were isolated in the case of infectious pathologies, 
hoverer there is no discussion elsewhere on the extent of the infections and the 
impact on the study outcome 
(6) Figures presented do not include animal number 
Report GLP content check by/date: J Birnie, 11  and 19 April 2012 
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Study identifier  15 Dr Soffritti Volume 1 
Study Title  
 
Report on long-term carcinogenicity bioassays to evaluate the potential 
biological effects, in particular carcinogenic, of aspartame administered in feed 
to SD rats. Protocol BT6008 
*OECD Guideline no: 451 Carcinogenicity Studies 
 
  Y  N  Comment 
*§         
17 Analytical information on the nutrient and dietary contaminant levels 
should be generated periodically, at least at the beginning of the 
study and when there is a change in the batch used, and should be 
included in the final report  
  √ 




17 Analytical information on the drinking water used in the study should 
similarly be provided  √     
39 Individual animal data should be provided for all parameters 
evaluated    √  Not present 
39 Additionally, all data should be summarised in tabular form showing 
for each test group        
  the number of animals at the start of the test  √     
  the number of animals found dead during the test or killed for 
humane reasons and the time of any death or humane kill    √   
  the number showing signs of toxicity, a description of the signs of 
toxicity observed, including time of onset, duration, and severity of 
any toxic effects 
  √   
   the number of animals showing lesions, the type of lesions and the 
percentage of animals displaying each type of lesion  √     
39 Summary data tables should provide the means and standard 
deviations (for continuous test data) of animals showing toxic effects 
or lesions, in addition to the grading of lesions 
  √  No SDs 
40 Historical control data, if evaluated, should be submitted from the 
same laboratory and relate to animals of the same age and strain 
generated during the five years preceding the study in question 
  √  20 years 
41 When applicable, numerical results should be evaluated by an 
appropriate and generally acceptable statistical method. The 
statistical methods and the data to be analysed should be selected 
during the design of the study. Selection should make provision for 
survival adjustments, if needed. 





42 The test report should contain the following information: 
  Test substance:        
  physical nature, purity, and physicochemical properties    √   
  identification data    √   
  source of substance  √     
  batch number    √   
  certificate of chemical analysis    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)       
  Test animals        
  species/strain used and justification for choice made  √     
  number, age, and sex of animals at start of test  √     
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test    √   
  Test conditions:       
  rationale for route of administration and dose selection  √     
  when applicable, the statistical methods used to analyse the data  √     
  details of test substance formulation/diet preparation    √   
  analytical data on achieved concentration stability and homogeneity 
of the preparation    √   CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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  Y  N  Comment 
  route of administration and details of the administration of the test 
substance  √     
  for inhalation studies, whether nose only or whole body    √  N/A 
  actual doses (mg/kg body weight/day), and conversion factor from 
diet/drinking water test substance concentration (mg/kg or ppm) to 
the actual dose, if applicable 
  √   
  details of food and water quality  √     
  Results (summary tabulated data and individual animal data should 
be presented)    √  No individual 
data 
  general       
  survival data  √  √  No individual 
data 
  body weight/body weight changes  √  √  No individual 
data 
  food consumption, calculations of food efficiency, if made, and 
water consumption, if applicable  √  √  No individual 
data 
  toxicokinetic data if available    √  N/A 
  opthalmoscopy (if available)    √  N/A 
  haematology (if available)    √  N/A 
  clinical chemistry (if available)    √  N/A 
  clinical findings       
  signs of toxicity    √   
  Incidence (and, if scored, severity) of any abnormality    √   
  nature, severity and duration of clinical observations (whether 
transitory or permanent)     √   
  necropsy data       
  terminal body weight    √   
  organ weights and their ratios, if applicable    √   
  necropsy findings; incidence and severity of abnormalities    √   
  histopathology       
  non neoplastic histopathological findings  √  √  No individual 
data 
  neoplastic histopathological findings  √  √  No individual 
data 
  correlation between gross and microscopic findings    √   
  detailed description of all treatment-related histopathological findings 
including severity gradings  √  √ 
No individual 
data 
No  severity 
  report of any peer review of slides    √   
  statistical treatment of results, as appropriate  √     
  discussion of results, including       
  discussion of any modelling approaches    √   
  dose-response relationships  √     
  historical control data  √     
  consideration of any mode of action information    √   
  BMD NOAL or LOAEL determination    √   
  relevance for humans  √     
  conclusions  √     
Comments: 
None 
Report content QA check by/date: J Birnie 11-19 April 2011 
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Section 1: Study details 
Document identification: 
Title  Histopathological Examination in a Carcinogenicity Study of SC-18862 in Slc:Wistar 
Rats [Non-GLP study]. Experiment No. 9748 (258-049) Final Report 
Authors  Iwata, H.  Date  2006 
Study Type  Histopathological evaluation  Dossier #  UN04 
Purpose of study: 
“To re-evaluate the carcinogenic potential of SC-18862, a 104-week carcinogenicity study in Slc:Wistar rats, in 
which SC-18862 was fed to rats at doses of 0, 1, 2, and 4 g/kg, was re-examined histopathologically”. 
Note: 
The samples examined in this study were from a previous 104 week carcinogenicity study, identified as 
Sponsor’s study number AP-104. They appear to be the main group samples from the two year bioassay 
reported by Ishii (1981); however, that report does not carry a Sponsor’s study number so it is impossible to be 
sure that it was the source of the samples used here. For the purposes of this review, therefore, only information 
which actually appears in document UN04 is recorded in this proforma. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Not stated 
Lot # (s)  Not stated 
Animals: 
Species:  Rat   Strain:  Slc:Wistar 
Source:  Not stated  Age/weight:  Not stated 
Comments:   See pathology comments. There is reason to believe that the tissues examined were 
from Fischer rather than Wister rats. 
Formulation: 
Route of administration  Via diet  Concentration  Not specified 
Formulation procedure  Not specified 
Confirmatory analysis  None indicated 
Comments  This follow up report does not describe the formulation of the diet and it is not 
possible to link it unequivocally to a parent study. 
Study design: 
Animal husbandry  Not specified 
Diet  Not specified 
Minimisation of bias  Not specified 
Blocking of groups  Not specified 
Number per group  60M/60F per group  Acclimatisation  Not specified 






Actual intakes  Not specified 
Basis for dose selection  Not specified CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Dose correction  Not specified 
Comments  See above; without linking this document to an original study report it is not possible 
to be sure of any aspect of the study’s conduct. 
In life procedures: 
General observations  None specified  Clinical chemistry   None specified 
Food consumption  None specified  Haematology  None specified 
Body weight  None specified  Urinalysis  None specified 
Ocular examinations  None specified  Other  None specified 
Comments  The report does not contain any information regarding the conduct of the original 
study. 
Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  None specified 
Tissues sampled  None specified 
Comments  The report does not contain any information regarding the handling of intercurrent 
deaths. 
Termination procedures: 
Termination method  Not specified 
Time to necropsy  Not specified  Parameters recorded  Not specified 
External assessment  Not specified 
Necropsy procedure  Not specified 
Tissues sampled 
Paraffin blocks from a carcinogenicity study of aspartame in Slc:Wistar rats were 
provided by the Sponsor. 
•  These were sectioned and stained with haematoxylin and eosin. 
Tissues examined: 
Brain  
Pituitary gland  
Salivary glands  
        (mandibular, sublingual and parotid)  
Lacrimal glands  
Harderian glands  
Thyroid glands  


























Bone marrow  
Bone 
Mammary glands 
Macroscopically abnormal organs/tissues 
•  In house peer review of all neoplastic and hyperplastic lesions was 
conducted. 
Fixation  Not specified  Storage conditions  Not specified 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Comments 
The report does not contain any information regarding the necropsy procedure. 
If the provisional identification of the study in the note at the beginning of this 
proforma is correct, the blocks used were 25 years old when the new sections were 
cut. The study report does not comment on the quality of the material, ease of 
processing or thickness of sections cut. When re-evaluating old paraffin embedded 
tissues it is common to re-embed them, but t is not clear whether this was done in 
this case. This limits the usefulness of the study for use in risk assessment. 
Statistical procedures: 
Data manipulation  Data recorded and processed by An-Pyo Center’s computer system 
Statistical tests used 
Differences in incidence of neoplastic and non-neoplastic findings between the 
control group and each treatment group were analysed by Fischer’s exact test 
(two-tailed). Significance levels set at p=0.05 and p=0.01. 
Results of in life observations: 
General observations  Not recorded 
Food consumption  Not recorded 
Growth  Not recorded 
Laboratory tests  Not recorded 
Ocular examinations  Not recorded 
Other  Not recorded 
Comments  No in life observations recorded. No reference is made to the original study report. 
Outcomes: 
Terminal body weights  Not recorded 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Increased incidence of mineralisation of renal pelvis in males at 2,000 and 4,000 
mg/kg/day and in females at 4,000 mg/kg/day. 
 
  Dose (mg/kg/day) 
  0  1,000  2,000  4,000 
Males 
Mineralisation (slight to marked)  18/60  23/60  37/59**  48/60** 
With transitional cell hyperplasia  1/60  1/60  1/59  9/60* 
Females 
Mineralisation (slight to marked)  46/60  48/60  53/59  59/60** 
With transitional cell hyperplasia  5/60  4/60  5/60  3/60 
 
•  Mineralisation was observed within or immediately beneath the transitional 
epithelium, especially at the junction between the papilla and pelvis. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  Classified as: 
o  Slight if the lesion was smaller than the diameter of 1 tubule 
o  Moderate if the lesion was the diameter of 1-3 tubules 
o  Marked if the lesion was larger than the diameter of 3 tubules 
•  Associated with transitional cell hyperplasia in males at 4,000 mg/kg/day. 
o  No atypical transitional cell hyperplasia was observed in animals with 
pelvic mineralisation. 
The authors’ discussion of this finding is as follows: 
•  “The incidence and severity of pelvic mineralization of the kidneys were 
greater in the male 2 g/kg group and 4 g/kg group and in the female 4 g/kg 
group, which thought to be an effect of SC-18862. In some animals, pelvic 
mineralization was accompanied by transitional cell hyperplasia, and the 
incidence was higher in the male 4 g/kg group. 
Chemical carcinogens that target the urinary tract can induce transitional 
cell hyperplasia with cell atypia, which is regarded as a preneoplastic 
lesion. The transitional cell hyperplasia accompanied by pelvic 
mineralization in this study was not associated with any atypia, and there 
was no increase in incidence of transitional cell papilloma/carcinoma in the 
kidneys or urinary bladder. Therefore, the transitional cell hyperplasia 
accompanied by pelvic mineralization may have occurred as a response to 
the mechanical irritation by the mineral deposition. 
It has already been reported that pelvic mineralization occurs 
spontaneously but is frequently exacerbated by certain substances that are 
poorly absorbed from the gastrointestinal tract and cause increased 
calcium absorption, such as xylitol, sucralose, kaolin, sorbitol, and 
magnesium sulphate, and the results suggest that the toxicological 
significance of this lesion is minimal.” 
Changes in the incidence of other non-neoplastic lesions were as follows: 
•  At 2,000 mg/kg/day: 
o  Decreased lymphocytic infiltration of the urinary bladder 
o  Reduced epididymal atrophy 
•  At 1,000 mg/kg/day: 
o  Reduced incidence of Harderian gland metaplasia of the 
lachrymal glands 
These effects were not considered to be compound-related 
Neoplastic lesions 
There were no significant differences in the incidence of tumours of any type 
between the control group and any treatment group. 
•  All lesions observed could have arisen spontaneously. 
Comparable distributions of: 
•  Number of benign and malignant tumours 
•  Total number of tumours 
•  Number of animals with multiple tumours 
Comments  The discussion of tumour incidence in the report text is very limited. 
Conclusions: 
Authors’ conclusions 
“In conclusion, there was no evidence of carcinogenic activity of SC-18862 in male or female Slc:Wistar rats.” 
Reviewer’s comments 
It is difficult to draw any conclusions from this study because of the lack of information regarding the conduct of 
the original study. The study provided no evidence of carcinogenic effects due to aspartame at dosed up to 4,000 
mg/kg/day. The results suggest increased mineralisation of the renal pelvis in males at 2,000-4,000 mg/kg/day 
and in females at 4,000 mg/kg/day, but this was not associated with transitional cell hyperplasia and is not 
considered to be of toxicological significance. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Study checked against OECD GLP Guidelines 
Compliance with current OECD guidelines  Not evaluated 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
Study does not claim GLP compliance, however, GLP check performed as other types N/A for this report. 
•  Not clear whether these were all of the animals from the main study or a subset, and if the latter, how 
they were selected. 
•  Not clear whether macroscopic results were available: to those preparing slides, to pathologists reading 
slides or to peer reviewers 
•  Little detail on tissue processing or whether any rectus needed  
•  Results of peer review not included nor referenced nor acknowledged if/that they confirmed the original 
pathologist 
•  No mention of any impact of decedent status on the results 
Not possible to confirm all information required by plan (not provided)  
Commentary: 
General comments 
This study is difficult to evaluate because it only comprises further histopathological evaluation of a previous 
chronic toxicity study which was not included in the list of key studies provided by EFSA. Internal evidence in the 
report strongly suggests that the study in question is the one reported by Ajinomoto in 1981 (Ishii, Koshimizu et al, 
1981); however, this identification cannot be made unequivocally because, while the report refers to a Sponsor’s 
study number (AP-104), the 1981 report does not have a study number. This being the case, the 2006 report has 
been reviewed as a stand-alone document rather than as a follow-up study. The review team had significant 
concerns regarding this study; in particular: 
•  The provenance of the blocks used is unclear because of the issue of study origin raised above. 
•  No reference is made to the age of the paraffin blocks used, but if our identification of the parent study is 
correct, they would have been at least 25 years old. This could have significantly affected the quality of 
sections obtained, and should at least have been discussed in the report. 
•  Finally, and most importantly, the team pathologist has questioned the strain of rat used in this study. 
The report states that they were of the Slc:Wistar strain but the spectrum of lesions observed suggests 
that they were much more likely to have been of Fischer origin. This raises serious doubts about the 
origin of the samples and even whether the correct blocks were evaluated. 
The recommendation of the review team, therefore, is that this study should not be used for risk assessment 
unless/until these issues are resolved. 
Strengths and limitations of study 
Strengths: 
•  Wide range of tissues examined. 
Limitations: 
•  This was only a follow up study. The provenance if the slides used is unclear, especially given that they 
do not appear to have been from the strain of rat specified in the report since the tumour profile of the 
animals as reported does not conform to that of Wistar rats. The very high incidences of Large Granular 
Lymphocyte leukaemia (70% of control males, 50 % control females) and interstitial cell hyperplasia and 
interstitial cell tumour (85% of control males) in the testes are indicative of Fischer rats. These two 
tumours have a low incidence in Wistar rats. 
Opinions of other commentators 
None known. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
The limited information in the study report indicates that the samples analysed were 
from a study having a group size of 60M/60F per group. 
•  The control groups were of the same size as the treatment groups. 
•  It is not clear whether this included all the samples from the original study. 
Three doses plus control 
•  This would allow limited evaluation of doses responses. 
Data quality 
Report clearly states that this was a non-GLP study. 
•  Study was conducted at a time when OECD GLP guideIines were in place. 
•  It would not be fully compliant if assessed against GLP requirements. 
Tissue dissection and fixation procedures are not described. 
•  If tissues are 25 years old, as implied, tissue quality could be an issue. 
The provenance of the tissues could not be verified. 
•  The samples do not appear to be from the strain specified. 
Peer review of histopathology findings mentioned in Methods but outcome not 
reported. 
Relevance of the study  Potentially provides information on histopathological changes in response to 
aspartame in an additional strain of rat. 
Adequacy of data sets 
Reports histopathology on a subset of samples from an original study which could not 
be identified unequivocally. 
Wide ranging list of tissues examined 
•  However, some recommended tissues were not examined: peripheral nerve, 
skeletal muscle, skin, eyes and spinal cord 
No in life observations or laboratory investigations. 
Data sources  Commercial study report, non-GLP (2006) 
Comments 
•  This document reports further histopathological evaluation of a previous chronic toxicity study which was 
not included in the list of key studies provided by EFSA. The samples examined in this study were from a 
previous 104 week carcinogenicity study, identified as Sponsor’s study number AP-104. They appear to 
be the main group samples from the two year bioassay reported by Ishii (1981); however, that report 
does not carry a Sponsor’s study number so it is impossible to be sure that it was the source of the 
samples used here. This being the case, the 2006 report has been reviewed as a stand-alone document 
rather than as a follow-up study. The review team had significant concerns regarding this study; in 
particular: 
o  The provenance of the blocks used is unclear because of the issue of study origin raised above. 
o  No reference is made to the age of the paraffin blocks used, but if our identification of the parent 
study is correct, they would have been at least 25 years old. This could have significantly 
affected the quality of sections obtained. 
o  Finally, and most importantly, the team pathologist has questioned the strain of rat used in this 
study. The report states that they were of the Slc:Wistar strain but the spectrum of lesions 
observed suggests that they were much more likely to have been of Fischer origin. This raises 
serious doubts about the origin of the samples and even whether the correct blocks were 
evaluated. 
•  The recommendation of the review team, therefore, is that this study should not be used for risk 
assessment unless/until these issues are resolved. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
Document identification: 
Title  Histopathological Examination in a Carcinogenicity Study of SC-18862 in Slc:Wistar 
Rats [Non-GLP study]. Experiment No. 9748 (258-049) Final Report 
Authors  Iwata, H.  Date  2006 
Study Type  Histopathological evaluation  Dossier #  UN04 
Purpose of study: 
“To re-evaluate the carcinogenic potential of SC-18862, a 104-week carcinogenicity study in Slc:Wistar rats, in 
which SC-18862 was fed to rats at doses of 0, 1, 2, and 4 g/kg, was reexamined histopathologically”. 
N.B. The samples examined appear to have been from the study reported by Ishii (1981); however, this is not 
made clear in the study report under review. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
Commonly used strain of rat for long term studies with low background incidences of tumours, non-neoplastic 
pathology. 
Please comment on the choice, age and health status of the animals used. 
The tumour profile of the rats on this study suggests that the strain is Fischer rat rather than Wistar (see below) 
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes  No 
Was the timing of planned sacrifices (if any) appropriate?  Yes  No 
Was the time from death to necropsy appropriate?  Yes  No 
Please add comments on the necropsy procedures used 
Not presented 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
Not presented 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes  No 
Was the fixation procedure appropriate and adequate?  Yes  No 
Please add comments on tissue sampling and preservation 
Comprehensive list of tissues examined from all animals. However, some recommended tissues were not 
examined: peripheral nerve, skeletal muscle, skin, eyes and spinal cord. 
Tissue dissection and fixation procedures not outlined in report. 
                                                             
1 Please delete as applicable CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Procedures as reported were standard 
Pathology findings: 
Please give your expert opinion on the findings reported 
In this study the greater incidence of pelvic mineralisation in males given 2 g/kg and both sexes given 4 g/kg is 
unequivocal. However, the incidence and severity grades of transitional cell hyperplasia in the kidneys were 
comparable in control and treated animals. The presence of mineralisation within certain cases of transitional 
hyperplasia might not be relevant since small amounts of mineral may have leached out of the sections during 
fixation or processing. Therefore I cannot agree with the implication given in the report that aspartame has 
affected the incidence of transitional hyperplasia in the kidneys. 
 
The tumour profile of the animals as reported does not conform to that of Wistar rats. The very high incidences of 
Large Granular Lymphocyte leukaemia (70% of control males, 50 % control females) and interstitial cell 
hyperplasia and interstitial cell tumour (85% of control males) in the testes are, in my opinion, indicative of Fisher 




Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Study Identifier  09 (UA04) 
Study Title  HISTOPATHOLOGICAL EXAMINATION IN A CARCINOGENICITY 
STUDY OF SC-18862 IN Slc:Wistar RATS [Non-GLP study] 
 
  Y  N  Comment  
General 
Reports of Principal investigators or scientists involved in the 
study should be signed and dated by them    √  No peer 
report 
The final report should be signed and dated by the Study Director 
to indicate acceptance of responsibility for the validity of the data. 
The extent of compliance with the with principles of GLP should 
be indicated 
  √  Unsigned 
Corrections and additions to a final report should be in the form of 
amendments. Amendments should be signed and dated by the 
Study Director 
  √  Presume 
N/A 
Reformatting of the final report to comply with the submission 
requirements of a national registration or regulatory authority 
does not constitute a correction, addition or amendment to the 
final report. 
  √  Presume 
N/A 
Identification of the study, the test item and the reference item 
A descriptive title  √     
Identification of the test item by code or name (IUPAC, CAS etc)    √  N/A 
Identification of  any reference item by name    √  N/A 
Characterisation of the test item including purity, stability, and 
homogeneity     √  N/A 
Information concerning the sponsor and the test facility 
Name and address of the sponsor  √     
Name and address of the test facilities and test sites involved  √     
Name and address of the study director  √     
Name and address of any principal investigator(s) and phase(s) 
of the study delegated, if applicable    √  N/A 
Name and address of scientists having contributed reports to the 
final report   √     
Dates 
Experimental starting and completion dates  √     
Statements 
A QA programme statement listing the types of inspections made 
and their dates, including the phase(s) inspected, and the dates 
any inspection results were reported to management and to the 
SD and PI(s), if applicable. This statement would also serve to 
confirm that the final report reflects the raw data.  
  √ 
 
Description of Materials and Test methods 
Description of materials and methods used  √  √ 
See 
comments 
(1) (2) (3) 
Reference to OECD test guideline or other test guideline or 
method    √  Presume 
N/A CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD GLP report content 
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Results 
A summary of results  √     
All information and data required by the study plan    √  Plan not 
available 
A presentation of the results, including calculations and 
determinations of statistical significance   √  √  See 
comment (4) 
An evaluation and discussion of the results and, where 





The location(s) where the study plan, samples of test and 
reference items, specimens, raw data , and the final report are to 
be stored 
√   
 
 
Organisation for Economic Co-operation and Development: 
ENV/MC/CHEM (98)17: OECD Principles on Good Laboratory Practice, as revised 
Comments: 
(1) Not clear whether these were all of the animals from the main study or a subset, and if 
the latter, how they were selected. 
(2) Not clear whether macroscopic results were available: to those preparing slides, to 
pathologists reading slides or to peer reviewers 
(3) Little detail on tissue processing or whether any recuts needed  
(4) Results of peer review not included nor referenced nor acknowledged if/that they 
confirmed the original pathologist 
(5) No mention of any impact of decedent status on the results 
Report GLP content check by/completion date: J Birnie 19 April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Document identification: 
Title  SC-19192: 110-Week Toxicity Study in the Mouse 
(P-T No. 985H73) Final Report 
Authors  Reno, F.E., Ferrell, J.F.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E76 
Purpose of study: 
“…to evaluate and characterize the effects of long term dietary feeding of SC-19192 in ICR Swiss albino mice”. 
Test Item: 
Chemical Identity  DKP (SC-19192)  Purity  Assumed 100% pure 
Lot # (s)  1R (weeks 0-51); 3R (Weeks 52-110) 
Animals: 
Species:  Mouse  Strain:  Albino 
CD-1 (HAM-ICR Swiss) 
Source:  Charles River, USA  Age/weight:  28 days old; 12-21 g 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration  Not specified 
Formulation procedure  Aspartame was incorporated into the basal diet on a w/w basis and thoroughly mixed 
in a twin-shell Patterson Kelley blender. 
Confirmatory analysis  None indicated 
Comments  The information provided on this aspect is rather limited; see QA comments. 
Study design: 
Animal husbandry  Mice housed individually in elevated wire mesh cages 
Food and water provided ad libitum. 
Diet  Wayne Laboratory Chow 
Minimisation of bias  Stratified randomisation by body weight for each sex; animals were arranged into 
four groups to give a homogeneous distribution of weights between groups. 
Blocking of groups  None indicated 
Number per group 
72M/72F controls 
35-37M/F* per test group 
*some mis-sexing at start 
Acclimatisation  Not specified 





Actual intakes  Matched planned doses to 
within 1% up to week 108 
Basis for dose selection  Not provided 
Dose correction  Adjusted according to body weight changes: weekly in weeks 0-4; fortnightly weeks 
5-12; every four weeks from week 13-108. 
Comments  Some details are missing from the report: see QA comments. 
No justification is provided for the doses selected. 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
In life procedures: 
General observations 
Daily for survival; general 
observations at time of 
weighing 
Clinical chemistry   At termination only 
Food consumption 
Weekly in weeks 0-4; 
fortnightly weeks 5-12; 
every four weeks from 
week 13-108. 
Haematology 
Mixed arteriovenous blood 
samples (0.25 ml) taken by 
segmental amputation of 
tail in weeks 5,10, 20, 23, 
40, 60 (6 mice per sex per 
group) and 110 (5-10 mice 
per sex per group) 
Body weight 
Weekly in weeks 0-4; 
fortnightly weeks 5-12; 
every four weeks from 
week 13-108. 
Urinalysis  At termination only 
Ocular examinations 
In weeks 4 (earliest point 
at which eyes were 
mature enough for 
examination), 20, 40, 
60 and 110. 
Other 
Observed for signs of 
toxicity and 
pharmacological effects 
and for development of 
palpable tissue masses. 
Comments  None 
Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  Terminal body weight 
Tissues sampled 
Necropsy performed under supervision of staff pathologist; representative tissues 
preserved unless precluded by autolysis. 
•  Presumably the same as those taken in planned necropsies, but this is not 
stated. 
Tissues examined: 
•  Skin, contents of major body cavities (head, thorax, abdomen, pelvis), 
internal and external aspects of GI tract 
•  Some carcasses showing advanced autolysis were placed into fixative 
whole after the abdominal and thoracic cavities had been opened and 
inspected. 
Comments  It is not clear to what extent autolysis was a problem in the analysis of decedents. 
Termination procedures: 
Termination method  Sodium pentobarbital anaesthesia followed by exsanguination. 
Time to necropsy  Presumably immediate  Parameters recorded  Terminal body weight 
Organ weights 
External assessment  Tissues of the major body cavities were examined, as well as skin and the internal 
and external aspects of the GI tract. 
Necropsy procedure 
Necropsy performed under supervision of staff pathologist. 
Terminal blood samples (1.25 ml) taken by arterial puncture of abdominal aorta. 
•  Clinical chemistry analyses conducted on serum from terminal blood 
samples were BUN, ALT, and ALP. 
•  Frozen serum samples from a representative number of mice per group 
were sent to the sponsor for determination of L-phenylalanine. 
Individual urine samples (0.15 ml) were collected by evacuation of urinary bladder at 
necropsy and analysed for pH, sugar, protein, occult blood, microscopic sediment 
and phenylketones. 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Tissues sampled 
Tissues sampled at necropsy: 
















Large intestine Mesenteric lymph node,  








Bone (rib junction) 
Bone marrow (femur) 
Skeletal muscle 
Nerve (Brachial plexus) 
Usual and unusual lesions 
     *weighed fresh 
     **weighed after fixation 
Histopathological examination was performed on all unusual or usual gross lesions 
from all animals at each treatment level, plus microscopic examination of 20-27 
grossly unremarkable organs from all control and 1,000 mg/kg/day dose animals and 
roughly 2/3 and 1/3 of animals at 500 and 250 mg/kg/day, respectively.  
•  Actual numbers of tissues analysed listed in report (Figure B, attached) 
Detailed microscopic evaluations were performed on brain and urinary bladder from 
all mice in the control and all three treated groups, including survivors and non-
survivors, for which suitable tissues were available for histologic preparation. 
•  Brain tissue was examined such that five coronal sections representing the 
major neuroanatomical areas of the brain were evaluated; two sections per 
block were examined thus providing a total of 10 brain sections per mouse. 
•  After gross examination of hemisected fixed bladder, four transverse bladder 
sections cut at 50 mM intervals were examined microscopically. 
All wet tissues, embedded tissues and mounted tissue sections were retained by 
Hazleton Laboratories. 
Fixation  10% NBF  Storage conditions  Not specified 
Comments  None 
Statistical procedures: 
Data manipulation  Not described 
Statistical tests used 
Bartlett’s test for a preliminary test of homogenicity of variances relating to rates of 
body weight change (compared by method of Rao), food consumption, terminal 
body weights, organ weights, organ weight/body weight ratios.  
•  Analysis of variance and Scheffe’s method of paired comparison when 
variances were homogeneous. 
•  Two sample t-test when variances were not homogeneous 
Survival rates after 108 wk compared by the method of Sachs 
•  A life-table technique was used to calculate the proportion of mice 
surviving the period in treated and control groups 
•  The two survival rates were compared by the t-test 
Clinical laboratory data were compared by the t-test. 
Tumour incidence (adjusted) was calculated by the method of Sachs, involving a 
life-table approach and survival rates. 
•  Control and treated adjusted tumour incidences were then compared by 
the t-test. 
The level of significance for all tests was set at 5%. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Results of in life observations: 
General observations 
There was no evidence of effects on physical appearance or behaviour of animals. 
Mortality was low during the first 16 months of the study and was ≤50% after 18 
months but increased during the last 6 months due to spontaneous disease. 
Statistical analysis of survival at week 108 according to life-table technique revealed 
no differences between control and treated groups. 
•  Except for decreased survival in females at 500 mg/kg/day 
•  This was not considered to be treatment-related since it did not affect 
mean survival time 
•  Mean survival to week 108 was 20-39%. 
Eight mice were lost during the study and were excluded from statistical analysis: 
•  Seven escaped 
•  One was accidentally killed 
Food consumption 
There was no significant difference in total food consumption during the first year of 
the study in females. 
•  Food consumption was significantly reduced in all treated male groups 
during the first year; not considered to be of biological significance since 
overall body weight gains were not adversely affected. 
Food consumption was not analysed statistically during Year Two of the study, but 
no marked effects were noted. 
Growth  There was no significant difference in body weight gain between control and treated 
groups for either sex. 
Laboratory tests 
Haematology tests carried out during the study (on six mice per group) were: 
o  Haematocrit 
o  Haemoglobin 
o  Erythrocyte count 
o  Total WBC count  
o  Differential WBC count  
o  Prothrombin time (wks 5, 10, 40, 60) 
There was no indication of compound-related alterations at any dose. 
•  Random fluctuations reaching statistical significance were occasionally 
observed but were considered of little biological significance; affected values 
generally remained within normal limits and differences in individual values 
between control and test mice were minor in degree. 
•  These findings were considered to have been caused by spontaneous disease. 
Ocular examinations 
There was no evidence of a compound-related effect. 
Opacity/cataract was observed in a small number of mice 
•  The absolute number of affected animals in treated groups was similar to 
or less than that in controls. 
Other 
Signs commonly observed in laboratory mice observed in a few animals during the 
first 18 months and increased in frequency during the last 6 months of the study. 
•  Incidences were similar in treated and control animals. Signs included: 
o  Hunched and/or bloated appearance 
o  Localised alopecia 
o  Reddened eyes 
o  Stained fur 
o  Roughening of the fur 
o  Sores on the body or extremities 
o  Subcutaneous abscesses 
o  Red vaginal discharge in females 
Palpable nodules, swollen areas and wart-like skin lesions were seen in 9/144 
control and 19/216 treated mice (mainly males). 
•  Incidence was much lower than in rat studies (E70, E33-4) 
Comments  Study may have been compromised by poor survival. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Outcomes: 
Terminal body weights 
Mean terminal body weights were significantly increased in males at 250 mg/kg/day. 
•  This finding was considered to be of minor biological significance since it was 
not an adverse effect. 
The only statistically significant difference in organ weights was that thyroid/body 
weight ratios were increased at 500 and 1,000 g/kg/day in females. 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Gross observations at necropsy failed to reveal consistent changes in any organs or 
tissues that could be attributed to compound administration. 
•  Gross necropsy findings comprised incidental findings common in mice of 
this age and strain and did not differ between control and treated groups. 
Microscopic examination of tissues indicated no consistent non-neoplastic 
alterations were detected which could be attributed to compound treatment. 
Non-neoplastic lesions observed but not attributed to treatment included: 
•  Deposits of amyloid in thyroid, adrenal, heart, spleen, liver, kidney, 
stomach, pancreas, small intestine, lymph nodes, salivary gland, testes, 
ovary 
•  Small mineral deposits in cerebral parenchyma 
•  Minimal to mild non-suppurative interstitial thyroiditis 
•  Hyperplasia of adrenal cortex 
•  Thrombosis involving the atria of the heart and associated with myocarditis 
•  Components of chronic pulmonary disease 
•  Manifestations of chronic kidney disease 
•  Inflammation of pancreas 
•  Nematodiasis in large intestine 
•  Interstitial mononuclear cell accumulation in salivary gland 
•  Hypospermatogenesis 
•  Follicular and/or haemorrhagic ovarian cysts 
•  Glandular dilatation and hyperplasia of uterus 
•  Mononuclear cell accumulation in the bladder 
Neoplastic lesions 
In no instance in either sex at any of the treated levels was the adjusted tumour 
incidence of any of the types of tumours analysed significantly higher than that of 
the respective controls. 
•  Tumour types considered: 
o  Any tumour 
o  Only benign tumour 
o  Any malignant tumour 
o  Primary lung tumour 
o  Lymphoreticular tumour 
o  Vascular tumour 
A detailed evaluation of brain tissues to determine the presence or absence of 
intracranial neoplasms was performed on all survivors and non-survivors for which 
suitable tissues were available. 
•  One primary brain neoplasm, diagnosed as a meningioma, was detected in 
a female control mouse. 
o  No other primary intracranial neoplasms were detected. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  Metastatic tumours were detected in the brains of: 
o  Four control males 
o  Two males at 250 mg/kg/day 
o  One female at each dose level 
A detailed evaluation of bladder sections was performed on all survivors and non-
survivors for which suitable tissues were available. 
•  No primary neoplasms were detected in the urinary bladder. 
•  Metastatic lymphosarcomas involving the bladder were detected in: 
o  One control male 
o  One male at 500 mg/kg/day 
o  One female at 250 mg/kg/day 
o  Two females at 500 mg/kg/day 
o  Four females at 1,000 mg/kg/day 
Other  
There was no consistent evidence of a compound related effect in clinical chemistry 
assays conducted at termination. 
Serum L-phenylalanine determinations were unremarkable in males 
•  Mean values for the three treated groups of females were significantly 
decreased. 
•  This finding was considered to be of little biological significance since 
differences in individual values were minor in degree. 
Results of terminal urinalysis were unremarkable. 
Comments  Number of clinical chemistry analyses limited by volume of obtainable from mice 
and lack of suitable microanalytical methods at the time. 
Conclusions: 
Authors’ conclusions 
Omitted from review copy 
Reviewer’s comments 
N.B. Page 4 of the study report, which presumably summarises the histopathological findings and conclusions, is 
missing from the copy in the EFSA dossier. 
This study does not indicate any chronic toxicity or carcinogenic effect due to DKP when administered to mice via 
the diet at doses up to 1,000 mg/kg/day. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  Not evaluated 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP Check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in 
the diet mix, and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No location of archiving data 
•  No Study Director (although report author) 
•  No reported method of identification. Animals were house singly but not mentioned how 
tissues/samples were identified. There was a concurrent study for some of the time, see study E75. 
Not possible to confirm protocol objectives and any changes, as protocol not provided CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Commentary: 
General comments 
Interpretation of this study would have been facilitated by the provision of a summary table combining tumour 
incidences in decedents and animals included in the terminal sacrifice; however, the study seems to be of good 
quality for the date when it was carried out. 
Strengths and limitations of study 
Strengths: 
•  Inclusion of a large control group to assist in evaluation of statistical significance 
•  Range of tissues sampled was state of the art for the date the study was conducted. 
Limitations: 
•  Laboratory investigations only performed on a subset of mice. 
•  Number of clinical chemistry analyses limited by volume of obtainable from mice and lack of suitable 
microanalytical methods at the time (noted in UAREP report). 
•  Poor tissue accountability 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). The panel reported a discrepancy in survival between their analysis and that of the original 
study investigators (Unattributed, 1978c). Comparison of the control haematology and clinical chemistry values 
between this study and the concurrent study (E75) revealed more statistically significant differences than 
expected. The reason for this could not be established retrospectively. No major issues were identified in relation 
to the histopathology findings reported. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Adequate size: 36 mice per sex per group 
•  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus control 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intake close to that planned. 
No issues with pathology conduct or interpretation 
Relevance of the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of data sets 
Laboratory investigations only performed on a subset of mice. 
Number of clinical chemistry analyses limited by volume of blood obtainable from 
mice and lack of suitable microanalytical methods at the time (noted by UAREP). 
Poor survival to termination: 20-39% per group 
Tissue accountability better than for concurrent study (E75) 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
•  This study was included in the UAREP authentication review in 1978. This noted a discrepancy between 
the survival data in the study report and the outcome of re-analysis, and also observed an unusually high 
incidence of statistically significant differences in control values between this study and E75, which was 
carried out concurrently. No histopathology issues were raised. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Reviewer Details 
Name: Lesley Stanley   Date:27-Apr-12 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 2: Pathology 
Document identification: 
Title  SC-19192: 110-Week Toxicity Study in the Mouse 
(P-T No. 985H73) Final Report 
Authors  Reno, F.E., Ferrell, J.F.  Date  1974 
Study Type  Chronic Toxicity  Dossier #  E76 
Purpose of study: 
“…to evaluate and characterize the effects of long term dietary feeding of SC-19192 in ICR Swiss albino mice”. 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains for long term studies.  
Please comment on the choice, age and health status of the animals used. 
The animals appeared to be healthy throughout. The histopathological findings encountered were representative 
of the range of spontaneous pathology seen in this mouse stain with high incidences of amyloid deposition, 
spindle cell hyperplasia in the adrenal gland and chronic kidney disease. 
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes   
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
Checked once per day. 
No indication as to time to necropsy of spontaneous deaths or whether the animals were refrigerated or the whole 
body opened and fixed until necropsy. 
Procedures as reported were fine.  
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No significant differences between controls and treated animals. No unusual findings were reported. However, 
assessment was made difficult by the absence of a summary table which combined the incidences in decedents 
and terminal sacrifice animals. 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
                                                             
1 Please delete as applicable CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Please add comments on tissue sampling and preservation 
The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was conducted 
but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, Harderian glands, 
parathyroid glands, skin, thymus and trachea. 
Tissue accountability was better than in the other contemporaneous mouse study but approximately 8% of males 
and 5% of females were lost from histology due to escapes and other mishaps. The harvest of small tissues was 
fairly good. However, only 57% and 51% of pituitaries were examined from males and females respectively. 
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Without seeing the slides it is impossible to comment on the quality of the sectioning, tissue placement, staining 
etc. were consistent across the groups 
Pathology findings: 
Please give your expert opinion on the findings reported 
Diagnoses listed in the summary tables appeared sensible and consistently reported and in keeping with the 
expected range in this strain. 
As might be expected occasional archaic terms have been used e.g. ‘reticulum cell sarcoma’ for ‘histiocytic 
sarcoma’, ‘lymphosarcoma’ for ‘malignant lymphoma’ etc. 
Assessment of non-neoplastic microscopic findings and necropsy findings is made difficult by the lack of tables 
giving the incidences in all animals. 
No significant criticism in the interpretation or conduct given the age of the study. 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Study Identifier 05 Reno 1974 (E76) 
Study Title  SC-19192: 110-Week Toxicity Study in the Mouse 
  Y  N  Comment 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √     
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  No purity 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √  (1) 
A description of the dosage, dosage regimen, route of 
administration, and duration.  √    No reported 
analyses 
A description of all circumstances that may have affected the 
quality or integrity of the data.  √     
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    (not named 
as SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.  √  √  Only for 
specimens 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √  Presume N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) No reported method of identification. Animals were housed singly but not mentioned how 
tissues/samples were identified. There was a concurrent study for some of the time, see 04.  
Report GLP content check by/date: J Birnie, 11-19 April 2012 
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Document identification: 
Title  SC-19192: 115 Week Oral Tumorigenicity Study in the Rat 
Volume I and Volume II (P-T No. 988S73) 
Authors  Rao, K. S., Stejskal, R., McConnell, R. G.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E77-8 
Purpose of study: 
“…to evaluate the safety and tumorigenic potential of SC-19192, and to induce and define such adverse effects 






Purity  Not specified 
Lot # (s) 
1R A6906, 4R Drogt IV-236B, 2R Drogt IV-232A, 2R Drogt IV-232B, 4R Drogt IV-
236A, 3R A-7273, 3R IV-233B, 2R IV-232C, 2R A-7274, 6R JDR 5-30A (A9805), 5R 
JD 5-18A (A9129), 7R JDR 5-30B (A9829). 
Animals: 
Species:  Rats  Strain:  Albino, Charles River CD 
Source:  Not stated  Age/weight:  4 wk old at start of dosing 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration  0.4-3.6% in months 1-4 
Formulation procedure 
DKP was incorporated into the diet on a w/w basis with thorough dry mixing using a 
Hobart Model VCM-40 mixer. Fresh diets were prepared weekly for the first four 
weeks, once every two weeks for the next 12 weeks and monthly thereafter. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry 
Rats housed individually in suspended wire mesh cages. 
Animal quarters air conditioned; temperature set at 72￿C 
Fluorescent lighting; 12 hr light/dark cycle 
Food and water were available ad libitum. 
Diet  Weeks 1-62: Rockland Rat/Mouse diet (complete)  
Weeks 63 to end of study: Purina rat chow 
Minimisation of bias  Animals separated according to sex; assigned individual cages by the complete 
randomisation design 
Blocking of groups 
Subdivided into six groups per sex of 30 rats per group. 
Initiation of dosing for the 12 housing sections staggered over 2 weeks. 
Each group subdivided into dosage groups of 12 control and 6 treated animals. 
Number per group  72M/72F controls 
36M/36F per test group  Acclimatisation  1 week 






Actual intakes  Within “roughly 10%” of 
planned doses.  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Basis for dose selection 
Commercial grade aspartame may contain 0-2% of the conversion product DKP (SC-
19192), which may also be produced under various laboratory conditions; thus 
humans consuming aspartame would also be exposed to DKP. 
Doses were designed to deliver 0, 100, 200 and 400 times, respectively, the 
estimated daily human intake. 
•  Based on estimated maximum daily human intake of 7.5 mg/kg orally, 
assuming 25% decomposition of 30 mg/kg/day intake of aspartame by a 27 
kg humans. 
Dose correction 
Group dosage calculations were made from group mean body weight and group 
mean food consumption determinations performed periodically. Food consumption 
data from rats which spilled food was not used for dosage calculations. 
The required concentrations were relatively low (0.4-3.6%) during the first 3-4 
months of the study. 
•  During this period the various diets used were isocaloric. 
Required concentrations increased to 3.9% and 7.9% to deliver 1,500 mg/kg/day and 
3,000 mg/kg/day during the latter part of the study.  
•  During this time the various diets were not isocaloric, so treated groups 
received proportionately fewer calories per unit of diet than controls during 
this period. 
•  This may have influenced body weight and food intake, but definitive 
conclusions regarding nutritional effects were not drawn because the study 
was not designed to address this question. 
Comments 
The concentration of DKP in the diet is only actually specified for the first four months 
of the study. 
The use of very high dietary concentrations of DKP, leading to a reduction in the 
nutritional value of the diet, may have impacted the health status of the rats as well 
as their growth. 
Wide fluctuations in compound intake occurred in various groups throughout the 
study. This could also have compromised the outcomes. 
In life procedures: 
General observations 
Daily for survival; full 
observations carried out 
at time of weighing 
Clinical chemistry  
Performed periodically on 
one group of 48 rats 
containing 6M/6F from 
each dosage group.  
Food consumption 
Weekly for first four 
weeks, fortnightly for the 
next 8 weeks and every 
four weeks thereafter. 
Haematology 
Samples collected into 
sodium citrate or sodium 
EDTA-containing tubes on 
days 42, 92, 189, 364, 547 
and 734. 
Body weight 
Weekly for first four 
weeks, fortnightly for the 
next 8 weeks and every 
four weeks thereafter. 
Urinalysis 
3-4 hour urine collection in 
metabolism cages on days 
42, 92, 190, 364, 547 and 
734. 
Ocular examinations 
Direct and/or indirect 
exams conducted at start 
of study and at periodic 
intervals during the study 
Other  None 
Comments  Laboratory investigations only performed on a subset of rats. 
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Procedure for intercurrent deaths: 
Time to necropsy  Immediately where 
possible.  Parameters recorded  Not specified 
Tissues sampled 
If immediate necropsy not possible, thoracic and abdominal cavities were opened 
and the entire carcass was immersed in NBF for subsequent gross examination and 
dissection.  
Comments  It is not clear to what extent autolysis was a problem in the analysis of decedents. 
Termination procedures: 
Termination method  Unfasted survivors were selected at random, anaesthetised with ether and 
exsanguinated via the abdominal aorta. 
Time to necropsy  Presumably immediate  Parameters recorded  Body weight 
Organ weights 
External assessment  Not described 
Necropsy procedure  Not described 
Tissues sampled 
Tissues sampled at necropsy: 
Stomach 




















Nerve (Brachial plexus) 
Brain 
Spinal cord 
Bone with bone marrow (rib junction) 
Bone marrow smear 
Salivary gland (submaxillary) 
Eye 
*weighed fresh 
Histopathological examination was performed on available tissues from all animals in 
the study; all usual and unusual gross lesions and tissue masses were examined 
microscopically. Tissues were submitted for processing unless severely autolysed. 
Representative blocks of fixed tissues were embedded in paraffin, sectioned and 
stained with haematoxylin and eosin. 
Tissue specimen selection for microscopic evaluation: 
•  One sagittal section of stomach including forestomach, fundus and pylorus 
•  One section each from left and right lateral lobes of liver 
•  One section from right middle lobe of lung 
•  One transverse section from each kidney 
•  One section through mid-ventricles of heart 
•  One section from each ovary/testis 
•  One section from 4th and 5th mammary glands 
•  Seven coronal sections of brain, representing major neuroanatomical areas. 
o  Fixed brain was cut in five coronal slices measuring approximately 4 
mm in thickness, numbered 1-5 and embedded in paraffin. 
§  Two microscopic sections each were cut at different levels 
from block 3 (optic chiasma) and block 5 (midportion of 
cerebellum with trapezoid body). 
§  One section was cut from each of blocks 1, 2 and 4. 
•  Fixed urinary bladder was bisected longitudinally and both hemispheres 
were embedded in one paraffin block. 
o   Two sections at different levels (four levels in all) were examined. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  One representative section was examined microscopically from each of the 
other organs listed. 
Additional tissue blocks from heart, liver, kidney and adrenal of survivors were frozen 
in liquid nitrogen and stored at -94￿F for subsequent processing, if indicated. 
Air dried smears of femoral marrow in foetal calf serum were stained with 
Romanowsky stain and stored for subsequent use if needed to supplement marrow 
sections. 
Fixation 
Eye and pituitary in 
Zenker’s; all other tissues 
in cold NBF. 
Storage conditions  Frozen samples at -94￿F; 
otherwise not stated. 
Comments  The study gives a great deal of detail on the range of tissues analysed and the 
histopathological methods used, but does not describe the necropsy procedure. 
Statistical procedures: 
Data manipulation 
Calculations at each time point were based on a treatment group of six. In cases 
where there were missing values, the group mean was substituted for missing 
values 
•  Except in the analysis of body weight, food consumption and autopsy 
data, where data from all survivors was used in the calculations. 
•  The data base per group varies with the attrition rate 
All primary tumours found in any animal were listed except for multiple primary 
neoplasms of the mammary gland. 
•  All tumours of different histological types or with different prognostic 
implications detected in the same animal were listed separately. 
•  If two histologically identical tumours were initially detected at different 
times in the same animal, both were listed 
•  Where multiple histologically identical tumours were detected on the same 
day in a single animal, only one was listed. 
Statistical tests used 
Each treatment mean was compared to the control mean. Statistically significant 
differences were determined by use of the calculated Least Significant Difference. 
•  This statistic is based upon the Student’s t-value and the pooled mean 
square (pooled over treatment groups) 
•  In cases where the difference between a treatment mean, disregarding 
the sign, is greater than the Least Significant Difference, the difference is 
statistically significant at the 5% level. 
Tumour incidence was evaluated by the Sachs life table technique 
•  The adjusted tumour index was tested for significance using Chi square 
Results of in life observations: 
General observations 
No evidence of effects on physical appearance or behaviour of animals. 
No compound-induced decrease in survival rate was observed in any of the groups 
throughout the treatment period. 
•  A significant increase in survival was observed at 1,500 and 3,000 
mg/kg/day at some time points 
Food consumption 
Food intake was not consistently affected by treatment during the first 196 days of 
the study. 
•  Food intake by males at 3,000 mg/kg/day increased over days 196 - 644. 
Growth 
Body weight gain was not affected notably during the early part of the study. 
•  There were fluctuations in males at 750 and 1,500 mg/kg/day during the 
first 12 weeks of the study. Body weight gain was significantly reduced 
over this period in males, but not in females, at 3,000 mg/kg/day 
Later in the study, significant reductions in body weight were present consistently in 
both males and females at 3,000 mg/kg/day and periodically at lower doses. 
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Haematocrit (micro method) 
Haemoglobin (cyanmethaemoglobin) 
Total RBC count (Coulter counter) 
Total WBC count (Coulter counter) 
Differential WBC count (smear) 






Glucose (not on day 547) 
Ketones (not on day 547) 
Bilirubin 
Microscopic sediment 
Urobilinogen (not on days 92, 734) 
Phenylketones 
 

















The same 48 rats were used for all laboratory tests throughout the study 
•  In cases where an animal employed for clinical testing died during the study 
another rat randomly chosen from a corresponding group was substituted. 
No biologically meaningful, compound-related changes were observed in the 
haematology parameters evaluated. 
•  Values in treated groups occasionally deviated from control values, but these 
deviations were considered to be due to chance. 
No biologically meaningful, compound-related changes were observed in the clinical 
chemistry parameters evaluated except “possibly” serum cholesterol. 
•  A mild but significant decrease in serum cholesterol was observed at 3,000 
mg/kg/day in females (from day 42) and males (from day 92). These trends 
persisted for the remainder of the study, were more perceptible towards the end 
of the study, and were considered to be treatment-related. There were no 
marked effects on serum cholesterol at lower doses. 
No biologically meaningful, compound-related changes were observed in the 
urinalysis parameters evaluated except “possibly” urinary pH. 
•  Significant decreases in urinary pH were observed at one or more time points in 
all treated female groups, and appears to be treatment related at 3,000 
mg/kg/day. This was thought to be related to excretion of acidic metabolites of 
DKP in rat urine. 
Ocular examinations  There was no evidence of any compound-related ocular alterations. In general the 
opthalmoscopic findings were consistent with expected changes due to aging. 
Other 
Signs of aging commonly observed in Charles River rats occurred at low or 
moderate incidence during the first year and with gradually increasing frequency 
during the second year of the study. These occurred at comparable rates in both 
treated groups as well as in the control group. Signs observed included: 
•  Hunched appearance 
•  Roughening of the fur 
•  Desquamation of the tail 
•  Sores on all parts of the body, particularly the tail 
•  Localised alopecia on extremities and body 
•  Stained fur 
•  Soft faeces CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Respiratory signs characterised by laboured breathing and wheezing increased to a 
similar extent in all groups during the second year of the study. 
During the course of the study, two transient unidentified infectious diseases, 
affecting control and treated rats equally, became apparent in the colony. 
•  An unidentified infectious disease was observed between weeks 12-14 of 
treatment, affecting control and treated animals with equal frequency and 
severity. 
o  Many of the animals exhibited a swollen neck due to enlargement of 
the submaxillary glands. 
o  The eyes of affected animals bulged, appeared red and exhibited 
moderate lacrimation. 
o  These symptoms were suggestive of sialodacryoadenitis (viral 
infection of the salivary and Harderian glands). 
o  All affected animals recovered within two weeks. 
•  A presumed bacterial infection, also affecting control and treated animals with 
equal frequency and severity, developed during weeks 48-52. Many animals in 
all groups became morbid. 
o  Affected animals exhibited anorexia, weight loss, laboured breathing 
and dyspnoea. Those which died had histologically evident moderate 
to severe pneumonia. 
o  All morbid rats were injected intramuscularly with potassium penicillin 
G (20,000 U) to reduce lethality and morbidity. 
o  Survivors recovered within two weeks 
o  17 animals died: 
§  8 control 
§  3 low dose 
§  4 medium dose 
§  2 high dose 
Comments 
This study was clearly compromised by the two outbreaks of infection described in 
the report; it is not, however, clear to what extent, if any, these affected the final 
outcome. See pathology comments. 
Outcomes: 
Terminal body weights 
No biologically meaningful compound-related variations in organ weights were 
observed.  
•  Significant changes in absolute heart, liver and thyroid weights were 
observed in some groups, but these were not reflected in organ/body 
weight ratios or associated with histopathological changes. 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions 
Severe autolysis precluded histological evaluation of tissues from 20 rats: 
•  10 controls (9M/1F) 
•  1M at 750 mg/kg day 
•  3M at 1,500 mg/kg/day 
•  3M/3F at 3,000 mg/kg/day 
There was no evidence for treatment-related non-neoplastic changes in any organ 
or tissue. No unusual non-neoplastic lesions were observed. 
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The non-neoplastic changes which were observed were: 
•  Spontaneous pulmonary alterations in most rats. These included chronic 
murine pneumonia, accompanied by: 
o  Bronchiectasis with varying degrees of severity 
o  Chronic interstitial pneumonitis with chronic inflammatory changes 
in alveolar septa 
o  Acute or chronic bronchitis 
o  Peribronchial lymphoid hyperplasia 
o  Oedema 
o  Focal abscesses 
o  Perivascular lymphocytic infiltration 
•  GI tract changes, including gastric inflammation and ulceration 
o  Cross sections of nematodes were detected in the large intestines 
of a few control and treated rats. 
•  Myocardial alterations in a few rats 
•  Spontaneous chronic nephritis in all groups 
•  Focal/nodular hyperplasia and inflammation of the liver 
•  Pigmentation and extramedullary haematopoiesis in spleen 
•  Mild pancreatitis, ductal hyperplasia, glandular atrophy, islet cell 
hyperplasia and chronic arteriosis. 
•  Pituitary changes including chromophobe hyperplasia, congestion, 
occasional cysts and haemorrhage 
•  Focal metaplasia, follicular hyperplasia and follicular atrophy in the thyroid 
•  Angiectasis of the adrenal 
•  Non-neoplastic changes in the mammary gland 
•  Seminiferous tubular atrophy and other incidental findings in the testis 
•  Minor changes in the bladder including cystitis, submucosal oedema, 
mucosal trabeculation, calculi, epithelial dysplasia and muscular 
hypertrophy. 
•  Inflammatory changes, metaplasia and hyperplasia in the uterus 
•  Follicular/luteal cysts in the ovary 
•  Reticular cell hyperplasia 
•  Occasional abnormalities in the brain, including abscesses, meningitis, 
vasculitis, congestion, focal calcification and focal haemorrhage. 
•  Occasional ocular keratitis, dacryoadenitis, retinal degeneration or 
synechia. 
All non-neoplastic alterations observed were considered to be spontaneous in 
nature, being compatible with the age and strain of rats used. 
Neoplastic lesions 
Tumour data were analysed by sex employing an actuarial (Life-table) technique 
which adjusts for differing survival rates between groups. Using this method, tumour 
incidence was based on the number of animals actually at risk in each group and 
sex. 
All gross lesions were diagnosed; no unusual tumours were encountered. 
The tumour types considered were: 
•  Any tumour 
•  Benign tumours only 
•  Any malignant tumour 
•  Any mammary tumour 
•  Benign mammary tumour 
•  Malignant mammary tumour 
•  Any pituitary tumour 
o  The last four categories represented the tumour types most 
commonly observed in the study 
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In no instance in either sex at any of the treated levels was the adjusted tumour 
incidence of any of the types of tumour analysed significantly higher than that of the 
respective controls.  
•  The adjusted tumour incidence for benign tumours only, any mammary 
tumour and benign mammary tumours was significantly lower in females at 
3,000 mg/kg/day than in controls. This was not considered to be treatment 
related 
•  There were no statistically significant differences in adjusted tumour 
incidence data for control and treated males. 
Comments  The study was affected by two outbreaks of infectious disease; see Section 2 
Conclusions: 
Authors’ conclusions 
“It is concluded that continuous dietary administration of SC-19192 to four week old rats of both sexes for 115 
weeks at dose levels of 3.0 g/kg/day or less, causes no biologically meaningful alterations in survival rate, rate of 
body weight gain, physical exam and haematology findings, and post-mortem gross or microscopic changes. No 
significant increase in incidence of tumours of any type was observed. A consistent significant decrease in the 
absolute body weight was observed at the high dose level in both sexes. Food intake was consistently affected in 
the high dose males only. SC-19192 produced a significant decrease in urinary pH in the high dose female group, 
which was attributed to acidic metabolites of SC-19192 in the urine; also a mild but significant decrease in serum 
cholesterol was observed at the high dose level only. Biologically meaningful alterations were not consistently 
observed at lower dose levels (1.5 g/kg/day or less), however.” 
Reviewer’s comments 
This study does not indicate any overt toxicity or carcinogenic effect due to DKP when administered to rats via the 
diet at doses up to 3,000 mg/kg/day, although body weight was affected at the highest doses administered. The 
impact of several outbreaks of infectious disease on the study outcome is not clear. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  Yes 
Justification for Internal Quality Review:  Included in FDA Authentication Review (Taylor, Goldberg et al, 
1977) and Bressler review (Bressler, 1977). 
QA comments 
GLP Check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in 
the diet mix, and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No location of archiving data 
•  No Study Director (although report author) 
•  No address of facility 
•  No start/finish dates 
Possible lack of a description of all circumstances that may have affected the quality or integrity of the data.: no 
discussion of missing PKU values 
Not possible to confirm protocol objectives and any changes, as protocol not provided 
OECD Guideline check: 
Test item: similar to above. Source of supply not reported. The guideline also calls for a CoA for the test item 
which was not present. 
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Otherwise: 
No justification for species/stain selected historic data nor referenced, no mention of quality of food, water, 
bedding (e.g. content/contaminant analyses). 
Some individual and other data required by current guidance not reported, e.g.  BMD NOAL or LOAEL 
determination 
Supplementary Check: 
A sample of items were cross-checked for internal consistency: Some inconsistencies were noted: 
•  There’s no information on the lack of results for urinary PKU for low and mid dosed animals at day 
734. (High and controls are negative). 
•  There seems to be a dose-related increase in the incidence of endometrial polyp: 1, 3, 12 and 18 
which has been described as sporadic. 
•  Discussion on page 79 attributes the lower incidence of myocarditis in medium and high dose 
groups as spontaneous, but doesn’t mention the higher incidence in low dose males 
Commentary: 
General comments 
Typically CD rats have high incidences of pituitary and mammary tumours and before the introduction of dietary 
improvements high incidences of chronic progressive nephropathy. 
The health status and growth of the rats may have been affected by nutritional deprivation due to the high 
concentration of DKP in the diet of the highest dose groups. 
Strengths and limitations of study 
Strengths 
•  Detailed description of sampling method for histopathology. 
Limitations 
•  Intercurrent clinical chemistry analysis undertaken, but only on 6 rats per group.  
•  Study compromised by two (possibly three; see below) outbreaks of infectious disease, one (or two) of 
which required treatment with penicillin. 
•  No table of necropsy findings in report. 
Opinions of other commentators 
This study was included in the FDA Authentication Review, which concluded that issues relating to the 
homogeneity of the diet used could not be resolved (Taylor, Goldberg et al, 1977). Various “divergent practices” 
were also identified, but the overall conclusion of the Authentication Review was that the three studies 
investigated appeared to be authentic.  
A review of this study, conducted by a panel appointed by the US Bureau of Foods, was completed in 1977 
(Bressler, 1977). The documents in the dossier do not make it clear whether this was the same review as the FDA 
Authentication Review mentioned above. The review was very detailed but the main concerns expressed may be 
summarised as follows: 
•  The batches of DKP used in the study were inadequately characterised and there was evidence that one 
of the purity assays had been repeated until an average value of 100% was obtained (N.B. The study 
report makes no comment on the purity of the material used. This was identified in our QA review as a 
shortcoming, but there is no internal evidence in the report of any intention to mislead). 
•  There was evidence of a third outbreak of disease in towards the end of the study, and four rats were 
treated with penicillin. 
•  The clinical chemistry methods used were not always those indicated in the study report. The panel 
considered that this could have affected the absolute values reported although no comment is made 
regarding any potential effects on the study’s outcomes. 
•  In general, the results of a re-reading of the histology slides were in agreement with the original 
diagnoses, although there were some discrepancies. This review was limited by the fact that original 
pathology record sheets had not been kept. The following additional findings were noted: 
o  Three ovarian neoplasms  
o  One chronic cystitis and diffuse hyperplasia 
o  One uterine polyp, which could have affected the dose-dependency 
o  One mass which was reported as “missing” in the study records CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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The report (Bressler, 1977) does not draw any definitive conclusions as to whether the numerous minor 
inconsistencies and omissions noted seriously compromised the reliability of the study’s overall findings. 
A further review (FDA, 1976) notes that terminal clinical chemistry analyses specified in the protocol were not 
conducted. This issue is not apparent from the report, which does not mention the intention to undertake these 
assays; however, such analysis would certainly have strengthened the study since treatment related changes in 
serum cholesterol had been identified at earlier time points. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Adequate size: 36 per sex per treatment group 
•  Control groups: 72 per sex to enhance statistical power 
Three dose levels plus controls 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Purity of DKP batches used not specified. 
Calculated compound intake within “roughly 10%” of that planned. 
Study compromised by outbreaks of infectious disease: see Section 2. 
No issues with pathology conduct or interpretation 
Relevance of the study  Conventional two-year bioassay in a standard laboratory rodent species 
Adequacy of data sets 
Significant number of animals died from infection and/or lost to histology due to 
severe autolysis 
Intercurrent clinical chemistry analysis undertaken, but only on 6 rats per group.  
Detailed description of sampling method for histopathology. 
Some clinical chemistry values missing 
No table of necropsy findings in report 
Data sources  Commercial study report, pre-GLP (1974) 
Comments 
•  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which 
concluded that it was authentic. It is also covered in the Bressler Report (Bressler, 1977), which identifies 
various issues in relation to quality but does not draw clear conclusions regarding its authenticity. A 
further FDA review notes the absence of terminal clinical chemistry analysis from the study report (FDA, 
1976). 
•  This study would not be considered fully compliant with the current OECD Guideline for carcinogenicity 
testing (Number 451), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Reviewer Details 
Name: Lesley Stanley   Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
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Document identification: 
Title  SC-19192: 115 Week Oral Tumorigenicity Study in the Rat 
Volume I and Volume II (P-T No. 988S73) 
Authors  Rao, K. S., Stejskal, R., McConnell, R. G.  Date  1974 
Study Type  Chronic toxicity  Dossier #  E77-8 
Purpose of study: 
“…to evaluate the safety and tumorigenic potential of SC-19192, and to induce and define such adverse effects 
as might occur only at prodigious multiples of the estimated daily human intake.” 
Test animals: 
Was the species and strain selected appropriate to achieve the aims of the study?  Yes1   
What are the advantages and limitations of the species/strain selected? 
One of the standard species/strains used in long-term bioassays for which historical control data is readily 
available. Typically CD rats have high incidences of pituitary and mammary tumours and before the introduction of 
dietary improvements high incidences of chronic progressive nephropathy. 
Please comment on the choice, age and health status of the animals used. 
An outbreak of sialodacryoadenitis was seen between weeks 12 and 14 weeks that resolved with no after effects. 
At 48 to 52 weeks an unidentified respiratory disease, probably chronic murine pneumonia, was observed which 
probably led to a non-dosage related increase in mortality. This condition was treated with penicillin G. Although 
undesirable I would not expect either of these conditions or the treatment to have affected the overall outcome of 
the study.  
Necropsy procedures: 
Was the procedure for dealing with intercurrent deaths appropriate?  Yes?    
Was the timing of planned sacrifices (if any) appropriate?  Yes   
Was the time from death to necropsy appropriate?  Yes   
Please add comments on the necropsy procedures used 
Mortality check once per day. However, 20 animals were lost to histology because of severe autolysis. 
No further comments. The procedures as reported were adequate. 
Macroscopic observations: 
Please add comments on the macroscopic observations recorded 
No table of necropsy findings could be found in the report 
Tissue sampling and preservation: 
Was the appropriate range of organs/tissues sampled?  Yes   
Were the appropriate tissue dissection techniques used?  Yes   
Was the fixation procedure appropriate and adequate?  Yes   
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Please add comments on tissue sampling and preservation 
The range of organs/tissues sampled was probably ‘state of the art’ for the time when the study was conducted 
but modern recommendations would require a few additional tissues e.g. aorta, oesophagus, Harderian glands, 
parathyroid glands, skin, thymus and trachea. Also noted that only one section of many of the paired organs was 
examined. 
Tissue accountability for some of the small tissues was poor for a rat study e.g. the percentage examined for eyes 
in control males was 54%, pituitary in the same group 74%, thyroid 76% and spinal cord 61%  
Histology: 
Were the appropriate embedding, sectioning and staining procedures used?  Yes   
Did the pathologist examine all the relevant tissues?  Yes   
Please add comments on histology 
Without seeing the slides it is impossible to comment on the quality of the sectioning, tissue placement, staining 
etc. were consistent across the groups. 
Pathology findings: 
Please give your expert opinion on the findings reported 
Examination of the summary revealed a range of findings that one would expect to be present in this strain of rat. 
No synonyms were noted in any of the tissues. 
 
As might be expected some of the tumour nomenclature was outdated e.g. ‘Reticulum cell sarcoma’, 
‘lymphosarcoma’ and ‘hyperplastic nodule’. 
 
I agreed with the study pathologist’s overall conclusions and considering the date when it was conducted I have 
no significant criticisms of its conduct. 
 
General comments: 
Please add any other comments on this study 
None 
Reviewer Details 
Name: Peter Millar  Date: April 2012 
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Study Identifier  06 1974 (E77-8) 
Study Title  SC-19192: 115 Week oral tumorigenicity study in the RAT 
  Y  N  Comment 
below 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No address 
nor dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 








A description of the dosage, dosage regimen, route of 
administration, and duration.  √  √  No analyses 
A description of all circumstances that may have affected the 
quality or integrity of the data.  √  √ 
No mention of 
missing PKU 
values 
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    (not named 
as SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.    √  Specimens 
only 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √  Presume N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
None 
Report GLP content check by/date: J Birnie 19 April 2012 
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Study identifier  06 1974 (E77-8) 
Study Title  SC-19192: 115 Week oral tumorigenicity study in the RAT 
*OECD Guideline no: 451 Carcinogenicity Studies 
 
*§    Y  N  Comment 
17  Analytical information on the nutrient and dietary contaminant levels 
should be generated periodically, at least at the beginning of the 
study and when there is a change in the batch used, and should be 
included in the final report  
  √   
17  Analytical information on the drinking water used in the study should 
similarly be provided    √   
39  Individual animal data should be provided for all parameters 
evaluated    √   
39  Additionally, all data should be summarised in tabular form showing 
for each test group        
  the number of animals at the start of the test  √     
  the number of animals found dead during the test or killed for 
humane reasons and the time of any death or humane kill  √     
  the number showing signs of toxicity, a description of the signs of 
toxicity observed, including time of onset, duration, and severity of 
any toxic effects 
  √   
   the number of animals showing lesions, the type of lesions and the 
percentage of animals displaying each type of lesion  √     
39  Summary data tables should provide the means and standard 
deviations (for continuous test data) of animals showing toxic effects 
or lesions, in addition to the grading of lesions 
√     
40  Historical control data, if evaluated, should be submitted from the 
same laboratory and relate to animals of the same age and strain 
generated during the five years preceding the study in question 
  √  N/A 
41  When applicable, numerical results should be evaluated by an 
appropriate and generally acceptable statistical method. The 
statistical methods and the data to be analysed should be selected 
during the design of the study. Selection should make provision for 
survival adjustments, if needed. 
√     
42  The test report should contain the following information: 
  Test substance:        
  physical nature, purity, and physicochemical properties    √  No purity. 
  identification data  √     
  source of substance    √   
  batch number  √     
  certificate of chemical analysis    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)    √  N/A 
  Test animals        
  species/strain used and justification for choice made  √  √  No 
justification 
  number, age, and sex of animals at start of test  √     
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test    √   
  Test conditions:       
  rationale for route of administration and dose selection  √     
  when applicable, the statistical methods used to analyse the data  √     
  details of test substance formulation/diet preparation  √     
  analytical data on achieved concentration stability and homogeneity 
of the preparation    √   
  route of administration and details of the administration of the test  √     CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 451: report content 
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*§    Y  N  Comment 
substance 
  for inhalation studies, whether nose only or whole body    √  N/A 
  actual doses (mg/kg body weight/day), and conversion factor from 
diet/drinking water test substance concentration (mg/kg or ppm) to 
the actual dose, if applicable 
√  √  No 
analyses 
  details of food and water quality    √   
  Results (summary tabulated data and individual animal data should 
be presented)       
  general       
  survival data  √     
 




  food consumption, calculations of food efficiency, if made, and 




  toxicokinetic data if available    √  N/A 
  opthalmoscopy (if available)  √     
  haematology (if available)  √     
  clinical chemistry (if available)  √     
  clinical findings       
 









  nature, severity and duration of clinical observations (whether 




  necropsy data       
  terminal body weight  √     
  organ weights and their ratios, if applicable  √     
  necropsy findings; incidence and severity of abnormalities  √     
  histopathology       
  non neoplastic histopathological findings  √     
  neoplastic histopathological findings  √     
  correlation between gross and microscopic findings  √     
  detailed description of all treatment-related histopathological findings 
including severity gradings  √     
  report of any peer review of slides    √  N/A 
  statistical treatment of results, as appropriate       
  discussion of results, including  √     
  discussion of any modelling approaches    √   
  dose-response relationships  √     
  historical control data    √   
  consideration of any mode of action information  √     
  BMD NOAL or LOAEL determination    √   
  relevance for humans    √   
  conclusions       
Comments: 
None 
Report content QA check by/date: J Birnie 19 April 2012 
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Study ID  06 1974 (E77-8) 
Study Title  SC-19192: 115 Week oral tumorigenicity study in the RAT 
Internal Consistency  
 
A sample of items were cross-checked for internal consistency: 
 
§  Some reported results vs tables and appendices 
§  Individual gross and microscopic observations vs: terminal body and organ weights, 
haematology/clin-path and urinalysis, listing of histologically proven tumours, 
narrative relating to early decedents, ophthalmoscopy for 7 animals 
§  Some calculated means, incidence data or frequency data values vs individual data 
for haematology and urinalysis, no of rats lost due to autolysis, and histologically 
proven tumours 
§  Some reported results vs incidence tables for a sample of tumours 
§  Incidence of pituitary tumours for Medium dose females vs incidence included in 
statistical analyses tables  
§  Methodology sections for consistence with reported data for haematology/clin-path 
and urinalysis 
§  Individual gross and microscopic observations  vs table of survival data fir high group 
males 
 
Some inconsistencies were noted: 
There’s no information on the lack of results for urinary PKU for low and mid dosed 
animals at day 734. (High and controls are negative). 
There seems to be a dose-related increase in the incidence of eudiometrical polyp: 1, 
3, 12, 18 which has been described as sporadic 
Discussion on page 79 attributes the lower incidence of myocarditis in medium and 
high dose groups as spontaneous, but doesn’t mention the higher incidence in low 
dose males 
 
Information relating to the test item  
 





J Birnie 19 April 2012 
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Section 1: Study details 
Document identification: 
Title  SC-18862: An Evaluation of the Embryotoxic and Teratogenic Potential in the Mouse. 
(Project No. 1218) 
Authors  Vondruska, J. F., Schroeder, R. E., Mitchell, A.  Date  1975 
Study Type  Embryotoxicity/teratogenicity  Dossier #  E89 
Purpose of study: 
“…to evaluate the embryotoxic and teratogenic potential of SC-18862 (aspartame) when by means of dietary 
incorporation to the pregnant albino mouse during the period of fatal organogenesis”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  0.29% DKP (assumed 
100% pure for formulation) 
Lot # (s)  59687, Q.C. C0075 
Animals: 
Species:  Mouse  Strain:  Charles River CD-1 
Source:  Not stated  Age/weight: 
Females 70 ± 5 days old 
at start of mating period 
Males from an in house 
breeding colony used for 
breeding only. 
Comments:   None 
Formulation: 




Formulation procedure  Compound administered by incorporation into diet. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry 
During acclimatisation, females housed on groups of four in suspended wire mesh 
cages. 
Animal quarters air-conditioned, temperature set at 72￿F 
Fluorescent lighting; 12 hr light/dark cycle. 
Mating units comprised 1M/4F 
•  Each mating unit contained one female from each dosing group, identified 
by tail painting. 
•  Mating verified by presence of copulation plug  
o  Day of plug appearance designated gestation day 0. 
•  After mating, females were returned to individual cages. 
Mated females hosed individually in suspended wire mesh cages. 
Diet and chlorinated tap water available continuously ad libitum 
Diet  Purina Rat Diet (Ralston Purina Co., St Louis, Mo, USA) 
Minimisation of bias  Simple randomisation procedure (reference cited) 
Blocking of groups  None indicated CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Number per group 
36F per dose placed in 
mating groups; ≥ 32 
females per group mated. 
Acclimatisation  2 weeks 
Mating period 4 weeks 
Start of dosing  pcd 5  Duration  Dosed from pcd 5 to pcd 











Basis for dose selection  Based on mice weighting 30 g and consuming 4 g food daily. The reason for choice 
of dose levels is not stated. 
Dose correction  None indicated. 
Comments 
Mating had to be continued over four weeks to ensure ≥32 females from each 
experimental group had mated; this means that there was a long gap in time 
between the first and last litters examined. 
The reason for mating one female from each dose group with each male is not 
stated; this could be a way of reducing bias but it also introduces the possibility of 
introducing errors when returning females to their home cages. 
No justification is provided for the doses selected. 
The exposure of foetuses in this study would not have been to aspartame itself but to 
its breakdown products (predominantly L-Phe, possibly also L-Asp and methanol). 
In life procedures: 
General observations  Daily  Clinical chemistry   None specified 
Food consumption  Daily  Haematology  None specified 
Body weight  pcd 0, 3, 6, 10, 13, 15, 18  Urinalysis  None specified 
Ocular examinations  None specified  Other  None specified 
Comments  Only very limited in life observations seem to have been conducted. 
Procedure for intercurrent deaths: 
Time to necropsy  N/A  Parameters recorded  N/A 
Tissues sampled  N/A 
Comments  Maternal survival was 100% 
Termination procedures: 
Termination method  Carbon dioxide euthanasia 
Time to necropsy  Presumably immediate  Parameters recorded  See below 
External assessment  Not described 
Necropsy procedure 
Uterine horns exposed and examined. 
•  Foetal swellings and resorption sites counted, positions recorded 
Uterus incised. 
•  Foetal viability determined on basis of respiratory movements, skin colour 
and movement of extremities and head 
Foetuses removed. 
•  Sexed 
•  Crown-rump distance measured 
•  Examined externally for gross malformations 
•  Preserved intact for assessment of malformations 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Tissues sampled 
Visceral examination of 1/3 of foetuses 
•  Sectioned by freehand technique of Wilson 
o  Head sectioned into four slices (~1 mm thick) in transverse plane 
to reveal abnormalities of palate, nasal cavities, eyes and brain 
o  Thorax sectioned (two slices (≤ 1mm thick)) starting at shoulder 
joint and continuing caudally to diaphragm to reveal abnormalities 
of thymus, heart, lungs, oesophagus, trachea, diaphragm and 
major blood vessels. 
o  Abdomen sectioned (three slices) 
§  One approximately 2 mm caudal to diaphragm and 
examined for abnormalities of the liver, aorta, spinal cord 
and stomach. 
§  One at level of renal pelvis, examined for anomalies of 
spinal cord, aorta, intestinal tract and kidneys. 
o  Structures found in pelvic cavity (i.e. ureters, bladder and 
reproductive tract) examined in situ after removal of intestine. 
•  Examined under dissecting microscope (7 x) 
•  All tissue slices from treated foetuses and from control foetuses with 
anomalies were transferred to glass vials filled with 70% ethanol for 
temporary storage. 
Skeletal examination of 2/3 of foetuses 
•  Fixed in 95% ethanol 
•  Eviscerated 
•  Macerated and cleared in 2.5% aqueous KOH 
•  Stained with saturated aqueous Alizarin Red S 
•  Differentiated with Mall’s solution 
•  Stored in 100% glycerine containing “several crystals of thymol to prevent 
bacterial growth”  
•  Examined by naked eye and/or dissecting microscope (7x) for anomalies 
•  Other parameters recorded 
o  Number and size of sterna ossification centres 
o  Degree of closure of cranial ossification 
o  Number of metacarpals, metatarsals and corresponding phalanges 
•  All treated and control skeletal preparations placed in temporary storage 
Fixation  See above  Storage conditions  Not specified 
Comments  The use of 95% ethanol as a fixative would have tended to dehydrate the skeletal 
samples, making them fragile and susceptible to damage. 
Statistical procedures: 
Data manipulation  Means and standard errors of various measured parameters calculated for each 
dosage group. 
Statistical tests used 
Two tailed Student’s t-test used to analyse mean maternal body weight data at 
each measurement interval, daily mean food consumption data, mean litter size 
and resorption data, mean foetal body weight and CRD data. 
Chi-Square test used to analyse maternal survival, conception rates, foetal sex 
ratios, incidence of litters containing foetuses only, foetuses and resorption sites 
and resorption sites only. 
Fisher Exact test used to analyse incidence of major foetal malformations and 
certain skeletal variants. 
Statistical significance set at p=0.05 in each test. 
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Results of in life observations: 
General observations 
No unusual physical or behavioural observations. 
No effect on: 
•  Maternal survival (100%) 
•  Conception rates 
o  77.1% in controls 
o  75.8% at 1,000 mg/kg/day 
o  84.4% at 2,000 mg/kg/day 
o  65.6% at 4,000 mg/kg/day 
•  Incidence of abortions and premature deliveries 
o  One abortion in a control female 
o  Premature deliveries in on female at 1,000 mg/kg/day and one at 
2,000 mg/kg/day 
o  Data from these three females were not included in statistical 
analysis of litter size, foetal size or malformation rates. 
Food consumption 
No effect. 
•  Daily food consumption quite variable but no consistent pattern of changes 
in response to aspartame 
Actual consumption of aspartame was approximately 40% higher than planned. 
Growth  No effect on maternal body weight changes. 
Laboratory tests  Not performed 
Ocular examinations  Not performed 
Other  Not performed 
Comments  In life observations very limited 
Outcomes: 
Terminal body weights  Not discussed 
Maternal parameters 
No unusual hysterotomy findings in 
•  35 controls 
•  33 dams at 1,000 mg/kg/day 
•  32 dams at 2,000 mg/kg/day 
•  32 dams at 4,000 mg/kg/day 
No effect on: 
•  Number of litters containing 
o  foetuses only 
o  both foetuses and resorption sites 
o  resorption sites only 
•  Mean litter size 
•  Mean number of resorptions per litter 
Five dead foetuses recovered 
•  One from a control 
•  One at 1,000 mg/kg/day 
•  Three at 2,000 mg/kg/day 
Litter examination 
Foetal examination 
No effect on mean: 
•  Foetal body weight (male and female pups) per litter 
•  Crown-rump distance per litter 
Malformations observed 
No effect on number of major malformations 
•  1/250 control foetuses (25 litters) 
o  Hypoplastic fourth thoracic vertebral centrum 
•  0/251 foetuses at 1,000 mg/kg/day (24 litters) CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  1/261 foetuses at 2,000 mg/kg/day (25 litters) 
o  Exencephaly, cleft palate, bilaterally open eyes 
•  0/204 foetuses at 4,000 mg/kg/day (20 litters) 
These findings were not unusual for the Charles River CD-1 mouse strain. 
Minor skeletal variants considered (per litter and per foetus) were: 
o  Reduced skull closure 
o  Poorly ossified supraoccipital bones 
o  Presence of 14 pairs of ribs 
o  Split 5th/6th sternebrae,  one or more/two split sternebrae 
o  Presence of an additional sternebra 
o  Presence of any sternebral variant 
o  Presence of any vertebral variant 
•  An increased incidence of poorly ossified supraoccipital bones per foetus 
was detected at 2,000 mg/kg/day 
•  Fewer foetuses with additional sternebrae were observed at 1,000 and 
4,000 mg/kg/day 
•  The number of litters with ≥1 foetus with one or more split sternebrae was 
increased at 4,000 mg/kg/day 
o  These observations were attributed to random variation and/or the 
effects of combining data. 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions  N/A 
Neoplastic lesions  N/A 
Comments 
Very few major malformations arose in this study but various minor malformations 
were observed. In particular, there was an increase in the number of litters in which 
≥1 foetus had one or more split sternebrae at 4,000 mg/kg/day. This is attributed by 
the authors to random variation and/or the effects of combining data, but the 
explanation given appears rather weak. 
Conclusions: 
Authors’ conclusions 
“Administration of SC-18862 to the Charles River CD-1 mouse by dietary incorporation at levels of up to 5.7 g/kg 
of body weight from gestation days 6 through 15 was without effect upon maternal survival and conception rates, 
maternal body weight changes, food consumption, the incidence of abortions and premature deliveries, the 
proportions of litters that consisted of foetuses only, of both foetuses and resorption sites, or of resorption sites 
only, mean litter size, mean number of resorptions per litter, mean male and female body weights and crown-rump 
distances, and the number of major malformations and skeletal variants, when compared on a fatal incidence and 
a litter incidence basis. All comparisons were made between the control group and each treated group with the 
level of significance at p < 0.05.” 
Reviewer’s comments 
This study does not indicate any clear cut effects on maternal, litter or foetus parameters due to aspartame when 
administered to rats via the diet at doses up to 4,000 mg/kg/day. The report provides no clear explanation for the 
increased incidence of split sternebrae observed. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  Yes 
Justification for Internal Quality Review:  Included in FDA Authentication Review (Taylor, Goldberg et al, 
1977) and Bressler review (Bressler, 1977). CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
QA comments 
GLP check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) * 
•  Procedure for identifying litters not described 
•  No Study Director (although report author) 
•  No start/finish dates 
•  Possible lack of a description of all circumstances that may have affected the quality or integrity of the 
data: The report doesn’t provide any information on why some data are missing  (“ND= no data”  flagged 
for some maternal SC-18862 consumption, food consumption and bodyweight values), nor discuss the 
impact. 
•  Some data aren’t presented in the report, but it isn’t clear from the report that these data have been 
retained and are available for review if ever needed. 
Not possible to confirm protocol objectives and any changes, as protocol not provided. A letter included with the 
report that shows independent review confirming Protocol adherence, although this appears to cover the Protocol 
only not study data*. 
OECD Guideline check: 
Test item: similar to above, characterisation etc required by current guidelines not present.  
Otherwise: 
No justification for dose selection; historic data nor referenced, no mention of quality of food, water, bedding (e.g. 
content/contaminant analyses). 
Some individual and other data required by current guidance not reported, e.g.  foetal soft tissue evaluation, 
maternal clinical signs, uterus weights, NOAEL estimation. 
Supplementary Check: 
It isn’t clear how the incidence of the major malformations has been calculated, in order to compare with the 
background incidence for the strain – e.g. per group 1/250, or study population? 1/966? 
Otherwise: the majority of reported values including some calculations were subjected to sample checking for 
internal consistency within the report. 
Some inconsistencies were noted 
•  Appendix Table 6 reports a statistically significant (lower) difference at  p<0.01 one of the skeletal 
observations. Throughout the narrative and at the end of the conclusion there is only reference to p< 
0.05. 
•  The rationale for excluding litters with resorptions only from calculating means, including means for 
resorptions isn’t clear (This has been done for all groups). 
•  The report doesn’t provide any information on why some data are missing  (“ND= no data”  flagged for 
some maternal SC-18862 consumption, food consumption and bodyweight values), nor discuss the 
impact 
•  Appendix Table 1: Summary of Hysterotomy data doesn’t make clear all of the litters that have been 
excluded from calculating the mean. 
•  There are a couple of tables with * and footnotes re. statistically significant different from control, but not 
clear which values this refers to, e.g. Appendix Tables 1 and 2  
•  There are 2 sets of mean data for food consumption, prior to the individual values and at the foot of each 
group’s individual values. The latter has some days that aren’t included in Figure 2 – thus a dip on 
gestation day 4 isn’t visible  
•  Methodology “foetuses were given a thorough gross external examination prior to being euthanised”  
implies some observations that aren’t reported. 
•  Some data aren’t presented in the report, but it isn’t clear from the report that these data have retained 
and are available for review if ever needed. 
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Commentary: 
General comments 
No further comments 
Strengths and limitations of study 
Limitations 
•  Limited study: maternal data, visceral abnormalities and skeletal malformations only 
•  Some individual and other data required by current guidance not reported. 
Opinions of other commentators 
The study report includes a letter from Dr Bernard L. Oser (Bernard L. Oser Associates Ltd, Food and Drug 
Consultants, NY, USA) stating that “The protocol appears to have been followed as described and in my opinion 
the results of the study support the conclusion reached by the authors, viz. that Aspartame was neither 
teratogenic nor embryotoxic to mice under the test conditions employed”. 
This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977). Various “divergent 
practices” were also identified, but the overall conclusion of the Authentication Review was that the three studies 
investigated appeared to be authentic. 
A review of this study, conducted by a panel appointed by the US Bureau of Foods, was completed in 1977 
(Bressler, 1977). The documents in the dossier do not make it clear whether this was the same review as the FDA 
Authentication Review mentioned above. The review was very detailed but the main concern expressed was that 
there was a failure of blinding in that the individual evaluating the foetuses for abnormalities was aware of which 
group they were from. The report (Bressler, 1977) does not draw definitive conclusions as to whether the 
numerous minor inconsistencies and omissions noted seriously compromised the reliability of the study’s overall 
findings. 
A review was also provided to the FDA as part of an evaluation of four Searle teratogenicity studies on aspartame 
(Collins, 1978). Collins did not express any concerns regarding this study, and concluded that it indicated no 
compound-related teratogenic effects at doses up to 4,000 mg/kg/day. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
≥32 dams per group mated 
•  ≥200 foetuses per group examined for visceral abnormalities 
•  ≥ 200 foetuses per group examined for skeletal malformations 
Three dose levels plus control 
Rationale for some data manipulations is unclear 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No details of diet preparation provided. 
Calculated compound intake up to 35% higher than planned. 
Report lacks information on why some data are missing (“ND= no data”  flagged for 
some maternal values), nor discuss the impact of these omissions. 
Relevance of the study  Evaluation of embryotoxicity and teratogenicity in a standard laboratory rodent 
species. 
Adequacy of data sets 
Maternal survival 100%. 
Limited in life observations; no laboratory investigations. 
No explicit description of visceral observations. 
Not clear how incidence of major malformations was calculated for comparison with 
background incidences. 
Data sources  Commercial study report, pre-GLP (1975) 
  
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Comments 
•  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
•  The study report was peer reviewed by an external consultant. 
•  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which 
concluded that it was authentic. It is also covered in the Bressler Report (Bressler, 1977), which identifies 
a failure of blinding in the foetal examination and a lack of documentation but does not draw clear 
conclusions regarding its authenticity. No substantive issues were raised in the review of Collins (Collins, 
1978). 
•  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley   Date: 27-Apr-12 
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FDAGLP report content 
Page 1 of 1 
Study Identifier 11 1975 (E89) 
Study Title  SC-18862: An Evaluation of Embryotoxic and Teratogenic Potential in the Mouse 
  Y  N  Comment 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.  √   
per letter from 
independent 
reviewer 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√     
Stability of the test and control articles under the conditions of 
administration.    √  nor homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and substrain, age, and 
procedure used for identification. 
√  √ 
How litters were 
identified is not 
described 
A description of the dosage, dosage regimen, route of 
administration, and duration.  √  √ 
No reported analyses 
to confirm dosage 
concentrations 
A description of all circumstances that may have affected the 
quality or integrity of the data.    √  See comment (1) 
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√  √  (Although not 
identified as SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.    √  See comment (2) 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.  √  √  (Although not 
identified as SD) 
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √ 
Nothing to indicate it 
is an amended report 
therefore assume 
N/A 
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) The report doesn’t provide any information on why some data are missing  (“ND= no data”  
flagged for some maternal SC-18862 consumption, food consumption and bodyweight values, nor 
discuss the impact 
(2) Some data aren’t presented in the report, but it isn’t clear from the report that these data have 
retained and are available for review if ever needed. 
Report GLP content check by/date: J Birnie, 18 April 2012 
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Study identifier  11 1975 (E89) 
Study Title  SC-18862: An Evaluation of Embryotoxic and teratogenic potential in the 
Mouse 
*OECD Guideline no: 414  Prenatal development 
 
*§    Y  N  Comment 
33  Data shall be reported individually and summarised in tabular 
form, showing for each test group and each generation the 
number of animals at the start of the test, the number of 
animals found dead during the test or killed for humane 
reasons, the time of any death or humane kill, the number of 
pregnant females, the number of animals showing signs of 
toxicity, a description of the signs of toxicity observed, 
including time of onset, duration, and severity of any toxic 
effects, the types of foetal observations, and all relevant litter 
data. 





34  Numerical results should be evaluated by an appropriate 
statistical method using the litter as the unit for data analysis. A 
generally accepted statistical method should be used; the 
statistical methods should be selected as part of the design of 
the study. Data from animals that do not survive to the 
scheduled kill should also be reported. These data may be 
included in group means where relevant. Relevance of the 
data from such an animal, and therefore inclusion or exclusion 
from any group mean(s), should be judged on an individual 
basis. 
√     
35  The findings of the Prenatal Developmental Toxicity Study 
should be evaluated in terms of the observed effects. The 
evaluation will include the following information: 
§ maternal and foetal test results, including an 
evaluation of the relationship, or lack thereof, between 
the exposure of the animals to the test substance and 
the incidence and severity of all findings; 
§ criteria used for categorising foetal external, soft 
tissue, and skeletal alterations if categorisation has 
been done; 
§ when appropriate, historical control data to enhance 
interpretation of study results; 
§ the numbers used in calculating all percentages or 
indices; 
§ adequate statistical analysis of the study findings, 
when appropriate, which should include sufficient 
§ information in the method of analysis, so that an 
independent reviewer/statistician can re-evaluate and 
reconstruct the analysis. 




37  The test report must include the following specific information: 
  Test substance:        
  physical nature, and, where relevant,  physicochemical 
properties  √     
  identification including CAS number if known/established  √  √  No CAS 
  purity    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)    √  N/A 
  Test animals        
  species/strain used   √     
  number, age  √     CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 414 report content 
 
Page 2 of 2 
*§    Y  N  Comment 
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test    √   
  Test conditions:       
  rationale for dose level selection    √   
  details of test substance formulation/diet preparation  √  √   
  achieved concentration stability and homogeneity of the 
preparation    √   
  details of the administration of the test substance  √     
  conversion from diet/drinking water test substance 
concentration (ppm) to the actual dose (mg/kg) if applicable  √     
  environmental conditions 




  details of food and water quality    √   
  Results        
  Maternal toxic response data by dose, including but not limited 
to:       
  the number of animals at the start of the test, the number of 
animals surviving, the number pregnant, and the number 
aborting, number of animals delivering early; day of death 
during the study or whether animals survived to termination 
√     
  day of death during the study or whether animals 
survived to termination  √     
  data from animals that do not survive to the scheduled kill 
should be reported but not included in the inter-group statistical 
comparisons 
√     
  day of observation of each abnormal clinical sign and its 
subsequent course    √   
  body weight, body weight change and gravid uterine 
weight, including, optionally, body weight change 
corrected for gravid uterine weight 
√  √  Uteri not 
weighed 
  food consumption and, if measured, water consumption;  √     
  necropsy findings, including uterine weight  √  √  Uteri not 
weighed 
  NOAEL values for maternal and developmental effects should 
be reported    √   
  Developmental endpoints by dose for litters with implants, 
including:       
  number and percent of live offspring  √     
  sex ratio  √     
  foetal body weight, preferably by sex and with sexes 
combined  √     
  external, soft tissue, and skeletal malformations and 
other relevant alterations  √  √  Not for soft 
tissue 
  criteria for categorisation if appropriate  √  √  Not for soft 
tissue 
  total number and percent of foetuses and litters with any 
external, soft tissue, or skeletal alteration, as well as the 
types and incidences of individual anomalies and other 
relevant alterations 
√  √  Not for soft 
tissue 
  discussion of results  √     
  conclusions  √     
Comments: 
None 
Report content QA check by/date : J Birnie, 18 April 2012 
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Supplementary QA Check 
 
Page 1 of 1 
Study ID  11 1975 (E89) 
Study Title  SC-18862: An evaluation of embryotoxic and 
teratogenic potential in the mouse 
Internal Consistency  
 
The majority of reported values including some calculations were subjected to 
sample checking for internal consistency within the report. 
 
Some inconsistencies were noted 
 
§  Appendix Table 6 reports a statistically significant (lower) difference at  p<0.01 one of 
the skeletal observations. Throughout the narrative and at the end of the conclusion 
there is only reference to p< 0.05. 
§  The rationale for excluding litters with resorptions only from calculating means, 
including means for resorptions isnt clear (This has been done for all groups). 
§  The report doesn’t provide any information on why some data are missing  (“ND= no 
data”  flagged for some maternal SC-18862 consumption, food consumption and 
bodyweight values), nor discuss the impact 
§  Appendix Table 1: Summary of Hysterotomy data doesn’t make clear all of the litters 
that have been excluded from calculating the mean. 
§  There are a couple of tables with * and footnotes re statistically significant different 
from control, but not clear which values this refers to, e.g. Appendix Tables 1 and 2  
§  There are 2 sets of mean data for food consumption, prior to the individual values and 
at the foot of each group’s individual values. The latter has some days that aren’t 
included in Figure 2 – thus a dip on gestation day 4 isn’t visible  
§  Methodology “foetuses were given a thorough gross external examination prior to 
being euthanized” implies some observations that aren’t reported. 
 
Information relating to the test item  
 
There is no information on stability and homogeneity in the diet mixtures, or whether 
any analysis was done to test actual concentrations. 
Other comment 
 
It isn’t clear how the incidence of the major malformations has been calculated, in 
order to compare with the background incidence for the strain) – e.g. per group 
1/250, or study population? 1/966? 
 
Some data aren’t presented in the report, but it isn’t clear from the report that these 
data have been retained and are available for review if ever needed. 
 
Name/date 
J Birnie, 18 April 2012 
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Section 1: Study details 
Document identification: 
Title  SC-18862: Evaluation of Embryotoxic and Teratogenic Potential in the Rat 
Authors  Schroeder, R. E., McConnell, R. G.  Date  1970 
Study Type  Embryotoxicity/teratogenicity  Dossier #  E5 
Purpose of study: 
“…to evaluate the embryotoxic and/or teratogenic potential of SC-18862, a nutritive dietary sweetening agent, 
when administered orally in the diet to the albino rat”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Assumed 100% pure 
Lot # (s)  74020 
Animals: 
Species:  Rat  Strain:  Charles River CD 
Source:  Not stated  Age/weight: 
Virgin females mated 
       at approx100 days old 
Proven males 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration 
2.34% to deliver 
         2,000 mg/kg/day 
5.00% to deliver 
         4,000 mg/kg/day 
Formulation procedure  Aspartame mixed into basal diet on a w/w basis by thorough mixing using Hobart 
Model V-1401 mixer. 
Confirmatory analysis  None indicated 
Comments  See QA comments 
Study design: 
Animal husbandry 
Rats housed in groups of two in suspended metal cages with wire mesh floors. 
•  For mating, individual males were housed with up to 3 females in solid 
bottomed Wahmann breeding cages (10x11x14”) with Ab-sorb-dri bedding. 
•  The three females in each mating cages were one from each dosage group 
•  Mating verified by presence of copulation plug and/or spermatozoa in 
vaginal smear; day of plug appearance designated gestation day 0. 
•  After mating, females were returned to individual cages. 
Mating was completed over an 11 day period. 
Diet and chlorinated tap water were available ad libitum throughout study. 
Diet  Rockland Mouse/Rat diet, complete, meal form (Teklad, Inc) 
Minimisation of bias  Not reported 
Blocking of groups  Not reported 
Number per group 
30F per dose placed in 
mating groups; ≥ 24 
females per group mated 
Acclimatisation  Approx 2 weeks 
Mating period 11 days 
Start of dosing  pcd 6  Duration  Dosed from pcds 6 to 15; 
sacrificed on pcd 20. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 









Basis for dose selection 
Multiples of average daily consumption for 24 kg child (0.05 g/kg/day), maximum 
mean consumption for 24 kg child (0.2 g/kg/day) and 50 kg adult (1 g/kg/day). 
•  Low dose =  
o  1000 x average child consumption 
o  250 x maximum child consumption 
o  100 x adult consumption 
•  High dose  =  
o  2000 x average child consumption 
o  500 x max child consumption 
o  200 x adult consumption 
Dose correction 
Dose based on mean maternal body weight on pcd 5 and food consumption on pcd 
4/5 of females which mated during the first two days of the mating period; readjusted 
on pcd 11 based on group mean maternal body weight and mean food consumption 
over pcds 8, 9 and 10. 
Comments 
The reason for mating one female from each dose group with each male is not 
stated; this could be a way of reducing bias but it also introduces the possibility of 
introducing errors when returning females to their home cages. 
The exposure of foetuses in this study would not have been to aspartame itself but to 
its breakdown products (predominantly L-Phe, possibly also L-Asp and methanol). 
In life procedures: 
General observations  Daily  Clinical chemistry   Not performed 
Food consumption  Daily   Haematology  Not performed 
Body weight  Determined periodically  Urinalysis  Not performed 
Ocular examinations  Not performed  Other  Not performed 
Comments  The information provided is very limited 
Procedure for intercurrent deaths: 
Time to necropsy  N/A  Parameters recorded  N/A 
Tissues sampled  N/A 
Comments  Survival was 100% 
Termination procedures: 
Termination method  Carbon dioxide euthanasia 
Time to necropsy  Presumably immediate  Parameters recorded  See below 
External assessment  Not described 
Necropsy procedure 
Uterine horns exposed and examined. 
•  Foetal swellings and resorption sites counted, positions recorded 
Uterus incised. 
•  Foetal viability determined on basis of respiratory movements, skin colour 
and movement of extremities and head 
Foetuses removed and sexed. 
•  Weighed to nearest 0.1 g 
•  Crown-rump distance measured 
•  Examined externally for gross malformations 
•  Preserved intact for assessment of malformations 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Tissues sampled 
For visceral irregularities (~1/3 of foetuses): 
•  Fixed in Bouin’s 
•  Sectioned by freehand technique of Wilson 
o  Head sectioned into five slices (~1 mm thick) to reveal 
abnormalities of palate, nasal cavities, eyes and brain 
o  Thorax sectioned into four slices (≤ 1mm thick) starting at shoulder 
joint and continuing caudally to diaphragm to reveal abnormalities 
of thymus, heart, lungs, oesophagus, trachea, diaphragm and 
major blood vessels. 
o  Abdomen sectioned as three slices 
§  One approximately 2 mm caudal to diaphragm and 
examined for abnormalities of the liver, aorta, 
oesophagus and spinal cord. 
§  One at level of stomach examined for abnormalities of 
spinal cord, aorta and intestinal tract 
§  One at level of renal pelvis, examined for anomalies of 
spinal cord, aorta and kidneys. 
o  Structures found in pelvic cavity (i.e. ureters, bladder and 
reproductive tract) examined in situ after removal of intestine. 
•  Examined under dissecting microscope 
•  All tissue slices from treated foetuses and from control foetuses with 
anomalies were transferred to polyethylene bags for temporary storage 
(conditions of storage not stated) 
For skeletal abnormalities (remaining foetuses): 
•  Fixed in 95% ethanol 
•  Eviscerated 
•  Soft tissues digested and cleared in 5% aqueous KOH solution 
•  Stained with Alizarin Red S 
•  Examined by naked eye and/or dissecting microscope for anomalies e.g. 
o  Absence or incomplete ossification of  cranial bones 
o  Incomplete ossification or abnormal shape of the vertebrae, long 
bones, ribs etc 
•  Other parameters recorded 
o  Number and size of sterna ossification centres 
o  Degree of closure of cranial ossification 
o  Number of metacarpals, metatarsals and corresponding phalanges 
•  All treated and control skeletal preparations placed in temporary storage 
Fixation  Bouin’s or 95% ethanol 
(see above)  Storage conditions 
In 100% glycerine 
containing “several 
crystals of thymol to 
prevent bacterial growth” 
(skeletal preparations) 
Comments  The use of 95% ethanol as a fixative would have tended to dehydrate the skeletal 
samples, making them fragile and susceptible to damage. 
Statistical procedures: 
Data manipulation  Means and standard errors of various measured parameters calculated for each 
dosage group. 
Statistical tests used  Significance tested using Student’s t-test with significance set. at p=0.05 
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Section 1: Study details 
Results of in life observations: 
General observations  Maternal mortality rate was zero; all animals survived 20 day gestation period. 
Food consumption 
Consumption in control and 2,000 mg/kg/day groups was similar. 
•  Decrease in mean food consumption at 4,000 mg/kg/day; this became less 
pronounced towards the end of the dosing period 
On returning to basal diet at end of dosing period, consumption in both aspartame 
groups increased to a level above that of controls until sacrificed. 
Growth  No difference in mean body weight between control and treated groups. 
Laboratory tests  Not performed 
Ocular examinations  Not performed 
Other  None 
Comments  None 
Outcomes: 
Terminal body weights  No difference in maternal body weight between control and treated groups. 
Maternal parameters 
No maternal mortality. 
No lesions of ovary or uterus observed. 
Similar incidence of foetal resorption in all groups 
•  Always involved foetuses at early stage of development. 
Litter examination 
No significant differences in mean: 
•  Litter size 
•  Foetal weight 
•  Crown-rump distance 
No non-viable foetuses in any group 
No difference in incidence of runts 
•  8/26 control litters 
•  8/24 litters at 2,000 mg/kg/day 
•  6/23 litters at 4,000 mg/kg/day 
Foetal examination 
No external irregularities observed among: 
•  315 control foetuses 
•  295 at 2,000 mg/kg/day 
•  294 at 4,000 mg/kg/day 
Malformations observed 
Visceral abnormalities observed in one embryo from each group: 
•  1/114 control foetuses 
•  1/108 at 2,000 mg/kg/day 
•  1/107 at 4,000 mg/kg/day 
o  Bilateral hydronephrosis and hydroureter in one control foetus 
o  Hydrocephalus in one foetus at 2,000 mg/kg/day and one at 4,000 
mg/kg/day; both were runts 
No skeletal abnormalities observed. 
•  0/201 control foetuses 
•  0/187 at 2,000 mg/kg/day 
•  0/187 at 4,000 mg/kg/day 
•  Slight differences in extent of ossification were attributed to slight 
differences in gestational age among litters at time of sacrifice 
•  Considerable differences in the level of ossification of cervical vertebral 
centra existed between control and treated groups 
•  Incidence of unossified cervical vertebral centra was similar in treated 
groups (79.7% and 82.9%) but higher than in controls, where it was 
unusually low (41.3% compared with normal value of ~80%). The authors 
state that “No meaningful explanation for this finding is apparent”. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions  N/A 
Neoplastic lesions  N/A 
Comments 
No significant skeletal abnormalities were observed although an unexplained 
difference in the incidence of unossified cervical vertebral centra was observed. This 
seems to have been related to an abnormally low incidence in control offspring 
rather than an increase in the offspring of treated rats. 
Conclusions: 
Authors’ conclusions 
“No evidence of treatment-induced anatomical alterations was observed in the 47 treated litters (589 term 
foetuses) examined. The level of ossification of the cervical vertebral centra in treated animals compared 
favourably with historical control data generated in these laboratories, but was notable higher than in the 
concurrent controls. No meaningful explanation for this finding is available, but it is considered unlikely to be 
treatment-related.” 
Reviewer’s comments 
This study does not indicate any clear cut effects on maternal, litter or foetus parameters due to aspartame when 
administered to rats via the diet at doses up to 4,000 mg/kg/day. The significance of the observed differences in 
ossification of the cervical vertebral centra is not clear. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  Yes 
Justification for Internal Quality Review:  Included in FDA Authentication Review (Taylor, Goldberg et al, 
1977) and Bressler review (Bressler, 1977). 
QA comments 
GLP Check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in 
the diet mix, and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  Procedure for identifying litters not described 
•  No Study Director (although report author) 
•  No start/finish dates 
•  Possible lack of a description of all circumstances that may have affected the quality or integrity of 
the data: There is no discussion on the rationale for applying a test for outliers, or what this means 
for the results. 
Not possible to confirm protocol objectives and any changes, as protocol not provided 
OECD Guideline check: 
Test item: similar to above, characterisation etc required by current guidelines not present.  
Otherwise: 
No historic data not presented nor referenced, no mention of quality of food, water, bedding (e.g. 
content/contaminant analyses). 
Some individual and other data required by current guidance not reported, e.g.  individual data, foetal soft tissue 
evaluation, maternal clinical signs, necropsy, uterus weights, NOAEL estimation. 
Supplementary Check: 
Where possible a sample of items was checked for internal consistency within the report. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Some inconsistencies were noted 
•  It isn’t clear from the report how the author assessed the stage of development of the resorptions 
(see page 17) 
•  There is no discussion of the visible increase in food consumption across all groups on Day 16. 
•  The intra-group variation in the extent of ossification has been attributed to slight differences in 
gestational age at the time of maternal sacrifice; it is not clear if the difference has been determined 
from observations within this study, and whether other results could also be affected. 
•  It is not clear from the tables that foetal swellings were examined and counted as required on page 3 
and reported on page 4, similarly for external examination fro gross malformation 
•  Page 3 indicate the first 24 mated rats were employed or the remainder of the study, although 




The significance of the minor anatomical variations observed is difficult to evaluate in the absence of reference to 
historical control data. 
Strengths and limitations of study 
Limitations 
•  Limited study: maternal data, visceral abnormalities and skeletal malformations only 
•  Some individual and other data required by current guidance not reported. 
•  No necropsy observations in ovary/uterus recorded. 
Opinions of other commentators 
This study was included in the FDA Authentication Review, although the visceral samples were not longer 
available (Taylor, Goldberg et al, 1977). Various “divergent practices” were also identified, but the overall 
conclusion of the Authentication Review was that the three studies investigated appeared to be authentic. 
A review of this study, conducted by a panel appointed by the US Bureau of Foods, was completed in 1977 
(Bressler, 1977). The documents in the dossier do not make it clear whether this was the same review as the FDA 
Authentication Review mentioned above. The review was very detailed but the main concerns expressed may be 
summarised as follows: 
•  There was a failure of blinding in that the individual evaluating the foetuses for abnormalities was aware 
of which group they were from. 
•  Numerous errors in record sheets, mostly mis-sexing of foetuses, were noted. 
•  No record sheets were kept for the skeletal examination of individual foetuses. 
The report (Bressler, 1977) does not draw any definitive conclusions as to whether the numerous minor 
inconsistencies and omissions noted seriously compromised the reliability of the study’s overall findings. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
≥24 dams per group (30 initially  mated) 
•  ≥100 foetuses per group examined for visceral abnormalities 
•  ~ 200 foetuses per group examined for skeletal malformations 
Two dose levels plus control 
•  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
No information provided regarding purity of test item. 
Other minor QA issues do not affect interpretation of the data. 
Calculated compound intakes close to those planned. 
Fixation in 95% ethanol would have made embryo preparations fragile 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Relevance of the study  Evaluation of embryotoxicity and teratogenicity in a standard laboratory rodent 
species. 
Adequacy of data sets 
Limited in life observations; no laboratory investigations. 
Some inconsistencies and omissions noted. 
Lack of individual data for some parameters. 
No necropsy observations on ovaries and uteri. 
Data sources  Commercial study report, pre-GLP (1970) 
Comments 
•  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
•  This study was included in the FDA Authentication Review (Taylor, Goldberg et al, 1977), which noted 
that the visceral samples were no longer available for review but concluded that the study was authentic. 
It is also covered in the Bressler Report (Bressler, 1977), which identifies a failure of blinding in the foetal 
examination and a lack of documentation but does not draw clear conclusions regarding its authenticity. 
•  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
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Study Identifier  10 1970 (E5) 
Study Title  Evaluation of Embryotoxic and Teratogenic Potential in the Rat 
  Y  N  Comment 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √  purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √ 
No source; 
No ID (1) 




A description of the dosage, dosage regimen, route of 
administration, and duration.  √  √  No analyses 
A description of all circumstances that may have affected the 
quality or integrity of the data.    √   
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
  √   
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.    √   
The locations where all specimens, raw data, and the final report 
are to be stored.    √   
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √   
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) Animals were housed individually post-mating and pre-dosing 
Report GLP content check by/date: J Birnie 19 April 2012 
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Study identifier  10 1970 (E5) 
Study Title  SC-18862: Evaluation of embryotoxic and teratogenic potential 
in the rat 
*OECD Guideline no: 414  Prenatal development 
 
*§    Y  N  Comment 
33  Data shall be reported individually and summarised in tabular 
form, showing for each test group and each generation the 
number of animals at the start of the test, the number of 
animals found dead during the test or killed for humane 
reasons, the time of any death or humane kill, the number of 
pregnant females, the number of animals showing signs of 
toxicity, a description of the signs of toxicity observed, 
including time of onset, duration, and severity of any toxic 
effects, the types of foetal observations, and all relevant litter 
data. 
√  √  Not all 
individual data 
34  Numerical results should be evaluated by an appropriate 
statistical method using the litter as the unit for data analysis. A 
generally accepted statistical method should be used; the 
statistical methods should be selected as part of the design of 
the study. Data from animals that do not survive to the 
scheduled kill should also be reported. These data may be 
included in group means where relevant. Relevance of the 
data from such an animal, and therefore inclusion or exclusion 
from any group mean(s), should be judged on an individual 
basis. 
√     
35  The findings of the Prenatal Developmental Toxicity Study 
should be evaluated in terms of the observed effects. The 
evaluation will include the following information: 
§ maternal and foetal test results, including an evaluation of 
the relationship, or lack thereof, between the exposure of 
the animals to the test substance and the incidence and 
severity of all findings; 
§ criteria used for categorising foetal external, soft tissue, 
and skeletal alterations if categorisation has been done; 
§ when appropriate, historical control data to enhance 
interpretation of study results; 
§ the numbers used in calculating all percentages or indices; 
§ adequate statistical analysis of the study findings, when 
appropriate, which should include sufficient 
§ information on the method of analysis, so that an 
independent reviewer/statistician can re-evaluate and 
reconstruct the analysis. 




37  The test report must include the following specific information: 
  Test substance:        
  physical nature, and, where relevant,  physicochemical 
properties  √     
  identification including CAS number if known/established  √  √  No CAS 
  purity    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)    √  N/A 
  Test animals        
  species/strain used   √     
  number, age  √     
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test    √   CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 414 report content 
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  Test conditions:       
  rationale for dose level selection  √    Not frequency 
  details of test substance formulation/diet preparation  √  √   
  achieved concentration stability and homogeneity of the 
preparation    √   
  details of the administration of the test substance  √     
  conversion from diet/drinking water test substance 
concentration (ppm) to the actual dose (mg/kg) if applicable  √  √  No actual 
analyses 
 
environmental conditions    √ 
No mention of 
bedding 
analyses 
  details of food and water quality    √   
  Results        
  Maternal toxic response data by dose, including but not limited 
to:       
  the number of animals at the start of the test, the number of 
animals surviving, the number pregnant, and the number 
aborting, number of animals delivering early; day of death 
during the study or whether animals survived to termination 
√     
  day of death during the study or whether animals 
survived to termination  √     
  data from animals that do not survive to the scheduled kill 
should be reported but not included in the inter-group statistical 
comparisons 
  √  N/A 
  day of observation of each abnormal clinical sign and its 
subsequent course    √   
  body weight, body weight change and gravid uterine 
weight, including, optionally, body weight change 
corrected for gravid uterine weight 
√  √  Only means 
per graph 
  food consumption and, if measured, water consumption;  √  √  Only means 
per graph 
  necropsy findings, including uterine weight    √   
  NOAEL values for maternal and developmental effects should 
be reported    √   
  Developmental endpoints by dose for litters with implants, 
including:       
  number and percent of live offspring  √     
  sex ratio  √     
  foetal body weight, preferably by sex and with sexes 
combined  √    Average 
  external, soft tissue, and skeletal malformations and 
other relevant alterations  √  √  Not for soft 
tissue 
  criteria for categorisation if appropriate  √  √  Not for soft 
tissue 
  total number and percent of foetuses and litters with any 
external, soft tissue, or skeletal alteration, as well as the 
types and incidences of individual anomalies and other 
relevant alterations 
√  √  Not for soft 
tissue 
  discussion of results  √     
  conclusions  √     
Comments: 
None 
Report content QA check by/date: J Birnie 11-19 April 2012 
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Study ID  10 1970 (E5)  
Study Title  SC-18862, Evaluation of Embryotoxic and teratogenic 
potential in the rat 
Internal Consistency  
 
Where possible a sample of items was checked for internal consistency within the 
report. 
 
Some inconsistencies were noted 
 
§  Its not clear from the tables that foetal swellings were examined and counted as 
required on page 3 and reported on page 4, similarly for external examination fro 
gross malformation 
§  Page 3 indicate the first 24 mated rats were employed or the remainder of the study, 
although control and low dose groups report 27 and 25 surviving females and 26 
pregnancies for the control group. 
§  There is no discussion of the visible increase in food consumption across all groups 
on Day 16. 
 
Information relating to the test item  
There is no information on the lot(s) of test item, or of its actual purity, stability and 
homogeneity in the diet mixtures, or how the % concentrations were derived (e.g. 
analysis of samples)  
Other comment 
 
The intra-group variation in the extent of ossification has been attributed to slight 
differences in gestational age at the time of maternal sacrifice, it is not clear if the 
difference has been determined from observations within this study, and whether 
other results could also be affected. 
There is no discussion on the rationale for applying a test for outliers, or what this 
means for the results.  
There aren’t any individual data reported for some parameters: 
No uterus or ovary necropsy observations  
It isn’t clear from the report how the author assessed the stage of development of the 
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Document identification: 
Title  SC-18862: An Evaluation of the Embryotoxic and Teratogenic Potential in the Rabbit 
(Project No. 1201) 
Authors  Vondruska, J. F., Schroeder, R. E., Mitchell, A.  Date  1975 
Study Type  Embryotoxicity/teratogenicity  Dossier #  E90 
Purpose of study: 
“…to determine the embryotoxic and teratogenic potential of SC-18862 (aspartame) when administered by 
gavage to the pregnant rabbit during the period of fatal organogenesis” and “…to provide additional rabbit 
teratology data with SC-18862 and to compare the embryotoxic and teratogenic impact of the two amino acids 




L-Phe (Lot # 79190) 
L-Asp (Lot # 98040) 
Purity  Assumed 100% pure 
Actually 0.29% DKP 
Lot # (s)  Aspartame Lot # 59687 (Q.C. C0075) 
Amino acids provided by Ajinomoto Company Inc., Tokyo, Japan 
Animals: 
Species:  Rabbit  Strain:  New Zealand White 
Leuenberg strain 
Source:  Pel-Freez Biological, Inc. 
USA  Age/weight: 
Mature nulliparous 
females; aged 8 months, 
mean 3.97 kg 
Males (n=20) used as 
semen donors 
Comments:   None 
Formulation: 
Route of administration  p.o.  Concentration  Aspartame 2.5%, 5%, 10% 
L-Phe: 4%; L-Asp: 5.5% 
Formulation procedure 
Suspended in 0.5% CMC (w/v) containing 1% Tween 80 (v/v); dosed intragastrically 
as two equal doses per day separated by an interval of at least three hours. 
•  Fresh dosing suspension prepared daily. 
•  Control animals received comparable volume of vehicle only (20 ml/kg) 
Confirmatory analysis  None specified 
Comments  See QA comments 
Study design: 
Animal husbandry 
Animals housed individually in stainless steel cages 
Animal quarters air conditions set to maintain constant temperature of 72￿C. 
Fluorescent lighting set to 12 hr light/dark cycle 
Food and water continuously available ad libitum throughout study 
Pregnancy induced by artificial insemination. 
•  20 proven males used as semen donors 
•  First and second ejaculates collected where possible using artificial vagina 
•  Ejaculate examined microscopically for sperm motility and density 
•  High rating samples pooled, diluted 1:9 with Sodium Chloride Injection, USP 
•  Females inseminated with 0.7 – 1.0 ml of diluted pooled semen containing 
≥ 2 x 107 sperm 
•  Ovulation induced immediately after insemination by injection of pituitary CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
luteinising hormone (PLH, Armour-Baldwin Labs, USA), 2 mg via marginal 
ear vein. 
Insemination procedures were performed on 17 separate days 
•  Usually 3 females/group/day except on last day (2 animals/group) 
•  In exceptional cases additional replacement animals were inseminated 
Diet  Rabbit Chow Special No. 5430 (Ralston Purina, USA) 
Minimisation of bias  Simple randomisation procedure 
Blocking of groups  None specified 
Number per group  50 per group except 
52 at 1,000 mg/kg/day  Acclimatisation  One month 
Start of dosing  pid 6  Duration  Dosed from pid 6 to pid 18; 






L-Phe 820 mg/kg/day 
L-Asp 1,100 mg/kg/day 
Actual intakes  As dosed 
Basis for dose selection  None provided 
Dose correction  Individual doses adjusted to body weight on pid 13 
Comments 
Report indicates that there were 50 rabbits per group except for 52 at 1,000 
mg/kg/day 
•  However, animal numbers indicate that the 1,000 mg/kg/day group had 
animal numbers 301-350 (i.e. only 50 numbers) 
•  Two females in this group suffered broken backs and had to be sacrificed. 
•  This is a common problem with large laboratory rabbits; it can indicate poor 
animal handling, but does occur accidentally 
•  These two rabbits were replaced; thus in this group, 52 rabbits were 
inseminated but only 50 completed the study 
No justification is provided for the doses selected. 
The exposure of foetuses in this study would not have been to aspartame itself but to 
its breakdown products (predominantly L-Phe, possibly also L-Asp and methanol). 
In life procedures: 
General observations  Daily, usually at time of 
compound administration  Clinical chemistry   None specified 
Food consumption 
Recorded daily by 
weighing food containers 
at beginning and end of 
each 24 hr period 
Haematology  None specified 
Body weight  On pid 0, 3, 6, 10, 13, 15, 
18, 22, 28  Urinalysis  None specified 
Ocular examinations  None specified  Other 
Abortions (foetal loss 
before pid 26) and 
premature deliveries (pid 
26-28) noted 
Comments  Only very limited in life observations seem to have been conducted. 
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Procedure for intercurrent deaths: 
Time to necropsy  Not specified  Parameters recorded  Not specified 
Tissues sampled 
Necropsies performed on animals which died or were sacrificed during the study.  
Main causes of intercurrent death were pneumonia, pyothorax and peritonitis 
•  Other causes of death were tracheal obstruction, faulty administration of 
test compound or undetermined 
•  All but one of the decedents were pregnant 
Comments  Most, if not all, of the intercurrent deaths were probably caused by mis-dosing. 
Termination procedures: 
Termination method  Air embolism 
Time to necropsy  Presumably immediate  Parameters recorded  Body weight 
External assessment  Not described 
Necropsy procedure 
Females sacrificed and abdominal cavity opened. 
Tissues examined in situ 
•  Heart 
•  Lungs 
•  Liver 
•  Kidneys 
•  Stomach 
•  Small intestine 
•  Large intestine 
•  Uterus and uterine contents 
•  Ovaries  
Ovarian and uterine horns exposed. Recorded: 
•  Number of corpora lutea, foetuses, resorption sites 
•  Relative position of each implantation along uterine horn 
•  Occurrence of abortion confirmed by presence of sites of former placental 
attachment visible to the naked eye. 
Foetuses removed from uterus 
•  Foetal viability determined on basis of respiratory movements, skin colour 
and movement of extremities and head 
•  Weight and CRD recorded 
•  Examined for gross external malformations 
•  Euthanized and preserved intact in fixative (see below) 
Tissues sampled 
Soft tissue examination of ~50% of foetuses 
•  Fixed in Bouin’s and sectioned by freehand technique of Wilson 
o  Head sectioned into five slices (~5 mm thick) in transverse plane to 
reveal abnormalities of palate, nasal cavities, eyes and brain 
o  Thorax sectioned into five slices (~2 mm thick) in transverse plane 
starting at shoulders and continuing caudally to diaphragm. 
Examined for abnormalities of thymus, heart, lungs, oesophagus, 
trachea, diaphragm and major blood vessels. 
o  Abdomen sectioned as three slices 
§  One approximately 8 mm caudal to diaphragm and 
examined for abnormalities of the liver, stomach and 
spinal cord. 
§  One at level of right kidney examined for abnormalities of 
kidney, liver, stomach, spleen and spinal cord 
§  One at level of left kidney, examined for anomalies of 
spinal cord, aorta and renal pelvis. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
o  Structures found in pelvic cavity (i.e. ureters, bladder and 
reproductive tract) examined in situ after removal of intestine. 
•  Examined under dissecting microscope (7x) 
•  All tissue slices from control and treated foetuses transferred to amber 
glass bottles containing 70% ethanol for temporary storage.  
Skeletal examination of ~50% of foetuses 
•  Fixed in 95% ethanol 
•  Eviscerated 
•  Macerated and cleared in 5% aqueous KOH 
•  Stained with saturated aqueous Alizarin Red S 
•  Stored in 100% glycerine containing “several crystals of thymol to prevent 
bacterial growth”  
•  Examined under dissecting microscope (7x) for malformations 
•  Other parameters recorded 
o  Number and size of sternebrae 
o  Degree of closure of cranial ossifications 
o  Number of metacarpals, metatarsals and corresponding phalanges 
•  All treated and control skeletal preparations placed in temporary storage 
Fixation  See above  Storage conditions   
Comments  The use of 95% ethanol as a fixative would have tended to dehydrate the skeletal 
samples, making them fragile and susceptible to damage. 
Statistical procedures: 
Data manipulation  Mean and standard errors calculated for each experimental group 
Statistical tests used 
Two-tailed Student’s t-test 
•  Used to compare maternal body weight, maternal food consumption, litter 
size, foetal body weight and foetal CRD data. 
Chi-Square test 
•  Used to analyse maternal survival, conception rates, incidence of litters 
containing foetuses only, foetuses and resorption sites and resorption 
sites only, incidence of abortions and premature deliveries, foetal sex 
ratios, incidence of certain anatomical variants. 
Univariate Wilcoxon Rank Sum Test 
•  Used to compare the mean number of foetal resorptions in control and 
treated groups 
Permutation test 
•  Used to evaluate distribution of litters containing ≥ 1 foetal resorptions 
Two-tailed Fisher Exact test 
•  Used to analyse incidence of major and minor foetal malformations on 
litter incidence and foetal incidence basis 
Statistical significance set at p=0.05 in each test 
•  Except for Fisher Exact Test (p < 0.01) 
Results of in life observations: 
General observations 
Survival rates did not differ significantly between insemination and pid 28 
•  Range was 92-98% 
Food consumption 
Mean food consumption at 500 mg/kg/day, 1,000 mg/kg/day and in L-Asp group did 
not differ from that of controls 
•  Consumption in these groups and controls did decrease to 75-90% of 
pretreatment values as a consequence of twice daily gavage procedure. 
Reduced food consumption was observed at 2,000 mg/kg/day aspartame and 820 
mg/kg/day L-Phe from pid 6 -18 (i.e. beginning on first day of dosing) CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
•  Consumption at 2,000 mg/kg/day decreased to ~25-25% of pretreatment 
levels and in L-Phe group to 50-60% of pretreatment values 
o  Significantly less than that of controls in both cases 
•  Led to loss of body weight from pid 10 onwards 
•  Significant from pid 13 onwards 
•  Most marked in females which later aborted 
•  In surviving females, consumption increased after cessation of dosing 
•  Returned to normal by pid 20 (L-Phe) or 22 (aspartame) 
Growth 
Mean body weights at 500 mg/kg/day, 1,000 mg/kg/day and in L-Phe and L-Asp 
groups did not differ significantly from those in control groups at any of the 
timepoints at which was measured. 
•  At 2,000 mg/kg/day body weight started to decrease on pid 10 
•  Body weight was significantly decreased on pids 13, 15, 18, 22 and 28 
•  Pattern was similar in the L-Phe group, but did not reach significance 
Laboratory tests  None reported 
Ocular examinations  None reported 
Other 
Conception rates did not differ significantly between controls and treated groups. 
•  Range was 75.5 – 94.1% 
•  Highest value includes two females subsequently lost from study 
Aborted pregnancies were diagnosed by presence of foetal-placental remnants 
and/or blood spots in cage or sub-floor cage pan prior to pid 26 
•  No abortions in control, 1,000 mg/kg/day or L-Asp groups 
•  2 abortions at 500 mg/kg/day 
•  24 abortions at 2,000 mg/kg/day 
•  4 in L-Phe group 
o  Most abortions occurred on pid 18-21, i.e. well after the reduction 
in food consumption and loss of body weight 
o  Corresponds with period of organogenesis 
o  Of dams aborting, two at 2,000 mg/kg/day and one from L-Phe 
group died. 
o  Proportion of pregnancies ending in abortion was greater at 2,000 
mg/kg/day (over 50%) than in controls (p < 0.01). 
Premature delivery defined as delivery of viable and/or non-viable foetuses between 
pid 26 and sacrifice on pid 28. 
•  Did not occur at 500 mg/kg/day, 2,000 mg/kg/day or in L-Asp group 
•  No significant difference in incidence between groups. 
Combined incidence of abortions and premature deliveries was significantly greater 
at 2,000 mg/kg/day than in controls (p < 0.01). 
•  No significant difference in incidence between controls and treatment 
groups. 
High dose rabbits (2,000 mg/kg/day) were subdivided into 
o  Dams surviving until pid 28 with pregnancy intact  
o  Dams surviving until pid 28 after aborting foetuses 
o  Non-pregnant animals and intercurrent decedents excluded 
•  Dams which did not abort maintained body weight at levels not significantly 
different from controls 
•  Dams which aborted had significantly reduced body weight on pids 13-28 
compared with controls and pids 18-28 compared with non-aborting dams 
•  Loss of body weight occurred several days before abortion, so was not a 
consequence of the abortion 
•  Abortion considered to be contingent upon rapid loss of body weight 
o  Both were a consequence of reduced food consumption, which 
was most marked in dams which aborted CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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The authors conclude that: 
•  “The degree of reduced food consumption varied between individual 
animals, and resulted in correspondingly variable individual weight losses. 
In certain animals this nutritional deprivation was not compatible with 
continued pregnancy, and abortion occurred about two weeks after the 
treatment period began. Developmentally, this period coincides with the 
completion of organogenesis and the onset of a period of rapid foetal 
growth. It is known that stress of this nature and magnitude, when applied 
to a pregnant animal, may result in abortion. The total nutrient intake is no 
longer adequate to maintain the needs of both the dam and the litter” 
The dose of L-Phe used in this study was equivalent to 75% of that delivered by the 
top dose of aspartame. 
•  The less severe weight loss and lower incidence of abortions observed 
with L-Phe were consistent with the lower effective dose received. 
•  The higher resorption rate in the L-Phe group may reflect a maternal 
response short of abortion. 
The authors conclude that: 
•  “It is apparent that most abortions may be a result of maternal nutritional 
deprivation, and may not be due to a direct effect of SC-18862 or L-
phenylalanine” 
Comments 
Severe difficulties were experienced at the highest dose use because of reduced 
food consumption leading to resorptions, abortion and premature delivery. The 
authors conclude that this was not a direct effect of aspartame, and they are 
probably correct; however, the reduction in food intake does seem to have been a 
consequence of exposure to L-Phe (derived from aspartame or delivered directly) 
and thus represents a potentially severe indirect effect, at least at the very high 
doses administered in this study. 
Outcomes: 
Terminal body weights  Not reported 
Maternal parameters 
Number of dams sacrificed on day 28 were 
•  46 controls 
•  46 at 500 mg/kg/day 
•  49 at 1,000 mg/kg/day 
•  46 at 2,000 mg/kg/day 
•  45 from L-Phe group 
•  48 from L-Asp group 
Incidence of maternal disease was not unusual for the laboratory rabbit and was not 
considered treatment-related. 
Litter examination 
There were no significant differences among surviving dams in proportions having 
litters comprising: 
•  Foetuses only 
•  Both foetuses and resorption sites 
•  Resorption sites only 
Mean litter sizes did not differ among treatment groups 
Mean number of resorption sites: 
•  Increased in 2,000 mg/kg/day and L-Phe dosed groups compared with 
controls 
•  Not significant because of small number of surviving litters and wide 
variability in these litters. 
•  Disproportionately large number of litters had high numbers of resorptions 
in the L-Phe group. 
•  Attributed to reduced food consumption and decreased body weights of 
dams. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  Considered to be consistent with the hypothesis that total nutritional intake 
is inversely proportional to L-Phe intake and that abortion and resorption 
occur in response to nutritional deprivation. 
o  More abortions in 2,000 mg/kg/day group because degree of 
nutritional deprivation was greater 
o  Milder deprivation in L-Phe group led to an increase in resorptions 
Foetal examination 
Total of 8 non-viable foetuses recovered at hysterotomy 
•  1 in control group 
•  4 at 500 mg/kg/day (one litter) 
•  1 in L-Phe group 
•  2 in L-Asp group ( two litters) 
Foetal sex distribution not affected except for increased proportion of females at 
2,000 mg/kg/day  
•  thought to be due to random variation. 
Mean foetal body weight and crown-rump distance reduced at 2,000 mg/kg/day 
aspartame and in L-Phe group. 
•  Attributed to effects of nutritional deprivation 
Malformations observed 
Number of foetuses examined: 
•  279 controls (35 litters) 
•  339 at 500 mg/kg/day (40 litters) 
•  344 at 1,000 mg/kg/day (44 litters) 
•  75 at 2,000 mg/kg/day (9 litters) 
•  186 from L-Phe group (26 litters) 
•  337 from L-Asp group (43 litters) 
For details of malformations observed, see Table 3 of study report (attached) 
•  Observed increased incidence of 13th rib at 2,000 mg/kg/day aspartame 
o  Similar trend observed in L-Phe group 
•  Numbers of tarsal and metacarpal ossification centres were reduced at 
2,000 mg/kg/day aspartame and in L-Phe group. 
o  This is an indication of compromised maternal nutrition and 
reduced foetal growth in this treatment group 
•  At 2,000 mg/kg/day 6th sternebral ossification centre was absent and 2nd 
sternebral ossification centre was small in a high proportion of foetuses. 
o  Suggested to be attributable to compromised nutrition and slowed 
foetal development 
o  Consistent with smaller mean foetal weight and reduced length of 
foetuses 
•  Skull ossification reduced in five foetuses from L-Asp group 
o  Attributed to random variation 
Increase in total number of malformations at 2,000 mg/kg/day aspartame and 820 
mg/kg/day L-Phe: 
•  Three instances of cleft palate at 2,000 mg/kg/day aspartame 
•  Five instances of umbilical hernia or omphalocele at 820 mg/kg/day L-Phe 
•  Also minor malformations including 
o  Vertebral defects 
o  Fused/split sternebrae 
•  All these effects were attributed to maternal food deprivation 
Statistical comparisons made were: 
o  Hydrocephalus only 
o  Cleft palate only 
o  Ventral midline defects only 
o  All major malformations combined 
o  All minor malformations combined 
o  All major and minor malformations combined CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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•  Incidence of malformations did not differ significantly between this study 
and historical control data (1,717 foetuses from 233 litters) 
•  No significant differences in incidence of abnormalities were observed at 
500 or 1,000 mg/kg/day aspartame or in L-Asp group. 
•  Incidence of the following categories was significantly increased at 2,000 
mg/kg/day compared with controls: 
o  Cleft palate, both on per litter and per foetus basis. 
o  All major malformations combined per foetus (mainly due to cleft 
palates) but not per litter 
o  All minor malformations combined per litter but not per foetus 
o  All major and minor malformations combined, both per litter and 
per foetus 
•  Incidence of the following categories was significantly increased in L-Phe 
group compared with control 
o  Ventral midline defects, both per litter and per foetus. 
o  All major malformations combined per foetus and per litter (mainly 
due to ventral midline defects) 
o  All major and minor malformations combined, both per foetus and 
per litter 
Examination of prematurely delivered pups, foetuses recovered from females dying 
spontaneously, and late resorptions 
•  13 control pups delivered by two control females on pid 27; no remarkable 
findings 
•  5 partially resorbed foetuses delivered to one dam at 1,000 mg/kg/day; 
could not be evaluated 
•  10 non-viable foetuses recovered from dam dying of bronchopneumonia on 
pid 28; externally unremarkable 
o  Two had supernumerary nasal sutures 
o  One had split second sternebrae 
o  These are classified as minor malformations 
•  5 pups delivered prematurely and one retained foetus in one dam from L-
Phe group on pid 27-28; could not be evaluated. 
•  5 non-viable pups delivered prematurely by one dam from L-Phe group on 
pid 28; four could be evaluated. 
o  One had supernumerary nasal sutures 
•  One late resorption with umbilical hernia in L-Phe group; remainder of litter 
normal. 
F1 generation  N/A 
F2 generation  N/A 
Non-neoplastic lesions  N/A 
Neoplastic lesions  N/A 
Comments 
These results indicate an increased incidence of various types of malformation at 
the highest dose of aspartame. The authors attribute these to the compromised 
nutritional status and body weight loss observed in the dams. Even so, they 
represent an adverse effect, albeit indirect, at this dose. 
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Conclusions: 
Authors’ conclusions 
“….intragastric intubation of 0.5 or 1.0 g/kg of SC-18862 or of 1.1 g/kg of L-aspartic acid in two divided doses daily 
by the pregnant rabbit exerts no apparent adverse effects. These levels produced no significant changes in any of 
the parameters measured. Statistically significant effects were produced at the 2 g/kg level; malformations 
observed may be a result of marked reduction in nutrient intake and resulting body weight loss in the maternal 
rabbit. Similar effects were produced by the administration of L-phenylalanine. Effects similar to those seen in this 
rabbit study as a result of severe reduction of nutrient intake because of the intragastic intubation of 2.0 g/kg of 
SC-18862 have also been observe by others following severe dietary restriction in rodents. Therefore, it appears 
that SC-18862 may be producing these effects by severely reducing nutrient intake, and not as a direct toxic 
effect. It is important to recognize that gastric intubation is necessary to achieve these intake levels of SC-18862”. 
Reviewer’s comments 
This study indicates clear cut effects on maternal, litter and foetus parameters due to aspartame when 
administered to rabbits by gavage at a dose of 2,000 mg/kg/day, though not at lower doses. These effects may 
not have been due to a direct effect of aspartame itself, but they still represent a consequence of dosing, even if 
the mechanism involved is indirect. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the 
batch(es) used, and for the duration of the test its actual concentration, homogeneity and stability in 
the diet mix, and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) * 
•  No location of archiving data 
•  Possible lack of a description of all circumstances that may have affected the quality or integrity of 
the data: the report doesn’t provide any information on why some data are missing  (“ND= no data”  
flagged for some maternal SC-18862 consumption, food consumption and body weight values), nor 
discuss the impact. 
•  Some data aren’t presented in the report, but it isn’t clear from the report that these data have 
retained and are available for review if ever needed. 
•  Procedure for identifying litters not described. 
•  No Study Director (although report author). 
•  No start/finish dates. 
Not possible to confirm protocol objectives and any changes, as protocol not provided. A letter included with the 
report that shows independent review confirming Protocol adherence, although this appears to cover the Protocol 
only not study data*.  
OECD Guideline check: 
Test item: similar to above, characterisation etc required by current guidelines not present. Also, no justification 
for vehicle choice. 
Otherwise: 
•  No justification for dose selection; historic data nor referenced, no mention of quality of food, water, 
bedding (e.g. content/contaminant analyses). 
•  Some data required by current guidance not reported: maternal clinical sigs, uterus weights, NOAEL 
estimation. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Commentary: 
General comments 
The high incidence of abortions, resorptions and premature deliveries seen in this study was attributed to reduced 
nutrient intake. The consequence of this was that only a limited number of high dose foetuses was available for 
evaluation (75 at 2,000 mg/kg/day vs. ~340 at lower doses and 279 controls). The use of gavage dosing was 
necessary to ensure intake of the planned doses of aspartame, but the dosing method itself led to problems, 
including reduced food consumption in all groups and a number of intercurrent deaths due to mis-dosing. 
Strengths and limitations of study 
Strengths 
•  Large study 
•  Detailed necropsies conducted 
Limitations 
•  Use of rabbit as a model 
o  Responds poorly to gavage dosing 
o  Very susceptible to appetite suppression by aspartame 
•  High incidence of resorptions, abortions and premature delivery, probably due to inadequate nutrition 
•  Use of 95% ethanol as fixative could have resulted in fragile foetal preparations  
Opinions of other commentators 
The study report includes a letter from Dr Bernard L. Oser (Bernard L. Oser Associates Ltd, Food and Drug 
Consultants, NY, USA) stating that “The protocol appears to have been followed as described and in my opinion 
the results of the study support the conclusion reached by the authors, viz. that Aspartame at doses up to 1 g/kg 
was neither teratogenic nor embryotoxic to rabbits under the test conditions employed. The effect at the 2 g/kg 
Aspartame level was not clear owing to significant reduction in maternal food intake.” 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). The review panel noted that the study was difficult to review because of the fragility of the 
samples (Unattributed, 1978c). Some discrepancies in diagnosis of malformations were noted, but most (7/10) of 
these were additional malformations in embryos which were already classified as malformed. There were also 
some discrepancies in the recording and reporting of data on food and body weight. Finally, the reviewers noted 
that there was an issue with the use of the rabbit as a model in this study. 
A review was also provided to the FDA as part of an evaluation of four Searle teratogenicity studies on aspartame 
(Collins, 1978). Collins did not express any concerns regarding this study; s/he noted that deleterious effects were 
evident at the highest dose administered (4,000 mg/kg/day) and that this observation was consistent with the 
results of other rabbit studies conducted by Searle.  
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Large study: 50 dams per group 
•  Number of foetuses per group examined varied (75-339) 
Three dose levels plus control, also L-Phe and L-Asp groups 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
Compound administered daily in controlled doses. 
Report lacks information on why some data are missing (“ND= no data” flagged for 
some maternal values), nor discuss the impact of these omissions. 
Relevance of the study  Evaluation of embryotoxicity and teratogenicity in a standard laboratory strain of rabbit 
Adequacy of data sets 
Survival 92-98% 
Limited in life observations; no laboratory investigations  
High incidence of resorptions, abortions and premature deliveries reduced number of 
foetuses available for examination. 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Detailed terminal analysis of dams and surviving foetuses 
Data sources  Commercial study report, pre-GLP (1975) 
Comments 
•  The exposure of foetuses in this study would not have been to aspartame itself but to its breakdown 
products (predominantly L-Phe, possibly also L-Asp and methanol). 
•  The study was compromised by a severe adverse effect on food consumption at the highest dose 
administered. Gavage dosing also affected food consumption in all groups. 
•  The study report was peer reviewed by an external consultant. 
•  This study was included in the UAREP authentication review in 1978. Some discrepancies were noted, 
along with the limitations of the rabbit as a model for this kind of study. No substantive issues were 
raised in the review of Collins (Collins, 1978). 
•  This study would not be considered fully compliant with the current OECD Guideline for prenatal 
development testing (Number 414), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Reviewer Details 
Name: Lesley Stanley  Date:27-Apr-12 
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Study Identifier  14 1975 (E90) 
Study Title  SC-18862: An evaluation of embryonic and teratogenic 
potential in the rabbit 
  Y  N  Comment 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.  √   
per letter from 
independent 
reviewer 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √ 
Not for all 
articles 
 
Stability of the test and control articles under the conditions of 
administration.    √   
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and substrain, age, and 
procedure used for identification. 





A description of the dosage, dosage regimen, route of 





A description of all circumstances that may have affected the 
quality or integrity of the data.    √  See comment 
(1) 
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√    Although not 
SD 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.  √     
The locations where all specimens, raw data, and the final report 
are to be stored.    √   
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.  √    Although not 
SD 
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √ 
Nothing to 





US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
(1) The report doesn’t provide any information on why some data are missing  (“ND= no data”  
flagged for some maternal SC-18862 consumption, food consumption and bodyweight values, 
nor discuss the impact 
(2) Some data aren’t presented in the report, but it isn’t clear from the report that these data 
have retained and are available for review if ever needed. 
Report GLP content check by/date: J Birnie, 18 April 2012 
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Study 
identifier  14 1975 (E90) 
Study Title  SC-18862: An Evaluation of Embryotoxic and teratogenic potential in the 
rabbit 
*OECD Guideline no: 414  Prenatal development 
 
*§    Y  N  Comment 
33  Data shall be reported individually and summarised in tabular 
form, showing for each test group and each generation the 
number of animals at the start of the test, the number of 
animals found dead during the test or killed for humane 
reasons, the time of any death or humane kill, the number of 
pregnant females, the number of animals showing signs of 
toxicity, a description of the signs of toxicity observed, 
including time of onset, duration, and severity of any toxic 
effects, the types of foetal observations, and all relevant litter 
data. 
√     
34  Numerical results should be evaluated by an appropriate 
statistical method using the litter as the unit for data analysis. 
A generally accepted statistical method should be used; the 
statistical methods should be selected as part of the design 
of the study. Data from animals that do not survive to the 
scheduled kill should also be reported. These data may be 
included in group means where relevant. Relevance of the 
data from such an animal, and therefore inclusion or 
exclusion from any group mean(s), should be judged on an 
individual basis. 
√     
35  The findings of the Prenatal Developmental Toxicity Study 
should be evaluated in terms of the observed effects. The 
evaluation will include the following information: 
§ maternal and foetal test results, including an 
evaluation of the relationship, or lack thereof, 
between the exposure of the animals to the test 
substance and the incidence and severity of all 
findings; 
§ criteria used for categorising foetal external, soft 
tissue, and skeletal alterations if categorisation has 
been done; 
§ when appropriate, historical control data to enhance 
interpretation of study results; 
§ the numbers used in calculating all percentages or 
indices; 
§ adequate statistical analysis of the study findings, 
when appropriate, which should include sufficient 
§ information in the method of analysis, so that an 
independent reviewer/statistician can re-evaluate and 
reconstruct the analysis. 
√    Historic data 
referenced 
37  The test report must include the following specific information: 
  Test substance:        
  physical nature, and, where relevant,  physicochemical 
properties  √  √  Not for all ietms 
  identification including CAS number if known/established  √  √  No CAS 
  purity    √  Not for all ietms 
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water)    √   
  Test animals        
  species/strain used   √     
  number, age  √     CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 414 report content 
 
Page 2 of 2 
*§    Y  N  Comment 
  source, housing conditions, diet, etc  √     
  individual weights of animals at the start of the test  √     
  Test conditions:       
  rationale for dose level selection    √   
  details of test substance formulation/diet preparation  √     
  achieved concentration stability and homogeneity of the 
preparation    √  No analyses 
  details of the administration of the test substance  √     
  conversion from diet/drinking water test substance 
concentration (ppm) to the actual dose (mg/kg) if applicable    √  N/A 
  environmental conditions 
  √ 
No mention of 
bedding 
analyses 
  details of food and water quality    √   
  Results        
  Maternal toxic response data by dose, including but not 
limited to:       
  the number of animals at the start of the test, the number of 
animals surviving, the number pregnant, and the number 
aborting, number of animals delivering early; day of death 
during the study or whether animals survived to termination 
√     
  day of death during the study or whether animals 
survived to termination  √     
  data from animals that do not survive to the scheduled kill 
should be reported but not included in the inter-group 
statistical comparisons 
√     
  day of observation of each abnormal clinical sign and its 
subsequent course    √   
  body weight, body weight change and gravid uterine 
weight, including, optionally, body weight change 
corrected for gravid uterine weight 
√  √  Uteri not 
weighed 
  food consumption and, if measured, water consumption;  √     
  necropsy findings, including uterine weight  √  √  Uteri not 
weighed 
  NOAEL values for maternal and developmental effects 
should be reported    √   
  Developmental endpoints by dose for litters with implants, 
including:       
  number and percent of live offspring  √     
  sex ratio  √     
  foetal body weight, preferably by sex and with sexes 
combined  √     
  external, soft tissue, and skeletal malformations and 
other relevant alterations  √     
  criteria for categorisation if appropriate  √     
  total number and percent of foetuses and litters with 
any external, soft tissue, or skeletal alteration, as well 
as the types and incidences of individual anomalies 
and other relevant alterations 
√     
  discussion of results  √     
  conclusions  √     
Comments: 
None 
Report content QA check by/date : J Birnie, 18 April 2012 
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Section 1: Study details 
Document identification: 
Title  Two-generation Reproduction Study - Rats. SC-18862 
Final Report. (P-T 867H71) 
Authors  Reno, F.E.  Date  1971 
Study Type  Two generation study  Dossier #  E11 
Purpose of study: 
“…to evaluate and characterize the effects of SC-18862 on the reproductive performance of albino rats”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Assumed 100% pure 
Lot # (s)  Various; not specified 
Animals: 
Species:  Rat  Strain:  Charles River CD 
Source:  Charles River  Age/weight:  90-100 days old at mating 
Comments:   None 
Formulation: 
Route of administration  Via diet  Concentration  Not specified 
Formulation procedure  Aspartame incorporated in diet by thorough mixing in a twin-shell, Patterson-Kelley 
blender to provide the appropriate dietary level for each group. 
Confirmatory analysis  None indicated  
Comments  See QA comments 
Study design: 
Animal husbandry 
Food and water were available ad libitum throughout the study. 
Prior to initiation of breeding, parental animals maintained in individual wire mesh 
cages and fed the appropriate diet for 9 wk (to 90-100 days of age). 
1M/2F per group used for first round of breeding (P1 generation). 
•  Males were rotated among females in each group at weekly intervals 
•  Breeding period lasted 3 wk 
•  Males returned to individual cages 
•  Females placed in individual nesting boxes to produce F1A litters 
•  F1A litters reduced to 10 per litter 24 hr post partum 
Spare F1A offspring from this study were used for lifetime toxicity study E70 
•  60M/60F controls 
•  40M/40F from each dose group 
10M/20F per treatment group used for second round of breeding (P2 generation) 
•  Except control females (n=19) 
•  Fed the appropriate diet for 9 wk (to 90-100 days of age) 
•  Bred as for P1 generation 
•  F2A litters reduced to 8 per litter. 
•  Five F2A litters were used for neonatal toxicity study E11 
•  Remaining litters used for evaluation of F2A weaning data 
•  All excess weanling and all P2 generation males and females sacrificed and 
discarded. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
The report notes that the study described involved animals maintained in animal care 
facilities fully accredited by the American Association for Accreditation of Laboratory 
Animal Care. 
Diet  Purina Laboratory Chow 
Minimisation of bias 
Stratified randomisation by body weight for each sex. 
•  Animals were placed into three groups taking into account the differences in 
body weights so that a homogeneous distribution of weights was obtained 
between groups. 
Blocking of groups  None indicated 
Number per group  12M/24F per group  Acclimatisation   
Start of dosing  Nine weeks before start 
of mating  Duration 
Two parental generations 










Basis for dose selection  Not provided 
Dose correction 
Fresh batches of diet prepared weekly.  
Dosages adjusted on the basis of group mean body weight and food consumption 
determined for each sex at intervals during the pre-breeding phase of treatment. 
Actual consumption determined in weeks 4 and 9 of pre-mating phase. 
Comments  No justification is provided for the doses selected. 
It is not clear how the parents for the second round of breeding were selected. 
In life procedures: 
General observations 
Before mating 
         (weeks 1, 4 and 9) 
At reduction of F1A litters 
to 10 pups per litter 
Clinical chemistry   None specified 
Food consumption  Weeks 1, 4 and 9 of pre-
mating phase  Haematology  None specified 
Body weight  Pups at 24 hr and at 
weaning  Urinalysis  None specified 
Ocular examinations  None specified  Other 
Number of conceptions 
Live births 
Stillbirths 
Size of natural and nursing litters 
Deaths during lactation period 
Gross signs of abnormality 
Comments  The information provided is very limited given the potential importance of the study. 
Procedure for intercurrent deaths: 
Time to necropsy  N/A  Parameters recorded  N/A 
Tissues sampled  N/A 
Comments  All P1 and P2 males and females survived their respective phases of study 
Termination procedures: 
Termination method  Not specified 
Time to necropsy  Presumably immediate  Parameters recorded  Body weights 
External assessment  Not described CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Necropsy procedure 
All P1 generation males and females sacrificed and discarded 
Necropsies performed on representative number of F1A offspring at weaning. 
Necropsies performed on approximately 1/3 of pups from 10 litters per groups (10 






















Fixation  10% NBF  Storage conditions 
Held for possible future 
examination (see study 
E11) 
Comments  The information provided is very limited given the potential importance of the study. 
Statistical procedures: 
Data manipulation 
Reproduction indices calculated as: 
•  Fertility index = number of pregnancies/number of females 
•  Gestation index = number of full term litters born/number of pregnancies 
•  Live birth index = number of pups alive at 24 hr/number of pups at birth 
•  Lactation index = number of pups weaned/number of pups nursed 
Statistical tests used  t-test at p = 0.05 
Results of in life observations: 
General observations  All P1 and P2 males and females survived their respective phases of study 
Appearance and behaviour of parental rats were comparable throughout the study 
Food consumption  Generally comparable between control and test groups 
Growth  Body weights during pre-mating periods were generally comparable between groups 
Laboratory tests  None reported 
Ocular examinations  None reported 
Other 
Incidental observations among a few control and test animals during one or both 
generations: 
•  Bloody crust on eyes 
•  Red eyelids 
•  Lacrimation 
•  Wheezing 
•  Hunched appearance 
•  Rough fur 
•  Alopecia 
•  Soft faeces 
Comments  The information provided is very limited given the potential importance of the study. 
 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Outcomes: 
Terminal body weights 
Parental terminal body weights were generally comparable between groups 
Body weight suppression at weaning among pups from 4,000 mg/kg/day groups. 
•  Evident in both F1A and F2A generations 
•  All other parameters comparable 
Maternal parameters 
No indication of a compound-related effect on indices of: 
•  Fertility 
•  Gestation 
•  Live births 
•  Lactation 
Litter examination 
No indication of a compound-related effect on: 
•  Mean litter size 
•  Mean pup weights at birth (24 hr) 
At weaning, significant body weight suppression was observed among pups at 
4,000 mg/kg/day but not at 2,000 mg/kg/day. 
Neonatal examination 
Incidental findings among pups from a few control and test litters: 
•  Weak/thin appearance 
•  Hunching 
•  Wheezing 
•  Laboured respiration 
•  Squinting 
Malformations observed  See below for F1 and F2 generation offspring 
F1 generation 
Necropsy findings were similar between control and test litters. 
No gross abnormalities observed among F1A pups examined: 
•  Three controls 
o  Small number examined reflects survival during lactation and 
group size requirement for subsequent lifetime toxicity study (E70) 
and P2 generation 
•  34 at 2,000 mg/kg/day 
•  28 at 4,000 mg/kg/day 
F2 generation 
Findings among 10M/10F pups per group: 
•  Lungs with dark red, abscessed or consolidated areas in: 
o  11 control pups 
o  11 pups at 2,000 mg/kg/day 
o  13 pups at 4,000 mg/kg/day  
•  Dilatation of renal pelvis in two control pups. 
•  Greenish tinge to kidneys in: 
o  2 control pups 
o  5 pups at 2,000 mg/kg/day 
o  2 pups at 4,000 mg/kg/day 
•  Dark red adrenals in 
o  4 pups at 2,000 mg/kg/day 
o  1 pup at 4,000 mg/kg/day 
•  Clear jelly-like substance covering salivary or submaxillary glands in 
o  1 control pup 
o  1 pup at 2,000 mg/kg/day 
•  Watery ovarian cysts in one female at 2,000 mg/kg/day 
Non-neoplastic lesions  No histology described 
Neoplastic lesions  No histology described 
Comments  The information provided is very limited given the potential importance of the study. 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Conclusions: 
Authors’ conclusions 
No clear conclusion drawn 
Reviewer’s comments 
This study does not indicate any clear cut effects on reproductive parameters due to aspartame when 
administered to rats via the diet at doses up to 4,000 mg/kg/day over two generations, but the range of 
parameters evaluated is very limited. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  Yes  
Justification for Internal Quality Review:  This is the only two generation reproduction study on aspartame 
QA comments 
GLP check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  No conclusion 
•  Procedure for identifying animals  
•  No Study Director (although report author) 
•  No start/finish dates 
No mention of how food was deprived in order to obtain fasting chemistry values, day 15 and Day 21 pp 
Not possible to confirm protocol objectives and any changes, as protocol not provided 
OECD Guideline check: 
Test item: similar to above, characterisation etc required by current guidelines not present.  
Otherwise: 
No justification for dose selection; no mention of quality of food, water, bedding (e.g. content/contaminant 
analyses). 
Quite a lot of maternal and litter data which would be required by current guidance not reported. 
Note: from the report it is not clear when administration of medicated feed stopped. Calculation of actual doses 
presented only up until mating, but not clear if dam received dosage during gestation and until weaning. 
Supplementary Check: 
•  Lack of information/clarity on dosing – which seems to have stopped at mating, rather than continuing to 
weaning 
•  No information on stability and homogeneity of diet mixes, or whether any analyses of concentrations 
were conducted. No calculations of actual doses given. 
No other internal inconsistencies within the report were noted, although there is very little data present. 
Commentary: 
General comments 
This study is very important because it is the only two generation in existence. The report is rather thin (literally: it 
only extends to 33 pages in total). It does not indicate any particular cause for concern and may be of use in risk 
assessment; however, the fact that this very sketchy report is the only two generation reproduction study in 
existence is a possible cause for concern. This is an important data gap in the aspartame portfolio. 
It should be noted that offspring from this study were also used for the assessment of neonatal toxicity (E9) and in 
a lifetime study (E70). CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Strengths and limitations of study 
Strengths 
•  The only two generation study in existence. 
Limitations 
•  Very limited study: few parameters evaluated,  limited in life observations, no laboratory investigations . 
•  Limited necropsies performed, no histological examination 
•  Small number of F1A offspring examined due to poor survival and prioritisation of other needs 
•  Many of the maternal and litter data which are required under current guidelines not reported. 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). the study findings were generally agreed, and the commentators noted that this study 
seemed to exhibit fewer problems and discrepancies than in other studies (Unattributed, 1978c).  
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
12 males and 12 females per treatment group for first round of breeding 
Two dose levels plus control 
•  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No evidence to confirm that compound was administered throughout gestation and 
lactation; calculated intakes variable, up to 22.5% lower than planned. 
No inconsistencies noted, but very few data presented 
Relevance of the study  Two generation reproductive toxicity study in a standard laboratory rodent species; 
the only one in the dossier 
Adequacy of data sets 
Limited in life observations; no laboratory investigations. 
No histological evaluation. 
Superficial evaluation of reproductive parameters; lacks in depth analysis. 
Small number of F1A offspring examined due to poor survival and need to populate P2 
generation and lifetime toxicity study. 
Some maternal and litter data not reported. 
Data sources  Commercial study report, pre-GLP (1971) 
Comments 
•  This study provides very limited information given the potential importance of the study.  
•  This study was included in the UAREP authentication review in 1978. The study findings were agreed 
and the reviewers noted that the study exhibited fewer problems and discrepancies than other studies. 
•  This study would not be considered fully compliant with the current OECD Guideline for 2-generation 
reprotox testing (Number 416), but the guideline was not in place when the study was conducted. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account 
Reviewer Details 
Name: Lesley Stanley   Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Study Identifier  13 (1971) E11 
Study Title  Two-Generation Reproduction Study-Rats 
  Y  N  Comment 
Name and address of the facility performing the study and the dates 
on which the study was initiated and completed.  √     
Objectives and procedures stated in the approved protocol, including 
any changes in the original protocol.    √  protocol not 
provided 
Statistical methods employed for analyzing the data.  √     
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √ 
No lot 
numbers; 
purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √  No reported ID 
method, 
A description of the dosage, dosage regimen, route of administration, 
and duration.  √  √  No analyses 
A description of all circumstances that may have affected the quality 
or integrity of the data.    √   
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√  √  Not SD 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√  √  No conclusion 
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.    √  N/A 
The locations where all specimens, raw data, and the final report are 
to be stored.    √   
The statement prepared and signed by the quality assurance unit as 
described in 58.35(b)(7): to be included with the final study report 
which shall specify the dates inspections were made and findings 
reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or corrected 
and the reasons for the correction or addition, and shall be signed 
and dated by the person responsible. 
  √   
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments 
None 
Report GLP content check by/date: J Birnie 19 April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 416: report content 
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Study identifier             13 (1971) E11 
Study Title  Two-Generation Reproduction Study-Rats SC-1886 
*OECD Guideline no: 416: 2-gen reprotox study 
 
*§    Y  N  Comment  
47  Data shall be reported individually and summarised in tabular 
form, showing for each test group and each generation the 
number of animals at the start of the test, the number of animals 
found dead during the test or killed for humane reasons, the time 
of any death or humane kill, the number of fertile animals, the 
number of pregnant females, the number of animals showing 
signs of toxicity, a description of the signs of toxicity observed, 
including time of onset, duration, and severity of any toxic effects, 
the types of foetal observations, and all relevant litter data. 
  √  See below 
48  Numerical results should be evaluated by an appropriate generally 
accepted statistical method. 
 The report should include sufficient information on the method of 
analyses and the computer program employed so that an 
independent reviewer/statistician can re-evaluate and reconstruct 
the analysis.  
√     
49  The findings should be evaluated in terms of the observed effects 
including necropsy and microscopic findings. The evaluation will 
include the relationship, or lack thereof, between the dose of the 
test substance and the presence or absence, incidence and 
severity of abnormalities, including gross lesions, identified target 
organs, affected fertility, clinical abnormalities, affected 
reproductive and litter performance, body weight changes, effects 
on mortality and any other toxic effects. The physicochemical 
properties of the test substance, and when available, 
toxicokinetics data should be taken into consideration when 
evaluating test results. 
  √   
50  A properly conducted reproductive toxicity test should provide a 
satisfactory estimation of a no-effect level and an understanding 
of adverse effects on reproduction, parturition, lactation, postnatal 
development including growth and sexual development. 
  √   
51  The test report must include the following specific information: 
  Test substance:        
  physical nature, and, where relevant,  physicochemical properties       
  identification   √  √  No lot nos, no 
homogeneity 
  purity    √   
  Vehicle (if appropriate): 
justification for choice of vehicle (if other than water) 
  √  N/A 
  Test animals        
  species/strain used   √     
  number, age, sex  √     
  source, housing conditions, diet, nesting materials etc  √  √  No nesting 
materials 
  individual weights of animals at the start of the test  √     
  Test conditions:       
  rationale for dose level selection    √   
  details of test substance formulation/diet preparation  √     
  achieved concentration stability and homogeneity of the 
preparation 
  √  No analyses 
reported 
  details of the administration of the test substance  √  √   
  conversion from diet/drinking water test substance concentration 
(ppm) to the actual dose (mg/kg) if applicable 
√  √   See comment 
(1) 
  details of food and water quality    √   CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
OECD Test Guideline 416: report content 
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*§    Y  N  Comment  
  Results        
  food consumption and, if measured, water consumption, food 
efficiency (body weight gain per gram of food consumed) and test 
material consumption for P and F1 animals, except for the period 
of cohabitation for at least the last third of lactation 
  √  Stops at  end 
of mating  
  absorption data (if available)    √   
  body weight data for P and F1 animals selected for mating   √     
  litter and pup weight data  √     
  body weight at sacrifice and absolute and relative organ weight 
data for the parental animals 
√  √  No organ wts 
  nature, severity and duration of clinical observations (whether 
reversible or not) 




  time of death during the study or whether animals survived 
to termination 
√     
  toxic response data by sex and dose, including indices of 
mating, fertility, gestation, birth, viability, and lactation; the 
report should indicate the numbers used in calculating 
these indices 
√    By litter only 
  toxic or other effects on reproduction, offspring, postnatal 
growth, etc 
  √   
  necropsy findings    √  Not for parents 
No individual 
data for F1 
  detailed description of all histopathological findings    √   
  number of P and F1 females cycling normally and cycle 
length 
  √   
   number of P and F1 females cycling normally and cycle 
length; total cauda epididymal sperm number, percent 
progressively motile sperm, percent morphologically normal 
sperm, and percent of sperm with each identified 
abnormality 
  √   
  time-to-mating, including the number of days until mating    √   
  gestation length    √   
  number of implantations, corpora lutea, litter size    √   
  number of live births and post-implantation loss  √  √   
  number of pups with grossly visible abnormalities, if 
determined the number of runts should be reported 
  √   
  data on physical landmarks in pups and other postnatal 
developmental data; physical landmarks evaluated should 
be justified 
  √   
  data on functional observations in pups and adults, as 
applicable 
  √   
  statistical treatment of results, where appropriate       
  discussion of results  √     
  conclusions including NOAEL for maternal and offspring effects     √   
Comments: 
(1) Not clear when dosing stopped. Calculation of actual doses presented only up until mating, but 
not clear if dam received dosage during gestation and until weaning. 
Report content QA check by/date: J Birnie 18-19 April 2012 
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Page 1 of 1 
Study ID  13 (1971) E11 
Study Title  Two-Generation Reproduction Study-Rats 
Internal Consistency 
 
No inconsistencies were noted, although there is very little data presented. 
Information relating to the test item 
 
There is no information on stability and homogeneity of diet mixes, or whether any 
analyses of concentrations were conducted. No calculations of actual doses given. 





J Birnie 19 April 2012 
 CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Document identification: 
Title  SC-18862: Toxicological Evaluation in the Neonatal Rat (Final Report. P-T 893H71) 
Authors  Reno, F.E., Ferrell, J.F.  Date  1972 
Study Type  Neonatal toxicity  Dossier #  E9 
Purpose of study: 
“…to evaluate and characterize the effects of SC-18862 on haematological and biochemical parameters and on 
tissues of rats one through 21 days of age”. 
Test Item: 
Chemical Identity  Aspartame (SC-18862)  Purity  Assumed 100% pure 
Lot # (s)  Various; not specified 
Animals: 
Species:  Rat  Strain:  Charles River CD 
Source:  F2A litters from two 
generation study (E11)  Age/weight:  Neonates 
Comments:   This study follows on from the two generation reproduction study (E9).  
Formulation: 
Route of administration  Dams exposed via diet  Concentration  N/A 
Formulation procedure  See study E11 
Confirmatory analysis  N/A 
Comments  No new treatment was initiated for this study. 
Study design: 
Animal husbandry 
The report notes that the study described involved animals maintained in animal care 
facilities fully accredited by the American Association for Accreditation of Laboratory 
Animal Care. 
No further detail is provided. 
Diet  N/A (except for possible consumption of solid diet during suckling) 
Minimisation of bias  Five culled F2A litters from two generation study (E11) were arbitrarily selected and 
utilised for evaluation of clinical pathology parameters.  
Blocking of groups  None indicated 
Number per group  20M/20Fper group  Acclimatisation   
Start of dosing  In utero  Duration 
Compound administered 
through two parental 
generations (P1 and P2) 
and two one-litter filial 
generations F1A  and F2A) 
Planned doses 




Actual intakes  See study E11 
Basis for dose selection 
See study E11. Test material was added to the dams’ feed at the indicated doses 
and was available to the pups through the milk of the mother, if present therein. The 
respective diets were available ad libitum and were accessible to the litters. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Dose correction  N/A 
Comments 
No new treatment was initiated for this study; the pups used were exposed in utero 
and via the milk. Since aspartame undergoes complete hydrolysis in the GI tract, it is 
extremely unlikely that pups were exposed to intact aspartame via the milk, although 
they could have been exposed to high levels of L-Phe derived from the aspartame in 
their dam’s diet. The pups could also have been exposed to aspartame itself if they 
started to consume solid diet as well as milk during the suckling period. 
In life procedures: 
General observations  See study E11  Clinical chemistry   pnd 15, 21 (10/group) 
Food consumption  N/A  Haematology  pnd 5, 15, 21 (10 /group) 
Body weight  Not specified  Urinalysis  Not specified 
Ocular examinations  Not specified  Other  Not specified 
Comments  The pups would have been too young for ocular examination at the time of sacrifice. 
Procedure for intercurrent deaths: 
Time to necropsy  One pup found dead  
on pnd 4  Parameters recorded  Terminal body weight 
Tissues sampled  Preserved whole in 10% NBF 
Comments  None 
Termination procedures: 
Termination method  Sodium pentobarbital anaesthesia (Diabutal; Diamond Laboratories, USA) 
Time to necropsy  Presumably immediate  Parameters recorded  None specified 
External assessment  Not specified 
Necropsy procedure 
Pups (evenly divided as to sex if possible) were selected for 
•  Clinical laboratory studies 
•  Tissue preservation 
•  Histopathological evaluation 
Ten pups per group (2 per litter) sacrificed 24 hr post partum 
•  Gross necropsy performed 
•  Tissues preserved for histopathology 
Ten pups per group (2 per litter) sacrificed on pnds 5, 15 and 21 
•  Blood taken by arterial puncture of abdominal aorta for clinical laboratory 
studies 
•  Gross necropsy performed 
•  Tissues preserved for histopathology 
Corroborative studies undertaken using kidneys from concurrent F2A litters 
Tissues sampled 
Blood 
Haematology parameters measured: 
•  Haematocrit 
•  Haemoglobin 
•  Erythrocyte count 
•  Total/differential WBC count 
 
Clinical chemistry parameters measured: 
•  Fasting blood sugar 
•  BUN 
•  Total serum protein 
•  Total serum bilirubin 
•  Serum ALT, ALP 








Mesenteric lymph node CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 















Bone marrow (sternum) 
Nerve with muscle 
Corroborative studies were undertaken as follows: 
•  Sections of kidney tissue from other F2A litters (10 per sex per group, aged 
28-30 days) from the original study (E11) were examined microscopically. 
Fixation  10% NBF  Storage conditions  Held at Hazelton Labs; 
Conditions not stated 
Comments  None 
Statistical procedures: 
Data manipulation  Not specified 
Statistical tests used  Not specified 
Results of in life observations: 
General observations 
No stillbirths among the five litters per group selected for this study. 
•  Litters had 5-7 male and 5 female pups per litter 
•  Mean body weights at 24 hr were 6-7 g 
External appearance 24 post partum was normal 
Observations during lactation period: 
•  Controls 
o  Two male and two female pups lost from one litter (presumably 
cannibalised); one female pup was hunched and thin, had bloody 
crust on nose 
o  Pups from one litter were unusually small at weaning 
o  One male pup from another litter found dead on pnd 4 (see 
intercurrent deaths, above) 
•  At 2,000 mg/kg/day 
o  Pups from one litter were unusually small during lactation period 
•  At 4,000 mg/kg/day 
o  One female pup lost (presumably cannibalised) 
Food consumption  Not reported 
Growth  Not reported 
Laboratory tests 
Haematology values: 
•  Haematocrit, haemoglobin and erythrocyte count were similar between 
groups. 
o  Slightly lower than in older animals; thought to be reflective of the 
age of the animals 
•  There was a general reduction in total leukocyte counts among treated 
groups at pnd 15 and 21 
o  Significant in males on pnd 15 and females on pnd 21 
Blood chemistry values comparable between control and test groups. 
•  ALP values differed between 15 and 21 days postpartum 
o  This is attributed to normal variation for animals of this age 
Ocular examinations  N/A 
Other  None reported 
Comments  Rather sketchy information provided in the study report CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Outcomes: 
Terminal body weights  Not reported 
Maternal parameters  N/A 
Litter examination  N/A 
Neonatal examination  N/A 
Malformations observed  N/A 
F1 generation  N/A 
F2 generation  No gross pathology observed in control or test pups killed by design 24 hr post 
partum or on pnd 5, 15 or 21. 
Non-neoplastic lesions 
No pathological alterations were detected in liver, heart or stomach. 
•  Small focal accumulations of polymorphonuclear cells were observed in the 
mucosa and submucosa of one pup at 2,000 mg/kg/day 
“Subtle histological alterations” were observed in kidney sections on pnd 15 and 21: 
•  Minimal to mild hypertrophy and vesiculation of nuclei in cells of tubules of 
the inner cortex, visible under low magnification as a basophilic band 
•  Observed in all pups examined on pnd 15 and in 6/9 on pnd 21 
•  Less severe on pnd 21 or in pups from 2,000 mg/kg/day group 
•  These changes were not considered to be compound-related 
•  Epithelial lines cystic spaces, presumably representing dilated tubules, 
were also present in occasional control and test animals 
The authors state that: 
•  “Assessment of the significance of these changes was rendered somewhat 
difficult owing to the normally changing morphology during this period of 
maturation”. 
Corroborative analysis undertaken in other offspring from study E11 at pnd 28-30 
•  No significant differences in kidney morphology were noted between 
control and test groups. 
•  The nuclear hypertrophy and vesiculation observed in pups at pnd 15 and 
21 were not detected in corroborative analysis. 
•  Interstitial nephritis and regenerative tubular epithelium were present in all 
groups, being at least as common in control as test pups. 
•  These changes were typically minimal to mild in degree. 
•  Spontaneous mineral deposits, tubular and pelvic dilatation were observed 
in small numbers of both control and treated pups. 
•  Minimal accumulation of inflammatory cells was detected in one control 
female and one male at 4,000 mg/kg/day. 
o  Considered to be an incidental finding 
Incidence of renal hypertrophy and/or vesiculation or renal tubular epithelial cells: 
 
  Age (days) 
  1  5  15  21  28-30 
Control   0/9  0/10  1/7  0/7  0/20 
2,000 mg/kg/day  0/10  0/10  0/10  2/10  0/20 
4,000 mg/kg/day  0/10  0/10  10/10  6/9  0/20 
 
The authors conclude that: 
•  “…no significant microscopic alterations were observed in these test 
animals which could be attributed to the experimental procedure. The fact 
that these latter animals were slightly older than those in which the 
previous findings were observed is borne out by the morphologic character 
of these latter animals.” CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Neoplastic lesions  Not reported 
Comments 
The histological changes seen in the kidney appear to be consistent with normal 
histological processes during postnatal development. There is evidence of an effect 
of treatment at pnd 15-21, but this is transient and appears to have resolved by pnd 
28-30. 
•  This result was discussed with the review team pathologist, who agreed 
that it was likely to be part of normal renal development and was unlikely to 
hold any toxicological significance. 
Conclusions: 
Authors’ conclusions 
“Inspection of the above data reveals a treatment-related effect of transient nature, unequivocally present at the 4 
g/kg/day level at 15 and 21 days age. A treatment-related effect in Group No. 2 at 21 days is equivocal, since the 
control group was not negative throughout. Such changes were not present in the treated rat at 28-30 days of 
age.” 
Reviewer’s comments 
The histological changes seen in the kidney in this study appear to be consistent with normal histological 
processes during postnatal development. There is evidence of an effect of treatment at pnd 15-21, but this is 
transient and appears to have resolved by pnd 28-30. 
Quality Assurance: 
Compliance with current GLP standards  See GLP checklist (attached). 
Compliance with current OECD guidelines  See OECD Guideline checklist (attached). 
Internal Quality Review attached?  No 
Justification for Internal Quality Review:  N/A 
QA comments 
GLP check: 
Study was reported before any GLPs extant. 
Key items missing that would exist in a GLP study: 
•  Insufficient information to support adequate characterisation of the test item(s) including the batch(es) 
used, and for the duration of the test its actual concentration, homogeneity and stability in the diet mix, 
and the actual concentrations consumed. 
•  No QA Statement (which also serves to confirm the report reflects the data) 
•  Procedure for identifying litters not described 
•  No Study Director (although report author) 
•  No start/finish dates 
Not possible to confirm protocol objectives and any changes, as protocol not provided 
Commentary: 
General comments 
No further comments 
Strengths and limitations of study 
Strengths 
•  The only study providing information on histological effects in neonates; also provides some clinical 
chemistry and haematology data. 
Limitations 
•  The study is very limited in scope. 
  CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
Section 1: Study details 
Opinions of other commentators 
This study was included in the Authentication Review undertaken by UAREP and reported in 1978 (Unattributed, 
1978a; 1978b; 1978c). One major error was identified: the study investigators forgot to correct the white blood cell 
counts for reticulocytes (Unattributed, 1978c). This error was not, however, believed to have materially affected 
the outcome of the study. The review panel agreed with the histological findings of the original investigators, in 
particular that the renal tubular cell nuclear changes observed appeared to be treatment related. 
Relevance to Risk Assessment (as defined by EFSA1) 
Study design and power 
Small number of F2A offspring from two generation study (20M/20F) examined at 
weaning. Follow up evaluation of pups from other F2A litters (10 per sex per group) at 
pnd 28-30. 
Two dose levels administered to dams, plus control 
•  Limited with respect to characterisation of dose response 
Data quality 
QA issues around test item 
•  Insufficient information to support adequate characterisation of the test 
item(s) including the batch(es) used and ongoing analysis in diet 
Other minor QA issues do not affect interpretation of the data. 
No evidence to confirm that compound was administered to dams throughout 
gestation and lactation. 
Relevance of the study  Provides information on effects on weanling rats of administration of aspartame to 
dams. 
Adequacy of data sets 
Limited laboratory investigations undertaken. 
Wide range of tissues sampled, but only histology reported is on kidney, liver, heart 
and stomach. 
•  Only 13-20 tissues per sex per group examined for initial litters selected 
Supplementary analysis of pups from other F2A litters (10 per sex per group) at pnd 
28-30. 
Information in study report is sketchy. 
Data sources  Commercial study report, pre-GLP (1972) 
Comments 
•  Since aspartame undergoes complete hydrolysis in the GI tract, it is extremely unlikely that pups were 
exposed to intact aspartame via the milk, although they could have been exposed to high levels of L-Phe 
derived from the aspartame in their dam’s diet. The pups could also have been exposed to aspartame 
itself if they started to consume solid diet as well as milk during the suckling period. 
•  This study was included in the UAREP authentication review in 1978. The review notes one significant 
technical error, but this did not materially affect the outcome of the study. The panel agreed with the 
histology findings. 
•  Despite the caveats noted above, the view of the review team is that this study is adequate for use in risk 
assessment as long as its limitations are taken into account. 
Reviewer Details 
Name: Lesley Stanley  Date: 27-Apr-12 
 
                                                             
1 EFSA (2009). "Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk 
Assessments carried out by EFSA. Part 2: General Principles " The EFSA Journal 1051: 1-22. CT/EFSA/ANS/2011/03: Aspartame Key Study Review Proforma 
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Study Identifier  12 1972 (E9) 
Study Title  SC-18862: Toxicological Evaluation in the Neonatal Rat 
  Y  N  Comment 
below 
Name and address of the facility performing the study and the 
dates on which the study was initiated and completed.  √  √  No dates 
Objectives and procedures stated in the approved protocol, 
including any changes in the original protocol.    √  Protocol not 
provided 
Statistical methods employed for analyzing the data.    √   
The test and control articles identified by name, chemical abstracts 
number or code number, strength, purity, and composition or other 
appropriate characteristics. 
√  √ 
No lot 
numbers; 
purity  not 
reported 
Stability of the test and control articles under the conditions of 
administration.    √  nor 
homogeneity 
A description of the methods used.  √     
A description of the test system used. Where applicable, the final 
report shall include the number of animals used, sex, body weight 
range, source of supply, species, strain and sub strain, age, and 
procedure used for identification. 
√  √  No reported 
ID method 
A description of the dosage, dosage regimen, route of 
administration, and duration.  √  √  No analyses 
A description of all circumstances that may have affected the 
quality or integrity of the data.    √   
The name of the study director, the names of other scientists or 
professionals, and the names of all supervisory personnel, involved 
in the study. 
√  √  (Not SD) 
A description of the transformations, calculations, or operations 
performed on the data, a summary and analysis of the data, and a 
statement of the conclusions drawn from the analysis. 
√     
The signed and dated reports of each of the individual scientists or 
other professionals involved in the study.    √   
The locations where all specimens, raw data, and the final report 
are to be stored.  √  √  Specimens 
only 
The statement prepared and signed by the quality assurance unit 
as described in 58.35(b)(7): to be included with the final study 
report which shall specify the dates inspections were made and 
findings reported to management and to the study director. 
  √   
The final report shall be signed and dated by the study director.    √   
Corrections or additions to a final report shall be in the form of an 
amendment by the study director. The amendment shall clearly 
identify that part of the final report that is being added to or 
corrected and the reasons for the correction or addition, and shall 
be signed and dated by the person responsible. 
  √   
US Code of Federal Regulations Title 21 Part 58: 
Good Laboratory Practice for Non-Clinical Laboratory studies 
Comments: 
No mention of how food was deprived in order to obtain fasting chemistry values, day 15 and 
Day 21 pp 
Report GLP content check by/date: J Birnie 19 April 2012 
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Supporting publications 2013:EN-399 
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
ABBREVIATIONS 
[X]  concentration of X 
5-HIAA  5-hydroxyindoleacetic acid 
5-HT  serotonin  
AARP  American Association of Retired Persons 
AspPhe  aspartylphenylalanine 
ADI  acceptable daily intake 
ALP  alkaline phosphatase 
ALT  alanine aminotransferase 
Asp  aspartic acid 
AST  aspartate aminotransferase  
AUC  area under the concentration-time curve 
β-AspPhe   N-β-L-aspartyl-L-phenylalanine 
BBB  blood-brain barrier 
BSA  bovine serum albumin 
BMI  basal metabolic index 
BUN  blood urea nitrogen 
BW  body weight 
CI  confidence interval 
CMC  carboxymethyl cellulose 
CMCRC  Cesare Maltoni Cancer Research Center  
COT  Committee on Toxicity of Chemicals in Food, Consumer, Products and the Environment 
CRD  crown-rump distance 
CT  computerised tomography 
cycloAspPhe  5-benzyl-3,6-dioxo-2-piperazineacetic acid 
CYP  cytochrome P450 
DKP  diketopiperazine 
DOPA  L-3,4-dihydroxyphenylalanine 
DOPAC  3,4-dihydroxyphenylacetic acid 
EEG  electroencephalogram 
EFSA  European Food Safety Authority 
ELISA  enzyme-linked immunosorbent assay 
EM  elecron microscopy 
EPA  US Environmental Protection Agancy 
ERF  European Ramazzini Foundation of Oncology and Environmental Sciences 
FDA  US Food and Drug Administration 
FETAX  Frog Embryo Teratogenesis Assay – Xenopus 
GI  gastrointestinal 
GLP  Good Laboratory Practice 
Glu  glutamate 
Gly  glycine 
GSH  glutathione 
GST  glutathione S-transferase 
HDL  high density lipoprotein 
HPLC  high performance liquid chromatography    Review of data on the food additive aspartame 
 
Supporting publications 2013:EN-399  
The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively 
by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender 
procedure. The present document is published complying with the transparency principle to which the European Food Safety Authority is 
subject. It may not be considered as an output adopted by EFSA. EFSA reserves its rights, view and position as regards the issues addressed 
and the conclusions reached in the present document, without prejudice to the rights of the authors. 
i.p.  intraperitoneal 
i.v.  intravenous 
Ile  isoleucine  
Leu  leucine 
LNAA  large neutral amino acid 
LPS  lipopolysaccharide 
Met  methionine  
MSG  monosodium glutamate  
MTBE  methyl tert-butyl ether 
NBF  neutral buffered formalin 
NT  neurotransmitter 
NTP  National Toxicology Programme 
NTP-CERHR  National Toxicology Program Center for the Evaluation of Risks to Human Reproduction 
NutraSweet  The NutraSweet Company 
OR  odds ratio 
p.o.  perioral 
pcd  post coital day 
Phe  phenylalanine 
pid  post-insemination day  
PKU  phenylketonuria 
PKU het  PKU heterozygote 
pnd  post natal day 
RIA  radioimmunoassay 
RR  risk ratio 
Searle  G.D. Searle and Co.  
STESS  Subjects Treatment Emergent Symptoms Scale 
THF  tetrahydrofolate 
TLC  thin layer chromatography 
Trp  tryptophan 
UAREP  Universities Associated for Research and Education in Pathology 
UDS  unscheduled DNA synthesis 
UGT  UDP-glucuronyl transferase 
Val  valine 
 